id	sid	tid	token	lemma	pos
biomedich-346	1	1	biology	biology	NOUN
biomedich-346	1	2	,	,	PUNCT
biomedich-346	1	3	medicine	medicine	NOUN
biomedich-346	1	4	,	,	PUNCT
biomedich-346	1	5	&	&	CCONJ
biomedich-346	1	6	natural	natural	ADJ
biomedich-346	1	7	product	product	NOUN
biomedich-346	1	8	chemistry	chemistry	NOUN
biomedich-346	1	9	issn	issn	VERB
biomedich-346	1	10	2089	2089	NUM
biomedich-346	1	11	-	-	SYM
biomedich-346	1	12	6514	6514	NUM
biomedich-346	1	13	(	(	PUNCT
biomedich-346	1	14	paper	paper	NOUN
biomedich-346	1	15	)	)	PUNCT
biomedich-346	1	16	volume	volume	NOUN
biomedich-346	1	17	12	12	NUM
biomedich-346	1	18	,	,	PUNCT
biomedich-346	1	19	number	number	NOUN
biomedich-346	1	20	1	1	NUM
biomedich-346	1	21	,	,	PUNCT
biomedich-346	1	22	april	april	PROPN
biomedich-346	1	23	2023	2023	NUM
biomedich-346	2	1	|	|	ADV
biomedich-346	2	2	pages	page	NOUN
biomedich-346	2	3	:	:	PUNCT
biomedich-346	2	4	343	343	NUM
biomedich-346	2	5	-	-	SYM
biomedich-346	2	6	361	361	NUM
biomedich-346	2	7	|	|	ADV
biomedich-346	2	8	doi	doi	NOUN
biomedich-346	2	9	:	:	PUNCT
biomedich-346	2	10	10.14421	10.14421	NUM
biomedich-346	2	11	/	/	SYM
biomedich-346	2	12	biomedich.2023.121.343	biomedich.2023.121.343	PROPN
biomedich-346	2	13	-	-	PUNCT
biomedich-346	2	14	361	361	NUM
biomedich-346	2	15	issn	issn	PROPN
biomedich-346	2	16	2540	2540	NUM
biomedich-346	2	17	-	-	SYM
biomedich-346	2	18	9328	9328	NUM
biomedich-346	2	19	(	(	PUNCT
biomedich-346	2	20	online	online	NOUN
biomedich-346	2	21	)	)	PUNCT
biomedich-346	2	22	nanotechnology	nanotechnology	NOUN
biomedich-346	2	23	-	-	PUNCT
biomedich-346	2	24	based	base	VERB
biomedich-346	2	25	vaccines	vaccine	NOUN
biomedich-346	2	26	mohamed	mohame	VERB
biomedich-346	2	27	hussein1	hussein1	PROPN
biomedich-346	2	28	,	,	PUNCT
biomedich-346	2	29	*	*	PUNCT
biomedich-346	2	30	,	,	PUNCT
biomedich-346	2	31	madiha	madiha	VERB
biomedich-346	2	32	mumtaz2	mumtaz2	PROPN
biomedich-346	2	33	,	,	PUNCT
biomedich-346	2	34	iqra	iqra	PROPN
biomedich-346	2	35	nasir3	nasir3	NOUN
biomedich-346	2	36	,	,	PUNCT
biomedich-346	2	37	anisa	anisa	PROPN
biomedich-346	2	38	abdullahi4	abdullahi4	PROPN
biomedich-346	2	39	1department	1department	NUM
biomedich-346	2	40	of	of	ADP
biomedich-346	2	41	biomedical	biomedical	ADJ
biomedich-346	2	42	science	science	NOUN
biomedich-346	2	43	,	,	PUNCT
biomedich-346	2	44	dubai	dubai	PROPN
biomedich-346	2	45	medical	medical	PROPN
biomedich-346	2	46	college	college	PROPN
biomedich-346	2	47	for	for	ADP
biomedich-346	2	48	girls	girl	NOUN
biomedich-346	2	49	,	,	PUNCT
biomedich-346	2	50	dubai	dubai	PROPN
biomedich-346	2	51	,	,	PUNCT
biomedich-346	2	52	united	united	PROPN
biomedich-346	2	53	arab	arab	PROPN
biomedich-346	2	54	emirates	emirates	PROPN
biomedich-346	2	55	2,3,4dubai	2,3,4dubai	NUM
biomedich-346	2	56	medical	medical	ADJ
biomedich-346	2	57	college	college	NOUN
biomedich-346	2	58	for	for	ADP
biomedich-346	2	59	girls	girl	NOUN
biomedich-346	2	60	,	,	PUNCT
biomedich-346	2	61	dubai	dubai	PROPN
biomedich-346	2	62	,	,	PUNCT
biomedich-346	2	63	united	united	PROPN
biomedich-346	2	64	arab	arab	PROPN
biomedich-346	2	65	emirates	emirates	PROPN
biomedich-346	2	66	.	.	PUNCT
biomedich-346	3	1	corresponding	correspond	VERB
biomedich-346	3	2	author	author	NOUN
biomedich-346	3	3	*	*	PUNCT
biomedich-346	3	4	dr.m.hussin@dmcg.edu	dr.m.hussin@dmcg.edu	NOUN
biomedich-346	3	5	abstract	abstract	ADJ
biomedich-346	3	6	several	several	ADJ
biomedich-346	3	7	new	new	ADJ
biomedich-346	3	8	infectious	infectious	ADJ
biomedich-346	3	9	diseases	disease	NOUN
biomedich-346	3	10	have	have	AUX
biomedich-346	3	11	developed	develop	VERB
biomedich-346	3	12	in	in	ADP
biomedich-346	3	13	recent	recent	ADJ
biomedich-346	3	14	years	year	NOUN
biomedich-346	3	15	,	,	PUNCT
biomedich-346	3	16	and	and	CCONJ
biomedich-346	3	17	a	a	DET
biomedich-346	3	18	few	few	ADJ
biomedich-346	3	19	old	old	ADJ
biomedich-346	3	20	ones	one	NOUN
biomedich-346	3	21	that	that	PRON
biomedich-346	3	22	were	be	AUX
biomedich-346	3	23	formerly	formerly	ADV
biomedich-346	3	24	thought	think	VERB
biomedich-346	3	25	to	to	PART
biomedich-346	3	26	pose	pose	VERB
biomedich-346	3	27	no	no	DET
biomedich-346	3	28	threat	threat	NOUN
biomedich-346	3	29	to	to	ADP
biomedich-346	3	30	humans	human	NOUN
biomedich-346	3	31	have	have	AUX
biomedich-346	3	32	made	make	VERB
biomedich-346	3	33	a	a	DET
biomedich-346	3	34	comeback	comeback	NOUN
biomedich-346	3	35	.	.	PUNCT
biomedich-346	4	1	millions	million	NOUN
biomedich-346	4	2	of	of	ADP
biomedich-346	4	3	fatalities	fatality	NOUN
biomedich-346	4	4	are	be	AUX
biomedich-346	4	5	attributed	attribute	VERB
biomedich-346	4	6	to	to	ADP
biomedich-346	4	7	these	these	DET
biomedich-346	4	8	illnesses	illness	NOUN
biomedich-346	4	9	together	together	ADV
biomedich-346	4	10	,	,	PUNCT
biomedich-346	4	11	having	have	VERB
biomedich-346	4	12	a	a	DET
biomedich-346	4	13	significant	significant	ADJ
biomedich-346	4	14	negative	negative	ADJ
biomedich-346	4	15	influence	influence	NOUN
biomedich-346	4	16	on	on	ADP
biomedich-346	4	17	the	the	DET
biomedich-346	4	18	worldwide	worldwide	ADJ
biomedich-346	4	19	socioeconomic	socioeconomic	ADJ
biomedich-346	4	20	and	and	CCONJ
biomedich-346	4	21	healthcare	healthcare	NOUN
biomedich-346	4	22	sectors	sector	NOUN
biomedich-346	4	23	.	.	PUNCT
biomedich-346	5	1	the	the	DET
biomedich-346	5	2	lack	lack	NOUN
biomedich-346	5	3	of	of	ADP
biomedich-346	5	4	appropriate	appropriate	ADJ
biomedich-346	5	5	medications	medication	NOUN
biomedich-346	5	6	for	for	ADP
biomedich-346	5	7	many	many	ADJ
biomedich-346	5	8	of	of	ADP
biomedich-346	5	9	these	these	DET
biomedich-346	5	10	disorders	disorder	NOUN
biomedich-346	5	11	is	be	AUX
biomedich-346	5	12	one	one	NUM
biomedich-346	5	13	of	of	ADP
biomedich-346	5	14	the	the	DET
biomedich-346	5	15	biggest	big	ADJ
biomedich-346	5	16	obstacles	obstacle	NOUN
biomedich-346	5	17	to	to	ADP
biomedich-346	5	18	treating	treat	VERB
biomedich-346	5	19	them	they	PRON
biomedich-346	5	20	.	.	PUNCT
biomedich-346	6	1	yet	yet	ADV
biomedich-346	6	2	,	,	PUNCT
biomedich-346	6	3	several	several	ADJ
biomedich-346	6	4	of	of	ADP
biomedich-346	6	5	the	the	DET
biomedich-346	6	6	most	most	ADV
biomedich-346	6	7	common	common	ADJ
biomedich-346	6	8	diseases	disease	NOUN
biomedich-346	6	9	currently	currently	ADV
biomedich-346	6	10	have	have	VERB
biomedich-346	6	11	no	no	DET
biomedich-346	6	12	vaccinations	vaccination	NOUN
biomedich-346	6	13	that	that	PRON
biomedich-346	6	14	are	be	AUX
biomedich-346	6	15	reliable	reliable	ADJ
biomedich-346	6	16	.	.	PUNCT
biomedich-346	7	1	the	the	DET
biomedich-346	7	2	ideal	ideal	ADJ
biomedich-346	7	3	vaccine	vaccine	NOUN
biomedich-346	7	4	should	should	AUX
biomedich-346	7	5	have	have	VERB
biomedich-346	7	6	several	several	ADJ
biomedich-346	7	7	key	key	ADJ
biomedich-346	7	8	characteristics	characteristic	NOUN
biomedich-346	7	9	,	,	PUNCT
biomedich-346	7	10	including	include	VERB
biomedich-346	7	11	safety	safety	NOUN
biomedich-346	7	12	,	,	PUNCT
biomedich-346	7	13	stability	stability	NOUN
biomedich-346	7	14	,	,	PUNCT
biomedich-346	7	15	and	and	CCONJ
biomedich-346	7	16	the	the	DET
biomedich-346	7	17	capacity	capacity	NOUN
biomedich-346	7	18	to	to	PART
biomedich-346	7	19	induce	induce	VERB
biomedich-346	7	20	a	a	DET
biomedich-346	7	21	sufficient	sufficient	ADJ
biomedich-346	7	22	and	and	CCONJ
biomedich-346	7	23	long	long	ADV
biomedich-346	7	24	-	-	PUNCT
biomedich-346	7	25	lasting	last	VERB
biomedich-346	7	26	immune	immune	ADJ
biomedich-346	7	27	response	response	NOUN
biomedich-346	7	28	with	with	ADP
biomedich-346	7	29	a	a	DET
biomedich-346	7	30	minimal	minimal	ADJ
biomedich-346	7	31	number	number	NOUN
biomedich-346	7	32	of	of	ADP
biomedich-346	7	33	doses	dose	NOUN
biomedich-346	7	34	.	.	PUNCT
biomedich-346	8	1	to	to	PART
biomedich-346	8	2	induce	induce	VERB
biomedich-346	8	3	protective	protective	ADJ
biomedich-346	8	4	immunity	immunity	NOUN
biomedich-346	8	5	against	against	ADP
biomedich-346	8	6	illnesses	illness	NOUN
biomedich-346	8	7	,	,	PUNCT
biomedich-346	8	8	different	different	ADJ
biomedich-346	8	9	generation	generation	NOUN
biomedich-346	8	10	vaccines	vaccine	NOUN
biomedich-346	8	11	are	be	AUX
biomedich-346	8	12	employed	employ	VERB
biomedich-346	8	13	,	,	PUNCT
biomedich-346	8	14	including	include	VERB
biomedich-346	8	15	attenuated	attenuated	ADJ
biomedich-346	8	16	or	or	CCONJ
biomedich-346	8	17	dead	dead	ADJ
biomedich-346	8	18	entire	entire	ADJ
biomedich-346	8	19	organisms	organism	NOUN
biomedich-346	8	20	(	(	PUNCT
biomedich-346	8	21	first	first	ADJ
biomedich-346	8	22	generation	generation	NOUN
biomedich-346	8	23	)	)	PUNCT
biomedich-346	8	24	,	,	PUNCT
biomedich-346	8	25	subunits	subunit	NOUN
biomedich-346	8	26	(	(	PUNCT
biomedich-346	8	27	second	second	ADJ
biomedich-346	8	28	generation	generation	NOUN
biomedich-346	8	29	)	)	PUNCT
biomedich-346	8	30	,	,	PUNCT
biomedich-346	8	31	and	and	CCONJ
biomedich-346	8	32	rna	rna	PROPN
biomedich-346	8	33	or	or	CCONJ
biomedich-346	8	34	dna	dna	PROPN
biomedich-346	8	35	vaccines	vaccine	NOUN
biomedich-346	8	36	(	(	PUNCT
biomedich-346	8	37	third	third	ADJ
biomedich-346	8	38	generation	generation	NOUN
biomedich-346	8	39	)	)	PUNCT
biomedich-346	8	40	.	.	PUNCT
biomedich-346	9	1	to	to	PART
biomedich-346	9	2	get	get	VERB
biomedich-346	9	3	beyond	beyond	ADP
biomedich-346	9	4	these	these	DET
biomedich-346	9	5	obstacles	obstacle	NOUN
biomedich-346	9	6	,	,	PUNCT
biomedich-346	9	7	a	a	DET
biomedich-346	9	8	reliable	reliable	ADJ
biomedich-346	9	9	vaccination	vaccination	NOUN
biomedich-346	9	10	delivery	delivery	NOUN
biomedich-346	9	11	mechanism	mechanism	NOUN
biomedich-346	9	12	is	be	AUX
biomedich-346	9	13	needed	need	VERB
biomedich-346	9	14	,	,	PUNCT
biomedich-346	9	15	one	one	NUM
biomedich-346	9	16	that	that	PRON
biomedich-346	9	17	not	not	PART
biomedich-346	9	18	only	only	ADV
biomedich-346	9	19	gets	get	VERB
biomedich-346	9	20	the	the	DET
biomedich-346	9	21	vaccine	vaccine	NOUN
biomedich-346	9	22	molecules	molecule	NOUN
biomedich-346	9	23	to	to	ADP
biomedich-346	9	24	the	the	DET
biomedich-346	9	25	target	target	NOUN
biomedich-346	9	26	region	region	NOUN
biomedich-346	9	27	where	where	SCONJ
biomedich-346	9	28	they	they	PRON
biomedich-346	9	29	can	can	AUX
biomedich-346	9	30	trigger	trigger	VERB
biomedich-346	9	31	long	long	ADV
biomedich-346	9	32	-	-	PUNCT
biomedich-346	9	33	lasting	last	VERB
biomedich-346	9	34	immune	immune	ADJ
biomedich-346	9	35	responses	response	NOUN
biomedich-346	9	36	but	but	CCONJ
biomedich-346	9	37	also	also	ADV
biomedich-346	9	38	has	have	VERB
biomedich-346	9	39	few	few	ADJ
biomedich-346	9	40	side	side	NOUN
biomedich-346	9	41	effects	effect	NOUN
biomedich-346	9	42	and	and	CCONJ
biomedich-346	9	43	uses	use	VERB
biomedich-346	9	44	fewer	few	ADJ
biomedich-346	9	45	doses	dose	NOUN
biomedich-346	9	46	.	.	PUNCT
biomedich-346	10	1	only	only	ADV
biomedich-346	10	2	a	a	DET
biomedich-346	10	3	few	few	ADJ
biomedich-346	10	4	hundred	hundred	NUM
biomedich-346	10	5	atoms	atom	NOUN
biomedich-346	10	6	make	make	VERB
biomedich-346	10	7	up	up	ADP
biomedich-346	10	8	the	the	DET
biomedich-346	10	9	majority	majority	NOUN
biomedich-346	10	10	of	of	ADP
biomedich-346	10	11	nanoparticles	nanoparticle	NOUN
biomedich-346	10	12	.	.	PUNCT
biomedich-346	11	1	nanoparticles	nanoparticle	NOUN
biomedich-346	11	2	have	have	VERB
biomedich-346	11	3	a	a	DET
biomedich-346	11	4	relatively	relatively	ADV
biomedich-346	11	5	significant	significant	ADJ
biomedich-346	11	6	surface	surface	NOUN
biomedich-346	11	7	area	area	NOUN
biomedich-346	11	8	-	-	PUNCT
biomedich-346	11	9	to	to	ADP
biomedich-346	11	10	-	-	PUNCT
biomedich-346	11	11	volume	volume	NOUN
biomedich-346	11	12	ratio	ratio	NOUN
biomedich-346	11	13	because	because	SCONJ
biomedich-346	11	14	of	of	ADP
biomedich-346	11	15	their	their	PRON
biomedich-346	11	16	extremely	extremely	ADV
biomedich-346	11	17	small	small	ADJ
biomedich-346	11	18	size	size	NOUN
biomedich-346	11	19	.	.	PUNCT
biomedich-346	12	1	nanoparticles	nanoparticle	NOUN
biomedich-346	12	2	can	can	AUX
biomedich-346	12	3	have	have	VERB
biomedich-346	12	4	surprising	surprising	ADJ
biomedich-346	12	5	optical	optical	ADJ
biomedich-346	12	6	,	,	PUNCT
biomedich-346	12	7	physical	physical	ADJ
biomedich-346	12	8	,	,	PUNCT
biomedich-346	12	9	and	and	CCONJ
biomedich-346	12	10	chemical	chemical	NOUN
biomedich-346	12	11	properties	property	NOUN
biomedich-346	12	12	due	due	ADJ
biomedich-346	12	13	to	to	ADP
biomedich-346	12	14	this	this	DET
biomedich-346	12	15	property	property	NOUN
biomedich-346	12	16	.	.	PUNCT
biomedich-346	13	1	nanotechnology	nanotechnology	NOUN
biomedich-346	13	2	has	have	VERB
biomedich-346	13	3	many	many	ADJ
biomedich-346	13	4	benefits	benefit	NOUN
biomedich-346	13	5	for	for	ADP
biomedich-346	13	6	the	the	DET
biomedich-346	13	7	creation	creation	NOUN
biomedich-346	13	8	of	of	ADP
biomedich-346	13	9	vaccines	vaccine	NOUN
biomedich-346	13	10	for	for	ADP
biomedich-346	13	11	the	the	DET
biomedich-346	13	12	next	next	ADJ
biomedich-346	13	13	generation	generation	NOUN
biomedich-346	13	14	.	.	PUNCT
biomedich-346	14	1	a	a	DET
biomedich-346	14	2	delivery	delivery	NOUN
biomedich-346	14	3	strategy	strategy	NOUN
biomedich-346	14	4	based	base	VERB
biomedich-346	14	5	on	on	ADP
biomedich-346	14	6	nanocarriers	nanocarrier	NOUN
biomedich-346	14	7	can	can	AUX
biomedich-346	14	8	shield	shield	VERB
biomedich-346	14	9	vaccines	vaccine	NOUN
biomedich-346	14	10	from	from	ADP
biomedich-346	14	11	early	early	ADJ
biomedich-346	14	12	deterioration	deterioration	NOUN
biomedich-346	14	13	,	,	PUNCT
biomedich-346	14	14	increase	increase	VERB
biomedich-346	14	15	stability	stability	NOUN
biomedich-346	14	16	,	,	PUNCT
biomedich-346	14	17	have	have	VERB
biomedich-346	14	18	high	high	ADJ
biomedich-346	14	19	adjuvant	adjuvant	ADJ
biomedich-346	14	20	qualities	quality	NOUN
biomedich-346	14	21	,	,	PUNCT
biomedich-346	14	22	and	and	CCONJ
biomedich-346	14	23	can	can	AUX
biomedich-346	14	24	help	help	VERB
biomedich-346	14	25	with	with	ADP
biomedich-346	14	26	the	the	DET
biomedich-346	14	27	targeted	target	VERB
biomedich-346	14	28	distribution	distribution	NOUN
biomedich-346	14	29	of	of	ADP
biomedich-346	14	30	an	an	DET
biomedich-346	14	31	immunogen	immunogen	NOUN
biomedich-346	14	32	.	.	PUNCT
biomedich-346	15	1	the	the	DET
biomedich-346	15	2	researcher	researcher	NOUN
biomedich-346	15	3	conducts	conduct	VERB
biomedich-346	15	4	an	an	DET
biomedich-346	15	5	examination	examination	NOUN
biomedich-346	15	6	of	of	ADP
biomedich-346	15	7	articles	article	NOUN
biomedich-346	15	8	that	that	PRON
biomedich-346	15	9	are	be	AUX
biomedich-346	15	10	in	in	ADP
biomedich-346	15	11	accordance	accordance	NOUN
biomedich-346	15	12	with	with	ADP
biomedich-346	15	13	the	the	DET
biomedich-346	15	14	issue	issue	NOUN
biomedich-346	15	15	to	to	PART
biomedich-346	15	16	be	be	AUX
biomedich-346	15	17	studied	study	VERB
biomedich-346	15	18	.	.	PUNCT
biomedich-346	16	1	articles	article	NOUN
biomedich-346	16	2	used	use	VERB
biomedich-346	16	3	in	in	ADP
biomedich-346	16	4	the	the	DET
biomedich-346	16	5	literature	literature	NOUN
biomedich-346	16	6	review	review	NOUN
biomedich-346	16	7	are	be	AUX
biomedich-346	16	8	obtained	obtain	VERB
biomedich-346	16	9	through	through	ADP
biomedich-346	16	10	the	the	DET
biomedich-346	16	11	database	database	NOUN
biomedich-346	16	12	of	of	ADP
biomedich-346	16	13	international	international	ADJ
biomedich-346	16	14	journal	journal	NOUN
biomedich-346	16	15	providers	provider	NOUN
biomedich-346	16	16	through	through	ADP
biomedich-346	16	17	pubmed	pubmed	PROPN
biomedich-346	16	18	,	,	PUNCT
biomedich-346	16	19	we	we	PRON
biomedich-346	16	20	investigated	investigate	VERB
biomedich-346	16	21	clinical	clinical	ADJ
biomedich-346	16	22	studies	study	NOUN
biomedich-346	16	23	and	and	CCONJ
biomedich-346	16	24	discussed	discuss	VERB
biomedich-346	16	25	what	what	PRON
biomedich-346	16	26	happened	happen	VERB
biomedich-346	16	27	in	in	ADP
biomedich-346	16	28	these	these	DET
biomedich-346	16	29	clinical	clinical	ADJ
biomedich-346	16	30	studies	study	NOUN
biomedich-346	16	31	and	and	CCONJ
biomedich-346	16	32	the	the	DET
biomedich-346	16	33	extent	extent	NOUN
biomedich-346	16	34	of	of	ADP
biomedich-346	16	35	the	the	DET
biomedich-346	16	36	effectiveness	effectiveness	NOUN
biomedich-346	16	37	of	of	ADP
biomedich-346	16	38	nanoparticle	nanoparticle	NOUN
biomedich-346	16	39	-	-	PUNCT
biomedich-346	16	40	based	base	VERB
biomedich-346	16	41	vaccines	vaccine	NOUN
biomedich-346	16	42	.	.	PUNCT
biomedich-346	17	1	in	in	ADP
biomedich-346	17	2	order	order	NOUN
biomedich-346	17	3	to	to	PART
biomedich-346	17	4	achieve	achieve	VERB
biomedich-346	17	5	effective	effective	ADJ
biomedich-346	17	6	vaccine	vaccine	NOUN
biomedich-346	17	7	distribution	distribution	NOUN
biomedich-346	17	8	and	and	CCONJ
biomedich-346	17	9	generate	generate	VERB
biomedich-346	17	10	the	the	DET
biomedich-346	17	11	required	require	VERB
biomedich-346	17	12	host	host	NOUN
biomedich-346	17	13	immunity	immunity	NOUN
biomedich-346	17	14	against	against	ADP
biomedich-346	17	15	infectious	infectious	ADJ
biomedich-346	17	16	diseases	disease	NOUN
biomedich-346	17	17	,	,	PUNCT
biomedich-346	17	18	this	this	DET
biomedich-346	17	19	review	review	NOUN
biomedich-346	17	20	article	article	NOUN
biomedich-346	17	21	focuses	focus	VERB
biomedich-346	17	22	on	on	ADP
biomedich-346	17	23	the	the	DET
biomedich-346	17	24	applications	application	NOUN
biomedich-346	17	25	of	of	ADP
biomedich-346	17	26	nanocarrier	nanocarrier	NOUN
biomedich-346	17	27	-	-	PUNCT
biomedich-346	17	28	based	base	VERB
biomedich-346	17	29	vaccine	vaccine	NOUN
biomedich-346	17	30	formulations	formulation	NOUN
biomedich-346	17	31	and	and	CCONJ
biomedich-346	17	32	the	the	DET
biomedich-346	17	33	methodologies	methodology	NOUN
biomedich-346	17	34	utilized	utilize	VERB
biomedich-346	17	35	for	for	ADP
biomedich-346	17	36	functionalizing	functionalizing	ADJ
biomedich-346	17	37	nanoparticles	nanoparticle	NOUN
biomedich-346	17	38	.	.	PUNCT
biomedich-346	18	1	keywords	keyword	NOUN
biomedich-346	18	2	:	:	PUNCT
biomedich-346	18	3	nanoparticles	nanoparticle	NOUN
biomedich-346	18	4	;	;	PUNCT
biomedich-346	18	5	immunogen	immunogen	NOUN
biomedich-346	18	6	;	;	PUNCT
biomedich-346	18	7	vaccines	vaccine	NOUN
biomedich-346	18	8	.	.	PUNCT
biomedich-346	19	1	introduction	introduction	NOUN
biomedich-346	19	2	the	the	DET
biomedich-346	19	3	creation	creation	NOUN
biomedich-346	19	4	of	of	ADP
biomedich-346	19	5	efficient	efficient	ADJ
biomedich-346	19	6	vaccines	vaccine	NOUN
biomedich-346	19	7	is	be	AUX
biomedich-346	19	8	the	the	DET
biomedich-346	19	9	ultimate	ultimate	ADJ
biomedich-346	19	10	objective	objective	NOUN
biomedich-346	19	11	in	in	ADP
biomedich-346	19	12	the	the	DET
biomedich-346	19	13	fight	fight	NOUN
biomedich-346	19	14	against	against	ADP
biomedich-346	19	15	the	the	DET
biomedich-346	19	16	spread	spread	NOUN
biomedich-346	19	17	and	and	CCONJ
biomedich-346	19	18	deadly	deadly	ADJ
biomedich-346	19	19	nature	nature	NOUN
biomedich-346	19	20	of	of	ADP
biomedich-346	19	21	many	many	ADJ
biomedich-346	19	22	of	of	ADP
biomedich-346	19	23	these	these	DET
biomedich-346	19	24	infectious	infectious	ADJ
biomedich-346	19	25	diseases	disease	NOUN
biomedich-346	19	26	.	.	PUNCT
biomedich-346	20	1	any	any	DET
biomedich-346	20	2	vaccination	vaccination	NOUN
biomedich-346	20	3	that	that	PRON
biomedich-346	20	4	is	be	AUX
biomedich-346	20	5	secure	secure	ADJ
biomedich-346	20	6	,	,	PUNCT
biomedich-346	20	7	stable	stable	ADJ
biomedich-346	20	8	,	,	PUNCT
biomedich-346	20	9	and	and	CCONJ
biomedich-346	20	10	able	able	ADJ
biomedich-346	20	11	to	to	PART
biomedich-346	20	12	trigger	trigger	VERB
biomedich-346	20	13	a	a	DET
biomedich-346	20	14	robust	robust	ADJ
biomedich-346	20	15	immune	immune	ADJ
biomedich-346	20	16	response	response	NOUN
biomedich-346	20	17	with	with	ADP
biomedich-346	20	18	a	a	DET
biomedich-346	20	19	minimal	minimal	ADJ
biomedich-346	20	20	number	number	NOUN
biomedich-346	20	21	of	of	ADP
biomedich-346	20	22	doses	dose	NOUN
biomedich-346	20	23	is	be	AUX
biomedich-346	20	24	desirable	desirable	ADJ
biomedich-346	20	25	.	.	PUNCT
biomedich-346	21	1	some	some	DET
biomedich-346	21	2	alternative	alternative	ADJ
biomedich-346	21	3	vaccine	vaccine	NOUN
biomedich-346	21	4	types	type	NOUN
biomedich-346	21	5	have	have	AUX
biomedich-346	21	6	demonstrated	demonstrate	VERB
biomedich-346	21	7	promising	promise	VERB
biomedich-346	21	8	outcomes	outcome	NOUN
biomedich-346	21	9	in	in	ADP
biomedich-346	21	10	their	their	PRON
biomedich-346	21	11	immunogenic	immunogenic	ADJ
biomedich-346	21	12	profiles	profile	NOUN
biomedich-346	21	13	,	,	PUNCT
biomedich-346	21	14	despite	despite	SCONJ
biomedich-346	21	15	the	the	DET
biomedich-346	21	16	fact	fact	NOUN
biomedich-346	21	17	that	that	SCONJ
biomedich-346	21	18	many	many	ADJ
biomedich-346	21	19	of	of	ADP
biomedich-346	21	20	the	the	DET
biomedich-346	21	21	frequently	frequently	ADV
biomedich-346	21	22	used	use	VERB
biomedich-346	21	23	vaccinations	vaccination	NOUN
biomedich-346	21	24	attenuate	attenuate	VERB
biomedich-346	21	25	or	or	CCONJ
biomedich-346	21	26	kill	kill	VERB
biomedich-346	21	27	complete	complete	ADJ
biomedich-346	21	28	organisms	organism	NOUN
biomedich-346	21	29	.	.	PUNCT
biomedich-346	22	1	some	some	PRON
biomedich-346	22	2	of	of	ADP
biomedich-346	22	3	the	the	DET
biomedich-346	22	4	top	top	ADJ
biomedich-346	22	5	options	option	NOUN
biomedich-346	22	6	for	for	ADP
biomedich-346	22	7	innovative	innovative	ADJ
biomedich-346	22	8	vaccinations	vaccination	NOUN
biomedich-346	22	9	include	include	VERB
biomedich-346	22	10	subunit	subunit	NOUN
biomedich-346	22	11	vaccines	vaccine	NOUN
biomedich-346	22	12	,	,	PUNCT
biomedich-346	22	13	often	often	ADV
biomedich-346	22	14	known	know	VERB
biomedich-346	22	15	as	as	ADP
biomedich-346	22	16	second	second	ADJ
biomedich-346	22	17	-	-	PUNCT
biomedich-346	22	18	generation	generation	NOUN
biomedich-346	22	19	vaccines	vaccine	NOUN
biomedich-346	22	20	,	,	PUNCT
biomedich-346	22	21	and	and	CCONJ
biomedich-346	22	22	third	third	ADJ
biomedich-346	22	23	-	-	PUNCT
biomedich-346	22	24	generation	generation	NOUN
biomedich-346	22	25	vaccines	vaccine	NOUN
biomedich-346	22	26	,	,	PUNCT
biomedich-346	22	27	which	which	PRON
biomedich-346	22	28	can	can	AUX
biomedich-346	22	29	be	be	AUX
biomedich-346	22	30	rnaor	rnaor	ADJ
biomedich-346	22	31	dna	dna	NOUN
biomedich-346	22	32	-	-	PUNCT
biomedich-346	22	33	based	base	VERB
biomedich-346	22	34	(	(	PUNCT
biomedich-346	22	35	doria	doria	PROPN
biomedich-346	22	36	-	-	PUNCT
biomedich-346	22	37	rose	rise	VERB
biomedich-346	22	38	et	et	PROPN
biomedich-346	22	39	al	al	PROPN
biomedich-346	22	40	.	.	PROPN
biomedich-346	22	41	,2021	,2021	PROPN
biomedich-346	22	42	;	;	PUNCT
biomedich-346	22	43	braz	braz	PROPN
biomedich-346	22	44	gomes	gomes	PROPN
biomedich-346	22	45	et	et	PROPN
biomedich-346	22	46	al	al	PROPN
biomedich-346	22	47	.	.	PROPN
biomedich-346	22	48	,	,	PUNCT
biomedich-346	22	49	2021	2021	NUM
biomedich-346	22	50	)	)	PUNCT
biomedich-346	22	51	.	.	PUNCT
biomedich-346	23	1	numerous	numerous	ADJ
biomedich-346	23	2	kinds	kind	NOUN
biomedich-346	23	3	of	of	ADP
biomedich-346	23	4	nanoparticles	nanoparticle	NOUN
biomedich-346	23	5	have	have	AUX
biomedich-346	23	6	innate	innate	ADJ
biomedich-346	23	7	physical	physical	ADJ
biomedich-346	23	8	characteristics	characteristic	NOUN
biomedich-346	23	9	that	that	PRON
biomedich-346	23	10	can	can	AUX
biomedich-346	23	11	cause	cause	VERB
biomedich-346	23	12	an	an	DET
biomedich-346	23	13	immunological	immunological	ADJ
biomedich-346	23	14	reaction	reaction	NOUN
biomedich-346	23	15	.	.	PUNCT
biomedich-346	24	1	it	it	PRON
biomedich-346	24	2	has	have	AUX
biomedich-346	24	3	been	be	AUX
biomedich-346	24	4	discovered	discover	VERB
biomedich-346	24	5	that	that	SCONJ
biomedich-346	24	6	cytokine	cytokine	NOUN
biomedich-346	24	7	and	and	CCONJ
biomedich-346	24	8	antibody	antibody	NOUN
biomedich-346	24	9	responses	response	NOUN
biomedich-346	24	10	can	can	AUX
biomedich-346	24	11	be	be	AUX
biomedich-346	24	12	induced	induce	VERB
biomedich-346	24	13	by	by	ADP
biomedich-346	24	14	gold	gold	NOUN
biomedich-346	24	15	,	,	PUNCT
biomedich-346	24	16	carbon	carbon	NOUN
biomedich-346	24	17	,	,	PUNCT
biomedich-346	24	18	dendrimers	dendrimer	NOUN
biomedich-346	24	19	,	,	PUNCT
biomedich-346	24	20	polymers	polymer	NOUN
biomedich-346	24	21	,	,	PUNCT
biomedich-346	24	22	and	and	CCONJ
biomedich-346	24	23	liposome	liposome	VERB
biomedich-346	24	24	nanoparticles	nanoparticle	NOUN
biomedich-346	24	25	.	.	PUNCT
biomedich-346	25	1	due	due	ADP
biomedich-346	25	2	to	to	ADP
biomedich-346	25	3	these	these	DET
biomedich-346	25	4	distinctive	distinctive	ADJ
biomedich-346	25	5	properties	property	NOUN
biomedich-346	25	6	,	,	PUNCT
biomedich-346	25	7	nanoparticles	nanoparticle	NOUN
biomedich-346	25	8	can	can	AUX
biomedich-346	25	9	now	now	ADV
biomedich-346	25	10	be	be	AUX
biomedich-346	25	11	used	use	VERB
biomedich-346	25	12	as	as	ADP
biomedich-346	25	13	adjuvants	adjuvant	NOUN
biomedich-346	25	14	to	to	PART
biomedich-346	25	15	boost	boost	VERB
biomedich-346	25	16	the	the	DET
biomedich-346	25	17	immunogenicity	immunogenicity	NOUN
biomedich-346	25	18	of	of	ADP
biomedich-346	25	19	potential	potential	ADJ
biomedich-346	25	20	vaccines	vaccine	NOUN
biomedich-346	25	21	rather	rather	ADV
biomedich-346	25	22	than	than	ADP
biomedich-346	25	23	just	just	ADV
biomedich-346	25	24	as	as	ADP
biomedich-346	25	25	vaccine	vaccine	NOUN
biomedich-346	25	26	delivery	delivery	NOUN
biomedich-346	25	27	systems	system	NOUN
biomedich-346	25	28	.	.	PUNCT
biomedich-346	26	1	the	the	DET
biomedich-346	26	2	nanoparticles	nanoparticle	NOUN
biomedich-346	26	3	utilized	utilize	VERB
biomedich-346	26	4	for	for	ADP
biomedich-346	26	5	this	this	DET
biomedich-346	26	6	purpose	purpose	NOUN
biomedich-346	26	7	are	be	AUX
biomedich-346	26	8	commonly	commonly	ADV
biomedich-346	26	9	between	between	ADP
biomedich-346	26	10	20	20	NUM
biomedich-346	26	11	and	and	CCONJ
biomedich-346	26	12	100	100	NUM
biomedich-346	26	13	nanometers	nanometer	NOUN
biomedich-346	26	14	in	in	ADP
biomedich-346	26	15	size	size	NOUN
biomedich-346	26	16	and	and	CCONJ
biomedich-346	26	17	are	be	AUX
biomedich-346	26	18	also	also	ADV
biomedich-346	26	19	known	know	VERB
biomedich-346	26	20	as	as	ADP
biomedich-346	26	21	nano	nano	NOUN
biomedich-346	26	22	-	-	PUNCT
biomedich-346	26	23	immune	immune	ADJ
biomedich-346	26	24	stimulators	stimulator	NOUN
biomedich-346	26	25	or	or	CCONJ
biomedich-346	26	26	activators	activator	NOUN
biomedich-346	26	27	(	(	PUNCT
biomedich-346	26	28	nm	nm	NOUN
biomedich-346	26	29	)	)	PUNCT
biomedich-346	26	30	.	.	PUNCT
biomedich-346	27	1	inorganic	inorganic	PROPN
biomedich-346	27	2	nps	nps	PROPN
biomedich-346	27	3	like	like	ADP
biomedich-346	27	4	iron	iron	NOUN
biomedich-346	27	5	and	and	CCONJ
biomedich-346	27	6	silica	silica	NOUN
biomedich-346	27	7	,	,	PUNCT
biomedich-346	27	8	polymeric	polymeric	ADJ
biomedich-346	27	9	nps	nps	PROPN
biomedich-346	27	10	like	like	ADP
biomedich-346	27	11	chitosan	chitosan	NOUN
biomedich-346	27	12	and	and	CCONJ
biomedich-346	27	13	poly(lacticco	poly(lacticco	NOUN
biomedich-346	27	14	-	-	PUNCT
biomedich-346	27	15	glycolic	glycolic	NOUN
biomedich-346	27	16	)	)	PUNCT
biomedich-346	27	17	acid	acid	NOUN
biomedich-346	27	18	(	(	PUNCT
biomedich-346	27	19	plga	plga	NOUN
biomedich-346	27	20	)	)	PUNCT
biomedich-346	27	21	,	,	PUNCT
biomedich-346	27	22	cholesterol	cholesterol	NOUN
biomedich-346	27	23	and	and	CCONJ
biomedich-346	27	24	lipid	lipid	NOUN
biomedich-346	27	25	liposomes	liposome	NOUN
biomedich-346	27	26	,	,	PUNCT
biomedich-346	27	27	and	and	CCONJ
biomedich-346	27	28	vlps	vlp	VERB
biomedich-346	27	29	are	be	AUX
biomedich-346	27	30	a	a	DET
biomedich-346	27	31	few	few	ADJ
biomedich-346	27	32	examples	example	NOUN
biomedich-346	27	33	of	of	ADP
biomedich-346	27	34	well	well	ADV
biomedich-346	27	35	-	-	PUNCT
biomedich-346	27	36	known	know	VERB
biomedich-346	27	37	nano	nano	NOUN
biomedich-346	27	38	-	-	PUNCT
biomedich-346	27	39	immune	immune	ADJ
biomedich-346	27	40	stimulators	stimulator	NOUN
biomedich-346	27	41	(	(	PUNCT
biomedich-346	27	42	bachmann	bachmann	PROPN
biomedich-346	27	43	et	et	PROPN
biomedich-346	27	44	al	al	PROPN
biomedich-346	27	45	.	.	PROPN
biomedich-346	27	46	,	,	PUNCT
biomedich-346	27	47	2010	2010	NUM
biomedich-346	27	48	;	;	PUNCT
biomedich-346	27	49	bachmann	bachmann	PROPN
biomedich-346	27	50	et	et	PROPN
biomedich-346	27	51	al	al	PROPN
biomedich-346	27	52	.	.	PROPN
biomedich-346	27	53	,	,	PUNCT
biomedich-346	27	54	1993	1993	NUM
biomedich-346	27	55	;	;	PUNCT
biomedich-346	27	56	baranov	baranov	NOUN
biomedich-346	27	57	et	et	NOUN
biomedich-346	27	58	al	al	PROPN
biomedich-346	27	59	.	.	PROPN
biomedich-346	27	60	,	,	PUNCT
biomedich-346	27	61	2020	2020	NUM
biomedich-346	27	62	)	)	PUNCT
biomedich-346	27	63	.	.	PUNCT
biomedich-346	28	1	nps	nps	PROPN
biomedich-346	28	2	as	as	ADP
biomedich-346	28	3	drug	drug	NOUN
biomedich-346	28	4	delivery	delivery	NOUN
biomedich-346	28	5	mechanisms	mechanism	NOUN
biomedich-346	28	6	,	,	PUNCT
biomedich-346	28	7	including	include	VERB
biomedich-346	28	8	antivirals	antiviral	NOUN
biomedich-346	28	9	,	,	PUNCT
biomedich-346	28	10	can	can	AUX
biomedich-346	28	11	inhibit	inhibit	VERB
biomedich-346	28	12	viral	viral	ADJ
biomedich-346	28	13	reproduction	reproduction	NOUN
biomedich-346	28	14	in	in	ADP
biomedich-346	28	15	host	host	NOUN
biomedich-346	28	16	cells	cell	NOUN
biomedich-346	28	17	by	by	ADP
biomedich-346	28	18	releasing	release	VERB
biomedich-346	28	19	antivirals	antiviral	NOUN
biomedich-346	28	20	from	from	ADP
biomedich-346	28	21	nps	nps	PROPN
biomedich-346	28	22	that	that	DET
biomedich-346	28	23	block	block	NOUN
biomedich-346	28	24	target	target	NOUN
biomedich-346	28	25	cell	cell	NOUN
biomedich-346	28	26	receptors	receptor	NOUN
biomedich-346	28	27	and	and	CCONJ
biomedich-346	28	28	releasing	release	VERB
biomedich-346	28	29	antivirals	antiviral	NOUN
biomedich-346	28	30	from	from	ADP
biomedich-346	28	31	absorbed	absorb	VERB
biomedich-346	28	32	nps	nps	PROPN
biomedich-346	28	33	that	that	PRON
biomedich-346	28	34	are	be	AUX
biomedich-346	28	35	released	release	VERB
biomedich-346	28	36	in	in	ADP
biomedich-346	28	37	a	a	DET
biomedich-346	28	38	target	target	NOUN
biomedich-346	28	39	cell	cell	NOUN
biomedich-346	28	40	.	.	PUNCT
biomedich-346	29	1	these	these	DET
biomedich-346	29	2	main	main	ADJ
biomedich-346	29	3	viral	viral	ADJ
biomedich-346	29	4	replication	replication	NOUN
biomedich-346	29	5	stages	stage	NOUN
biomedich-346	29	6	include	include	VERB
biomedich-346	29	7	transcription	transcription	NOUN
biomedich-346	29	8	,	,	PUNCT
biomedich-346	29	9	replication	replication	NOUN
biomedich-346	29	10	of	of	ADP
biomedich-346	29	11	phage	phage	NOUN
biomedich-346	29	12	dna	dna	NOUN
biomedich-346	29	13	,	,	PUNCT
biomedich-346	29	14	synthesis	synthesis	NOUN
biomedich-346	29	15	of	of	ADP
biomedich-346	29	16	protein	protein	NOUN
biomedich-346	29	17	,	,	PUNCT
biomedich-346	29	18	and	and	CCONJ
biomedich-346	29	19	assembly	assembly	NOUN
biomedich-346	29	20	.	.	PUNCT
biomedich-346	30	1	because	because	SCONJ
biomedich-346	30	2	of	of	ADP
biomedich-346	30	3	their	their	PRON
biomedich-346	30	4	potential	potential	NOUN
biomedich-346	30	5	to	to	PART
biomedich-346	30	6	create	create	VERB
biomedich-346	30	7	prolonged	prolonged	ADJ
biomedich-346	30	8	antigen	antigen	ADJ
biomedich-346	30	9	discharge	discharge	NOUN
biomedich-346	30	10	after	after	ADP
biomedich-346	30	11	vaccination	vaccination	NOUN
biomedich-346	30	12	injection	injection	NOUN
biomedich-346	30	13	and	and	CCONJ
biomedich-346	30	14	to	to	PART
biomedich-346	30	15	elicit	elicit	VERB
biomedich-346	30	16	an	an	DET
biomedich-346	30	17	immune	immune	ADJ
biomedich-346	30	18	response	response	NOUN
biomedich-346	30	19	,	,	PUNCT
biomedich-346	30	20	manuscript	manuscript	NOUN
biomedich-346	30	21	received	receive	VERB
biomedich-346	30	22	:	:	PUNCT
biomedich-346	30	23	16	16	NUM
biomedich-346	30	24	march	march	NOUN
biomedich-346	30	25	,	,	PUNCT
biomedich-346	30	26	2023	2023	NUM
biomedich-346	30	27	.	.	PUNCT
biomedich-346	31	1	revision	revision	NOUN
biomedich-346	31	2	accepted	accept	VERB
biomedich-346	31	3	:	:	PUNCT
biomedich-346	31	4	28	28	NUM
biomedich-346	31	5	march	march	NOUN
biomedich-346	31	6	,	,	PUNCT
biomedich-346	31	7	2023	2023	NUM
biomedich-346	31	8	.	.	PUNCT
biomedich-346	32	1	published	publish	VERB
biomedich-346	32	2	:	:	PUNCT
biomedich-346	32	3	21	21	NUM
biomedich-346	32	4	june	june	PROPN
biomedich-346	32	5	,	,	PUNCT
biomedich-346	32	6	2023	2023	NUM
biomedich-346	32	7	.	.	PUNCT
biomedich-346	33	1	https://doi.org/10.14421/biomedich.2023.121.343-361	https://doi.org/10.14421/biomedich.2023.121.343-361	NOUN
biomedich-346	33	2	344	344	NUM
biomedich-346	33	3	biology	biology	NOUN
biomedich-346	33	4	,	,	PUNCT
biomedich-346	33	5	medicine	medicine	NOUN
biomedich-346	33	6	,	,	PUNCT
biomedich-346	33	7	&	&	CCONJ
biomedich-346	33	8	natural	natural	ADJ
biomedich-346	33	9	product	product	NOUN
biomedich-346	33	10	chemistry	chemistry	NOUN
biomedich-346	33	11	12	12	NUM
biomedich-346	33	12	(	(	PUNCT
biomedich-346	33	13	1	1	NUM
biomedich-346	33	14	)	)	PUNCT
biomedich-346	33	15	,	,	PUNCT
biomedich-346	33	16	2023	2023	NUM
biomedich-346	33	17	:	:	PUNCT
biomedich-346	33	18	343	343	NUM
biomedich-346	33	19	-	-	SYM
biomedich-346	33	20	361	361	NUM
biomedich-346	33	21	nps	nps	PROPN
biomedich-346	33	22	based	base	VERB
biomedich-346	33	23	on	on	ADP
biomedich-346	33	24	organic	organic	ADJ
biomedich-346	33	25	and	and	CCONJ
biomedich-346	33	26	inorganic	inorganic	ADJ
biomedich-346	33	27	compositions	composition	NOUN
biomedich-346	33	28	have	have	AUX
biomedich-346	33	29	received	receive	VERB
biomedich-346	33	30	extensive	extensive	ADJ
biomedich-346	33	31	research	research	NOUN
biomedich-346	33	32	as	as	ADP
biomedich-346	33	33	innovative	innovative	ADJ
biomedich-346	33	34	vaccine	vaccine	NOUN
biomedich-346	33	35	approaches	approach	NOUN
biomedich-346	33	36	.	.	PUNCT
biomedich-346	34	1	nps	nps	PROPN
biomedich-346	34	2	can	can	AUX
biomedich-346	34	3	also	also	ADV
biomedich-346	34	4	create	create	VERB
biomedich-346	34	5	an	an	DET
biomedich-346	34	6	antigen	antigen	ADJ
biomedich-346	34	7	discharge	discharge	NOUN
biomedich-346	34	8	that	that	PRON
biomedich-346	34	9	is	be	AUX
biomedich-346	34	10	controlled	control	VERB
biomedich-346	34	11	and	and	CCONJ
biomedich-346	34	12	low	low	ADJ
biomedich-346	34	13	speed	speed	NOUN
biomedich-346	34	14	,	,	PUNCT
biomedich-346	34	15	creating	create	VERB
biomedich-346	34	16	a	a	DET
biomedich-346	34	17	depot	depot	NOUN
biomedich-346	34	18	at	at	ADP
biomedich-346	34	19	the	the	DET
biomedich-346	34	20	injection	injection	NOUN
biomedich-346	34	21	site	site	NOUN
biomedich-346	34	22	that	that	PRON
biomedich-346	34	23	offers	offer	VERB
biomedich-346	34	24	the	the	DET
biomedich-346	34	25	option	option	NOUN
biomedich-346	34	26	of	of	ADP
biomedich-346	34	27	antigen	antigen	ADJ
biomedich-346	34	28	preservation	preservation	NOUN
biomedich-346	34	29	over	over	ADP
biomedich-346	34	30	antigen	antigen	ADJ
biomedich-346	34	31	degradation	degradation	NOUN
biomedich-346	34	32	(	(	PUNCT
biomedich-346	34	33	de	de	X
biomedich-346	34	34	souza	souza	PROPN
biomedich-346	34	35	et	et	PROPN
biomedich-346	34	36	al	al	PROPN
biomedich-346	34	37	.	.	PROPN
biomedich-346	34	38	,2021	,2021	PROPN
biomedich-346	34	39	;	;	PUNCT
biomedich-346	34	40	abo	abo	NOUN
biomedich-346	34	41	-	-	PUNCT
biomedich-346	34	42	zeid	zeid	NOUN
biomedich-346	34	43	et	et	NOUN
biomedich-346	34	44	al	al	PROPN
biomedich-346	34	45	.	.	PROPN
biomedich-346	34	46	,	,	PUNCT
biomedich-346	34	47	2020	2020	NUM
biomedich-346	34	48	;	;	PUNCT
biomedich-346	34	49	chen	chen	PROPN
biomedich-346	34	50	and	and	CCONJ
biomedich-346	34	51	2020	2020	NUM
biomedich-346	34	52	;	;	PUNCT
biomedich-346	34	53	chen	chen	PROPN
biomedich-346	34	54	et	et	PROPN
biomedich-346	34	55	al	al	PROPN
biomedich-346	34	56	.	.	PROPN
biomedich-346	34	57	,	,	PUNCT
biomedich-346	34	58	2013	2013	NUM
biomedich-346	34	59	)	)	PUNCT
biomedich-346	34	60	.	.	PUNCT
biomedich-346	35	1	when	when	SCONJ
biomedich-346	35	2	compared	compare	VERB
biomedich-346	35	3	to	to	ADP
biomedich-346	35	4	conventional	conventional	ADJ
biomedich-346	35	5	vaccine	vaccine	NOUN
biomedich-346	35	6	techniques	technique	NOUN
biomedich-346	35	7	,	,	PUNCT
biomedich-346	35	8	nano	nano	NOUN
biomedich-346	35	9	carrier	carrier	NOUN
biomedich-346	35	10	-	-	PUNCT
biomedich-346	35	11	based	base	VERB
biomedich-346	35	12	delivery	delivery	NOUN
biomedich-346	35	13	systems	system	NOUN
biomedich-346	35	14	have	have	VERB
biomedich-346	35	15	a	a	DET
biomedich-346	35	16	number	number	NOUN
biomedich-346	35	17	of	of	ADP
biomedich-346	35	18	benefits	benefit	NOUN
biomedich-346	35	19	,	,	PUNCT
biomedich-346	35	20	including	include	VERB
biomedich-346	35	21	as	as	ADP
biomedich-346	35	22	greater	great	ADJ
biomedich-346	35	23	adjuvant	adjuvant	ADJ
biomedich-346	35	24	characteristics	characteristic	NOUN
biomedich-346	35	25	,	,	PUNCT
biomedich-346	35	26	superior	superior	ADJ
biomedich-346	35	27	stability	stability	NOUN
biomedich-346	35	28	,	,	PUNCT
biomedich-346	35	29	and	and	CCONJ
biomedich-346	35	30	increased	increase	VERB
biomedich-346	35	31	protection	protection	NOUN
biomedich-346	35	32	against	against	ADP
biomedich-346	35	33	premature	premature	ADJ
biomedich-346	35	34	degradation	degradation	NOUN
biomedich-346	35	35	.	.	PUNCT
biomedich-346	36	1	nanocarriers	nanocarrier	NOUN
biomedich-346	36	2	can	can	AUX
biomedich-346	36	3	shield	shield	VERB
biomedich-346	36	4	the	the	DET
biomedich-346	36	5	immunogen	immunogen	NOUN
biomedich-346	36	6	from	from	ADP
biomedich-346	36	7	early	early	ADJ
biomedich-346	36	8	proteolytic	proteolytic	ADJ
biomedich-346	36	9	degradation	degradation	NOUN
biomedich-346	36	10	,	,	PUNCT
biomedich-346	36	11	allowing	allow	VERB
biomedich-346	36	12	researchers	researcher	NOUN
biomedich-346	36	13	to	to	PART
biomedich-346	36	14	investigate	investigate	VERB
biomedich-346	36	15	alternative	alternative	ADJ
biomedich-346	36	16	delivery	delivery	NOUN
biomedich-346	36	17	methods	method	NOUN
biomedich-346	36	18	when	when	SCONJ
biomedich-346	36	19	utilized	utilize	VERB
biomedich-346	36	20	to	to	PART
biomedich-346	36	21	encapsulate	encapsulate	VERB
biomedich-346	36	22	or	or	CCONJ
biomedich-346	36	23	coat	coat	VERB
biomedich-346	36	24	the	the	DET
biomedich-346	36	25	surface	surface	NOUN
biomedich-346	36	26	of	of	ADP
biomedich-346	36	27	an	an	DET
biomedich-346	36	28	antigen	antigen	NOUN
biomedich-346	36	29	.	.	PUNCT
biomedich-346	37	1	nanocarriers	nanocarrier	NOUN
biomedich-346	37	2	can	can	AUX
biomedich-346	37	3	enhance	enhance	VERB
biomedich-346	37	4	the	the	DET
biomedich-346	37	5	specificity	specificity	NOUN
biomedich-346	37	6	of	of	ADP
biomedich-346	37	7	antigen	antigen	ADJ
biomedich-346	37	8	delivery	delivery	NOUN
biomedich-346	37	9	to	to	ADP
biomedich-346	37	10	apcs	apc	NOUN
biomedich-346	37	11	and	and	CCONJ
biomedich-346	37	12	lengthen	lengthen	VERB
biomedich-346	37	13	the	the	DET
biomedich-346	37	14	time	time	NOUN
biomedich-346	37	15	for	for	ADP
biomedich-346	37	16	antigen	antigen	ADJ
biomedich-346	37	17	presentation	presentation	NOUN
biomedich-346	37	18	to	to	ADP
biomedich-346	37	19	these	these	DET
biomedich-346	37	20	cells	cell	NOUN
biomedich-346	37	21	and	and	CCONJ
biomedich-346	37	22	other	other	ADJ
biomedich-346	37	23	crucial	crucial	ADJ
biomedich-346	37	24	immune	immune	ADJ
biomedich-346	37	25	cells	cell	NOUN
biomedich-346	37	26	essential	essential	ADJ
biomedich-346	37	27	for	for	ADP
biomedich-346	37	28	long	long	ADJ
biomedich-346	37	29	-	-	PUNCT
biomedich-346	37	30	term	term	NOUN
biomedich-346	37	31	immunity	immunity	NOUN
biomedich-346	37	32	in	in	ADP
biomedich-346	37	33	addition	addition	NOUN
biomedich-346	37	34	to	to	ADP
biomedich-346	37	35	their	their	PRON
biomedich-346	37	36	protective	protective	ADJ
biomedich-346	37	37	properties	property	NOUN
biomedich-346	37	38	.	.	PUNCT
biomedich-346	38	1	many	many	ADJ
biomedich-346	38	2	different	different	ADJ
biomedich-346	38	3	types	type	NOUN
biomedich-346	38	4	of	of	ADP
biomedich-346	38	5	nanoparticles	nanoparticle	NOUN
biomedich-346	38	6	,	,	PUNCT
biomedich-346	38	7	including	include	VERB
biomedich-346	38	8	inorganic	inorganic	ADJ
biomedich-346	38	9	and	and	CCONJ
biomedich-346	38	10	polymeric	polymeric	ADJ
biomedich-346	38	11	nanoparticles	nanoparticle	NOUN
biomedich-346	38	12	,	,	PUNCT
biomedich-346	38	13	virus	virus	NOUN
biomedich-346	38	14	-	-	PUNCT
biomedich-346	38	15	like	like	ADJ
biomedich-346	38	16	particles	particle	NOUN
biomedich-346	38	17	(	(	PUNCT
biomedich-346	38	18	vlps	vlps	PROPN
biomedich-346	38	19	)	)	PUNCT
biomedich-346	38	20	,	,	PUNCT
biomedich-346	38	21	liposomes	liposome	NOUN
biomedich-346	38	22	,	,	PUNCT
biomedich-346	38	23	and	and	CCONJ
biomedich-346	38	24	self	self	NOUN
biomedich-346	38	25	-	-	PUNCT
biomedich-346	38	26	assembled	assemble	VERB
biomedich-346	38	27	protein	protein	NOUN
biomedich-346	38	28	nanoparticles	nanoparticle	NOUN
biomedich-346	38	29	,	,	PUNCT
biomedich-346	38	30	have	have	AUX
biomedich-346	38	31	been	be	AUX
biomedich-346	38	32	investigated	investigate	VERB
biomedich-346	38	33	as	as	ADP
biomedich-346	38	34	potential	potential	ADJ
biomedich-346	38	35	antigen	antigen	ADJ
biomedich-346	38	36	carriers	carrier	NOUN
biomedich-346	38	37	for	for	ADP
biomedich-346	38	38	vaccines	vaccine	NOUN
biomedich-346	38	39	.	.	PUNCT
biomedich-346	39	1	viral	viral	ADJ
biomedich-346	39	2	antigens	antigen	NOUN
biomedich-346	39	3	have	have	AUX
biomedich-346	39	4	been	be	AUX
biomedich-346	39	5	effectively	effectively	ADV
biomedich-346	39	6	delivered	deliver	VERB
biomedich-346	39	7	using	use	VERB
biomedich-346	39	8	biocompatible	biocompatible	ADJ
biomedich-346	39	9	inorganic	inorganic	ADJ
biomedich-346	39	10	nanoparticles	nanoparticle	NOUN
biomedich-346	39	11	like	like	ADP
biomedich-346	39	12	gold	gold	NOUN
biomedich-346	39	13	,	,	PUNCT
biomedich-346	39	14	carbon	carbon	NOUN
biomedich-346	39	15	,	,	PUNCT
biomedich-346	39	16	and	and	CCONJ
biomedich-346	39	17	silica	silica	NOUN
biomedich-346	39	18	(	(	PUNCT
biomedich-346	39	19	choi	choi	NOUN
biomedich-346	39	20	et	et	PROPN
biomedich-346	39	21	al	al	PROPN
biomedich-346	39	22	.	.	PROPN
biomedich-346	39	23	,	,	PUNCT
biomedich-346	39	24	2021	2021	NUM
biomedich-346	39	25	;	;	PUNCT
biomedich-346	39	26	chen	chen	PROPN
biomedich-346	39	27	et	et	PROPN
biomedich-346	39	28	al	al	PROPN
biomedich-346	39	29	.	.	PROPN
biomedich-346	39	30	,	,	PUNCT
biomedich-346	39	31	2016	2016	NUM
biomedich-346	39	32	)	)	PUNCT
biomedich-346	39	33	.	.	PUNCT
biomedich-346	40	1	figure	figure	NOUN
biomedich-346	40	2	1	1	NUM
biomedich-346	40	3	.	.	PUNCT
biomedich-346	40	4	schematic	schematic	ADJ
biomedich-346	40	5	representation	representation	NOUN
biomedich-346	40	6	of	of	ADP
biomedich-346	40	7	different	different	ADJ
biomedich-346	40	8	types	type	NOUN
biomedich-346	40	9	of	of	ADP
biomedich-346	40	10	nanoparticles	nanoparticle	NOUN
biomedich-346	40	11	(	(	PUNCT
biomedich-346	40	12	nps	nps	PROPN
biomedich-346	40	13	)	)	PUNCT
biomedich-346	40	14	(	(	PUNCT
biomedich-346	40	15	heinz	heinz	PROPN
biomedich-346	40	16	et	et	PROPN
biomedich-346	40	17	al	al	PROPN
biomedich-346	40	18	.	.	PROPN
biomedich-346	40	19	,	,	PUNCT
biomedich-346	40	20	2017	2017	NUM
biomedich-346	40	21	)	)	PUNCT
biomedich-346	40	22	.	.	PUNCT
biomedich-346	41	1	materials	material	NOUN
biomedich-346	41	2	and	and	CCONJ
biomedich-346	41	3	methods	method	NOUN
biomedich-346	41	4	researchers	researcher	NOUN
biomedich-346	41	5	conduct	conduct	VERB
biomedich-346	41	6	an	an	DET
biomedich-346	41	7	examination	examination	NOUN
biomedich-346	41	8	of	of	ADP
biomedich-346	41	9	articles	article	NOUN
biomedich-346	41	10	that	that	PRON
biomedich-346	41	11	are	be	AUX
biomedich-346	41	12	in	in	ADP
biomedich-346	41	13	accordance	accordance	NOUN
biomedich-346	41	14	with	with	ADP
biomedich-346	41	15	the	the	DET
biomedich-346	41	16	issue	issue	NOUN
biomedich-346	41	17	to	to	PART
biomedich-346	41	18	be	be	AUX
biomedich-346	41	19	studied	study	VERB
biomedich-346	41	20	.	.	PUNCT
biomedich-346	42	1	determination	determination	NOUN
biomedich-346	42	2	of	of	ADP
biomedich-346	42	3	literature	literature	NOUN
biomedich-346	42	4	search	search	NOUN
biomedich-346	42	5	keywords	keyword	NOUN
biomedich-346	42	6	(	(	PUNCT
biomedich-346	42	7	search	search	NOUN
biomedich-346	42	8	string	string	NOUN
biomedich-346	42	9	based	base	VERB
biomedich-346	42	10	on	on	ADP
biomedich-346	42	11	pi	pi	NOUN
biomedich-346	42	12	(	(	PUNCT
biomedich-346	42	13	e	e	NOUN
biomedich-346	42	14	)	)	PUNCT
biomedich-346	42	15	cot	cot	NOUN
biomedich-346	42	16	framework	framework	NOUN
biomedich-346	42	17	(	(	PUNCT
biomedich-346	42	18	p	p	NOUN
biomedich-346	42	19	=	=	NOUN
biomedich-346	42	20	patient	patient	ADJ
biomedich-346	42	21	/	/	SYM
biomedich-346	42	22	problem	problem	NOUN
biomedich-346	42	23	;	;	PUNCT
biomedich-346	42	24	i	i	PRON
biomedich-346	42	25	/	/	SYM
biomedich-346	42	26	e	e	NOUN
biomedich-346	42	27	=	=	NOUN
biomedich-346	42	28	exposure	exposure	NOUN
biomedich-346	42	29	/	/	SYM
biomedich-346	42	30	implementation	implementation	NOUN
biomedich-346	42	31	;	;	PUNCT
biomedich-346	42	32	c=	c=	NOUN
biomedich-346	42	33	control	control	NOUN
biomedich-346	42	34	/	/	SYM
biomedich-346	42	35	comparison	comparison	NOUN
biomedich-346	42	36	intervention	intervention	NOUN
biomedich-346	42	37	,	,	PUNCT
biomedich-346	42	38	o	o	NOUN
biomedich-346	42	39	=	=	NOUN
biomedich-346	42	40	outcome	outcome	NOUN
biomedich-346	42	41	,	,	PUNCT
biomedich-346	42	42	t	t	NOUN
biomedich-346	42	43	=	=	PUNCT
biomedich-346	42	44	time	time	NOUN
biomedich-346	42	45	)	)	PUNCT
biomedich-346	42	46	because	because	SCONJ
biomedich-346	42	47	a	a	DET
biomedich-346	42	48	good	good	ADJ
biomedich-346	42	49	question	question	NOUN
biomedich-346	42	50	will	will	AUX
biomedich-346	42	51	help	help	VERB
biomedich-346	42	52	determine	determine	VERB
biomedich-346	42	53	the	the	DET
biomedich-346	42	54	scope	scope	NOUN
biomedich-346	42	55	of	of	ADP
biomedich-346	42	56	the	the	DET
biomedich-346	42	57	review	review	NOUN
biomedich-346	42	58	and	and	CCONJ
biomedich-346	42	59	help	help	VERB
biomedich-346	42	60	the	the	DET
biomedich-346	42	61	strategy	strategy	NOUN
biomedich-346	42	62	of	of	ADP
biomedich-346	42	63	finding	find	VERB
biomedich-346	42	64	the	the	DET
biomedich-346	42	65	article	article	NOUN
biomedich-346	42	66	.	.	PUNCT
biomedich-346	43	1	articles	article	NOUN
biomedich-346	43	2	used	use	VERB
biomedich-346	43	3	in	in	ADP
biomedich-346	43	4	the	the	DET
biomedich-346	43	5	literature	literature	NOUN
biomedich-346	43	6	review	review	NOUN
biomedich-346	43	7	are	be	AUX
biomedich-346	43	8	obtained	obtain	VERB
biomedich-346	43	9	through	through	ADP
biomedich-346	43	10	the	the	DET
biomedich-346	43	11	database	database	NOUN
biomedich-346	43	12	of	of	ADP
biomedich-346	43	13	international	international	ADJ
biomedich-346	43	14	journal	journal	NOUN
biomedich-346	43	15	providers	provider	NOUN
biomedich-346	43	16	through	through	ADP
biomedich-346	43	17	pubmed	pubmed	PROPN
biomedich-346	43	18	,	,	PUNCT
biomedich-346	43	19	from	from	ADP
biomedich-346	43	20	2021	2021	NUM
biomedich-346	43	21	-	-	SYM
biomedich-346	43	22	2023	2023	NUM
biomedich-346	43	23	,	,	PUNCT
biomedich-346	43	24	clinical	clinical	ADJ
biomedich-346	43	25	trials	trial	NOUN
biomedich-346	43	26	only	only	ADV
biomedich-346	43	27	.	.	PUNCT
biomedich-346	44	1	the	the	DET
biomedich-346	44	2	author	author	NOUN
biomedich-346	44	3	opens	open	VERB
biomedich-346	44	4	www.pubmed.com	www.pubmed.com	X
biomedich-346	44	5	.	.	PUNCT
biomedich-346	45	1	researchers	researcher	NOUN
biomedich-346	45	2	wrote	write	VERB
biomedich-346	45	3	keywords	keyword	NOUN
biomedich-346	45	4	according	accord	VERB
biomedich-346	45	5	to	to	ADP
biomedich-346	45	6	mesh	mesh	NOUN
biomedich-346	45	7	(	(	PUNCT
biomedich-346	45	8	medical	medical	ADJ
biomedich-346	45	9	subject	subject	ADJ
biomedich-346	45	10	heading	heading	NOUN
biomedich-346	45	11	)	)	PUNCT
biomedich-346	45	12	namely	namely	ADV
biomedich-346	45	13	“	"	PUNCT
biomedich-346	45	14	nanoparticle	nanoparticle	NOUN
biomedich-346	45	15	vaccine	vaccine	NOUN
biomedich-346	45	16	”	"	PUNCT
biomedich-346	45	17	and	and	CCONJ
biomedich-346	45	18	selected	select	VERB
biomedich-346	45	19	full	full	ADJ
biomedich-346	45	20	text	text	NOUN
biomedich-346	45	21	.	.	PUNCT
biomedich-346	46	1	1	1	X
biomedich-346	46	2	.	.	X
biomedich-346	46	3	inclusion	inclusion	NOUN
biomedich-346	46	4	criteria	criterion	NOUN
biomedich-346	46	5	population	population	NOUN
biomedich-346	46	6	or	or	CCONJ
biomedich-346	46	7	sample	sample	NOUN
biomedich-346	46	8	is	be	AUX
biomedich-346	46	9	(	(	PUNCT
biomedich-346	46	10	nanoparticle	nanoparticle	NOUN
biomedich-346	46	11	-	-	PUNCT
biomedich-346	46	12	based	base	VERB
biomedich-346	46	13	vaccines	vaccine	NOUN
biomedich-346	46	14	)	)	PUNCT
biomedich-346	46	15	.	.	PUNCT
biomedich-346	47	1	2	2	X
biomedich-346	47	2	.	.	X
biomedich-346	47	3	exclusion	exclusion	NOUN
biomedich-346	47	4	criteria	criterion	NOUN
biomedich-346	47	5	population	population	NOUN
biomedich-346	47	6	or	or	CCONJ
biomedich-346	47	7	sample	sample	NOUN
biomedich-346	47	8	other	other	ADJ
biomedich-346	47	9	(	(	PUNCT
biomedich-346	47	10	nanoparticle	nanoparticle	NOUN
biomedich-346	47	11	-	-	PUNCT
biomedich-346	47	12	based	base	VERB
biomedich-346	47	13	vaccines	vaccine	NOUN
biomedich-346	47	14	)	)	PUNCT
biomedich-346	47	15	.	.	PUNCT
biomedich-346	48	1	results	result	NOUN
biomedich-346	48	2	and	and	CCONJ
biomedich-346	48	3	discussion	discussion	NOUN
biomedich-346	48	4	table	table	NOUN
biomedich-346	48	5	1	1	NUM
biomedich-346	48	6	.	.	PUNCT
biomedich-346	49	1	(	(	PUNCT
biomedich-346	49	2	alimehmeti	alimehmeti	NOUN
biomedich-346	49	3	,	,	PUNCT
biomedich-346	49	4	2021	2021	NUM
biomedich-346	49	5	)	)	PUNCT
biomedich-346	49	6	,	,	PUNCT
biomedich-346	49	7	found	find	VERB
biomedich-346	49	8	that	that	SCONJ
biomedich-346	49	9	severe	severe	ADJ
biomedich-346	49	10	covid-19	covid-19	PROPN
biomedich-346	49	11	occurred	occur	VERB
biomedich-346	49	12	in	in	ADP
biomedich-346	49	13	30	30	NUM
biomedich-346	49	14	participants	participant	NOUN
biomedich-346	49	15	,	,	PUNCT
biomedich-346	49	16	with	with	ADP
biomedich-346	49	17	one	one	NUM
biomedich-346	49	18	fatality	fatality	NOUN
biomedich-346	49	19	;	;	PUNCT
biomedich-346	49	20	all	all	DET
biomedich-346	49	21	30	30	NUM
biomedich-346	49	22	were	be	AUX
biomedich-346	49	23	in	in	ADP
biomedich-346	49	24	the	the	DET
biomedich-346	49	25	placebo	placebo	NOUN
biomedich-346	49	26	group	group	NOUN
biomedich-346	49	27	.	.	PUNCT
biomedich-346	50	1	moderate	moderate	ADJ
biomedich-346	50	2	,	,	PUNCT
biomedich-346	50	3	transient	transient	ADJ
biomedich-346	50	4	reactogenicity	reactogenicity	NOUN
biomedich-346	50	5	after	after	ADP
biomedich-346	50	6	vaccination	vaccination	NOUN
biomedich-346	50	7	occurred	occur	VERB
biomedich-346	50	8	more	more	ADV
biomedich-346	50	9	frequently	frequently	ADV
biomedich-346	50	10	in	in	ADP
biomedich-346	50	11	the	the	DET
biomedich-346	50	12	mrna1273	mrna1273	PROPN
biomedich-346	50	13	group	group	NOUN
biomedich-346	50	14	.	.	PUNCT
biomedich-346	51	1	serious	serious	ADJ
biomedich-346	51	2	adverse	adverse	ADJ
biomedich-346	51	3	events	event	NOUN
biomedich-346	51	4	were	be	AUX
biomedich-346	51	5	rare	rare	ADJ
biomedich-346	51	6	,	,	PUNCT
biomedich-346	51	7	and	and	CCONJ
biomedich-346	51	8	the	the	DET
biomedich-346	51	9	incidence	incidence	NOUN
biomedich-346	51	10	was	be	AUX
biomedich-346	51	11	similar	similar	ADJ
biomedich-346	51	12	in	in	ADP
biomedich-346	51	13	the	the	DET
biomedich-346	51	14	two	two	NUM
biomedich-346	51	15	groups	group	NOUN
biomedich-346	51	16	.	.	PUNCT
biomedich-346	52	1	thomas	thomas	PROPN
biomedich-346	52	2	et	et	PROPN
biomedich-346	52	3	al	al	PROPN
biomedich-346	52	4	.	.	PROPN
biomedich-346	52	5	,	,	PUNCT
biomedich-346	52	6	2021	2021	NUM
biomedich-346	52	7	,	,	PUNCT
biomedich-346	52	8	found	find	VERB
biomedich-346	52	9	that	that	SCONJ
biomedich-346	52	10	vaccine	vaccine	NOUN
biomedich-346	52	11	efficacy	efficacy	NOUN
biomedich-346	52	12	of	of	ADP
biomedich-346	52	13	86	86	NUM
biomedich-346	52	14	to	to	PART
biomedich-346	52	15	100	100	NUM
biomedich-346	52	16	%	%	NOUN
biomedich-346	52	17	was	be	AUX
biomedich-346	52	18	seen	see	VERB
biomedich-346	52	19	across	across	ADP
biomedich-346	52	20	countries	country	NOUN
biomedich-346	52	21	and	and	CCONJ
biomedich-346	52	22	in	in	ADP
biomedich-346	52	23	populations	population	NOUN
biomedich-346	52	24	with	with	ADP
biomedich-346	52	25	diverse	diverse	ADJ
biomedich-346	52	26	ages	age	NOUN
biomedich-346	52	27	,	,	PUNCT
biomedich-346	52	28	sexes	sex	NOUN
biomedich-346	52	29	,	,	PUNCT
biomedich-346	52	30	races	race	NOUN
biomedich-346	52	31	,	,	PUNCT
biomedich-346	52	32	or	or	CCONJ
biomedich-346	52	33	ethnic	ethnic	ADJ
biomedich-346	52	34	groups	group	NOUN
biomedich-346	52	35	,	,	PUNCT
biomedich-346	52	36	and	and	CCONJ
biomedich-346	52	37	risk	risk	NOUN
biomedich-346	52	38	factors	factor	NOUN
biomedich-346	52	39	for	for	ADP
biomedich-346	52	40	covid-19	covid-19	PROPN
biomedich-346	52	41	among	among	ADP
biomedich-346	52	42	participants	participant	NOUN
biomedich-346	52	43	without	without	ADP
biomedich-346	52	44	evidence	evidence	NOUN
biomedich-346	52	45	of	of	ADP
biomedich-346	52	46	previous	previous	ADJ
biomedich-346	52	47	infection	infection	NOUN
biomedich-346	52	48	with	with	ADP
biomedich-346	52	49	sars	sar	NOUN
biomedich-346	52	50	-	-	PUNCT
biomedich-346	52	51	cov-2	cov-2	NOUN
biomedich-346	52	52	.	.	PUNCT
biomedich-346	52	53	vaccine	vaccine	NOUN
biomedich-346	52	54	efficacy	efficacy	NOUN
biomedich-346	52	55	against	against	ADP
biomedich-346	52	56	the	the	DET
biomedich-346	52	57	severe	severe	ADJ
biomedich-346	52	58	disease	disease	NOUN
biomedich-346	52	59	was	be	AUX
biomedich-346	52	60	96.7	96.7	NUM
biomedich-346	52	61	%	%	NOUN
biomedich-346	52	62	(	(	PUNCT
biomedich-346	52	63	95	95	NUM
biomedich-346	52	64	%	%	NOUN
biomedich-346	52	65	ci	ci	NOUN
biomedich-346	52	66	,	,	PUNCT
biomedich-346	52	67	80.3	80.3	NUM
biomedich-346	52	68	to	to	ADP
biomedich-346	52	69	hussein	hussein	PROPN
biomedich-346	52	70	et	et	PROPN
biomedich-346	52	71	al	al	PROPN
biomedich-346	52	72	.	.	PROPN
biomedich-346	52	73	–	–	PUNCT
biomedich-346	52	74	nanotechnology	nanotechnology	NOUN
biomedich-346	52	75	-	-	PUNCT
biomedich-346	52	76	based	base	VERB
biomedich-346	52	77	vaccines	vaccine	NOUN
biomedich-346	52	78	345	345	NUM
biomedich-346	52	79	99.9	99.9	NUM
biomedich-346	52	80	)	)	PUNCT
biomedich-346	52	81	.	.	PUNCT
biomedich-346	53	1	in	in	ADP
biomedich-346	53	2	south	south	PROPN
biomedich-346	53	3	africa	africa	PROPN
biomedich-346	53	4	,	,	PUNCT
biomedich-346	53	5	where	where	SCONJ
biomedich-346	53	6	the	the	DET
biomedich-346	53	7	sars	sar	NOUN
biomedich-346	53	8	-	-	PUNCT
biomedich-346	53	9	cov-2	cov-2	NOUN
biomedich-346	53	10	variant	variant	NOUN
biomedich-346	53	11	of	of	ADP
biomedich-346	53	12	concern	concern	NOUN
biomedich-346	53	13	b.1.351	b.1.351	NOUN
biomedich-346	53	14	(	(	PUNCT
biomedich-346	53	15	or	or	CCONJ
biomedich-346	53	16	beta	beta	NOUN
biomedich-346	53	17	)	)	PUNCT
biomedich-346	53	18	was	be	AUX
biomedich-346	53	19	predominant	predominant	ADJ
biomedich-346	53	20	,	,	PUNCT
biomedich-346	53	21	a	a	DET
biomedich-346	53	22	vaccine	vaccine	NOUN
biomedich-346	53	23	efficacy	efficacy	NOUN
biomedich-346	53	24	of	of	ADP
biomedich-346	53	25	100	100	NUM
biomedich-346	53	26	%	%	NOUN
biomedich-346	53	27	(	(	PUNCT
biomedich-346	53	28	95	95	NUM
biomedich-346	53	29	%	%	NOUN
biomedich-346	53	30	ci	ci	NOUN
biomedich-346	53	31	,	,	PUNCT
biomedich-346	53	32	53.5	53.5	NUM
biomedich-346	53	33	to	to	PART
biomedich-346	53	34	100	100	NUM
biomedich-346	53	35	)	)	PUNCT
biomedich-346	53	36	was	be	AUX
biomedich-346	53	37	observed	observe	VERB
biomedich-346	53	38	.	.	PUNCT
biomedich-346	54	1	heath	heath	PROPN
biomedich-346	54	2	et	et	PROPN
biomedich-346	54	3	al	al	PROPN
biomedich-346	54	4	.	.	PROPN
biomedich-346	54	5	,	,	PUNCT
biomedich-346	54	6	2021	2021	NUM
biomedich-346	54	7	,	,	PUNCT
biomedich-346	54	8	found	find	VERB
biomedich-346	54	9	that	that	SCONJ
biomedich-346	54	10	a	a	DET
biomedich-346	54	11	post	post	X
biomedich-346	54	12	hoc	hoc	X
biomedich-346	54	13	analysis	analysis	NOUN
biomedich-346	54	14	showed	show	VERB
biomedich-346	54	15	an	an	DET
biomedich-346	54	16	efficacy	efficacy	NOUN
biomedich-346	54	17	of	of	ADP
biomedich-346	54	18	86.3	86.3	NUM
biomedich-346	54	19	%	%	NOUN
biomedich-346	54	20	(	(	PUNCT
biomedich-346	54	21	95	95	NUM
biomedich-346	54	22	%	%	NOUN
biomedich-346	54	23	ci	ci	NOUN
biomedich-346	54	24	,	,	PUNCT
biomedich-346	54	25	71.3	71.3	NUM
biomedich-346	54	26	to	to	ADP
biomedich-346	54	27	93.5	93.5	NUM
biomedich-346	54	28	)	)	PUNCT
biomedich-346	54	29	against	against	ADP
biomedich-346	54	30	the	the	DET
biomedich-346	54	31	b.1.1.7	b.1.1.7	PROPN
biomedich-346	54	32	(	(	PUNCT
biomedich-346	54	33	or	or	CCONJ
biomedich-346	54	34	alpha	alpha	NOUN
biomedich-346	54	35	)	)	PUNCT
biomedich-346	54	36	variant	variant	NOUN
biomedich-346	54	37	and	and	CCONJ
biomedich-346	54	38	96.4	96.4	NUM
biomedich-346	54	39	%	%	NOUN
biomedich-346	54	40	(	(	PUNCT
biomedich-346	54	41	95	95	NUM
biomedich-346	54	42	%	%	NOUN
biomedich-346	54	43	ci	ci	NOUN
biomedich-346	54	44	,	,	PUNCT
biomedich-346	54	45	73.8	73.8	NUM
biomedich-346	54	46	to	to	PART
biomedich-346	54	47	99.5	99.5	NUM
biomedich-346	54	48	)	)	PUNCT
biomedich-346	54	49	against	against	ADP
biomedich-346	54	50	non	non	ADJ
biomedich-346	54	51	-	-	ADJ
biomedich-346	54	52	b.1.1.7	b.1.1.7	ADJ
biomedich-346	54	53	variants	variant	NOUN
biomedich-346	54	54	.	.	PUNCT
biomedich-346	55	1	reactogenicity	reactogenicity	NOUN
biomedich-346	55	2	was	be	AUX
biomedich-346	55	3	generally	generally	ADV
biomedich-346	55	4	mild	mild	ADJ
biomedich-346	55	5	and	and	CCONJ
biomedich-346	55	6	transient	transient	ADJ
biomedich-346	55	7	.	.	PUNCT
biomedich-346	56	1	the	the	DET
biomedich-346	56	2	incidence	incidence	NOUN
biomedich-346	56	3	of	of	ADP
biomedich-346	56	4	serious	serious	ADJ
biomedich-346	56	5	adverse	adverse	ADJ
biomedich-346	56	6	events	event	NOUN
biomedich-346	56	7	was	be	AUX
biomedich-346	56	8	low	low	ADJ
biomedich-346	56	9	and	and	CCONJ
biomedich-346	56	10	similar	similar	ADJ
biomedich-346	56	11	in	in	ADP
biomedich-346	56	12	the	the	DET
biomedich-346	56	13	two	two	NUM
biomedich-346	56	14	groups	group	NOUN
biomedich-346	56	15	.	.	PUNCT
biomedich-346	57	1	houser	houser	PROPN
biomedich-346	57	2	et	et	PROPN
biomedich-346	57	3	al	al	PROPN
biomedich-346	57	4	.	.	PROPN
biomedich-346	57	5	,	,	PUNCT
biomedich-346	57	6	2022	2022	NUM
biomedich-346	57	7	,	,	PUNCT
biomedich-346	57	8	found	find	VERB
biomedich-346	57	9	that	that	SCONJ
biomedich-346	57	10	exploratory	exploratory	ADJ
biomedich-346	57	11	analyses	analysis	NOUN
biomedich-346	57	12	identified	identify	VERB
biomedich-346	57	13	neutralizing	neutralize	VERB
biomedich-346	57	14	antibody	antibody	NOUN
biomedich-346	57	15	responses	response	NOUN
biomedich-346	57	16	elicited	elicit	VERB
biomedich-346	57	17	by	by	ADP
biomedich-346	57	18	the	the	DET
biomedich-346	57	19	h2ha	h2ha	NOUN
biomedich-346	57	20	-	-	PUNCT
biomedich-346	57	21	ferritin	ferritin	ADJ
biomedich-346	57	22	vaccine	vaccine	NOUN
biomedich-346	57	23	in	in	ADP
biomedich-346	57	24	both	both	DET
biomedich-346	57	25	h2	h2	NOUN
biomedich-346	57	26	-	-	PUNCT
biomedich-346	57	27	naive	naive	ADJ
biomedich-346	57	28	and	and	CCONJ
biomedich-346	57	29	h2exposed	h2expose	VERB
biomedich-346	57	30	populations	population	NOUN
biomedich-346	57	31	.	.	PUNCT
biomedich-346	58	1	furthermore	furthermore	ADV
biomedich-346	58	2	,	,	PUNCT
biomedich-346	58	3	broadly	broadly	ADV
biomedich-346	58	4	neutralizing	neutralize	VERB
biomedich-346	58	5	antibody	antibody	NOUN
biomedich-346	58	6	responses	response	NOUN
biomedich-346	58	7	against	against	ADP
biomedich-346	58	8	group	group	NOUN
biomedich-346	58	9	1	1	NUM
biomedich-346	58	10	influenza	influenza	NOUN
biomedich-346	58	11	viruses	virus	NOUN
biomedich-346	58	12	,	,	PUNCT
biomedich-346	58	13	including	include	VERB
biomedich-346	58	14	both	both	CCONJ
biomedich-346	58	15	seasonal	seasonal	ADJ
biomedich-346	58	16	h1	h1	NOUN
biomedich-346	58	17	and	and	CCONJ
biomedich-346	58	18	avian	avian	ADJ
biomedich-346	58	19	h5	h5	NOUN
biomedich-346	58	20	subtypes	subtype	NOUN
biomedich-346	58	21	,	,	PUNCT
biomedich-346	58	22	were	be	AUX
biomedich-346	58	23	induced	induce	VERB
biomedich-346	58	24	in	in	ADP
biomedich-346	58	25	the	the	DET
biomedich-346	58	26	h2	h2	NOUN
biomedich-346	58	27	-	-	PUNCT
biomedich-346	58	28	naive	naive	ADJ
biomedich-346	58	29	population	population	NOUN
biomedich-346	58	30	by	by	ADP
biomedich-346	58	31	targeting	target	VERB
biomedich-346	58	32	the	the	DET
biomedich-346	58	33	ha	ha	NOUN
biomedich-346	58	34	stem	stem	NOUN
biomedich-346	58	35	.	.	PUNCT
biomedich-346	59	1	this	this	DET
biomedich-346	59	2	ferritin	ferritin	ADJ
biomedich-346	59	3	nanoparticle	nanoparticle	NOUN
biomedich-346	59	4	vaccine	vaccine	NOUN
biomedich-346	59	5	technology	technology	NOUN
biomedich-346	59	6	represents	represent	VERB
biomedich-346	59	7	a	a	DET
biomedich-346	59	8	novel	novel	NOUN
biomedich-346	59	9	,	,	PUNCT
biomedich-346	59	10	safe	safe	ADJ
biomedich-346	59	11	and	and	CCONJ
biomedich-346	59	12	immunogenic	immunogenic	ADJ
biomedich-346	59	13	platform	platform	NOUN
biomedich-346	59	14	with	with	ADP
biomedich-346	59	15	potential	potential	ADJ
biomedich-346	59	16	application	application	NOUN
biomedich-346	59	17	for	for	ADP
biomedich-346	59	18	pandemic	pandemic	ADJ
biomedich-346	59	19	preparedness	preparedness	NOUN
biomedich-346	59	20	and	and	CCONJ
biomedich-346	59	21	universal	universal	ADJ
biomedich-346	59	22	influenza	influenza	ADJ
biomedich-346	59	23	vaccine	vaccine	NOUN
biomedich-346	59	24	development	development	NOUN
biomedich-346	59	25	.	.	PUNCT
biomedich-346	60	1	shinde	shinde	PROPN
biomedich-346	60	2	et	et	PROPN
biomedich-346	60	3	al	al	PROPN
biomedich-346	60	4	.	.	PROPN
biomedich-346	60	5	,	,	PUNCT
biomedich-346	60	6	2021	2021	NUM
biomedich-346	60	7	,	,	PUNCT
biomedich-346	60	8	found	find	VERB
biomedich-346	60	9	that	that	SCONJ
biomedich-346	60	10	of	of	ADP
biomedich-346	60	11	41	41	NUM
biomedich-346	60	12	sequenced	sequence	VERB
biomedich-346	60	13	isolates	isolate	NOUN
biomedich-346	60	14	,	,	PUNCT
biomedich-346	60	15	38	38	NUM
biomedich-346	60	16	(	(	PUNCT
biomedich-346	60	17	92.7	92.7	NUM
biomedich-346	60	18	%	%	NOUN
biomedich-346	60	19	)	)	PUNCT
biomedich-346	60	20	were	be	AUX
biomedich-346	60	21	the	the	DET
biomedich-346	60	22	b.1.351	b.1.351	NOUN
biomedich-346	60	23	variant	variant	NOUN
biomedich-346	60	24	.	.	PUNCT
biomedich-346	61	1	post	post	VERB
biomedich-346	61	2	hoc	hoc	X
biomedich-346	61	3	vaccine	vaccine	NOUN
biomedich-346	61	4	efficacy	efficacy	NOUN
biomedich-346	61	5	against	against	ADP
biomedich-346	61	6	b.1.351	b.1.351	NOUN
biomedich-346	61	7	was	be	AUX
biomedich-346	61	8	51.0	51.0	NUM
biomedich-346	61	9	%	%	NOUN
biomedich-346	61	10	(	(	PUNCT
biomedich-346	61	11	95	95	NUM
biomedich-346	61	12	%	%	NOUN
biomedich-346	61	13	ci	ci	NOUN
biomedich-346	61	14	,	,	PUNCT
biomedich-346	61	15	-0.6	-0.6	NOUN
biomedich-346	61	16	to	to	ADP
biomedich-346	61	17	76.2	76.2	NUM
biomedich-346	61	18	)	)	PUNCT
biomedich-346	61	19	among	among	ADP
biomedich-346	61	20	the	the	DET
biomedich-346	61	21	hiv	hiv	PROPN
biomedich-346	61	22	-	-	PUNCT
biomedich-346	61	23	negative	negative	ADJ
biomedich-346	61	24	participants	participant	NOUN
biomedich-346	61	25	.	.	PUNCT
biomedich-346	62	1	preliminary	preliminary	ADJ
biomedich-346	62	2	local	local	ADJ
biomedich-346	62	3	and	and	CCONJ
biomedich-346	62	4	systemic	systemic	ADJ
biomedich-346	62	5	reactogenicity	reactogenicity	NOUN
biomedich-346	62	6	events	event	NOUN
biomedich-346	62	7	were	be	AUX
biomedich-346	62	8	more	more	ADV
biomedich-346	62	9	common	common	ADJ
biomedich-346	62	10	in	in	ADP
biomedich-346	62	11	the	the	DET
biomedich-346	62	12	vaccine	vaccine	NOUN
biomedich-346	62	13	group	group	NOUN
biomedich-346	62	14	;	;	PUNCT
biomedich-346	62	15	serious	serious	ADJ
biomedich-346	62	16	adverse	adverse	ADJ
biomedich-346	62	17	events	event	NOUN
biomedich-346	62	18	were	be	AUX
biomedich-346	62	19	rare	rare	ADJ
biomedich-346	62	20	in	in	ADP
biomedich-346	62	21	both	both	DET
biomedich-346	62	22	groups	group	NOUN
biomedich-346	62	23	.	.	PUNCT
biomedich-346	63	1	dunkle	dunkle	PROPN
biomedich-346	63	2	et	et	PROPN
biomedich-346	63	3	al	al	PROPN
biomedich-346	63	4	.	.	PROPN
biomedich-346	63	5	,	,	PUNCT
biomedich-346	63	6	2022	2022	NUM
biomedich-346	63	7	,	,	PUNCT
biomedich-346	63	8	found	find	VERB
biomedich-346	63	9	that	that	SCONJ
biomedich-346	63	10	ten	ten	NUM
biomedich-346	63	11	moderate	moderate	ADJ
biomedich-346	63	12	and	and	CCONJ
biomedich-346	63	13	4	4	NUM
biomedich-346	63	14	severe	severe	ADJ
biomedich-346	63	15	cases	case	NOUN
biomedich-346	63	16	occurred	occur	VERB
biomedich-346	63	17	,	,	PUNCT
biomedich-346	63	18	all	all	PRON
biomedich-346	63	19	in	in	ADP
biomedich-346	63	20	placebo	placebo	NOUN
biomedich-346	63	21	recipients	recipient	NOUN
biomedich-346	63	22	,	,	PUNCT
biomedich-346	63	23	yielding	yield	VERB
biomedich-346	63	24	vaccine	vaccine	NOUN
biomedich-346	63	25	efficacy	efficacy	NOUN
biomedich-346	63	26	against	against	ADP
biomedich-346	63	27	the	the	DET
biomedich-346	63	28	moderate	moderate	ADJ
biomedich-346	63	29	-	-	PUNCT
biomedich-346	63	30	to	to	ADP
biomedich-346	63	31	-	-	PUNCT
biomedich-346	63	32	severe	severe	ADJ
biomedich-346	63	33	disease	disease	NOUN
biomedich-346	63	34	of	of	ADP
biomedich-346	63	35	100	100	NUM
biomedich-346	63	36	%	%	NOUN
biomedich-346	63	37	(	(	PUNCT
biomedich-346	63	38	95	95	NUM
biomedich-346	63	39	%	%	NOUN
biomedich-346	63	40	ci	ci	NOUN
biomedich-346	63	41	,	,	PUNCT
biomedich-346	63	42	87.0	87.0	NUM
biomedich-346	63	43	to	to	PART
biomedich-346	63	44	100	100	NUM
biomedich-346	63	45	)	)	PUNCT
biomedich-346	63	46	.	.	PUNCT
biomedich-346	64	1	most	most	ADV
biomedich-346	64	2	sequenced	sequence	VERB
biomedich-346	64	3	viral	viral	ADJ
biomedich-346	64	4	genomes	genome	NOUN
biomedich-346	64	5	(	(	PUNCT
biomedich-346	64	6	48	48	NUM
biomedich-346	64	7	of	of	ADP
biomedich-346	64	8	61	61	NUM
biomedich-346	64	9	,	,	PUNCT
biomedich-346	64	10	79	79	NUM
biomedich-346	64	11	%	%	NOUN
biomedich-346	64	12	)	)	PUNCT
biomedich-346	64	13	were	be	AUX
biomedich-346	64	14	variants	variant	NOUN
biomedich-346	64	15	of	of	ADP
biomedich-346	64	16	concern	concern	NOUN
biomedich-346	64	17	or	or	CCONJ
biomedich-346	64	18	interest	interest	NOUN
biomedich-346	64	19	largely	largely	ADV
biomedich-346	64	20	b.1.1.7	b.1.1.7	CCONJ
biomedich-346	64	21	(	(	PUNCT
biomedich-346	64	22	alpha	alpha	NOUN
biomedich-346	64	23	)	)	PUNCT
biomedich-346	64	24	(	(	PUNCT
biomedich-346	64	25	31	31	NUM
biomedich-346	64	26	of	of	ADP
biomedich-346	64	27	the	the	DET
biomedich-346	64	28	35	35	NUM
biomedich-346	64	29	genomes	genome	NOUN
biomedich-346	64	30	for	for	ADP
biomedich-346	64	31	variants	variant	NOUN
biomedich-346	64	32	of	of	ADP
biomedich-346	64	33	concern	concern	NOUN
biomedich-346	64	34	,	,	PUNCT
biomedich-346	64	35	89	89	NUM
biomedich-346	64	36	%	%	NOUN
biomedich-346	64	37	)	)	PUNCT
biomedich-346	64	38	.	.	PUNCT
biomedich-346	65	1	vaccine	vaccine	NOUN
biomedich-346	65	2	efficacy	efficacy	NOUN
biomedich-346	65	3	against	against	ADP
biomedich-346	65	4	any	any	DET
biomedich-346	65	5	variant	variant	NOUN
biomedich-346	65	6	of	of	ADP
biomedich-346	65	7	concern	concern	NOUN
biomedich-346	65	8	or	or	CCONJ
biomedich-346	65	9	interest	interest	NOUN
biomedich-346	65	10	was	be	AUX
biomedich-346	65	11	92.6	92.6	NUM
biomedich-346	65	12	%	%	NOUN
biomedich-346	65	13	(	(	PUNCT
biomedich-346	65	14	95	95	NUM
biomedich-346	65	15	%	%	NOUN
biomedich-346	65	16	ci	ci	NOUN
biomedich-346	65	17	,	,	PUNCT
biomedich-346	65	18	83.6	83.6	NUM
biomedich-346	65	19	to	to	ADP
biomedich-346	65	20	96.7	96.7	NUM
biomedich-346	65	21	)	)	PUNCT
biomedich-346	65	22	.	.	PUNCT
biomedich-346	66	1	reactogenicity	reactogenicity	NOUN
biomedich-346	66	2	was	be	AUX
biomedich-346	66	3	mostly	mostly	ADV
biomedich-346	66	4	mild	mild	ADJ
biomedich-346	66	5	to	to	AUX
biomedich-346	66	6	moderate	moderate	ADJ
biomedich-346	66	7	and	and	CCONJ
biomedich-346	66	8	transient	transient	ADJ
biomedich-346	66	9	but	but	CCONJ
biomedich-346	66	10	was	be	AUX
biomedich-346	66	11	more	more	ADV
biomedich-346	66	12	frequent	frequent	ADJ
biomedich-346	66	13	among	among	ADP
biomedich-346	66	14	nvx	nvx	NOUN
biomedich-346	66	15	-	-	PUNCT
biomedich-346	66	16	cov2373	cov2373	NOUN
biomedich-346	66	17	recipients	recipient	NOUN
biomedich-346	66	18	than	than	ADP
biomedich-346	66	19	among	among	ADP
biomedich-346	66	20	placebo	placebo	NOUN
biomedich-346	66	21	recipients	recipient	NOUN
biomedich-346	66	22	and	and	CCONJ
biomedich-346	66	23	was	be	AUX
biomedich-346	66	24	more	more	ADV
biomedich-346	66	25	frequent	frequent	ADJ
biomedich-346	66	26	after	after	ADP
biomedich-346	66	27	the	the	DET
biomedich-346	66	28	second	second	ADJ
biomedich-346	66	29	dose	dose	NOUN
biomedich-346	66	30	than	than	ADP
biomedich-346	66	31	after	after	ADP
biomedich-346	66	32	the	the	DET
biomedich-346	66	33	first	first	ADJ
biomedich-346	66	34	dose	dose	NOUN
biomedich-346	66	35	.	.	PUNCT
biomedich-346	67	1	wei	wei	PROPN
biomedich-346	67	2	et	et	PROPN
biomedich-346	67	3	al	al	PROPN
biomedich-346	67	4	.	.	PROPN
biomedich-346	67	5	,	,	PUNCT
biomedich-346	67	6	2022	2022	NUM
biomedich-346	67	7	,	,	PUNCT
biomedich-346	67	8	found	find	VERB
biomedich-346	67	9	that	that	SCONJ
biomedich-346	67	10	,	,	PUNCT
biomedich-346	67	11	with	with	ADP
biomedich-346	67	12	a	a	DET
biomedich-346	67	13	combined	combine	VERB
biomedich-346	67	14	endpoint	endpoint	NOUN
biomedich-346	67	15	of	of	ADP
biomedich-346	67	16	hbeag	hbeag	ADJ
biomedich-346	67	17	seroconversion	seroconversion	NOUN
biomedich-346	67	18	,	,	PUNCT
biomedich-346	67	19	alanine	alanine	NOUN
biomedich-346	67	20	aminotransferase	aminotransferase	PROPN
biomedich-346	67	21	normalization	normalization	NOUN
biomedich-346	67	22	and	and	CCONJ
biomedich-346	67	23	hbv	hbv	NOUN
biomedich-346	67	24	dna	dna	PROPN
biomedich-346	67	25	<	<	X
biomedich-346	67	26	2,000	2,000	NUM
biomedich-346	67	27	iu	iu	NOUN
biomedich-346	67	28	/	/	SYM
biomedich-346	67	29	ml	ml	NOUN
biomedich-346	67	30	,	,	PUNCT
biomedich-346	67	31	both	both	DET
biomedich-346	67	32	900	900	NUM
biomedich-346	67	33	µg	µg	ADP
biomedich-346	67	34	(	(	PUNCT
biomedich-346	67	35	18.1	18.1	NUM
biomedich-346	67	36	%	%	NOUN
biomedich-346	67	37	)	)	PUNCT
biomedich-346	67	38	and	and	CCONJ
biomedich-346	67	39	600	600	NUM
biomedich-346	67	40	µg	µg	ADV
biomedich-346	67	41	(	(	PUNCT
biomedich-346	67	42	14.3	14.3	NUM
biomedich-346	67	43	%	%	NOUN
biomedich-346	67	44	)	)	PUNCT
biomedich-346	67	45	,	,	PUNCT
biomedich-346	67	46	resulted	result	VERB
biomedich-346	67	47	in	in	ADP
biomedich-346	67	48	significantly	significantly	ADV
biomedich-346	67	49	higher	high	ADJ
biomedich-346	67	50	rate	rate	NOUN
biomedich-346	67	51	versus	versus	ADP
biomedich-346	67	52	placebo	placebo	NOUN
biomedich-346	67	53	(	(	PUNCT
biomedich-346	67	54	5.0	5.0	NUM
biomedich-346	67	55	%	%	NOUN
biomedich-346	67	56	)	)	PUNCT
biomedich-346	67	57	(	(	PUNCT
biomedich-346	67	58	p	p	X
biomedich-346	67	59	=	=	PUNCT
biomedich-346	67	60	0.002	0.002	NUM
biomedich-346	67	61	and	and	CCONJ
biomedich-346	67	62	p	p	NOUN
biomedich-346	67	63	=	=	NOUN
biomedich-346	67	64	0.02	0.02	NUM
biomedich-346	67	65	,	,	PUNCT
biomedich-346	67	66	respectively	respectively	ADV
biomedich-346	67	67	)	)	PUNCT
biomedich-346	67	68	at	at	ADP
biomedich-346	67	69	week	week	NOUN
biomedich-346	67	70	76	76	NUM
biomedich-346	67	71	.	.	PUNCT
biomedich-346	68	1	in	in	ADP
biomedich-346	68	2	stage	stage	NOUN
biomedich-346	68	3	2	2	NUM
biomedich-346	68	4	,	,	PUNCT
biomedich-346	68	5	none	none	NOUN
biomedich-346	68	6	(	(	PUNCT
biomedich-346	68	7	0	0	NUM
biomedich-346	68	8	of	of	ADP
biomedich-346	68	9	20	20	NUM
biomedich-346	68	10	)	)	PUNCT
biomedich-346	68	11	of	of	ADP
biomedich-346	68	12	900	900	NUM
biomedich-346	68	13	µg	µg	ADV
biomedich-346	68	14	εpa-44	εpa-44	NOUN
biomedich-346	68	15	-	-	PUNCT
biomedich-346	68	16	treated	treat	VERB
biomedich-346	68	17	patients	patient	NOUN
biomedich-346	68	18	experienced	experience	VERB
biomedich-346	68	19	a	a	DET
biomedich-346	68	20	serologic	serologic	ADJ
biomedich-346	68	21	relapse	relapse	NOUN
biomedich-346	68	22	.	.	PUNCT
biomedich-346	69	1	the	the	DET
biomedich-346	69	2	safety	safety	NOUN
biomedich-346	69	3	profile	profile	NOUN
biomedich-346	69	4	of	of	ADP
biomedich-346	69	5	εpa-44	εpa-44	NUM
biomedich-346	69	6	was	be	AUX
biomedich-346	69	7	comparable	comparable	ADJ
biomedich-346	69	8	to	to	ADP
biomedich-346	69	9	that	that	PRON
biomedich-346	69	10	of	of	ADP
biomedich-346	69	11	the	the	DET
biomedich-346	69	12	placebo	placebo	NOUN
biomedich-346	69	13	.	.	PUNCT
biomedich-346	70	1	sahin	sahin	PROPN
biomedich-346	70	2	et	et	PROPN
biomedich-346	70	3	al	al	PROPN
biomedich-346	70	4	.	.	PROPN
biomedich-346	70	5	,	,	PUNCT
biomedich-346	70	6	2021	2021	NUM
biomedich-346	70	7	,	,	PUNCT
biomedich-346	70	8	found	find	VERB
biomedich-346	70	9	that	that	SCONJ
biomedich-346	70	10	most	most	ADJ
biomedich-346	70	11	participants	participant	NOUN
biomedich-346	70	12	had	have	VERB
biomedich-346	70	13	a	a	DET
biomedich-346	70	14	strong	strong	ADJ
biomedich-346	70	15	response	response	NOUN
biomedich-346	70	16	of	of	ADP
biomedich-346	70	17	ifnγ+	ifnγ+	NOUN
biomedich-346	70	18	or	or	CCONJ
biomedich-346	70	19	il-2	il-2	PROPN
biomedich-346	70	20	+	+	PROPN
biomedich-346	70	21	cd8	cd8	PROPN
biomedich-346	70	22	+	+	PROPN
biomedich-346	70	23	and	and	CCONJ
biomedich-346	70	24	cd4	cd4	PROPN
biomedich-346	70	25	+	+	PROPN
biomedich-346	70	26	t	t	PROPN
biomedich-346	70	27	helper	helper	NOUN
biomedich-346	70	28	type	type	NOUN
biomedich-346	70	29	1	1	NUM
biomedich-346	70	30	cells	cell	NOUN
biomedich-346	70	31	,	,	PUNCT
biomedich-346	70	32	which	which	PRON
biomedich-346	70	33	was	be	AUX
biomedich-346	70	34	detectable	detectable	ADJ
biomedich-346	70	35	throughout	throughout	ADP
biomedich-346	70	36	the	the	DET
biomedich-346	70	37	full	full	ADJ
biomedich-346	70	38	observation	observation	NOUN
biomedich-346	70	39	period	period	NOUN
biomedich-346	70	40	of	of	ADP
biomedich-346	70	41	nine	nine	NUM
biomedich-346	70	42	weeks	week	NOUN
biomedich-346	70	43	following	follow	VERB
biomedich-346	70	44	the	the	DET
biomedich-346	70	45	boost	boost	NOUN
biomedich-346	70	46	.	.	PUNCT
biomedich-346	71	1	using	use	VERB
biomedich-346	71	2	peptide	peptide	NOUN
biomedich-346	71	3	-	-	PUNCT
biomedich-346	71	4	mhc	mhc	NOUN
biomedich-346	71	5	multimer	multimer	NOUN
biomedich-346	71	6	technology	technology	NOUN
biomedich-346	71	7	,	,	PUNCT
biomedich-346	71	8	we	we	PRON
biomedich-346	71	9	identified	identify	VERB
biomedich-346	71	10	several	several	ADJ
biomedich-346	71	11	bnt162b2	bnt162b2	NOUN
biomedich-346	71	12	-	-	PUNCT
biomedich-346	71	13	induced	induce	VERB
biomedich-346	71	14	epitopes	epitope	NOUN
biomedich-346	71	15	that	that	PRON
biomedich-346	71	16	were	be	AUX
biomedich-346	71	17	presented	present	VERB
biomedich-346	71	18	by	by	ADP
biomedich-346	71	19	frequent	frequent	ADJ
biomedich-346	71	20	mhc	mhc	PROPN
biomedich-346	71	21	alleles	allele	NOUN
biomedich-346	71	22	and	and	CCONJ
biomedich-346	71	23	conserved	conserve	VERB
biomedich-346	71	24	in	in	ADP
biomedich-346	71	25	mutant	mutant	ADJ
biomedich-346	71	26	strains	strain	NOUN
biomedich-346	71	27	.	.	PUNCT
biomedich-346	72	1	one	one	NUM
biomedich-346	72	2	week	week	NOUN
biomedich-346	72	3	after	after	ADP
biomedich-346	72	4	the	the	DET
biomedich-346	72	5	boost	boost	NOUN
biomedich-346	72	6	,	,	PUNCT
biomedich-346	72	7	epitope	epitope	NOUN
biomedich-346	72	8	-	-	PUNCT
biomedich-346	72	9	specific	specific	ADJ
biomedich-346	72	10	cd8	cd8	PROPN
biomedich-346	72	11	+	+	PROPN
biomedich-346	72	12	t	t	NOUN
biomedich-346	72	13	cells	cell	NOUN
biomedich-346	72	14	of	of	ADP
biomedich-346	72	15	the	the	DET
biomedich-346	72	16	early	early	ADV
biomedich-346	72	17	-	-	PUNCT
biomedich-346	72	18	differentiated	differentiate	VERB
biomedich-346	72	19	effector	effector	NOUN
biomedich-346	72	20	-	-	PUNCT
biomedich-346	72	21	memory	memory	NOUN
biomedich-346	72	22	phenotype	phenotype	NOUN
biomedich-346	72	23	comprised	comprise	VERB
biomedich-346	72	24	0.02	0.02	NUM
biomedich-346	72	25	-	-	SYM
biomedich-346	72	26	2.92	2.92	NUM
biomedich-346	72	27	%	%	NOUN
biomedich-346	72	28	of	of	ADP
biomedich-346	72	29	total	total	ADJ
biomedich-346	72	30	circulating	circulating	PROPN
biomedich-346	72	31	cd8	cd8	PROPN
biomedich-346	72	32	+	+	PROPN
biomedich-346	72	33	t	t	NOUN
biomedich-346	72	34	cells	cell	NOUN
biomedich-346	72	35	and	and	CCONJ
biomedich-346	72	36	were	be	AUX
biomedich-346	72	37	detectable	detectable	ADJ
biomedich-346	72	38	(	(	PUNCT
biomedich-346	72	39	0.01	0.01	NUM
biomedich-346	72	40	-	-	PUNCT
biomedich-346	72	41	0.28	0.28	NUM
biomedich-346	72	42	%	%	NOUN
biomedich-346	72	43	)	)	PUNCT
biomedich-346	72	44	eight	eight	NUM
biomedich-346	72	45	weeks	week	NOUN
biomedich-346	72	46	later	later	ADV
biomedich-346	72	47	.	.	PUNCT
biomedich-346	73	1	in	in	ADP
biomedich-346	73	2	summary	summary	NOUN
biomedich-346	73	3	,	,	PUNCT
biomedich-346	73	4	bnt162b2	bnt162b2	PROPN
biomedich-346	73	5	elicits	elicit	VERB
biomedich-346	73	6	an	an	DET
biomedich-346	73	7	adaptive	adaptive	ADJ
biomedich-346	73	8	humoral	humoral	ADJ
biomedich-346	73	9	and	and	CCONJ
biomedich-346	73	10	poly	poly	ADJ
biomedich-346	73	11	-	-	PUNCT
biomedich-346	73	12	specific	specific	ADJ
biomedich-346	73	13	cellular	cellular	ADJ
biomedich-346	73	14	immune	immune	ADJ
biomedich-346	73	15	response	response	NOUN
biomedich-346	73	16	against	against	ADP
biomedich-346	73	17	epitopes	epitope	NOUN
biomedich-346	73	18	that	that	PRON
biomedich-346	73	19	are	be	AUX
biomedich-346	73	20	conserved	conserve	VERB
biomedich-346	73	21	in	in	ADP
biomedich-346	73	22	a	a	DET
biomedich-346	73	23	broad	broad	ADJ
biomedich-346	73	24	range	range	NOUN
biomedich-346	73	25	of	of	ADP
biomedich-346	73	26	variants	variant	NOUN
biomedich-346	73	27	,	,	PUNCT
biomedich-346	73	28	at	at	ADP
biomedich-346	73	29	well	well	ADV
biomedich-346	73	30	-	-	PUNCT
biomedich-346	73	31	tolerated	tolerate	VERB
biomedich-346	73	32	doses	dose	NOUN
biomedich-346	73	33	.	.	PUNCT
biomedich-346	74	1	datoo	datoo	PROPN
biomedich-346	74	2	et	et	PROPN
biomedich-346	74	3	al	al	PROPN
biomedich-346	74	4	.	.	PROPN
biomedich-346	74	5	,	,	PUNCT
biomedich-346	74	6	2021	2021	NUM
biomedich-346	74	7	,	,	PUNCT
biomedich-346	74	8	found	find	VERB
biomedich-346	74	9	that	that	SCONJ
biomedich-346	74	10	participants	participant	NOUN
biomedich-346	74	11	vaccinated	vaccinate	VERB
biomedich-346	74	12	with	with	ADP
biomedich-346	74	13	r21	r21	NOUN
biomedich-346	74	14	/	/	SYM
biomedich-346	74	15	mm	mm	PROPN
biomedich-346	74	16	showed	show	VERB
biomedich-346	74	17	high	high	ADJ
biomedich-346	74	18	titers	titer	NOUN
biomedich-346	74	19	of	of	ADP
biomedich-346	74	20	malaria	malaria	NOUN
biomedich-346	74	21	-	-	PUNCT
biomedich-346	74	22	specific	specific	ADJ
biomedich-346	74	23	anti	anti	ADJ
biomedich-346	74	24	-	-	ADJ
biomedich-346	74	25	asn	asn	ADJ
biomedich-346	74	26	-	-	PUNCT
biomedich-346	74	27	ala	ala	PROPN
biomedich-346	74	28	-	-	PUNCT
biomedich-346	74	29	asn	asn	NOUN
biomedich-346	74	30	-	-	PUNCT
biomedich-346	74	31	pro	pro	ADJ
biomedich-346	74	32	(	(	PUNCT
biomedich-346	74	33	nanp	nanp	ADJ
biomedich-346	74	34	)	)	PUNCT
biomedich-346	74	35	antibodies	antibodie	VERB
biomedich-346	74	36	28	28	NUM
biomedich-346	74	37	days	day	NOUN
biomedich-346	74	38	after	after	ADP
biomedich-346	74	39	the	the	DET
biomedich-346	74	40	third	third	ADJ
biomedich-346	74	41	vaccination	vaccination	NOUN
biomedich-346	74	42	,	,	PUNCT
biomedich-346	74	43	which	which	PRON
biomedich-346	74	44	were	be	AUX
biomedich-346	74	45	almost	almost	ADV
biomedich-346	74	46	doubled	double	VERB
biomedich-346	74	47	with	with	ADP
biomedich-346	74	48	the	the	DET
biomedich-346	74	49	higher	high	ADJ
biomedich-346	74	50	adjuvant	adjuvant	ADJ
biomedich-346	74	51	dose	dose	PROPN
biomedich-346	74	52	.	.	PUNCT
biomedich-346	75	1	titres	titre	NOUN
biomedich-346	75	2	waned	wane	VERB
biomedich-346	75	3	but	but	CCONJ
biomedich-346	75	4	were	be	AUX
biomedich-346	75	5	boosted	boost	VERB
biomedich-346	75	6	to	to	ADP
biomedich-346	75	7	levels	level	NOUN
biomedich-346	75	8	similar	similar	ADJ
biomedich-346	75	9	to	to	AUX
biomedich-346	75	10	peak	peak	VERB
biomedich-346	75	11	titers	titer	NOUN
biomedich-346	75	12	after	after	ADP
biomedich-346	75	13	the	the	DET
biomedich-346	75	14	primary	primary	ADJ
biomedich-346	75	15	series	series	NOUN
biomedich-346	75	16	of	of	ADP
biomedich-346	75	17	vaccinations	vaccination	NOUN
biomedich-346	75	18	after	after	SCONJ
biomedich-346	75	19	a	a	DET
biomedich-346	75	20	fourth	fourth	ADJ
biomedich-346	75	21	dose	dose	NOUN
biomedich-346	75	22	administered	administer	VERB
biomedich-346	75	23	1	1	NUM
biomedich-346	75	24	year	year	NOUN
biomedich-346	75	25	later	later	ADV
biomedich-346	75	26	.	.	PUNCT
biomedich-346	76	1	toback	toback	VERB
biomedich-346	76	2	et	et	PROPN
biomedich-346	76	3	al	al	PROPN
biomedich-346	76	4	.	.	PROPN
biomedich-346	76	5	,	,	PUNCT
biomedich-346	76	6	2022	2022	NUM
biomedich-346	76	7	,	,	PUNCT
biomedich-346	76	8	found	find	VERB
biomedich-346	76	9	that	that	SCONJ
biomedich-346	76	10	no	no	DET
biomedich-346	76	11	episodes	episode	NOUN
biomedich-346	76	12	of	of	ADP
biomedich-346	76	13	anaphylaxis	anaphylaxis	ADJ
biomedich-346	76	14	or	or	CCONJ
biomedich-346	76	15	deaths	death	NOUN
biomedich-346	76	16	were	be	AUX
biomedich-346	76	17	reported	report	VERB
biomedich-346	76	18	within	within	ADP
biomedich-346	76	19	the	the	DET
biomedich-346	76	20	substudy	substudy	NOUN
biomedich-346	76	21	.	.	PUNCT
biomedich-346	77	1	co	co	NOUN
biomedich-346	77	2	-	-	NOUN
biomedich-346	77	3	administration	administration	NOUN
biomedich-346	77	4	resulted	result	VERB
biomedich-346	77	5	in	in	ADP
biomedich-346	77	6	no	no	DET
biomedich-346	77	7	change	change	NOUN
biomedich-346	77	8	to	to	ADP
biomedich-346	77	9	the	the	DET
biomedich-346	77	10	influenza	influenza	NOUN
biomedich-346	77	11	vaccine	vaccine	NOUN
biomedich-346	77	12	immune	immune	ADJ
biomedich-346	77	13	response	response	NOUN
biomedich-346	77	14	although	although	SCONJ
biomedich-346	77	15	a	a	DET
biomedich-346	77	16	reduction	reduction	NOUN
biomedich-346	77	17	in	in	ADP
biomedich-346	77	18	antibody	antibody	NOUN
biomedich-346	77	19	responses	response	NOUN
biomedich-346	77	20	to	to	ADP
biomedich-346	77	21	the	the	DET
biomedich-346	77	22	nvx	nvx	NOUN
biomedich-346	77	23	-	-	PUNCT
biomedich-346	77	24	cov2373	cov2373	NOUN
biomedich-346	77	25	vaccine	vaccine	NOUN
biomedich-346	77	26	was	be	AUX
biomedich-346	77	27	noted	note	VERB
biomedich-346	77	28	.	.	PUNCT
biomedich-346	78	1	nvx	nvx	PROPN
biomedich-346	78	2	-	-	PUNCT
biomedich-346	78	3	cov2373	cov2373	PROPN
biomedich-346	78	4	vaccine	vaccine	NOUN
biomedich-346	78	5	efficacy	efficacy	NOUN
biomedich-346	78	6	in	in	ADP
biomedich-346	78	7	the	the	DET
biomedich-346	78	8	substudy	substudy	NOUN
biomedich-346	78	9	(	(	PUNCT
biomedich-346	78	10	ie	ie	X
biomedich-346	78	11	,	,	PUNCT
biomedich-346	78	12	participants	participant	NOUN
biomedich-346	78	13	aged	age	VERB
biomedich-346	78	14	18	18	NUM
biomedich-346	78	15	to	to	ADP
biomedich-346	78	16	<	<	X
biomedich-346	78	17	65	65	NUM
biomedich-346	78	18	years	year	NOUN
biomedich-346	78	19	)	)	PUNCT
biomedich-346	78	20	was	be	AUX
biomedich-346	78	21	87·5	87·5	NOUN
biomedich-346	78	22	%	%	NOUN
biomedich-346	78	23	(	(	PUNCT
biomedich-346	78	24	95	95	NUM
biomedich-346	78	25	%	%	NOUN
biomedich-346	78	26	ci	ci	PROPN
biomedich-346	78	27	-0·2	-0·2	PROPN
biomedich-346	78	28	to	to	ADP
biomedich-346	78	29	98·4	98·4	NOUN
biomedich-346	78	30	)	)	PUNCT
biomedich-346	78	31	,	,	PUNCT
biomedich-346	78	32	and	and	CCONJ
biomedich-346	78	33	in	in	ADP
biomedich-346	78	34	the	the	DET
biomedich-346	78	35	main	main	ADJ
biomedich-346	78	36	study	study	NOUN
biomedich-346	78	37	was	be	AUX
biomedich-346	78	38	89·8	89·8	NUM
biomedich-346	78	39	%	%	NOUN
biomedich-346	78	40	(	(	PUNCT
biomedich-346	78	41	95	95	NUM
biomedich-346	78	42	%	%	NOUN
biomedich-346	78	43	ci	ci	NOUN
biomedich-346	78	44	79·7	79·7	NUM
biomedich-346	78	45	-	-	PUNCT
biomedich-346	78	46	95·5	95·5	NUM
biomedich-346	78	47	)	)	PUNCT
biomedich-346	78	48	.	.	PUNCT
biomedich-346	79	1	maruggi	maruggi	NOUN
biomedich-346	79	2	et	et	PROPN
biomedich-346	79	3	al	al	PROPN
biomedich-346	79	4	.	.	PROPN
biomedich-346	79	5	,	,	PUNCT
biomedich-346	79	6	2022	2022	NUM
biomedich-346	79	7	,	,	PUNCT
biomedich-346	79	8	found	find	VERB
biomedich-346	79	9	that	that	SCONJ
biomedich-346	79	10	high	high	ADJ
biomedich-346	79	11	frequencies	frequency	NOUN
biomedich-346	79	12	of	of	ADP
biomedich-346	79	13	spike	spike	ADJ
biomedich-346	79	14	-	-	PUNCT
biomedich-346	79	15	specific	specific	ADJ
biomedich-346	79	16	germinal	germinal	ADJ
biomedich-346	79	17	center	center	NOUN
biomedich-346	79	18	b	b	NOUN
biomedich-346	79	19	,	,	PUNCT
biomedich-346	79	20	th0	th0	PROPN
biomedich-346	79	21	/	/	SYM
biomedich-346	79	22	th1	th1	PROPN
biomedich-346	79	23	cd4	cd4	PROPN
biomedich-346	79	24	,	,	PUNCT
biomedich-346	79	25	and	and	CCONJ
biomedich-346	79	26	cd8	cd8	PROPN
biomedich-346	79	27	t	t	PROPN
biomedich-346	79	28	cell	cell	NOUN
biomedich-346	79	29	responses	response	NOUN
biomedich-346	79	30	were	be	AUX
biomedich-346	79	31	observed	observe	VERB
biomedich-346	79	32	in	in	ADP
biomedich-346	79	33	mice	mouse	NOUN
biomedich-346	79	34	.	.	PUNCT
biomedich-346	80	1	local	local	ADJ
biomedich-346	80	2	tolerance	tolerance	NOUN
biomedich-346	80	3	,	,	PUNCT
biomedich-346	80	4	potential	potential	ADJ
biomedich-346	80	5	systemic	systemic	ADJ
biomedich-346	80	6	toxicity	toxicity	NOUN
biomedich-346	80	7	,	,	PUNCT
biomedich-346	80	8	and	and	CCONJ
biomedich-346	80	9	biodistribution	biodistribution	NOUN
biomedich-346	80	10	of	of	ADP
biomedich-346	80	11	the	the	DET
biomedich-346	80	12	vaccine	vaccine	NOUN
biomedich-346	80	13	were	be	AUX
biomedich-346	80	14	characterized	characterize	VERB
biomedich-346	80	15	in	in	ADP
biomedich-346	80	16	rats	rat	NOUN
biomedich-346	80	17	.	.	PUNCT
biomedich-346	81	1	in	in	ADP
biomedich-346	81	2	hamsters	hamster	NOUN
biomedich-346	81	3	,	,	PUNCT
biomedich-346	81	4	the	the	DET
biomedich-346	81	5	vaccine	vaccine	NOUN
biomedich-346	81	6	candidate	candidate	NOUN
biomedich-346	81	7	was	be	AUX
biomedich-346	81	8	well	well	ADV
biomedich-346	81	9	-	-	PUNCT
biomedich-346	81	10	tolerated	tolerate	VERB
biomedich-346	81	11	,	,	PUNCT
biomedich-346	81	12	markedly	markedly	ADV
biomedich-346	81	13	reduced	reduce	VERB
biomedich-346	81	14	viral	viral	ADJ
biomedich-346	81	15	load	load	NOUN
biomedich-346	81	16	in	in	ADP
biomedich-346	81	17	the	the	DET
biomedich-346	81	18	upper	upper	ADJ
biomedich-346	81	19	and	and	CCONJ
biomedich-346	81	20	lower	low	ADJ
biomedich-346	81	21	airways	airway	NOUN
biomedich-346	81	22	,	,	PUNCT
biomedich-346	81	23	and	and	CCONJ
biomedich-346	81	24	protected	protect	VERB
biomedich-346	81	25	animals	animal	NOUN
biomedich-346	81	26	against	against	ADP
biomedich-346	81	27	disease	disease	NOUN
biomedich-346	81	28	in	in	ADP
biomedich-346	81	29	a	a	DET
biomedich-346	81	30	dose	dose	NOUN
biomedich-346	81	31	-	-	PUNCT
biomedich-346	81	32	dependent	dependent	ADJ
biomedich-346	81	33	manner	manner	NOUN
biomedich-346	81	34	,	,	PUNCT
biomedich-346	81	35	with	with	ADP
biomedich-346	81	36	no	no	DET
biomedich-346	81	37	evidence	evidence	NOUN
biomedich-346	81	38	of	of	ADP
biomedich-346	81	39	disease	disease	NOUN
biomedich-346	81	40	enhancement	enhancement	NOUN
biomedich-346	81	41	following	follow	VERB
biomedich-346	81	42	the	the	DET
biomedich-346	81	43	sars	sar	NOUN
biomedich-346	81	44	-	-	PUNCT
biomedich-346	81	45	cov-2	cov-2	NOUN
biomedich-346	81	46	challenge	challenge	NOUN
biomedich-346	81	47	.	.	PUNCT
biomedich-346	82	1	therefore	therefore	ADV
biomedich-346	82	2	,	,	PUNCT
biomedich-346	82	3	the	the	DET
biomedich-346	82	4	sars	sar	NOUN
biomedich-346	82	5	-	-	PUNCT
biomedich-346	82	6	cov-2	cov-2	NOUN
biomedich-346	82	7	sam	sam	PROPN
biomedich-346	82	8	(	(	PUNCT
biomedich-346	82	9	lnp	lnp	PROPN
biomedich-346	82	10	)	)	PUNCT
biomedich-346	82	11	vaccine	vaccine	NOUN
biomedich-346	82	12	candidate	candidate	NOUN
biomedich-346	82	13	has	have	VERB
biomedich-346	82	14	a	a	DET
biomedich-346	82	15	favorable	favorable	ADJ
biomedich-346	82	16	safety	safety	NOUN
biomedich-346	82	17	profile	profile	NOUN
biomedich-346	82	18	,	,	PUNCT
biomedich-346	82	19	elicits	elicit	VERB
biomedich-346	82	20	robust	robust	ADJ
biomedich-346	82	21	protective	protective	ADJ
biomedich-346	82	22	immune	immune	ADJ
biomedich-346	82	23	responses	response	NOUN
biomedich-346	82	24	against	against	ADP
biomedich-346	82	25	multiple	multiple	ADJ
biomedich-346	82	26	sars	sar	NOUN
biomedich-346	82	27	-	-	PUNCT
biomedich-346	82	28	cov-2	cov-2	NOUN
biomedich-346	82	29	variants	variant	NOUN
biomedich-346	82	30	,	,	PUNCT
biomedich-346	82	31	and	and	CCONJ
biomedich-346	82	32	has	have	AUX
biomedich-346	82	33	been	be	AUX
biomedich-346	82	34	advanced	advanced	ADJ
biomedich-346	82	35	to	to	PART
biomedich-346	82	36	phase	phase	VERB
biomedich-346	82	37	1	1	NUM
biomedich-346	82	38	clinical	clinical	ADJ
biomedich-346	82	39	evaluation	evaluation	NOUN
biomedich-346	82	40	.	.	PUNCT
biomedich-346	83	1	madhi	madhi	NOUN
biomedich-346	83	2	et	et	PROPN
biomedich-346	83	3	al	al	PROPN
biomedich-346	83	4	.	.	PROPN
biomedich-346	83	5	,	,	PUNCT
biomedich-346	83	6	2022	2022	NUM
biomedich-346	83	7	,	,	PUNCT
biomedich-346	83	8	found	find	VERB
biomedich-346	83	9	that	that	SCONJ
biomedich-346	83	10	,	,	PUNCT
biomedich-346	83	11	of	of	ADP
biomedich-346	83	12	the	the	DET
biomedich-346	83	13	serious	serious	ADJ
biomedich-346	83	14	adverse	adverse	ADJ
biomedich-346	83	15	events	event	NOUN
biomedich-346	83	16	that	that	PRON
biomedich-346	83	17	occurred	occur	VERB
biomedich-346	83	18	among	among	ADP
biomedich-346	83	19	hiv	hiv	PROPN
biomedich-346	83	20	-	-	PUNCT
biomedich-346	83	21	negative	negative	ADJ
biomedich-346	83	22	people	people	NOUN
biomedich-346	83	23	(	(	PUNCT
biomedich-346	83	24	of	of	ADP
biomedich-346	83	25	whom	whom	PRON
biomedich-346	83	26	,	,	PUNCT
biomedich-346	83	27	two	two	NUM
biomedich-346	83	28	[	[	NOUN
biomedich-346	83	29	0·1	0·1	NUM
biomedich-346	83	30	%	%	NOUN
biomedich-346	83	31	]	]	PUNCT
biomedich-346	83	32	were	be	AUX
biomedich-346	83	33	baseline	baseline	ADJ
biomedich-346	83	34	sars	sar	NOUN
biomedich-346	83	35	-	-	PUNCT
biomedich-346	83	36	cov-2	cov-2	NOUN
biomedich-346	83	37	-	-	PUNCT
biomedich-346	83	38	negative	negative	ADJ
biomedich-346	83	39	and	and	CCONJ
biomedich-346	83	40	four	four	NUM
biomedich-346	83	41	[	[	X
biomedich-346	83	42	0·6	0·6	X
biomedich-346	83	43	%	%	NOUN
biomedich-346	83	44	]	]	PUNCT
biomedich-346	83	45	were	be	AUX
biomedich-346	83	46	baseline	baseline	ADJ
biomedich-346	83	47	sars	sar	NOUN
biomedich-346	83	48	-	-	PUNCT
biomedich-346	83	49	cov-2	cov-2	NOUN
biomedich-346	83	50	-	-	ADJ
biomedich-346	83	51	positive	positive	ADJ
biomedich-346	83	52	)	)	PUNCT
biomedich-346	83	53	and	and	CCONJ
biomedich-346	83	54	people	people	NOUN
biomedich-346	83	55	living	live	VERB
biomedich-346	83	56	with	with	ADP
biomedich-346	83	57	hiv-1	hiv-1	X
biomedich-346	83	58	(	(	PUNCT
biomedich-346	83	59	for	for	ADP
biomedich-346	83	60	whom	whom	PRON
biomedich-346	83	61	there	there	PRON
biomedich-346	83	62	were	be	VERB
biomedich-346	83	63	no	no	DET
biomedich-346	83	64	serious	serious	ADJ
biomedich-346	83	65	adverse	adverse	ADJ
biomedich-346	83	66	events	event	NOUN
biomedich-346	83	67	)	)	PUNCT
biomedich-346	83	68	in	in	ADP
biomedich-346	83	69	the	the	DET
biomedich-346	83	70	nvx	nvx	PROPN
biomedich-346	83	71	-	-	PUNCT
biomedich-346	83	72	cov2373	cov2373	NOUN
biomedich-346	83	73	group	group	NOUN
biomedich-346	83	74	,	,	PUNCT
biomedich-346	83	75	none	none	NOUN
biomedich-346	83	76	were	be	AUX
biomedich-346	83	77	assessed	assess	VERB
biomedich-346	83	78	as	as	ADP
biomedich-346	83	79	related	relate	VERB
biomedich-346	83	80	to	to	ADP
biomedich-346	83	81	the	the	DET
biomedich-346	83	82	vaccine	vaccine	NOUN
biomedich-346	83	83	.	.	PUNCT
biomedich-346	84	1	among	among	ADP
biomedich-346	84	2	participants	participant	NOUN
biomedich-346	84	3	who	who	PRON
biomedich-346	84	4	were	be	AUX
biomedich-346	84	5	baseline	baseline	PROPN
biomedich-346	84	6	sars	sar	NOUN
biomedich-346	84	7	-	-	PUNCT
biomedich-346	84	8	cov-2	cov-2	NOUN
biomedich-346	84	9	-	-	PUNCT
biomedich-346	84	10	negative	negative	ADJ
biomedich-346	84	11	in	in	ADP
biomedich-346	84	12	the	the	DET
biomedich-346	84	13	nvxcov2373	nvxcov2373	PROPN
biomedich-346	84	14	group	group	NOUN
biomedich-346	84	15	,	,	PUNCT
biomedich-346	84	16	the	the	DET
biomedich-346	84	17	anti	anti	ADJ
biomedich-346	84	18	-	-	ADJ
biomedich-346	84	19	spike	spike	ADJ
biomedich-346	84	20	igg	igg	PROPN
biomedich-346	84	21	geometric	geometric	ADJ
biomedich-346	84	22	mean	mean	NOUN
biomedich-346	84	23	titers	titer	NOUN
biomedich-346	84	24	(	(	PUNCT
biomedich-346	84	25	gmts	gmts	PROPN
biomedich-346	84	26	)	)	PUNCT
biomedich-346	84	27	and	and	CCONJ
biomedich-346	84	28	seroconversion	seroconversion	NOUN
biomedich-346	84	29	rates	rate	NOUN
biomedich-346	84	30	(	(	PUNCT
biomedich-346	84	31	scrs	scrs	PROPN
biomedich-346	84	32	)	)	PUNCT
biomedich-346	84	33	were	be	AUX
biomedich-346	84	34	lower	low	ADJ
biomedich-346	84	35	in	in	ADP
biomedich-346	84	36	people	people	NOUN
biomedich-346	84	37	living	live	VERB
biomedich-346	84	38	with	with	ADP
biomedich-346	84	39	hiv-1	hiv-1	PUNCT
biomedich-346	84	40	(	(	PUNCT
biomedich-346	84	41	n=62	n=62	ADV
biomedich-346	84	42	)	)	PUNCT
biomedich-346	84	43	than	than	ADP
biomedich-346	84	44	in	in	ADP
biomedich-346	84	45	hivnegative	hivnegative	ADJ
biomedich-346	84	46	people	people	NOUN
biomedich-346	84	47	(	(	PUNCT
biomedich-346	84	48	n=1234	n=1234	NOUN
biomedich-346	84	49	)	)	PUNCT
biomedich-346	84	50	following	follow	VERB
biomedich-346	84	51	the	the	DET
biomedich-346	84	52	first	first	ADJ
biomedich-346	84	53	vaccination	vaccination	NOUN
biomedich-346	84	54	(	(	PUNCT
biomedich-346	84	55	gmt	gmt	NOUN
biomedich-346	84	56	:	:	PUNCT
biomedich-346	84	57	508·6	508·6	NOUN
biomedich-346	84	58	vs	vs	ADP
biomedich-346	84	59	1195·3	1195·3	PROPN
biomedich-346	84	60	elisa	elisa	NOUN
biomedich-346	84	61	units	unit	NOUN
biomedich-346	84	62	[	[	X
biomedich-346	84	63	eu]/ml	eu]/ml	ADJ
biomedich-346	84	64	;	;	PUNCT
biomedich-346	84	65	scr	scr	NOUN
biomedich-346	84	66	:	:	PUNCT
biomedich-346	84	67	51·6	51·6	NUM
biomedich-346	84	68	%	%	NOUN
biomedich-346	84	69	vs	vs	ADP
biomedich-346	84	70	81·3	81·3	NUM
biomedich-346	84	71	%	%	NOUN
biomedich-346	84	72	)	)	PUNCT
biomedich-346	84	73	;	;	PUNCT
biomedich-346	84	74	and	and	CCONJ
biomedich-346	84	75	similarly	similarly	ADV
biomedich-346	84	76	so	so	ADV
biomedich-346	84	77	14	14	NUM
biomedich-346	84	78	days	day	NOUN
biomedich-346	84	79	after	after	ADP
biomedich-346	84	80	the	the	DET
biomedich-346	84	81	second	second	ADJ
biomedich-346	84	82	vaccination	vaccination	NOUN
biomedich-346	84	83	for	for	ADP
biomedich-346	84	84	gmts	gmts	NOUN
biomedich-346	84	85	(	(	PUNCT
biomedich-346	84	86	14	14	NUM
biomedich-346	84	87	420·5	420·5	NUM
biomedich-346	84	88	vs	vs	ADP
biomedich-346	84	89	31	31	NUM
biomedich-346	84	90	631·8	631·8	NUM
biomedich-346	84	91	eu	eu	PROPN
biomedich-346	84	92	/	/	SYM
biomedich-346	84	93	ml	ml	PROPN
biomedich-346	84	94	)	)	PUNCT
biomedich-346	84	95	,	,	PUNCT
biomedich-346	84	96	whereas	whereas	SCONJ
biomedich-346	84	97	the	the	DET
biomedich-346	84	98	scr	scr	NOUN
biomedich-346	84	99	was	be	AUX
biomedich-346	84	100	similar	similar	ADJ
biomedich-346	84	101	at	at	ADP
biomedich-346	84	102	this	this	DET
biomedich-346	84	103	point	point	NOUN
biomedich-346	84	104	(	(	PUNCT
biomedich-346	84	105	100·0	100·0	NUM
biomedich-346	84	106	%	%	NOUN
biomedich-346	84	107	vs	vs	ADP
biomedich-346	84	108	99·3	99·3	NUM
biomedich-346	84	109	%	%	NOUN
biomedich-346	84	110	)	)	PUNCT
biomedich-346	84	111	.	.	PUNCT
biomedich-346	85	1	in	in	ADP
biomedich-346	85	2	the	the	DET
biomedich-346	85	3	nvx	nvx	PROPN
biomedich-346	85	4	-	-	PUNCT
biomedich-346	85	5	cov2373	cov2373	NOUN
biomedich-346	85	6	group	group	NOUN
biomedich-346	85	7	,	,	PUNCT
biomedich-346	85	8	antispike	antispike	PROPN
biomedich-346	85	9	igg	igg	PROPN
biomedich-346	85	10	gmts	gmts	VERB
biomedich-346	85	11	14	14	NUM
biomedich-346	85	12	days	day	NOUN
biomedich-346	85	13	after	after	SCONJ
biomedich-346	85	14	the	the	DET
biomedich-346	85	15	second	second	ADJ
biomedich-346	85	16	vaccination	vaccination	NOUN
biomedich-346	85	17	were	be	AUX
biomedich-346	85	18	substantially	substantially	ADV
biomedich-346	85	19	higher	high	ADJ
biomedich-346	85	20	in	in	ADP
biomedich-346	85	21	those	those	PRON
biomedich-346	85	22	who	who	PRON
biomedich-346	85	23	were	be	AUX
biomedich-346	85	24	baseline	baseline	PROPN
biomedich-346	85	25	sars	sar	NOUN
biomedich-346	85	26	-	-	PUNCT
biomedich-346	85	27	cov-2	cov-2	NOUN
biomedich-346	85	28	-	-	ADJ
biomedich-346	85	29	positive	positive	ADJ
biomedich-346	85	30	than	than	ADP
biomedich-346	85	31	in	in	ADP
biomedich-346	85	32	those	those	PRON
biomedich-346	85	33	who	who	PRON
biomedich-346	85	34	were	be	AUX
biomedich-346	85	35	baseline	baseline	PROPN
biomedich-346	85	36	sars	sar	NOUN
biomedich-346	85	37	-	-	PUNCT
biomedich-346	85	38	cov-2	cov-2	NOUN
biomedich-346	85	39	-	-	ADJ
biomedich-346	85	40	seronegative	seronegative	ADJ
biomedich-346	85	41	for	for	ADP
biomedich-346	85	42	hiv	hiv	PROPN
biomedich-346	85	43	-	-	PUNCT
biomedich-346	85	44	negative	negative	ADJ
biomedich-346	85	45	participants	participant	NOUN
biomedich-346	85	46	(	(	PUNCT
biomedich-346	85	47	100	100	NUM
biomedich-346	85	48	666·1	666·1	NOUN
biomedich-346	85	49	vs	vs	ADP
biomedich-346	85	50	31	31	NUM
biomedich-346	85	51	631·8	631·8	NUM
biomedich-346	85	52	eu	eu	PROPN
biomedich-346	85	53	/	/	SYM
biomedich-346	85	54	ml	ml	PROPN
biomedich-346	85	55	)	)	PUNCT
biomedich-346	85	56	and	and	CCONJ
biomedich-346	85	57	for	for	ADP
biomedich-346	85	58	people	people	NOUN
biomedich-346	85	59	living	live	VERB
biomedich-346	85	60	with	with	ADP
biomedich-346	85	61	hiv-1	hiv-1	PUNCT
biomedich-346	85	62	(	(	PUNCT
biomedich-346	85	63	98	98	NUM
biomedich-346	85	64	399·5	399·5	NUM
biomedich-346	85	65	vs	vs	ADP
biomedich-346	85	66	14	14	NUM
biomedich-346	85	67	420·5	420·5	NUM
biomedich-346	85	68	eu	eu	PROPN
biomedich-346	85	69	/	/	SYM
biomedich-346	85	70	ml	ml	VERB
biomedich-346	85	71	)	)	PUNCT
biomedich-346	85	72	.	.	PUNCT
biomedich-346	86	1	this	this	PRON
biomedich-346	86	2	was	be	AUX
biomedich-346	86	3	also	also	ADV
biomedich-346	86	4	the	the	DET
biomedich-346	86	5	case	case	NOUN
biomedich-346	86	6	for	for	ADP
biomedich-346	86	7	angiotensin	angiotensin	NOUN
biomedich-346	86	8	-	-	PUNCT
biomedich-346	86	9	converting	convert	VERB
biomedich-346	86	10	enzyme	enzyme	NOUN
biomedich-346	86	11	2	2	NUM
biomedich-346	86	12	receptor	receptor	NOUN
biomedich-346	86	13	-	-	PUNCT
biomedich-346	86	14	binding	bind	VERB
biomedich-346	86	15	antibody	antibody	NOUN
biomedich-346	86	16	and	and	CCONJ
biomedich-346	86	17	neutralizing	neutralize	VERB
biomedich-346	86	18	antibody	antibody	NOUN
biomedich-346	86	19	346	346	NUM
biomedich-346	86	20	biology	biology	NOUN
biomedich-346	86	21	,	,	PUNCT
biomedich-346	86	22	medicine	medicine	NOUN
biomedich-346	86	23	,	,	PUNCT
biomedich-346	86	24	&	&	CCONJ
biomedich-346	86	25	natural	natural	ADJ
biomedich-346	86	26	product	product	NOUN
biomedich-346	86	27	chemistry	chemistry	NOUN
biomedich-346	86	28	12	12	NUM
biomedich-346	86	29	(	(	PUNCT
biomedich-346	86	30	1	1	NUM
biomedich-346	86	31	)	)	PUNCT
biomedich-346	86	32	,	,	PUNCT
biomedich-346	86	33	2023	2023	NUM
biomedich-346	86	34	:	:	PUNCT
biomedich-346	86	35	343	343	NUM
biomedich-346	86	36	-	-	SYM
biomedich-346	86	37	361	361	NUM
biomedich-346	86	38	titers	titer	NOUN
biomedich-346	86	39	.	.	PUNCT
biomedich-346	87	1	stuart	stuart	PROPN
biomedich-346	87	2	et	et	PROPN
biomedich-346	87	3	al	al	PROPN
biomedich-346	87	4	.	.	PROPN
biomedich-346	87	5	,	,	PUNCT
biomedich-346	87	6	2022	2022	NUM
biomedich-346	87	7	,	,	PUNCT
biomedich-346	87	8	found	find	VERB
biomedich-346	87	9	that	that	SCONJ
biomedich-346	87	10	,	,	PUNCT
biomedich-346	87	11	between	between	ADP
biomedich-346	87	12	april	april	PROPN
biomedich-346	87	13	19	19	NUM
biomedich-346	87	14	and	and	CCONJ
biomedich-346	87	15	may	may	PROPN
biomedich-346	87	16	14	14	NUM
biomedich-346	87	17	,	,	PUNCT
biomedich-346	87	18	2021	2021	NUM
biomedich-346	87	19	,	,	PUNCT
biomedich-346	87	20	1072	1072	NUM
biomedich-346	87	21	participants	participant	NOUN
biomedich-346	87	22	were	be	AUX
biomedich-346	87	23	enrolled	enrol	VERB
biomedich-346	87	24	at	at	ADP
biomedich-346	87	25	a	a	DET
biomedich-346	87	26	median	median	NOUN
biomedich-346	87	27	of	of	ADP
biomedich-346	87	28	9·4	9·4	NUM
biomedich-346	87	29	weeks	week	NOUN
biomedich-346	87	30	after	after	ADP
biomedich-346	87	31	receipt	receipt	NOUN
biomedich-346	87	32	of	of	ADP
biomedich-346	87	33	a	a	DET
biomedich-346	87	34	single	single	ADJ
biomedich-346	87	35	dose	dose	NOUN
biomedich-346	87	36	of	of	ADP
biomedich-346	87	37	chad	chad	PROPN
biomedich-346	87	38	(	(	PUNCT
biomedich-346	87	39	n=540	n=540	PROPN
biomedich-346	87	40	,	,	PUNCT
biomedich-346	87	41	47	47	NUM
biomedich-346	87	42	%	%	NOUN
biomedich-346	87	43	female	female	NOUN
biomedich-346	87	44	)	)	PUNCT
biomedich-346	87	45	or	or	CCONJ
biomedich-346	87	46	bnt	bnt	PROPN
biomedich-346	87	47	(	(	PUNCT
biomedich-346	87	48	n=532	n=532	PROPN
biomedich-346	87	49	,	,	PUNCT
biomedich-346	87	50	40	40	NUM
biomedich-346	87	51	%	%	NOUN
biomedich-346	87	52	female	female	NOUN
biomedich-346	87	53	)	)	PUNCT
biomedich-346	87	54	.	.	PUNCT
biomedich-346	88	1	in	in	ADP
biomedich-346	88	2	chad	chad	PROPN
biomedich-346	88	3	-	-	PUNCT
biomedich-346	88	4	primed	prime	VERB
biomedich-346	88	5	participants	participant	NOUN
biomedich-346	88	6	,	,	PUNCT
biomedich-346	88	7	geometric	geometric	ADJ
biomedich-346	88	8	mean	mean	NOUN
biomedich-346	88	9	concentration	concentration	NOUN
biomedich-346	88	10	(	(	PUNCT
biomedich-346	88	11	gmc	gmc	NOUN
biomedich-346	88	12	)	)	PUNCT
biomedich-346	88	13	28	28	NUM
biomedich-346	88	14	days	day	NOUN
biomedich-346	88	15	after	after	ADP
biomedich-346	88	16	a	a	DET
biomedich-346	88	17	boost	boost	NOUN
biomedich-346	88	18	of	of	ADP
biomedich-346	88	19	sarscov-2	sarscov-2	NUM
biomedich-346	88	20	anti	anti	ADJ
biomedich-346	88	21	-	-	ADJ
biomedich-346	88	22	spike	spike	ADJ
biomedich-346	88	23	igg	igg	NOUN
biomedich-346	88	24	in	in	ADP
biomedich-346	88	25	recipients	recipient	NOUN
biomedich-346	88	26	of	of	ADP
biomedich-346	88	27	chad	chad	PROPN
biomedich-346	88	28	/	/	SYM
biomedich-346	88	29	m1273	m1273	PROPN
biomedich-346	88	30	(	(	PUNCT
biomedich-346	88	31	20	20	NUM
biomedich-346	88	32	114	114	NUM
biomedich-346	88	33	elisa	elisa	NOUN
biomedich-346	88	34	laboratory	laboratory	NOUN
biomedich-346	88	35	units	unit	NOUN
biomedich-346	88	36	[	[	X
biomedich-346	88	37	elu]/ml	elu]/ml	NOUN
biomedich-346	88	38	[	[	PUNCT
biomedich-346	88	39	95	95	NUM
biomedich-346	88	40	%	%	NOUN
biomedich-346	88	41	ci	ci	NOUN
biomedich-346	88	42	18	18	NUM
biomedich-346	88	43	160	160	NUM
biomedich-346	88	44	to	to	ADP
biomedich-346	88	45	22	22	NUM
biomedich-346	88	46	279	279	NUM
biomedich-346	88	47	]	]	PUNCT
biomedich-346	88	48	)	)	PUNCT
biomedich-346	88	49	and	and	CCONJ
biomedich-346	88	50	chad	chad	PROPN
biomedich-346	88	51	/	/	SYM
biomedich-346	88	52	nvx	nvx	PROPN
biomedich-346	88	53	(	(	PUNCT
biomedich-346	88	54	5597	5597	NUM
biomedich-346	88	55	elu	elu	NOUN
biomedich-346	88	56	/	/	SYM
biomedich-346	88	57	ml	ml	PROPN
biomedich-346	88	58	[	[	X
biomedich-346	88	59	4756	4756	NUM
biomedich-346	88	60	to	to	ADP
biomedich-346	88	61	6586	6586	NUM
biomedich-346	88	62	]	]	PUNCT
biomedich-346	88	63	)	)	PUNCT
biomedich-346	88	64	was	be	AUX
biomedich-346	88	65	non	non	ADJ
biomedich-346	88	66	-	-	ADJ
biomedich-346	88	67	inferior	inferior	ADJ
biomedich-346	88	68	to	to	ADP
biomedich-346	88	69	that	that	PRON
biomedich-346	88	70	of	of	ADP
biomedich-346	88	71	chad	chad	PROPN
biomedich-346	88	72	/	/	SYM
biomedich-346	88	73	chad	chad	PROPN
biomedich-346	88	74	recipients	recipient	NOUN
biomedich-346	88	75	(	(	PUNCT
biomedich-346	88	76	1971	1971	NUM
biomedich-346	88	77	elu	elu	NOUN
biomedich-346	88	78	/	/	SYM
biomedich-346	88	79	ml	ml	X
biomedich-346	89	1	[	[	X
biomedich-346	89	2	1718	1718	NUM
biomedich-346	89	3	to	to	ADP
biomedich-346	89	4	2262	2262	NUM
biomedich-346	89	5	]	]	PUNCT
biomedich-346	89	6	)	)	PUNCT
biomedich-346	89	7	with	with	ADP
biomedich-346	89	8	a	a	DET
biomedich-346	89	9	gmr	gmr	NOUN
biomedich-346	89	10	of	of	ADP
biomedich-346	89	11	10·2	10·2	NUM
biomedich-346	89	12	(	(	PUNCT
biomedich-346	89	13	one	one	NUM
biomedich-346	89	14	-	-	PUNCT
biomedich-346	89	15	sided	sided	ADJ
biomedich-346	89	16	98·75	98·75	NUM
biomedich-346	89	17	%	%	NOUN
biomedich-346	89	18	ci	ci	NOUN
biomedich-346	89	19	8·4	8·4	NUM
biomedich-346	89	20	to	to	ADP
biomedich-346	89	21	∞	∞	NUM
biomedich-346	89	22	)	)	PUNCT
biomedich-346	89	23	for	for	ADP
biomedich-346	89	24	chad	chad	PROPN
biomedich-346	89	25	/	/	SYM
biomedich-346	89	26	m1273	m1273	PROPN
biomedich-346	89	27	and	and	CCONJ
biomedich-346	89	28	2·8	2·8	NUM
biomedich-346	89	29	(	(	PUNCT
biomedich-346	89	30	2·2	2·2	NUM
biomedich-346	89	31	to	to	ADP
biomedich-346	89	32	∞	∞	NUM
biomedich-346	89	33	)	)	PUNCT
biomedich-346	89	34	for	for	ADP
biomedich-346	89	35	chad	chad	PROPN
biomedich-346	89	36	/	/	SYM
biomedich-346	89	37	nvx	nvx	PROPN
biomedich-346	89	38	,	,	PUNCT
biomedich-346	89	39	compared	compare	VERB
biomedich-346	89	40	with	with	ADP
biomedich-346	89	41	chad	chad	PROPN
biomedich-346	89	42	/	/	SYM
biomedich-346	89	43	chad	chad	PROPN
biomedich-346	89	44	.	.	PUNCT
biomedich-346	90	1	in	in	ADP
biomedich-346	90	2	bnt	bnt	PROPN
biomedich-346	90	3	-	-	PUNCT
biomedich-346	90	4	primed	prime	VERB
biomedich-346	90	5	participants	participant	NOUN
biomedich-346	90	6	,	,	PUNCT
biomedich-346	90	7	noninferiority	noninferiority	NOUN
biomedich-346	90	8	was	be	AUX
biomedich-346	90	9	shown	show	VERB
biomedich-346	90	10	for	for	ADP
biomedich-346	90	11	bnt	bnt	PROPN
biomedich-346	90	12	/	/	SYM
biomedich-346	90	13	m1273	m1273	PROPN
biomedich-346	90	14	(	(	PUNCT
biomedich-346	90	15	gmc	gmc	PROPN
biomedich-346	90	16	22	22	NUM
biomedich-346	90	17	978	978	NUM
biomedich-346	90	18	elu	elu	NOUN
biomedich-346	90	19	/	/	SYM
biomedich-346	90	20	ml	ml	X
biomedich-346	91	1	[	[	X
biomedich-346	91	2	95	95	NUM
biomedich-346	91	3	%	%	NOUN
biomedich-346	91	4	ci	ci	NOUN
biomedich-346	91	5	20	20	NUM
biomedich-346	91	6	597	597	NUM
biomedich-346	91	7	to	to	PART
biomedich-346	91	8	25	25	NUM
biomedich-346	91	9	636	636	NUM
biomedich-346	91	10	]	]	PUNCT
biomedich-346	91	11	)	)	PUNCT
biomedich-346	91	12	but	but	CCONJ
biomedich-346	91	13	not	not	PART
biomedich-346	91	14	for	for	ADP
biomedich-346	91	15	bnt	bnt	PROPN
biomedich-346	91	16	/	/	SYM
biomedich-346	91	17	nvx	nvx	PROPN
biomedich-346	91	18	(	(	PUNCT
biomedich-346	91	19	8874	8874	NUM
biomedich-346	91	20	elu	elu	NOUN
biomedich-346	91	21	/	/	SYM
biomedich-346	91	22	ml	ml	X
biomedich-346	92	1	[	[	X
biomedich-346	92	2	7391	7391	NUM
biomedich-346	92	3	to	to	ADP
biomedich-346	92	4	10	10	NUM
biomedich-346	92	5	654	654	NUM
biomedich-346	92	6	]	]	PUNCT
biomedich-346	92	7	)	)	PUNCT
biomedich-346	93	1	,	,	PUNCT
biomedich-346	93	2	compared	compare	VERB
biomedich-346	93	3	with	with	ADP
biomedich-346	93	4	bnt	bnt	PROPN
biomedich-346	93	5	/	/	SYM
biomedich-346	93	6	bnt	bnt	PROPN
biomedich-346	93	7	(	(	PUNCT
biomedich-346	93	8	16	16	NUM
biomedich-346	93	9	929	929	NUM
biomedich-346	93	10	elu	elu	NOUN
biomedich-346	93	11	/	/	SYM
biomedich-346	93	12	ml	ml	X
biomedich-346	94	1	[	[	X
biomedich-346	94	2	15	15	NUM
biomedich-346	94	3	025	025	NUM
biomedich-346	94	4	to	to	PART
biomedich-346	94	5	19	19	NUM
biomedich-346	94	6	075	075	NUM
biomedich-346	94	7	]	]	PUNCT
biomedich-346	94	8	)	)	PUNCT
biomedich-346	94	9	with	with	ADP
biomedich-346	94	10	a	a	DET
biomedich-346	94	11	gmr	gmr	NOUN
biomedich-346	94	12	of	of	ADP
biomedich-346	94	13	1·3	1·3	NUM
biomedich-346	94	14	(	(	PUNCT
biomedich-346	94	15	one	one	NUM
biomedich-346	94	16	-	-	PUNCT
biomedich-346	94	17	sided	sided	ADJ
biomedich-346	94	18	98·75	98·75	NUM
biomedich-346	94	19	%	%	NOUN
biomedich-346	94	20	ci	ci	NOUN
biomedich-346	94	21	1·1	1·1	NUM
biomedich-346	94	22	to	to	ADP
biomedich-346	94	23	∞	∞	NUM
biomedich-346	94	24	)	)	PUNCT
biomedich-346	94	25	for	for	ADP
biomedich-346	94	26	bnt	bnt	PROPN
biomedich-346	94	27	/	/	SYM
biomedich-346	94	28	m1273	m1273	PROPN
biomedich-346	94	29	and	and	CCONJ
biomedich-346	94	30	0·5	0·5	NUM
biomedich-346	94	31	(	(	PUNCT
biomedich-346	94	32	0·4	0·4	NUM
biomedich-346	94	33	to	to	ADP
biomedich-346	94	34	∞	∞	NUM
biomedich-346	94	35	)	)	PUNCT
biomedich-346	94	36	for	for	ADP
biomedich-346	94	37	bnt	bnt	PROPN
biomedich-346	94	38	/	/	SYM
biomedich-346	94	39	nvx	nvx	PROPN
biomedich-346	94	40	,	,	PUNCT
biomedich-346	94	41	compared	compare	VERB
biomedich-346	94	42	with	with	ADP
biomedich-346	94	43	bnt	bnt	PROPN
biomedich-346	94	44	/	/	SYM
biomedich-346	94	45	bnt	bnt	PROPN
biomedich-346	94	46	;	;	PUNCT
biomedich-346	94	47	however	however	ADV
biomedich-346	94	48	,	,	PUNCT
biomedich-346	94	49	nvx	nvx	PROPN
biomedich-346	94	50	still	still	ADV
biomedich-346	94	51	induced	induce	VERB
biomedich-346	94	52	an	an	DET
biomedich-346	94	53	18	18	NUM
biomedich-346	94	54	-	-	ADJ
biomedich-346	94	55	fold	fold	ADJ
biomedich-346	94	56	rise	rise	NOUN
biomedich-346	94	57	in	in	ADP
biomedich-346	94	58	gmc	gmc	ADJ
biomedich-346	94	59	28	28	NUM
biomedich-346	94	60	days	day	NOUN
biomedich-346	94	61	after	after	ADP
biomedich-346	94	62	vaccination	vaccination	NOUN
biomedich-346	94	63	.	.	PUNCT
biomedich-346	95	1	there	there	PRON
biomedich-346	95	2	were	be	VERB
biomedich-346	95	3	15	15	NUM
biomedich-346	95	4	serious	serious	ADJ
biomedich-346	95	5	adverse	adverse	ADJ
biomedich-346	95	6	events	event	NOUN
biomedich-346	95	7	,	,	PUNCT
biomedich-346	95	8	none	none	NOUN
biomedich-346	95	9	considered	consider	VERB
biomedich-346	95	10	related	related	ADJ
biomedich-346	95	11	to	to	ADP
biomedich-346	95	12	immunization	immunization	NOUN
biomedich-346	95	13	.	.	PUNCT
biomedich-346	96	1	aldrich	aldrich	PROPN
biomedich-346	96	2	et	et	PROPN
biomedich-346	96	3	al	al	PROPN
biomedich-346	96	4	.	.	PROPN
biomedich-346	96	5	,	,	PUNCT
biomedich-346	96	6	2021	2021	NUM
biomedich-346	96	7	,	,	PUNCT
biomedich-346	96	8	found	find	VERB
biomedich-346	96	9	that	that	SCONJ
biomedich-346	96	10	,	,	PUNCT
biomedich-346	96	11	as	as	ADP
biomedich-346	96	12	initially	initially	ADV
biomedich-346	96	13	tested	test	VERB
biomedich-346	96	14	doses	dose	NOUN
biomedich-346	96	15	of	of	ADP
biomedich-346	96	16	5	5	NUM
biomedich-346	96	17	μg	μg	NOUN
biomedich-346	96	18	cv7202	cv7202	PROPN
biomedich-346	96	19	elicited	elicit	VERB
biomedich-346	96	20	unacceptably	unacceptably	ADV
biomedich-346	96	21	high	high	ADJ
biomedich-346	96	22	reactogenicity	reactogenicity	NOUN
biomedich-346	96	23	we	we	PRON
biomedich-346	96	24	subsequently	subsequently	ADV
biomedich-346	96	25	tested	test	VERB
biomedich-346	96	26	1	1	NUM
biomedich-346	96	27	and	and	CCONJ
biomedich-346	96	28	2	2	NUM
biomedich-346	96	29	μg	μg	PROPN
biomedich-346	96	30	doses	dose	NOUN
biomedich-346	96	31	which	which	PRON
biomedich-346	96	32	were	be	AUX
biomedich-346	96	33	better	well	ADV
biomedich-346	96	34	tolerated	tolerate	VERB
biomedich-346	96	35	.	.	PUNCT
biomedich-346	97	1	no	no	DET
biomedich-346	97	2	vaccine	vaccine	NOUN
biomedich-346	97	3	-	-	PUNCT
biomedich-346	97	4	related	relate	VERB
biomedich-346	97	5	serious	serious	ADJ
biomedich-346	97	6	adverse	adverse	ADJ
biomedich-346	97	7	events	event	NOUN
biomedich-346	97	8	or	or	CCONJ
biomedich-346	97	9	withdrawals	withdrawal	NOUN
biomedich-346	97	10	occurred	occur	VERB
biomedich-346	97	11	.	.	PUNCT
biomedich-346	98	1	low	low	ADJ
biomedich-346	98	2	,	,	PUNCT
biomedich-346	98	3	dose	dose	NOUN
biomedich-346	98	4	-	-	PUNCT
biomedich-346	98	5	dependent	dependent	ADJ
biomedich-346	98	6	vnt	vnt	PROPN
biomedich-346	98	7	responses	response	NOUN
biomedich-346	98	8	were	be	AUX
biomedich-346	98	9	detectable	detectable	ADJ
biomedich-346	98	10	from	from	ADP
biomedich-346	98	11	day	day	NOUN
biomedich-346	98	12	15	15	NUM
biomedich-346	98	13	,	,	PUNCT
biomedich-346	98	14	and	and	CCONJ
biomedich-346	98	15	by	by	ADP
biomedich-346	98	16	day	day	NOUN
biomedich-346	98	17	29	29	NUM
biomedich-346	98	18	%	%	NOUN
biomedich-346	98	19	,	,	PUNCT
biomedich-346	98	20	31	31	NUM
biomedich-346	98	21	%	%	NOUN
biomedich-346	98	22	,	,	PUNCT
biomedich-346	98	23	and	and	CCONJ
biomedich-346	98	24	22	22	NUM
biomedich-346	98	25	%	%	NOUN
biomedich-346	98	26	of	of	ADP
biomedich-346	98	27	1	1	NUM
biomedich-346	98	28	,	,	PUNCT
biomedich-346	98	29	2	2	NUM
biomedich-346	98	30	,	,	PUNCT
biomedich-346	98	31	and	and	CCONJ
biomedich-346	98	32	5	5	NUM
biomedich-346	98	33	μg	μg	PROPN
biomedich-346	98	34	groups	group	NOUN
biomedich-346	98	35	,	,	PUNCT
biomedich-346	98	36	respectively	respectively	ADV
biomedich-346	98	37	,	,	PUNCT
biomedich-346	98	38	had	have	AUX
biomedich-346	98	39	vnts	vnt	NOUN
biomedich-346	98	40	≥	≥	PRON
biomedich-346	98	41	0·5	0·5	NUM
biomedich-346	98	42	iu	iu	ADP
biomedich-346	98	43	/	/	SYM
biomedich-346	98	44	ml	ml	NOUN
biomedich-346	98	45	,	,	PUNCT
biomedich-346	98	46	considered	consider	VERB
biomedich-346	98	47	an	an	DET
biomedich-346	98	48	adequate	adequate	ADJ
biomedich-346	98	49	response	response	NOUN
biomedich-346	98	50	by	by	ADP
biomedich-346	98	51	the	the	DET
biomedich-346	98	52	who	who	PRON
biomedich-346	98	53	.	.	PUNCT
biomedich-346	99	1	after	after	ADP
biomedich-346	99	2	two	two	NUM
biomedich-346	99	3	1	1	NUM
biomedich-346	99	4	or	or	CCONJ
biomedich-346	99	5	2	2	NUM
biomedich-346	99	6	μg	μg	NOUN
biomedich-346	99	7	doses	dose	NOUN
biomedich-346	99	8	all	all	DET
biomedich-346	99	9	recipients	recipient	NOUN
biomedich-346	99	10	had	have	VERB
biomedich-346	99	11	titers	titer	NOUN
biomedich-346	99	12	≥	≥	NUM
biomedich-346	99	13	0.5	0.5	NUM
biomedich-346	99	14	iu	iu	NOUN
biomedich-346	99	15	/	/	SYM
biomedich-346	99	16	ml	ml	VERB
biomedich-346	99	17	by	by	ADP
biomedich-346	99	18	day	day	NOUN
biomedich-346	99	19	43	43	NUM
biomedich-346	99	20	.	.	PUNCT
biomedich-346	100	1	day	day	NOUN
biomedich-346	100	2	57	57	NUM
biomedich-346	100	3	gmts	gmts	NOUN
biomedich-346	100	4	were	be	AUX
biomedich-346	100	5	not	not	PART
biomedich-346	100	6	significantly	significantly	ADV
biomedich-346	100	7	lower	low	ADJ
biomedich-346	100	8	than	than	ADP
biomedich-346	100	9	those	those	PRON
biomedich-346	100	10	with	with	ADP
biomedich-346	100	11	rabipur	rabipur	NOUN
biomedich-346	100	12	,	,	PUNCT
biomedich-346	100	13	which	which	PRON
biomedich-346	100	14	elicited	elicit	VERB
biomedich-346	100	15	adequate	adequate	ADJ
biomedich-346	100	16	responses	response	NOUN
biomedich-346	100	17	in	in	ADP
biomedich-346	100	18	all	all	DET
biomedich-346	100	19	vaccinees	vaccinee	NOUN
biomedich-346	100	20	after	after	ADP
biomedich-346	100	21	two	two	NUM
biomedich-346	100	22	doses	dose	NOUN
biomedich-346	100	23	.	.	PUNCT
biomedich-346	101	1	cv7202elicited	cv7202elicite	VERB
biomedich-346	101	2	vnt	vnt	PROPN
biomedich-346	101	3	was	be	AUX
biomedich-346	101	4	significantly	significantly	ADV
biomedich-346	101	5	correlated	correlate	VERB
biomedich-346	101	6	with	with	ADP
biomedich-346	101	7	rabv	rabv	NOUN
biomedich-346	101	8	-	-	PUNCT
biomedich-346	101	9	gspecific	gspecific	ADJ
biomedich-346	101	10	igg	igg	PROPN
biomedich-346	101	11	antibodies	antibodie	VERB
biomedich-346	101	12	(	(	PUNCT
biomedich-346	101	13	r2	r2	PROPN
biomedich-346	101	14	=	=	SYM
biomedich-346	101	15	0.8319	0.8319	NUM
biomedich-346	101	16	,	,	PUNCT
biomedich-346	101	17	p	p	X
biomedich-346	101	18	<	<	X
biomedich-346	101	19	0.0001	0.0001	NUM
biomedich-346	101	20	)	)	PUNCT
biomedich-346	101	21	.	.	PUNCT
biomedich-346	102	1	shinde	shinde	PROPN
biomedich-346	102	2	et	et	PROPN
biomedich-346	102	3	al	al	PROPN
biomedich-346	102	4	.	.	PROPN
biomedich-346	102	5	,	,	PUNCT
biomedich-346	102	6	2022	2022	NUM
biomedich-346	102	7	,	,	PUNCT
biomedich-346	102	8	found	find	VERB
biomedich-346	102	9	that	that	SCONJ
biomedich-346	102	10	more	more	ADV
biomedich-346	102	11	solicited	solicited	ADJ
biomedich-346	102	12	adverse	adverse	ADJ
biomedich-346	102	13	events	event	NOUN
biomedich-346	102	14	were	be	AUX
biomedich-346	102	15	reported	report	VERB
biomedich-346	102	16	by	by	ADP
biomedich-346	102	17	participants	participant	NOUN
biomedich-346	102	18	in	in	ADP
biomedich-346	102	19	the	the	DET
biomedich-346	102	20	qniv	qniv	ADJ
biomedich-346	102	21	group	group	NOUN
biomedich-346	102	22	(	(	PUNCT
biomedich-346	102	23	551	551	NUM
biomedich-346	102	24	[	[	X
biomedich-346	102	25	41·3	41·3	NUM
biomedich-346	102	26	%	%	NOUN
biomedich-346	102	27	]	]	PUNCT
biomedich-346	102	28	of	of	ADP
biomedich-346	102	29	1333	1333	NUM
biomedich-346	102	30	)	)	PUNCT
biomedich-346	102	31	than	than	ADP
biomedich-346	102	32	in	in	ADP
biomedich-346	102	33	the	the	DET
biomedich-346	102	34	iiv4	iiv4	PROPN
biomedich-346	102	35	group	group	NOUN
biomedich-346	102	36	(	(	PUNCT
biomedich-346	102	37	420	420	NUM
biomedich-346	102	38	[	[	X
biomedich-346	102	39	31·8	31·8	NUM
biomedich-346	102	40	%	%	NOUN
biomedich-346	102	41	]	]	PUNCT
biomedich-346	102	42	of	of	ADP
biomedich-346	102	43	1319	1319	NUM
biomedich-346	102	44	)	)	PUNCT
biomedich-346	102	45	,	,	PUNCT
biomedich-346	102	46	and	and	CCONJ
biomedich-346	102	47	were	be	AUX
biomedich-346	102	48	comprised	comprise	VERB
biomedich-346	102	49	primarily	primarily	ADV
biomedich-346	102	50	of	of	ADP
biomedich-346	102	51	mild	mild	ADJ
biomedich-346	102	52	to	to	ADP
biomedich-346	102	53	moderate	moderate	ADJ
biomedich-346	102	54	transient	transient	ADJ
biomedich-346	102	55	injection	injection	NOUN
biomedich-346	102	56	site	site	NOUN
biomedich-346	102	57	pain	pain	NOUN
biomedich-346	102	58	(	(	PUNCT
biomedich-346	102	59	341	341	NUM
biomedich-346	102	60	[	[	X
biomedich-346	102	61	25·6	25·6	NUM
biomedich-346	102	62	%	%	NOUN
biomedich-346	102	63	]	]	PUNCT
biomedich-346	102	64	in	in	ADP
biomedich-346	102	65	the	the	DET
biomedich-346	102	66	qniv	qniv	ADJ
biomedich-346	102	67	group	group	NOUN
biomedich-346	102	68	vs	vs	ADP
biomedich-346	102	69	212	212	NUM
biomedich-346	102	70	[	[	X
biomedich-346	102	71	16·1	16·1	NUM
biomedich-346	102	72	%	%	NOUN
biomedich-346	102	73	]	]	PUNCT
biomedich-346	102	74	in	in	ADP
biomedich-346	102	75	the	the	DET
biomedich-346	102	76	iiv4	iiv4	PROPN
biomedich-346	102	77	group	group	NOUN
biomedich-346	102	78	)	)	PUNCT
biomedich-346	102	79	.	.	PUNCT
biomedich-346	103	1	formica	formica	NOUN
biomedich-346	103	2	et	et	PROPN
biomedich-346	103	3	al	al	PROPN
biomedich-346	103	4	.	.	PROPN
biomedich-346	103	5	,	,	PUNCT
biomedich-346	103	6	2021	2021	NUM
biomedich-346	103	7	,	,	PUNCT
biomedich-346	103	8	found	find	VERB
biomedich-346	103	9	that	that	SCONJ
biomedich-346	103	10	,	,	PUNCT
biomedich-346	103	11	neutralizing	neutralize	VERB
biomedich-346	103	12	antibody	antibody	NOUN
biomedich-346	103	13	responses	response	NOUN
biomedich-346	103	14	exceeded	exceed	VERB
biomedich-346	103	15	those	those	PRON
biomedich-346	103	16	seen	see	VERB
biomedich-346	103	17	in	in	ADP
biomedich-346	103	18	a	a	DET
biomedich-346	103	19	panel	panel	NOUN
biomedich-346	103	20	of	of	ADP
biomedich-346	103	21	convalescent	convalescent	NOUN
biomedich-346	103	22	sera	sera	NOUN
biomedich-346	103	23	for	for	ADP
biomedich-346	103	24	both	both	DET
biomedich-346	103	25	age	age	NOUN
biomedich-346	103	26	groups	group	NOUN
biomedich-346	103	27	.	.	PUNCT
biomedich-346	104	1	study	study	NOUN
biomedich-346	104	2	limitations	limitation	NOUN
biomedich-346	104	3	include	include	VERB
biomedich-346	104	4	the	the	DET
biomedich-346	104	5	relatively	relatively	ADV
biomedich-346	104	6	short	short	ADJ
biomedich-346	104	7	duration	duration	NOUN
biomedich-346	104	8	of	of	ADP
biomedich-346	104	9	safety	safety	NOUN
biomedich-346	104	10	follow	follow	NOUN
biomedich-346	104	11	-	-	PUNCT
biomedich-346	104	12	up	up	NOUN
biomedich-346	104	13	to	to	ADP
biomedich-346	104	14	date	date	NOUN
biomedich-346	104	15	and	and	CCONJ
biomedich-346	104	16	the	the	DET
biomedich-346	104	17	current	current	ADJ
biomedich-346	104	18	lack	lack	NOUN
biomedich-346	104	19	of	of	ADP
biomedich-346	104	20	immune	immune	ADJ
biomedich-346	104	21	persistence	persistence	NOUN
biomedich-346	104	22	data	datum	NOUN
biomedich-346	104	23	beyond	beyond	ADP
biomedich-346	104	24	the	the	DET
biomedich-346	104	25	primary	primary	ADJ
biomedich-346	104	26	vaccination	vaccination	NOUN
biomedich-346	104	27	regimen	regimen	NOUN
biomedich-346	104	28	time	time	NOUN
biomedich-346	104	29	point	point	NOUN
biomedich-346	104	30	assessments	assessment	NOUN
biomedich-346	104	31	,	,	PUNCT
biomedich-346	104	32	but	but	CCONJ
biomedich-346	104	33	these	these	DET
biomedich-346	104	34	data	datum	NOUN
biomedich-346	104	35	will	will	AUX
biomedich-346	104	36	accumulate	accumulate	VERB
biomedich-346	104	37	over	over	ADP
biomedich-346	104	38	time	time	NOUN
biomedich-346	104	39	.	.	PUNCT
biomedich-346	105	1	khobragade	khobragade	PROPN
biomedich-346	105	2	et	et	PROPN
biomedich-346	105	3	al	al	PROPN
biomedich-346	105	4	.	.	PROPN
biomedich-346	105	5	,	,	PUNCT
biomedich-346	105	6	2021	2021	NUM
biomedich-346	105	7	,	,	PUNCT
biomedich-346	105	8	found	find	VERB
biomedich-346	105	9	that	that	SCONJ
biomedich-346	105	10	the	the	DET
biomedich-346	105	11	socio	socio	NOUN
biomedich-346	105	12	-	-	PUNCT
biomedich-346	105	13	demographic	demographic	ADJ
biomedich-346	105	14	characteristics	characteristic	NOUN
biomedich-346	105	15	of	of	ADP
biomedich-346	105	16	the	the	DET
biomedich-346	105	17	two	two	NUM
biomedich-346	105	18	arms	arm	NOUN
biomedich-346	105	19	were	be	AUX
biomedich-346	105	20	comparable	comparable	ADJ
biomedich-346	105	21	.	.	PUNCT
biomedich-346	106	1	about	about	ADV
biomedich-346	106	2	9.9	9.9	NUM
biomedich-346	106	3	%	%	NOUN
biomedich-346	106	4	of	of	ADP
biomedich-346	106	5	subjects	subject	NOUN
biomedich-346	106	6	in	in	ADP
biomedich-346	106	7	the	the	DET
biomedich-346	106	8	recombinant	recombinant	ADJ
biomedich-346	106	9	rabies	rabie	NOUN
biomedich-346	106	10	g	g	NOUN
biomedich-346	106	11	protein	protein	NOUN
biomedich-346	106	12	vaccine	vaccine	NOUN
biomedich-346	106	13	arm	arm	NOUN
biomedich-346	106	14	and	and	CCONJ
biomedich-346	106	15	17.2	17.2	NUM
biomedich-346	106	16	%	%	NOUN
biomedich-346	106	17	of	of	ADP
biomedich-346	106	18	subjects	subject	NOUN
biomedich-346	106	19	in	in	ADP
biomedich-346	106	20	the	the	DET
biomedich-346	106	21	reference	reference	NOUN
biomedich-346	106	22	arm	arm	NOUN
biomedich-346	106	23	reported	report	VERB
biomedich-346	106	24	adverse	adverse	ADJ
biomedich-346	106	25	events	event	NOUN
biomedich-346	106	26	.	.	PUNCT
biomedich-346	107	1	the	the	DET
biomedich-346	107	2	sero	sero	NOUN
biomedich-346	107	3	-	-	PUNCT
biomedich-346	107	4	protection	protection	NOUN
biomedich-346	107	5	on	on	ADP
biomedich-346	107	6	day	day	NOUN
biomedich-346	107	7	14	14	NUM
biomedich-346	107	8	was	be	AUX
biomedich-346	107	9	found	find	VERB
biomedich-346	107	10	to	to	PART
biomedich-346	107	11	be	be	AUX
biomedich-346	107	12	99.24	99.24	NUM
biomedich-346	107	13	%	%	NOUN
biomedich-346	107	14	and	and	CCONJ
biomedich-346	107	15	97.72	97.72	NUM
biomedich-346	107	16	%	%	NOUN
biomedich-346	107	17	in	in	ADP
biomedich-346	107	18	the	the	DET
biomedich-346	107	19	recombinant	recombinant	ADJ
biomedich-346	107	20	rabies	rabie	NOUN
biomedich-346	107	21	g	g	NOUN
biomedich-346	107	22	protein	protein	NOUN
biomedich-346	107	23	vaccine	vaccine	NOUN
biomedich-346	107	24	arm	arm	NOUN
biomedich-346	107	25	and	and	CCONJ
biomedich-346	107	26	reference	reference	NOUN
biomedich-346	107	27	vaccine	vaccine	NOUN
biomedich-346	107	28	arm	arm	VERB
biomedich-346	107	29	respectively	respectively	ADV
biomedich-346	107	30	and	and	CCONJ
biomedich-346	107	31	the	the	DET
biomedich-346	107	32	difference	difference	NOUN
biomedich-346	107	33	was	be	AUX
biomedich-346	107	34	statistically	statistically	ADV
biomedich-346	107	35	nonsignificant	nonsignificant	ADJ
biomedich-346	107	36	.	.	PUNCT
biomedich-346	108	1	august	august	PROPN
biomedich-346	108	2	et	et	PROPN
biomedich-346	108	3	al	al	PROPN
biomedich-346	108	4	.	.	PROPN
biomedich-346	108	5	,	,	PUNCT
biomedich-346	108	6	2021	2021	NUM
biomedich-346	108	7	,	,	PUNCT
biomedich-346	108	8	found	find	VERB
biomedich-346	108	9	that	that	SCONJ
biomedich-346	108	10	further	further	ADJ
biomedich-346	108	11	evaluation	evaluation	NOUN
biomedich-346	108	12	of	of	ADP
biomedich-346	108	13	the	the	DET
biomedich-346	108	14	potential	potential	ADJ
biomedich-346	108	15	therapeutic	therapeutic	ADJ
biomedich-346	108	16	use	use	NOUN
biomedich-346	108	17	of	of	ADP
biomedich-346	108	18	mrna-1944	mrna-1944	NOUN
biomedich-346	108	19	in	in	ADP
biomedich-346	108	20	clinical	clinical	ADJ
biomedich-346	108	21	trials	trial	NOUN
biomedich-346	108	22	for	for	ADP
biomedich-346	108	23	the	the	DET
biomedich-346	108	24	treatment	treatment	NOUN
biomedich-346	108	25	of	of	ADP
biomedich-346	108	26	chikv	chikv	ADJ
biomedich-346	108	27	infection	infection	NOUN
biomedich-346	108	28	is	be	AUX
biomedich-346	108	29	warranted	warrant	VERB
biomedich-346	108	30	.	.	PUNCT
biomedich-346	109	1	shinde	shinde	PROPN
biomedich-346	109	2	et	et	PROPN
biomedich-346	109	3	al	al	PROPN
biomedich-346	109	4	.	.	PROPN
biomedich-346	109	5	,	,	PUNCT
biomedich-346	109	6	2021	2021	NUM
biomedich-346	109	7	,	,	PUNCT
biomedich-346	109	8	found	find	VERB
biomedich-346	109	9	that	that	SCONJ
biomedich-346	109	10	,	,	PUNCT
biomedich-346	109	11	overall	overall	ADJ
biomedich-346	109	12	,	,	PUNCT
biomedich-346	109	13	similar	similar	ADJ
biomedich-346	109	14	frequencies	frequency	NOUN
biomedich-346	109	15	of	of	ADP
biomedich-346	109	16	solicited	solicited	ADJ
biomedich-346	109	17	and	and	CCONJ
biomedich-346	109	18	unsolicited	unsolicited	ADJ
biomedich-346	109	19	adverse	adverse	ADJ
biomedich-346	109	20	events	event	NOUN
biomedich-346	109	21	were	be	AUX
biomedich-346	109	22	reported	report	VERB
biomedich-346	109	23	in	in	ADP
biomedich-346	109	24	all	all	DET
biomedich-346	109	25	treatment	treatment	NOUN
biomedich-346	109	26	groups	group	NOUN
biomedich-346	109	27	.	.	PUNCT
biomedich-346	110	1	kremsner	kremsner	PROPN
biomedich-346	110	2	et	et	PROPN
biomedich-346	110	3	al	al	PROPN
biomedich-346	110	4	.	.	PROPN
biomedich-346	110	5	,	,	PUNCT
biomedich-346	110	6	2021	2021	NUM
biomedich-346	110	7	,	,	PUNCT
biomedich-346	110	8	found	find	VERB
biomedich-346	110	9	that	that	SCONJ
biomedich-346	110	10	responses	response	NOUN
biomedich-346	110	11	to	to	ADP
biomedich-346	110	12	12	12	NUM
biomedich-346	110	13	μg	μg	NOUN
biomedich-346	110	14	were	be	AUX
biomedich-346	110	15	comparable	comparable	ADJ
biomedich-346	110	16	to	to	ADP
biomedich-346	110	17	those	those	PRON
biomedich-346	110	18	observed	observe	VERB
biomedich-346	110	19	in	in	ADP
biomedich-346	110	20	convalescent	convalescent	NOUN
biomedich-346	110	21	sera	sera	NOUN
biomedich-346	110	22	from	from	ADP
biomedich-346	110	23	known	know	VERB
biomedich-346	110	24	covid-19	covid-19	PROPN
biomedich-346	110	25	patients	patient	NOUN
biomedich-346	110	26	.	.	PUNCT
biomedich-346	111	1	mallory	mallory	PROPN
biomedich-346	111	2	et	et	PROPN
biomedich-346	111	3	al	al	PROPN
biomedich-346	111	4	.	.	PROPN
biomedich-346	111	5	,	,	PUNCT
biomedich-346	111	6	2022	2022	NUM
biomedich-346	111	7	,	,	PUNCT
biomedich-346	111	8	found	find	VERB
biomedich-346	111	9	that	that	SCONJ
biomedich-346	111	10	1610	1610	NUM
biomedich-346	111	11	participants	participant	NOUN
biomedich-346	111	12	were	be	AUX
biomedich-346	111	13	screened	screen	VERB
biomedich-346	111	14	from	from	ADP
biomedich-346	111	15	aug	aug	PROPN
biomedich-346	111	16	24	24	NUM
biomedich-346	111	17	,	,	PUNCT
biomedich-346	111	18	2020	2020	NUM
biomedich-346	111	19	,	,	PUNCT
biomedich-346	111	20	to	to	PART
biomedich-346	111	21	sept	sept	PROPN
biomedich-346	111	22	25	25	NUM
biomedich-346	111	23	,	,	PUNCT
biomedich-346	111	24	2020	2020	NUM
biomedich-346	111	25	.	.	PUNCT
biomedich-346	112	1	1282	1282	NUM
biomedich-346	112	2	participants	participant	NOUN
biomedich-346	112	3	were	be	AUX
biomedich-346	112	4	enrolled	enrol	VERB
biomedich-346	112	5	,	,	PUNCT
biomedich-346	112	6	of	of	ADP
biomedich-346	112	7	whom	whom	PRON
biomedich-346	112	8	173	173	NUM
biomedich-346	112	9	were	be	AUX
biomedich-346	112	10	assigned	assign	VERB
biomedich-346	112	11	again	again	ADV
biomedich-346	112	12	to	to	ADP
biomedich-346	112	13	placebo	placebo	NOUN
biomedich-346	112	14	(	(	PUNCT
biomedich-346	112	15	group	group	NOUN
biomedich-346	112	16	a	a	NOUN
biomedich-346	112	17	)	)	PUNCT
biomedich-346	112	18	,	,	PUNCT
biomedich-346	112	19	106	106	NUM
biomedich-346	112	20	were	be	AUX
biomedich-346	112	21	re	re	VERB
biomedich-346	112	22	-	-	VERB
biomedich-346	112	23	randomized	randomize	VERB
biomedich-346	112	24	to	to	ADP
biomedich-346	112	25	nvx	nvx	NOUN
biomedich-346	112	26	-	-	PUNCT
biomedich-346	112	27	cov2373	cov2373	NOUN
biomedich-346	112	28	-	-	PUNCT
biomedich-346	112	29	placebo	placebo	NOUN
biomedich-346	112	30	(	(	PUNCT
biomedich-346	112	31	group	group	NOUN
biomedich-346	112	32	b1	b1	PROPN
biomedich-346	112	33	)	)	PUNCT
biomedich-346	112	34	,	,	PUNCT
biomedich-346	112	35	and	and	CCONJ
biomedich-346	112	36	104	104	NUM
biomedich-346	112	37	were	be	AUX
biomedich-346	112	38	rerandomized	rerandomize	VERB
biomedich-346	112	39	to	to	ADP
biomedich-346	112	40	nvx	nvx	NOUN
biomedich-346	112	41	-	-	PUNCT
biomedich-346	112	42	cov2373	cov2373	NOUN
biomedich-346	112	43	-	-	PUNCT
biomedich-346	112	44	nvx	nvx	NOUN
biomedich-346	112	45	-	-	PUNCT
biomedich-346	112	46	cov2373	cov2373	NOUN
biomedich-346	112	47	(	(	PUNCT
biomedich-346	112	48	group	group	NOUN
biomedich-346	112	49	b2	b2	PROPN
biomedich-346	112	50	)	)	PUNCT
biomedich-346	112	51	;	;	PUNCT
biomedich-346	112	52	after	after	ADP
biomedich-346	112	53	accounting	account	VERB
biomedich-346	112	54	for	for	ADP
biomedich-346	112	55	exclusions	exclusion	NOUN
biomedich-346	112	56	and	and	CCONJ
biomedich-346	112	57	incorrect	incorrect	ADJ
biomedich-346	112	58	administration	administration	NOUN
biomedich-346	112	59	,	,	PUNCT
biomedich-346	112	60	172	172	NUM
biomedich-346	112	61	participants	participant	NOUN
biomedich-346	112	62	in	in	ADP
biomedich-346	112	63	group	group	PROPN
biomedich-346	112	64	a	a	PROPN
biomedich-346	112	65	,	,	PUNCT
biomedich-346	112	66	102	102	NUM
biomedich-346	112	67	in	in	ADP
biomedich-346	112	68	group	group	NOUN
biomedich-346	112	69	b1	b1	NOUN
biomedich-346	112	70	,	,	PUNCT
biomedich-346	112	71	and	and	CCONJ
biomedich-346	112	72	105	105	NUM
biomedich-346	112	73	in	in	ADP
biomedich-346	112	74	group	group	NOUN
biomedich-346	112	75	b2	b2	NOUN
biomedich-346	112	76	were	be	AUX
biomedich-346	112	77	analysed	analyse	VERB
biomedich-346	112	78	for	for	ADP
biomedich-346	112	79	safety	safety	NOUN
biomedich-346	112	80	.	.	PUNCT
biomedich-346	113	1	following	follow	VERB
biomedich-346	113	2	the	the	DET
biomedich-346	113	3	active	active	ADJ
biomedich-346	113	4	booster	booster	NOUN
biomedich-346	113	5	,	,	PUNCT
biomedich-346	113	6	the	the	DET
biomedich-346	113	7	proportion	proportion	NOUN
biomedich-346	113	8	of	of	ADP
biomedich-346	113	9	participants	participant	NOUN
biomedich-346	113	10	with	with	ADP
biomedich-346	113	11	available	available	ADJ
biomedich-346	113	12	data	datum	NOUN
biomedich-346	113	13	reporting	report	VERB
biomedich-346	113	14	local	local	ADJ
biomedich-346	113	15	(	(	PUNCT
biomedich-346	113	16	80	80	NUM
biomedich-346	113	17	[	[	SYM
biomedich-346	113	18	82	82	NUM
biomedich-346	113	19	%	%	NOUN
biomedich-346	113	20	]	]	PUNCT
biomedich-346	113	21	of	of	ADP
biomedich-346	113	22	97	97	NUM
biomedich-346	113	23	participants	participant	NOUN
biomedich-346	113	24	had	have	VERB
biomedich-346	113	25	any	any	DET
biomedich-346	113	26	adverse	adverse	ADJ
biomedich-346	113	27	event	event	NOUN
biomedich-346	113	28	;	;	PUNCT
biomedich-346	113	29	13	13	NUM
biomedich-346	114	1	[	[	SYM
biomedich-346	114	2	13	13	NUM
biomedich-346	114	3	%	%	NOUN
biomedich-346	114	4	]	]	PUNCT
biomedich-346	114	5	had	have	VERB
biomedich-346	114	6	a	a	DET
biomedich-346	114	7	grade	grade	NOUN
biomedich-346	114	8	≥3	≥3	NOUN
biomedich-346	114	9	events	event	NOUN
biomedich-346	114	10	)	)	PUNCT
biomedich-346	114	11	and	and	CCONJ
biomedich-346	114	12	systemic	systemic	ADJ
biomedich-346	114	13	(	(	PUNCT
biomedich-346	114	14	75	75	NUM
biomedich-346	114	15	[	[	X
biomedich-346	114	16	77	77	NUM
biomedich-346	114	17	%	%	NOUN
biomedich-346	114	18	]	]	PUNCT
biomedich-346	114	19	of	of	ADP
biomedich-346	114	20	98	98	NUM
biomedich-346	114	21	participants	participant	NOUN
biomedich-346	114	22	had	have	VERB
biomedich-346	114	23	any	any	DET
biomedich-346	114	24	adverse	adverse	ADJ
biomedich-346	114	25	event	event	NOUN
biomedich-346	114	26	;	;	PUNCT
biomedich-346	115	1	15	15	NUM
biomedich-346	115	2	[	[	SYM
biomedich-346	115	3	15	15	NUM
biomedich-346	115	4	%	%	NOUN
biomedich-346	115	5	]	]	PUNCT
biomedich-346	115	6	had	have	VERB
biomedich-346	115	7	a	a	DET
biomedich-346	115	8	grade	grade	NOUN
biomedich-346	115	9	≥3	≥3	PROPN
biomedich-346	115	10	events	event	NOUN
biomedich-346	115	11	)	)	PUNCT
biomedich-346	115	12	reactions	reaction	NOUN
biomedich-346	115	13	was	be	AUX
biomedich-346	115	14	higher	high	ADJ
biomedich-346	115	15	than	than	ADP
biomedich-346	115	16	after	after	ADP
biomedich-346	115	17	primary	primary	ADJ
biomedich-346	115	18	vaccination	vaccination	NOUN
biomedich-346	115	19	(	(	PUNCT
biomedich-346	115	20	175	175	NUM
biomedich-346	116	1	[	[	X
biomedich-346	116	2	70	70	NUM
biomedich-346	116	3	%	%	NOUN
biomedich-346	116	4	]	]	PUNCT
biomedich-346	116	5	of	of	ADP
biomedich-346	116	6	250	250	NUM
biomedich-346	116	7	participants	participant	NOUN
biomedich-346	116	8	had	have	VERB
biomedich-346	116	9	any	any	DET
biomedich-346	116	10	local	local	ADJ
biomedich-346	116	11	adverse	adverse	ADJ
biomedich-346	116	12	event	event	NOUN
biomedich-346	116	13	,	,	PUNCT
biomedich-346	116	14	13	13	NUM
biomedich-346	116	15	[	[	SYM
biomedich-346	116	16	5	5	NUM
biomedich-346	116	17	%	%	NOUN
biomedich-346	116	18	]	]	PUNCT
biomedich-346	116	19	had	have	VERB
biomedich-346	116	20	a	a	DET
biomedich-346	116	21	grade	grade	NOUN
biomedich-346	116	22	≥3	≥3	NOUN
biomedich-346	116	23	events	event	NOUN
biomedich-346	116	24	;	;	PUNCT
biomedich-346	116	25	132	132	NUM
biomedich-346	116	26	[	[	SYM
biomedich-346	116	27	53	53	NUM
biomedich-346	116	28	%	%	NOUN
biomedich-346	116	29	]	]	PUNCT
biomedich-346	116	30	of	of	ADP
biomedich-346	116	31	250	250	NUM
biomedich-346	116	32	had	have	VERB
biomedich-346	116	33	any	any	DET
biomedich-346	116	34	systemic	systemic	ADJ
biomedich-346	116	35	adverse	adverse	ADJ
biomedich-346	116	36	event	event	NOUN
biomedich-346	116	37	,	,	PUNCT
biomedich-346	116	38	14	14	NUM
biomedich-346	116	39	[	[	SYM
biomedich-346	116	40	6	6	NUM
biomedich-346	116	41	%	%	NOUN
biomedich-346	116	42	]	]	PUNCT
biomedich-346	116	43	had	have	VERB
biomedich-346	116	44	a	a	DET
biomedich-346	116	45	grade	grade	NOUN
biomedich-346	116	46	≥3	≥3	NOUN
biomedich-346	116	47	events	event	NOUN
biomedich-346	116	48	)	)	PUNCT
biomedich-346	116	49	.	.	PUNCT
biomedich-346	117	1	local	local	ADJ
biomedich-346	117	2	and	and	CCONJ
biomedich-346	117	3	systemic	systemic	ADJ
biomedich-346	117	4	events	event	NOUN
biomedich-346	117	5	were	be	AUX
biomedich-346	117	6	transient	transient	ADJ
biomedich-346	117	7	in	in	ADP
biomedich-346	117	8	nature	nature	NOUN
biomedich-346	117	9	(	(	PUNCT
biomedich-346	117	10	median	median	ADJ
biomedich-346	117	11	duration	duration	NOUN
biomedich-346	117	12	1·0	1·0	NUM
biomedich-346	117	13	-	-	SYM
biomedich-346	117	14	2·5	2·5	NUM
biomedich-346	117	15	days	day	NOUN
biomedich-346	117	16	)	)	PUNCT
biomedich-346	117	17	.	.	PUNCT
biomedich-346	118	1	in	in	ADP
biomedich-346	118	2	the	the	DET
biomedich-346	118	3	per	per	ADP
biomedich-346	118	4	-	-	PUNCT
biomedich-346	118	5	protocol	protocol	NOUN
biomedich-346	118	6	immunogenicity	immunogenicity	NOUN
biomedich-346	118	7	population	population	NOUN
biomedich-346	118	8	at	at	ADP
biomedich-346	118	9	day	day	NOUN
biomedich-346	118	10	217	217	NUM
biomedich-346	118	11	(	(	PUNCT
biomedich-346	118	12	167	167	NUM
biomedich-346	118	13	participants	participant	NOUN
biomedich-346	118	14	in	in	ADP
biomedich-346	118	15	group	group	PROPN
biomedich-346	118	16	a	a	PROPN
biomedich-346	118	17	,	,	PUNCT
biomedich-346	118	18	101	101	NUM
biomedich-346	118	19	participants	participant	NOUN
biomedich-346	118	20	in	in	ADP
biomedich-346	118	21	group	group	NOUN
biomedich-346	118	22	b1	b1	PROPN
biomedich-346	118	23	,	,	PUNCT
biomedich-346	118	24	101	101	NUM
biomedich-346	118	25	participants	participant	NOUN
biomedich-346	118	26	in	in	ADP
biomedich-346	118	27	group	group	NOUN
biomedich-346	118	28	b2	b2	NOUN
biomedich-346	118	29	)	)	PUNCT
biomedich-346	118	30	,	,	PUNCT
biomedich-346	118	31	igg	igg	PROPN
biomedich-346	118	32	geometric	geometric	ADJ
biomedich-346	118	33	mean	mean	NOUN
biomedich-346	118	34	titers	titer	NOUN
biomedich-346	118	35	(	(	PUNCT
biomedich-346	118	36	gmt	gmt	PROPN
biomedich-346	118	37	)	)	PUNCT
biomedich-346	118	38	had	have	AUX
biomedich-346	118	39	increased	increase	VERB
biomedich-346	118	40	by	by	ADP
biomedich-346	118	41	4·7	4·7	NOUN
biomedich-346	118	42	-	-	ADJ
biomedich-346	118	43	fold	fold	ADJ
biomedich-346	118	44	and	and	CCONJ
biomedich-346	118	45	mn50	mn50	PROPN
biomedich-346	118	46	gmt	gmt	PROPN
biomedich-346	118	47	by	by	ADP
biomedich-346	118	48	4·1	4·1	NOUN
biomedich-346	118	49	-	-	NOUN
biomedich-346	118	50	fold	fold	ADJ
biomedich-346	118	51	for	for	ADP
biomedich-346	118	52	the	the	DET
biomedich-346	118	53	ancestral	ancestral	ADJ
biomedich-346	118	54	sars	sar	NOUN
biomedich-346	118	55	-	-	PUNCT
biomedich-346	118	56	cov-2	cov-2	PART
biomedich-346	118	57	strain	strain	NOUN
biomedich-346	118	58	compared	compare	VERB
biomedich-346	118	59	with	with	ADP
biomedich-346	118	60	the	the	DET
biomedich-346	118	61	day	day	NOUN
biomedich-346	118	62	35	35	NUM
biomedich-346	118	63	titers.heath	titers.heath	NOUN
biomedich-346	118	64	et	et	PROPN
biomedich-346	118	65	al	al	PROPN
biomedich-346	118	66	.	.	PROPN
biomedich-346	118	67	,	,	PUNCT
biomedich-346	118	68	2023	2023	NUM
biomedich-346	118	69	,	,	PUNCT
biomedich-346	118	70	found	find	VERB
biomedich-346	118	71	that	that	SCONJ
biomedich-346	118	72	the	the	DET
biomedich-346	118	73	incidence	incidence	NOUN
biomedich-346	118	74	of	of	ADP
biomedich-346	118	75	serious	serious	ADJ
biomedich-346	118	76	adverse	adverse	ADJ
biomedich-346	118	77	events	event	NOUN
biomedich-346	118	78	and	and	CCONJ
biomedich-346	118	79	adverse	adverse	ADJ
biomedich-346	118	80	events	event	NOUN
biomedich-346	118	81	of	of	ADP
biomedich-346	118	82	special	special	ADJ
biomedich-346	118	83	interest	interest	NOUN
biomedich-346	118	84	were	be	AUX
biomedich-346	118	85	similar	similar	ADJ
biomedich-346	118	86	between	between	ADP
biomedich-346	118	87	groups	group	NOUN
biomedich-346	118	88	.	.	PUNCT
biomedich-346	119	1	lovell	lovell	PROPN
biomedich-346	119	2	et	et	PROPN
biomedich-346	119	3	al	al	PROPN
biomedich-346	119	4	.	.	PROPN
biomedich-346	119	5	,	,	PUNCT
biomedich-346	119	6	2022	2022	NUM
biomedich-346	119	7	,	,	PUNCT
biomedich-346	119	8	found	find	VERB
biomedich-346	119	9	that	that	SCONJ
biomedich-346	119	10	,	,	PUNCT
biomedich-346	119	11	neutralizing	neutralize	VERB
biomedich-346	119	12	antibodies	antibody	NOUN
biomedich-346	119	13	levels	level	NOUN
biomedich-346	119	14	of	of	ADP
biomedich-346	119	15	the	the	DET
biomedich-346	119	16	low	low	ADV
biomedich-346	119	17	-	-	PUNCT
biomedich-346	119	18	dose	dose	NOUN
biomedich-346	119	19	and	and	CCONJ
biomedich-346	119	20	high	high	ADV
biomedich-346	119	21	-	-	PUNCT
biomedich-346	119	22	dose	dose	VERB
biomedich-346	119	23	ecv19	ecv19	PROPN
biomedich-346	119	24	groups	group	NOUN
biomedich-346	119	25	had	have	VERB
biomedich-346	119	26	frnt50	frnt50	NOUN
biomedich-346	119	27	geometric	geometric	ADJ
biomedich-346	119	28	mean	mean	ADJ
biomedich-346	119	29	values	value	NOUN
biomedich-346	119	30	of	of	ADP
biomedich-346	119	31	129	129	NUM
biomedich-346	119	32	and	and	CCONJ
biomedich-346	119	33	316	316	NUM
biomedich-346	119	34	,	,	PUNCT
biomedich-346	119	35	respectively	respectively	ADV
biomedich-346	119	36	.	.	PUNCT
biomedich-346	120	1	boosting	boost	VERB
biomedich-346	120	2	responses	response	NOUN
biomedich-346	120	3	and	and	CCONJ
biomedich-346	120	4	dose	dose	NOUN
biomedich-346	120	5	responses	response	NOUN
biomedich-346	120	6	were	be	AUX
biomedich-346	120	7	observed	observe	VERB
biomedich-346	120	8	.	.	PUNCT
biomedich-346	121	1	antibodies	antibodie	VERB
biomedich-346	121	2	against	against	ADP
biomedich-346	121	3	the	the	DET
biomedich-346	121	4	rbd	rbd	NOUN
biomedich-346	121	5	correlated	correlate	VERB
biomedich-346	121	6	with	with	ADP
biomedich-346	121	7	antibodies	antibody	NOUN
biomedich-346	121	8	against	against	ADP
biomedich-346	121	9	the	the	DET
biomedich-346	121	10	spike	spike	NOUN
biomedich-346	121	11	and	and	CCONJ
biomedich-346	121	12	with	with	ADP
biomedich-346	121	13	virus	virus	NOUN
biomedich-346	121	14	neutralization	neutralization	NOUN
biomedich-346	121	15	.	.	PUNCT
biomedich-346	122	1	gatechompol	gatechompol	NOUN
biomedich-346	122	2	et	et	PROPN
biomedich-346	122	3	al	al	PROPN
biomedich-346	122	4	.	.	PROPN
biomedich-346	122	5	,	,	PUNCT
biomedich-346	122	6	2022	2022	NUM
biomedich-346	122	7	,	,	PUNCT
biomedich-346	122	8	found	find	VERB
biomedich-346	122	9	that	that	SCONJ
biomedich-346	122	10	,	,	PUNCT
biomedich-346	122	11	an	an	DET
biomedich-346	122	12	mrna	mrna	NOUN
biomedich-346	122	13	vaccine	vaccine	NOUN
biomedich-346	122	14	expressing	express	VERB
biomedich-346	122	15	a	a	DET
biomedich-346	122	16	prefusion	prefusion	NOUN
biomedich-346	122	17	non	non	ADJ
biomedich-346	122	18	-	-	ADJ
biomedich-346	122	19	stabilized	stabilized	ADJ
biomedich-346	122	20	spike	spike	ADJ
biomedich-346	122	21	protein	protein	NOUN
biomedich-346	122	22	is	be	AUX
biomedich-346	122	23	safe	safe	ADJ
biomedich-346	122	24	and	and	CCONJ
biomedich-346	122	25	highly	highly	ADV
biomedich-346	122	26	immunogenic	immunogenic	ADJ
biomedich-346	122	27	.	.	PUNCT
biomedich-346	123	1	masuda	masuda	PROPN
biomedich-346	123	2	et	et	PROPN
biomedich-346	123	3	al	al	PROPN
biomedich-346	123	4	.	.	PROPN
biomedich-346	123	5	,	,	PUNCT
biomedich-346	123	6	2022	2022	NUM
biomedich-346	123	7	,	,	PUNCT
biomedich-346	123	8	found	find	VERB
biomedich-346	123	9	that	that	SCONJ
biomedich-346	123	10	,	,	PUNCT
biomedich-346	123	11	between	between	ADP
biomedich-346	123	12	12	12	NUM
biomedich-346	123	13	february	february	NOUN
biomedich-346	123	14	2021	2021	NUM
biomedich-346	123	15	and	and	CCONJ
biomedich-346	123	16	17	17	NUM
biomedich-346	123	17	march	march	NOUN
biomedich-346	123	18	2021	2021	NUM
biomedich-346	123	19	,	,	PUNCT
biomedich-346	123	20	326	326	NUM
biomedich-346	123	21	subjects	subject	NOUN
biomedich-346	123	22	were	be	AUX
biomedich-346	123	23	screened	screen	VERB
biomedich-346	123	24	,	,	PUNCT
biomedich-346	123	25	and	and	CCONJ
biomedich-346	123	26	200	200	NUM
biomedich-346	123	27	participants	participant	NOUN
biomedich-346	123	28	enrolled	enrol	VERB
biomedich-346	123	29	and	and	CCONJ
biomedich-346	123	30	randomized	randomize	VERB
biomedich-346	123	31	:	:	PUNCT
biomedich-346	123	32	nvx	nvx	PROPN
biomedich-346	123	33	-	-	PUNCT
biomedich-346	123	34	cov2373	cov2373	PROPN
biomedich-346	123	35	,	,	PUNCT
biomedich-346	123	36	n	n	NOUN
biomedich-346	123	37	=	=	SYM
biomedich-346	123	38	150	150	NUM
biomedich-346	123	39	;	;	PUNCT
biomedich-346	123	40	placebo	placebo	NOUN
biomedich-346	123	41	,	,	PUNCT
biomedich-346	123	42	n	n	NOUN
biomedich-346	123	43	=	=	SYM
biomedich-346	123	44	50	50	NUM
biomedich-346	123	45	.	.	PUNCT
biomedich-346	124	1	solicited	solicit	VERB
biomedich-346	124	2	adverse	adverse	ADJ
biomedich-346	124	3	events	event	NOUN
biomedich-346	124	4	(	(	PUNCT
biomedich-346	124	5	aes	aes	NOUN
biomedich-346	124	6	)	)	PUNCT
biomedich-346	124	7	through	through	ADP
biomedich-346	124	8	7	7	NUM
biomedich-346	124	9	days	day	NOUN
biomedich-346	124	10	after	after	SCONJ
biomedich-346	124	11	each	each	DET
biomedich-346	124	12	injection	injection	NOUN
biomedich-346	124	13	occurred	occur	VERB
biomedich-346	124	14	in	in	ADP
biomedich-346	124	15	121/150	121/150	PROPN
biomedich-346	124	16	(	(	PUNCT
biomedich-346	124	17	80.7	80.7	NUM
biomedich-346	124	18	%	%	NOUN
biomedich-346	124	19	)	)	PUNCT
biomedich-346	124	20	and	and	CCONJ
biomedich-346	124	21	11/50	11/50	NUM
biomedich-346	124	22	(	(	PUNCT
biomedich-346	124	23	22.0	22.0	NUM
biomedich-346	124	24	%	%	NOUN
biomedich-346	124	25	)	)	PUNCT
biomedich-346	124	26	participants	participant	NOUN
biomedich-346	124	27	in	in	ADP
biomedich-346	124	28	the	the	DET
biomedich-346	124	29	nvx	nvx	NOUN
biomedich-346	124	30	-	-	PUNCT
biomedich-346	124	31	cov2373	cov2373	PROPN
biomedich-346	124	32	and	and	CCONJ
biomedich-346	124	33	placebo	placebo	NOUN
biomedich-346	124	34	arms	arm	NOUN
biomedich-346	124	35	,	,	PUNCT
biomedich-346	124	36	respectively	respectively	ADV
biomedich-346	124	37	.	.	PUNCT
biomedich-346	125	1	in	in	ADP
biomedich-346	125	2	the	the	DET
biomedich-346	125	3	nvx	nvx	NOUN
biomedich-346	125	4	-	-	PUNCT
biomedich-346	125	5	cov2373	cov2373	NOUN
biomedich-346	125	6	arm	arm	NOUN
biomedich-346	125	7	,	,	PUNCT
biomedich-346	125	8	tenderness	tenderness	NOUN
biomedich-346	125	9	and	and	CCONJ
biomedich-346	125	10	injection	injection	NOUN
biomedich-346	125	11	site	site	NOUN
biomedich-346	125	12	pain	pain	NOUN
biomedich-346	125	13	were	be	AUX
biomedich-346	125	14	the	the	DET
biomedich-346	125	15	most	most	ADV
biomedich-346	125	16	frequently	frequently	ADV
biomedich-346	125	17	reported	report	VERB
biomedich-346	125	18	solicited	solicit	VERB
biomedich-346	125	19	aes	aes	NOUN
biomedich-346	125	20	after	after	ADP
biomedich-346	125	21	each	each	DET
biomedich-346	125	22	vaccination	vaccination	NOUN
biomedich-346	125	23	,	,	PUNCT
biomedich-346	125	24	irrespective	irrespective	ADV
biomedich-346	125	25	of	of	ADP
biomedich-346	125	26	age	age	NOUN
biomedich-346	125	27	.	.	PUNCT
biomedich-346	126	1	robust	robust	ADJ
biomedich-346	126	2	immune	immune	ADJ
biomedich-346	126	3	responses	response	NOUN
biomedich-346	126	4	occurred	occur	VERB
biomedich-346	126	5	with	with	ADP
biomedich-346	126	6	nvx	nvx	NOUN
biomedich-346	126	7	-	-	PUNCT
biomedich-346	126	8	cov2373	cov2373	PROPN
biomedich-346	126	9	hussein	hussein	PROPN
biomedich-346	126	10	et	et	PROPN
biomedich-346	126	11	al	al	PROPN
biomedich-346	126	12	.	.	PROPN
biomedich-346	126	13	–	–	PUNCT
biomedich-346	126	14	nanotechnology	nanotechnology	NOUN
biomedich-346	126	15	-	-	PUNCT
biomedich-346	126	16	based	base	VERB
biomedich-346	126	17	vaccines	vaccine	NOUN
biomedich-346	126	18	347	347	NUM
biomedich-346	126	19	(	(	PUNCT
biomedich-346	126	20	n	n	NOUN
biomedich-346	126	21	=	=	SYM
biomedich-346	126	22	150	150	NUM
biomedich-346	126	23	)	)	PUNCT
biomedich-346	126	24	by	by	ADP
biomedich-346	126	25	day	day	NOUN
biomedich-346	126	26	36	36	NUM
biomedich-346	126	27	:	:	PUNCT
biomedich-346	126	28	igg	igg	NOUN
biomedich-346	126	29	geometric	geometric	ADJ
biomedich-346	126	30	mean	mean	NOUN
biomedich-346	126	31	fold	fold	NOUN
biomedich-346	126	32	rise	rise	NOUN
biomedich-346	126	33	(	(	PUNCT
biomedich-346	126	34	95	95	NUM
biomedich-346	126	35	%	%	NOUN
biomedich-346	126	36	confidence	confidence	NOUN
biomedich-346	126	37	interval	interval	NOUN
biomedich-346	126	38	)	)	PUNCT
biomedich-346	126	39	259	259	NUM
biomedich-346	126	40	(	(	PUNCT
biomedich-346	126	41	219	219	NUM
biomedich-346	126	42	,	,	PUNCT
biomedich-346	126	43	306	306	NUM
biomedich-346	126	44	)	)	PUNCT
biomedich-346	126	45	;	;	PUNCT
biomedich-346	126	46	seroconversion	seroconversion	NOUN
biomedich-346	126	47	rate	rate	NOUN
biomedich-346	126	48	100	100	NUM
biomedich-346	126	49	%	%	NOUN
biomedich-346	126	50	(	(	PUNCT
biomedich-346	126	51	97.6	97.6	NUM
biomedich-346	126	52	,	,	PUNCT
biomedich-346	126	53	100	100	NUM
biomedich-346	126	54	)	)	PUNCT
biomedich-346	126	55	.	.	PUNCT
biomedich-346	127	1	no	no	DET
biomedich-346	127	2	such	such	ADJ
biomedich-346	127	3	response	response	NOUN
biomedich-346	127	4	occurred	occur	VERB
biomedich-346	127	5	with	with	ADP
biomedich-346	127	6	a	a	DET
biomedich-346	127	7	placebo	placebo	NOUN
biomedich-346	127	8	(	(	PUNCT
biomedich-346	127	9	n	n	NOUN
biomedich-346	127	10	=	=	NUM
biomedich-346	127	11	49	49	NUM
biomedich-346	127	12	)	)	PUNCT
biomedich-346	127	13	.	.	PUNCT
biomedich-346	128	1	ishikawa	ishikawa	PROPN
biomedich-346	128	2	et	et	PROPN
biomedich-346	128	3	al	al	PROPN
biomedich-346	128	4	.	.	PROPN
biomedich-346	128	5	,	,	PUNCT
biomedich-346	128	6	2021	2021	NUM
biomedich-346	128	7	,	,	PUNCT
biomedich-346	128	8	found	find	VERB
biomedich-346	128	9	that	that	SCONJ
biomedich-346	128	10	the	the	DET
biomedich-346	128	11	most	most	ADV
biomedich-346	128	12	common	common	ADJ
biomedich-346	128	13	adverse	adverse	ADJ
biomedich-346	128	14	event	event	NOUN
biomedich-346	128	15	(	(	PUNCT
biomedich-346	128	16	ae	ae	PROPN
biomedich-346	128	17	)	)	PUNCT
biomedich-346	128	18	was	be	AUX
biomedich-346	128	19	injection	injection	NOUN
biomedich-346	128	20	site	site	NOUN
biomedich-346	128	21	skin	skin	NOUN
biomedich-346	128	22	reaction	reaction	NOUN
biomedich-346	128	23	(	(	PUNCT
biomedich-346	128	24	86.7	86.7	NUM
biomedich-346	128	25	%	%	NOUN
biomedich-346	128	26	)	)	PUNCT
biomedich-346	128	27	.	.	PUNCT
biomedich-346	129	1	no	no	DET
biomedich-346	129	2	grade	grade	NOUN
biomedich-346	129	3	3	3	NUM
biomedich-346	129	4	or	or	CCONJ
biomedich-346	129	5	higher	high	ADJ
biomedich-346	129	6	drug	drug	NOUN
biomedich-346	129	7	-	-	PUNCT
biomedich-346	129	8	related	relate	VERB
biomedich-346	129	9	aes	aes	NOUN
biomedich-346	129	10	were	be	AUX
biomedich-346	129	11	observed	observe	VERB
biomedich-346	129	12	.	.	PUNCT
biomedich-346	130	1	no	no	DET
biomedich-346	130	2	tumor	tumor	NOUN
biomedich-346	130	3	responses	response	NOUN
biomedich-346	130	4	were	be	AUX
biomedich-346	130	5	observed	observe	VERB
biomedich-346	130	6	,	,	PUNCT
biomedich-346	130	7	and	and	CCONJ
biomedich-346	130	8	three	three	NUM
biomedich-346	130	9	patients	patient	NOUN
biomedich-346	130	10	(	(	PUNCT
biomedich-346	130	11	30	30	NUM
biomedich-346	130	12	%	%	NOUN
biomedich-346	130	13	)	)	PUNCT
biomedich-346	130	14	had	have	VERB
biomedich-346	130	15	stable	stable	ADJ
biomedich-346	130	16	disease	disease	NOUN
biomedich-346	130	17	.	.	PUNCT
biomedich-346	131	1	the	the	DET
biomedich-346	131	2	immune	immune	ADJ
biomedich-346	131	3	response	response	NOUN
biomedich-346	131	4	was	be	AUX
biomedich-346	131	5	comparable	comparable	ADJ
biomedich-346	131	6	between	between	ADP
biomedich-346	131	7	the	the	DET
biomedich-346	131	8	two	two	NUM
biomedich-346	131	9	cohorts	cohort	NOUN
biomedich-346	131	10	,	,	PUNCT
biomedich-346	131	11	and	and	CCONJ
biomedich-346	131	12	all	all	DET
biomedich-346	131	13	patients	patient	NOUN
biomedich-346	131	14	(	(	PUNCT
biomedich-346	131	15	100	100	NUM
biomedich-346	131	16	%	%	NOUN
biomedich-346	131	17	)	)	PUNCT
biomedich-346	131	18	achieved	achieve	VERB
biomedich-346	131	19	antibody	antibody	NOUN
biomedich-346	131	20	responses	response	NOUN
biomedich-346	131	21	with	with	ADP
biomedich-346	131	22	a	a	DET
biomedich-346	131	23	median	median	NOUN
biomedich-346	131	24	of	of	ADP
biomedich-346	131	25	2.5	2.5	NUM
biomedich-346	131	26	vaccinations	vaccination	NOUN
biomedich-346	131	27	.	.	PUNCT
biomedich-346	132	1	comparing	compare	VERB
biomedich-346	132	2	chp	chp	NOUN
biomedich-346	132	3	-	-	PUNCT
biomedich-346	132	4	ny	ny	NOUN
biomedich-346	132	5	-	-	PUNCT
biomedich-346	132	6	eso-1	eso-1	NOUN
biomedich-346	132	7	alone	alone	ADJ
biomedich-346	132	8	to	to	ADP
biomedich-346	132	9	the	the	DET
biomedich-346	132	10	poly	poly	ADJ
biomedich-346	132	11	-	-	PUNCT
biomedich-346	132	12	iclc	iclc	NOUN
biomedich-346	132	13	combination	combination	NOUN
biomedich-346	132	14	,	,	PUNCT
biomedich-346	132	15	all	all	DET
biomedich-346	132	16	patients	patient	NOUN
biomedich-346	132	17	in	in	ADP
biomedich-346	132	18	both	both	DET
biomedich-346	132	19	groups	group	NOUN
biomedich-346	132	20	exhibited	exhibit	VERB
biomedich-346	132	21	antibody	antibody	NOUN
biomedich-346	132	22	responses	response	NOUN
biomedich-346	132	23	,	,	PUNCT
biomedich-346	132	24	but	but	CCONJ
biomedich-346	132	25	the	the	DET
biomedich-346	132	26	titers	titer	NOUN
biomedich-346	132	27	were	be	AUX
biomedich-346	132	28	higher	high	ADJ
biomedich-346	132	29	in	in	ADP
biomedich-346	132	30	the	the	DET
biomedich-346	132	31	combination	combination	NOUN
biomedich-346	132	32	group	group	NOUN
biomedich-346	132	33	.	.	PUNCT
biomedich-346	133	1	in	in	ADP
biomedich-346	133	2	a	a	DET
biomedich-346	133	3	mouse	mouse	NOUN
biomedich-346	133	4	model	model	NOUN
biomedich-346	133	5	,	,	PUNCT
biomedich-346	133	6	adding	add	VERB
biomedich-346	133	7	an	an	DET
biomedich-346	133	8	anti	anti	ADJ
biomedich-346	133	9	-	-	ADJ
biomedich-346	133	10	pd-1	pd-1	ADJ
biomedich-346	133	11	antibody	antibody	NOUN
biomedich-346	133	12	to	to	ADP
biomedich-346	133	13	the	the	DET
biomedich-346	133	14	combination	combination	NOUN
biomedich-346	133	15	of	of	ADP
biomedich-346	133	16	chp	chp	NOUN
biomedich-346	133	17	-	-	PUNCT
biomedich-346	133	18	ny	ny	NOUN
biomedich-346	133	19	-	-	PUNCT
biomedich-346	133	20	eso-1	eso-1	NOUN
biomedich-346	133	21	/	/	SYM
biomedich-346	133	22	poly	poly	ADJ
biomedich-346	133	23	-	-	PUNCT
biomedich-346	133	24	iclc	iclc	NOUN
biomedich-346	133	25	suppressed	suppress	VERB
biomedich-346	133	26	the	the	DET
biomedich-346	133	27	growth	growth	NOUN
biomedich-346	133	28	of	of	ADP
biomedich-346	133	29	ny	ny	NOUN
biomedich-346	133	30	-	-	PUNCT
biomedich-346	133	31	eso-1	eso-1	NOUN
biomedich-346	133	32	-	-	PUNCT
biomedich-346	133	33	expressing	express	VERB
biomedich-346	133	34	tumors	tumor	NOUN
biomedich-346	133	35	.	.	PUNCT
biomedich-346	134	1	combining	combine	VERB
biomedich-346	134	2	the	the	DET
biomedich-346	134	3	vaccine	vaccine	NOUN
biomedich-346	134	4	with	with	ADP
biomedich-346	134	5	pd-1	pd-1	VERB
biomedich-346	134	6	blockade	blockade	NOUN
biomedich-346	134	7	holds	hold	VERB
biomedich-346	134	8	promise	promise	NOUN
biomedich-346	134	9	in	in	ADP
biomedich-346	134	10	human	human	ADJ
biomedich-346	134	11	trials	trial	NOUN
biomedich-346	134	12	.	.	PUNCT
biomedich-346	135	1	li	li	PROPN
biomedich-346	135	2	et	et	PROPN
biomedich-346	135	3	al	al	PROPN
biomedich-346	135	4	.	.	PROPN
biomedich-346	135	5	,	,	PUNCT
biomedich-346	135	6	2022	2022	NUM
biomedich-346	135	7	,	,	PUNCT
biomedich-346	135	8	found	find	VERB
biomedich-346	135	9	that	that	SCONJ
biomedich-346	135	10	,	,	PUNCT
biomedich-346	135	11	in	in	ADP
biomedich-346	135	12	younger	young	ADJ
biomedich-346	135	13	participants	participant	NOUN
biomedich-346	135	14	,	,	PUNCT
biomedich-346	135	15	neutralizing	neutralize	VERB
biomedich-346	135	16	antibody	antibody	NOUN
biomedich-346	135	17	(	(	PUNCT
biomedich-346	135	18	nab	nab	NOUN
biomedich-346	135	19	)	)	PUNCT
biomedich-346	135	20	geometric	geometric	ADJ
biomedich-346	135	21	mean	mean	NOUN
biomedich-346	135	22	titers	titer	NOUN
biomedich-346	135	23	(	(	PUNCT
biomedich-346	135	24	gmts	gmts	PROPN
biomedich-346	135	25	)	)	PUNCT
biomedich-346	135	26	for	for	ADP
biomedich-346	135	27	the	the	PRON
biomedich-346	135	28	10	10	NUM
biomedich-346	135	29	and	and	CCONJ
biomedich-346	135	30	30	30	NUM
biomedich-346	135	31	µg	µg	ADV
biomedich-346	135	32	dose	dose	NOUN
biomedich-346	135	33	levels	level	NOUN
biomedich-346	135	34	declined	decline	VERB
biomedich-346	135	35	from	from	ADP
biomedich-346	135	36	233	233	NUM
biomedich-346	135	37	and	and	CCONJ
biomedich-346	135	38	254	254	NUM
biomedich-346	135	39	(	(	PUNCT
biomedich-346	135	40	21	21	NUM
biomedich-346	135	41	days	day	NOUN
biomedich-346	135	42	after	after	ADP
biomedich-346	135	43	dose	dose	NOUN
biomedich-346	135	44	2	2	NUM
biomedich-346	135	45	)	)	PUNCT
biomedich-346	135	46	to	to	ADP
biomedich-346	135	47	55	55	NUM
biomedich-346	135	48	and	and	CCONJ
biomedich-346	135	49	87	87	NUM
biomedich-346	135	50	at	at	ADP
biomedich-346	135	51	month	month	NOUN
biomedich-346	135	52	3	3	NUM
biomedich-346	135	53	,	,	PUNCT
biomedich-346	135	54	respectively	respectively	ADV
biomedich-346	135	55	,	,	PUNCT
biomedich-346	135	56	and	and	CCONJ
biomedich-346	135	57	to	to	ADP
biomedich-346	135	58	16	16	NUM
biomedich-346	135	59	and	and	CCONJ
biomedich-346	135	60	27	27	NUM
biomedich-346	135	61	at	at	ADP
biomedich-346	135	62	month	month	NOUN
biomedich-346	135	63	6	6	NUM
biomedich-346	135	64	,	,	PUNCT
biomedich-346	135	65	respectively	respectively	ADV
biomedich-346	135	66	.	.	PUNCT
biomedich-346	136	1	in	in	ADP
biomedich-346	136	2	older	old	ADJ
biomedich-346	136	3	participants	participant	NOUN
biomedich-346	136	4	,	,	PUNCT
biomedich-346	136	5	nab	nab	ADJ
biomedich-346	136	6	gmts	gmts	NOUN
biomedich-346	136	7	declined	decline	VERB
biomedich-346	136	8	from	from	ADP
biomedich-346	136	9	80	80	NUM
biomedich-346	136	10	and	and	CCONJ
biomedich-346	136	11	160	160	NUM
biomedich-346	136	12	(	(	PUNCT
biomedich-346	136	13	21	21	NUM
biomedich-346	136	14	days	day	NOUN
biomedich-346	136	15	after	after	ADP
biomedich-346	136	16	dose	dose	NOUN
biomedich-346	136	17	2	2	NUM
biomedich-346	136	18	)	)	PUNCT
biomedich-346	136	19	to	to	ADP
biomedich-346	136	20	10	10	NUM
biomedich-346	136	21	and	and	CCONJ
biomedich-346	136	22	21	21	NUM
biomedich-346	136	23	at	at	ADP
biomedich-346	136	24	month	month	NOUN
biomedich-346	136	25	6	6	NUM
biomedich-346	136	26	.	.	PUNCT
biomedich-346	137	1	overall	overall	ADJ
biomedich-346	137	2	,	,	PUNCT
biomedich-346	137	3	higher	high	ADJ
biomedich-346	137	4	antibody	antibody	NOUN
biomedich-346	137	5	titers	titer	NOUN
biomedich-346	137	6	were	be	AUX
biomedich-346	137	7	observed	observe	VERB
biomedich-346	137	8	in	in	ADP
biomedich-346	137	9	younger	young	ADJ
biomedich-346	137	10	participants	participant	NOUN
biomedich-346	137	11	,	,	PUNCT
biomedich-346	137	12	and	and	CCONJ
biomedich-346	137	13	the	the	DET
biomedich-346	137	14	30	30	NUM
biomedich-346	137	15	µg	µg	NOUN
biomedich-346	137	16	dose	dose	NOUN
biomedich-346	137	17	induced	induce	VERB
biomedich-346	137	18	higher	high	ADJ
biomedich-346	137	19	levels	level	NOUN
biomedich-346	137	20	of	of	ADP
biomedich-346	137	21	nab	nab	NOUN
biomedich-346	137	22	,	,	PUNCT
biomedich-346	137	23	which	which	PRON
biomedich-346	137	24	declined	decline	VERB
biomedich-346	137	25	more	more	ADV
biomedich-346	137	26	slowly	slowly	ADV
biomedich-346	137	27	by	by	ADP
biomedich-346	137	28	month	month	NOUN
biomedich-346	137	29	6	6	NUM
biomedich-346	137	30	.	.	PUNCT
biomedich-346	138	1	no	no	DET
biomedich-346	138	2	serious	serious	ADJ
biomedich-346	138	3	adverse	adverse	ADJ
biomedich-346	138	4	events	event	NOUN
biomedich-346	138	5	were	be	AUX
biomedich-346	138	6	reported	report	VERB
biomedich-346	138	7	in	in	ADP
biomedich-346	138	8	the	the	DET
biomedich-346	138	9	vaccine	vaccine	NOUN
biomedich-346	138	10	group	group	NOUN
biomedich-346	138	11	.	.	PUNCT
biomedich-346	139	1	wei	wei	PROPN
biomedich-346	139	2	et	et	PROPN
biomedich-346	139	3	al	al	PROPN
biomedich-346	139	4	.	.	PROPN
biomedich-346	139	5	,	,	PUNCT
biomedich-346	139	6	2021	2021	NUM
biomedich-346	139	7	,	,	PUNCT
biomedich-346	139	8	found	find	VERB
biomedich-346	139	9	that	that	SCONJ
biomedich-346	139	10	epnp	epnp	NOUN
biomedich-346	139	11	,	,	PUNCT
biomedich-346	139	12	carrying	carry	VERB
biomedich-346	139	13	the	the	DET
biomedich-346	139	14	neutralizing	neutralizing	ADJ
biomedich-346	139	15	epitope	epitope	NOUN
biomedich-346	139	16	hla121	hla121	PROPN
biomedich-346	139	17	-	-	PUNCT
biomedich-346	139	18	138	138	NUM
biomedich-346	139	19	,	,	PUNCT
biomedich-346	139	20	is	be	AUX
biomedich-346	139	21	a	a	DET
biomedich-346	139	22	good	good	ADJ
biomedich-346	139	23	candidate	candidate	NOUN
biomedich-346	139	24	for	for	ADP
biomedich-346	139	25	a	a	DET
biomedich-346	139	26	vaccine	vaccine	NOUN
biomedich-346	139	27	against	against	ADP
biomedich-346	139	28	sa	sa	PROPN
biomedich-346	139	29	.	.	PUNCT
biomedich-346	139	30	table	table	NOUN
biomedich-346	140	1	1	1	NUM
biomedich-346	140	2	.	.	PUNCT
biomedich-346	141	1	clinical	clinical	ADJ
biomedich-346	141	2	studies	study	NOUN
biomedich-346	141	3	using	use	VERB
biomedich-346	141	4	nanotechnology	nanotechnology	NOUN
biomedich-346	141	5	-	-	PUNCT
biomedich-346	141	6	based	base	VERB
biomedich-346	141	7	vaccines	vaccine	NOUN
biomedich-346	141	8	.	.	PUNCT
biomedich-346	142	1	authors	author	NOUN
biomedich-346	142	2	title	title	VERB
biomedich-346	142	3	date	date	NOUN
biomedich-346	142	4	and	and	CCONJ
biomedich-346	142	5	type	type	NOUN
biomedich-346	142	6	of	of	ADP
biomedich-346	142	7	the	the	DET
biomedich-346	142	8	study	study	NOUN
biomedich-346	142	9	method	method	NOUN
biomedich-346	142	10	results	result	VERB
biomedich-346	142	11	alimehmeti	alimehmeti	NOUN
biomedich-346	142	12	efficacy	efficacy	NOUN
biomedich-346	142	13	and	and	CCONJ
biomedich-346	142	14	safety	safety	NOUN
biomedich-346	142	15	of	of	ADP
biomedich-346	142	16	the	the	DET
biomedich-346	142	17	mrna-1273	mrna-1273	ADJ
biomedich-346	142	18	sars	sar	NOUN
biomedich-346	142	19	-	-	PUNCT
biomedich-346	142	20	cov-2	cov-2	NOUN
biomedich-346	142	21	vaccine	vaccine	NOUN
biomedich-346	142	22	clinical	clinical	ADJ
biomedich-346	142	23	trial	trial	NOUN
biomedich-346	142	24	2021	2021	NUM
biomedich-346	143	1	this	this	DET
biomedich-346	143	2	phase	phase	NOUN
biomedich-346	143	3	3	3	NUM
biomedich-346	143	4	randomized	randomize	VERB
biomedich-346	143	5	,	,	PUNCT
biomedich-346	143	6	observer	observer	NOUN
biomedich-346	143	7	-	-	PUNCT
biomedich-346	143	8	blinded	blinded	ADJ
biomedich-346	143	9	,	,	PUNCT
biomedich-346	143	10	placebocontrolled	placebocontrolle	VERB
biomedich-346	143	11	trial	trial	NOUN
biomedich-346	143	12	was	be	AUX
biomedich-346	143	13	conducted	conduct	VERB
biomedich-346	143	14	at	at	ADP
biomedich-346	143	15	99	99	NUM
biomedich-346	143	16	centers	center	NOUN
biomedich-346	143	17	across	across	ADP
biomedich-346	143	18	the	the	DET
biomedich-346	143	19	united	united	PROPN
biomedich-346	143	20	states	states	PROPN
biomedich-346	143	21	.	.	PUNCT
biomedich-346	144	1	persons	person	NOUN
biomedich-346	144	2	at	at	ADP
biomedich-346	144	3	high	high	ADJ
biomedich-346	144	4	risk	risk	NOUN
biomedich-346	144	5	for	for	ADP
biomedich-346	144	6	sars	sar	NOUN
biomedich-346	144	7	-	-	PUNCT
biomedich-346	144	8	cov-2	cov-2	PART
biomedich-346	144	9	infection	infection	NOUN
biomedich-346	144	10	or	or	CCONJ
biomedich-346	144	11	its	its	PRON
biomedich-346	144	12	complications	complication	NOUN
biomedich-346	144	13	were	be	AUX
biomedich-346	144	14	randomly	randomly	ADV
biomedich-346	144	15	assigned	assign	VERB
biomedich-346	144	16	in	in	ADP
biomedich-346	144	17	a	a	DET
biomedich-346	144	18	1:1	1:1	NUM
biomedich-346	144	19	ratio	ratio	NOUN
biomedich-346	144	20	to	to	PART
biomedich-346	144	21	receive	receive	VERB
biomedich-346	144	22	two	two	NUM
biomedich-346	144	23	intramuscular	intramuscular	ADJ
biomedich-346	144	24	injections	injection	NOUN
biomedich-346	144	25	of	of	ADP
biomedich-346	144	26	mrna-1273	mrna-1273	NOUN
biomedich-346	144	27	(	(	PUNCT
biomedich-346	144	28	100	100	NUM
biomedich-346	144	29	μg	μg	NOUN
biomedich-346	144	30	)	)	PUNCT
biomedich-346	144	31	or	or	CCONJ
biomedich-346	144	32	a	a	DET
biomedich-346	144	33	placebo	placebo	NOUN
biomedich-346	144	34	28	28	NUM
biomedich-346	144	35	days	day	NOUN
biomedich-346	144	36	apart	apart	ADV
biomedich-346	144	37	.	.	PUNCT
biomedich-346	145	1	the	the	DET
biomedich-346	145	2	primary	primary	ADJ
biomedich-346	145	3	endpoint	endpoint	NOUN
biomedich-346	145	4	was	be	AUX
biomedich-346	145	5	the	the	DET
biomedich-346	145	6	prevention	prevention	NOUN
biomedich-346	145	7	of	of	ADP
biomedich-346	145	8	covid-19	covid-19	PROPN
biomedich-346	145	9	illness	illness	NOUN
biomedich-346	145	10	with	with	ADP
biomedich-346	145	11	onset	onset	NOUN
biomedich-346	145	12	at	at	ADP
biomedich-346	145	13	least	least	ADV
biomedich-346	145	14	14	14	NUM
biomedich-346	145	15	days	day	NOUN
biomedich-346	145	16	after	after	ADP
biomedich-346	145	17	the	the	DET
biomedich-346	145	18	second	second	ADJ
biomedich-346	145	19	injection	injection	NOUN
biomedich-346	145	20	in	in	ADP
biomedich-346	145	21	participants	participant	NOUN
biomedich-346	145	22	who	who	PRON
biomedich-346	145	23	had	have	AUX
biomedich-346	145	24	not	not	PART
biomedich-346	145	25	previously	previously	ADV
biomedich-346	145	26	been	be	AUX
biomedich-346	145	27	infected	infect	VERB
biomedich-346	145	28	with	with	ADP
biomedich-346	145	29	sars	sar	NOUN
biomedich-346	145	30	-	-	PUNCT
biomedich-346	145	31	cov-2	cov-2	NOUN
biomedich-346	145	32	.	.	PUNCT
biomedich-346	146	1	severe	severe	ADJ
biomedich-346	146	2	covid-19	covid-19	PROPN
biomedich-346	146	3	occurred	occur	VERB
biomedich-346	146	4	in	in	ADP
biomedich-346	146	5	30	30	NUM
biomedich-346	146	6	participants	participant	NOUN
biomedich-346	146	7	,	,	PUNCT
biomedich-346	146	8	with	with	ADP
biomedich-346	146	9	one	one	NUM
biomedich-346	146	10	fatality	fatality	NOUN
biomedich-346	146	11	;	;	PUNCT
biomedich-346	146	12	all	all	DET
biomedich-346	146	13	30	30	NUM
biomedich-346	146	14	were	be	AUX
biomedich-346	146	15	in	in	ADP
biomedich-346	146	16	the	the	DET
biomedich-346	146	17	placebo	placebo	NOUN
biomedich-346	146	18	group	group	NOUN
biomedich-346	146	19	.	.	PUNCT
biomedich-346	147	1	moderate	moderate	ADJ
biomedich-346	147	2	,	,	PUNCT
biomedich-346	147	3	transient	transient	ADJ
biomedich-346	147	4	reactogenicity	reactogenicity	NOUN
biomedich-346	147	5	after	after	ADP
biomedich-346	147	6	vaccination	vaccination	NOUN
biomedich-346	147	7	occurred	occur	VERB
biomedich-346	147	8	more	more	ADV
biomedich-346	147	9	frequently	frequently	ADV
biomedich-346	147	10	in	in	ADP
biomedich-346	147	11	the	the	DET
biomedich-346	147	12	mrna-1273	mrna-1273	ADJ
biomedich-346	147	13	group	group	NOUN
biomedich-346	147	14	.	.	PUNCT
biomedich-346	148	1	serious	serious	ADJ
biomedich-346	148	2	adverse	adverse	ADJ
biomedich-346	148	3	events	event	NOUN
biomedich-346	148	4	were	be	AUX
biomedich-346	148	5	rare	rare	ADJ
biomedich-346	148	6	,	,	PUNCT
biomedich-346	148	7	and	and	CCONJ
biomedich-346	148	8	the	the	DET
biomedich-346	148	9	incidence	incidence	NOUN
biomedich-346	148	10	was	be	AUX
biomedich-346	148	11	similar	similar	ADJ
biomedich-346	148	12	in	in	ADP
biomedich-346	148	13	the	the	DET
biomedich-346	148	14	two	two	NUM
biomedich-346	148	15	groups	group	NOUN
biomedich-346	148	16	.	.	PUNCT
biomedich-346	149	1	thomas	thomas	PROPN
biomedich-346	149	2	et	et	PROPN
biomedich-346	149	3	al	al	PROPN
biomedich-346	149	4	.	.	PROPN
biomedich-346	149	5	safety	safety	PROPN
biomedich-346	149	6	and	and	CCONJ
biomedich-346	149	7	efficacy	efficacy	NOUN
biomedich-346	149	8	of	of	ADP
biomedich-346	149	9	the	the	DET
biomedich-346	149	10	bnt162b2	bnt162b2	PROPN
biomedich-346	149	11	mrna	mrna	PROPN
biomedich-346	149	12	covid-19	covid-19	PROPN
biomedich-346	149	13	vaccine	vaccine	NOUN
biomedich-346	149	14	through	through	ADP
biomedich-346	149	15	6	6	NUM
biomedich-346	149	16	months	month	NOUN
biomedich-346	149	17	randomized	randomize	VERB
biomedich-346	149	18	controlled	control	VERB
biomedich-346	149	19	trial	trial	NOUN
biomedich-346	149	20	2021	2021	NUM
biomedich-346	149	21	in	in	ADP
biomedich-346	149	22	an	an	DET
biomedich-346	149	23	ongoing	ongoing	ADJ
biomedich-346	149	24	,	,	PUNCT
biomedich-346	149	25	placebocontrolled	placebocontrolle	VERB
biomedich-346	149	26	,	,	PUNCT
biomedich-346	149	27	observer	observer	NOUN
biomedich-346	149	28	-	-	PUNCT
biomedich-346	149	29	blinded	blinded	ADJ
biomedich-346	149	30	,	,	PUNCT
biomedich-346	149	31	multinational	multinational	ADJ
biomedich-346	149	32	,	,	PUNCT
biomedich-346	149	33	pivotal	pivotal	ADJ
biomedich-346	149	34	efficacy	efficacy	NOUN
biomedich-346	149	35	trial	trial	NOUN
biomedich-346	149	36	,	,	PUNCT
biomedich-346	149	37	we	we	PRON
biomedich-346	149	38	randomly	randomly	ADV
biomedich-346	149	39	assigned	assign	VERB
biomedich-346	149	40	44,165	44,165	NUM
biomedich-346	149	41	participants	participant	NOUN
biomedich-346	149	42	16	16	NUM
biomedich-346	149	43	years	year	NOUN
biomedich-346	149	44	of	of	ADP
biomedich-346	149	45	age	age	NOUN
biomedich-346	149	46	or	or	CCONJ
biomedich-346	149	47	older	old	ADJ
biomedich-346	149	48	and	and	CCONJ
biomedich-346	149	49	2264	2264	NUM
biomedich-346	149	50	participants	participant	NOUN
biomedich-346	149	51	12	12	NUM
biomedich-346	149	52	to	to	PART
biomedich-346	149	53	15	15	NUM
biomedich-346	149	54	years	year	NOUN
biomedich-346	149	55	of	of	ADP
biomedich-346	149	56	age	age	NOUN
biomedich-346	149	57	to	to	PART
biomedich-346	149	58	receive	receive	VERB
biomedich-346	149	59	two	two	NUM
biomedich-346	149	60	30	30	NUM
biomedich-346	149	61	-	-	PUNCT
biomedich-346	149	62	μg	μg	NUM
biomedich-346	149	63	doses	dose	NOUN
biomedich-346	149	64	,	,	PUNCT
biomedich-346	149	65	at	at	ADP
biomedich-346	149	66	21	21	NUM
biomedich-346	149	67	days	day	NOUN
biomedich-346	149	68	apart	apart	ADV
biomedich-346	149	69	,	,	PUNCT
biomedich-346	149	70	of	of	ADP
biomedich-346	149	71	bnt162b2	bnt162b2	NOUN
biomedich-346	149	72	or	or	CCONJ
biomedich-346	149	73	placebo	placebo	NOUN
biomedich-346	149	74	.	.	PUNCT
biomedich-346	150	1	the	the	DET
biomedich-346	150	2	trial	trial	NOUN
biomedich-346	150	3	endpoints	endpoint	NOUN
biomedich-346	150	4	were	be	AUX
biomedich-346	150	5	vaccine	vaccine	NOUN
biomedich-346	150	6	efficacy	efficacy	NOUN
biomedich-346	150	7	against	against	ADP
biomedich-346	150	8	laboratory	laboratory	NOUN
biomedich-346	150	9	-	-	PUNCT
biomedich-346	150	10	confirmed	confirm	VERB
biomedich-346	150	11	covid-19	covid-19	PROPN
biomedich-346	150	12	and	and	CCONJ
biomedich-346	150	13	safety	safety	NOUN
biomedich-346	150	14	,	,	PUNCT
biomedich-346	150	15	which	which	PRON
biomedich-346	150	16	were	be	AUX
biomedich-346	150	17	both	both	PRON
biomedich-346	150	18	evaluated	evaluate	VERB
biomedich-346	150	19	6	6	NUM
biomedich-346	150	20	months	month	NOUN
biomedich-346	150	21	after	after	ADP
biomedich-346	150	22	vaccination	vaccination	NOUN
biomedich-346	150	23	.	.	PUNCT
biomedich-346	151	1	vaccine	vaccine	NOUN
biomedich-346	151	2	efficacy	efficacy	NOUN
biomedich-346	151	3	of	of	ADP
biomedich-346	151	4	86	86	NUM
biomedich-346	151	5	to	to	PART
biomedich-346	151	6	100	100	NUM
biomedich-346	151	7	%	%	NOUN
biomedich-346	151	8	was	be	AUX
biomedich-346	151	9	seen	see	VERB
biomedich-346	151	10	across	across	ADP
biomedich-346	151	11	countries	country	NOUN
biomedich-346	151	12	and	and	CCONJ
biomedich-346	151	13	in	in	ADP
biomedich-346	151	14	populations	population	NOUN
biomedich-346	151	15	with	with	ADP
biomedich-346	151	16	diverse	diverse	ADJ
biomedich-346	151	17	ages	age	NOUN
biomedich-346	151	18	,	,	PUNCT
biomedich-346	151	19	sexes	sex	NOUN
biomedich-346	151	20	,	,	PUNCT
biomedich-346	151	21	races	race	NOUN
biomedich-346	151	22	,	,	PUNCT
biomedich-346	151	23	or	or	CCONJ
biomedich-346	151	24	ethnic	ethnic	ADJ
biomedich-346	151	25	groups	group	NOUN
biomedich-346	151	26	,	,	PUNCT
biomedich-346	151	27	and	and	CCONJ
biomedich-346	151	28	risk	risk	NOUN
biomedich-346	151	29	factors	factor	NOUN
biomedich-346	151	30	for	for	ADP
biomedich-346	151	31	covid-19	covid-19	PROPN
biomedich-346	151	32	among	among	ADP
biomedich-346	151	33	participants	participant	NOUN
biomedich-346	151	34	without	without	ADP
biomedich-346	151	35	evidence	evidence	NOUN
biomedich-346	151	36	of	of	ADP
biomedich-346	151	37	previous	previous	ADJ
biomedich-346	151	38	infection	infection	NOUN
biomedich-346	151	39	with	with	ADP
biomedich-346	151	40	sars	sar	NOUN
biomedich-346	151	41	-	-	PUNCT
biomedich-346	151	42	cov-2	cov-2	NOUN
biomedich-346	151	43	.	.	PUNCT
biomedich-346	151	44	vaccine	vaccine	NOUN
biomedich-346	151	45	efficacy	efficacy	NOUN
biomedich-346	151	46	against	against	ADP
biomedich-346	151	47	the	the	DET
biomedich-346	151	48	severe	severe	ADJ
biomedich-346	151	49	disease	disease	NOUN
biomedich-346	151	50	was	be	AUX
biomedich-346	151	51	96.7	96.7	NUM
biomedich-346	151	52	%	%	NOUN
biomedich-346	151	53	(	(	PUNCT
biomedich-346	151	54	95	95	NUM
biomedich-346	151	55	%	%	NOUN
biomedich-346	151	56	ci	ci	NOUN
biomedich-346	151	57	,	,	PUNCT
biomedich-346	151	58	80.3	80.3	NUM
biomedich-346	151	59	to	to	ADP
biomedich-346	151	60	99.9	99.9	NUM
biomedich-346	151	61	)	)	PUNCT
biomedich-346	151	62	.	.	PUNCT
biomedich-346	152	1	in	in	ADP
biomedich-346	152	2	south	south	PROPN
biomedich-346	152	3	africa	africa	PROPN
biomedich-346	152	4	,	,	PUNCT
biomedich-346	152	5	where	where	SCONJ
biomedich-346	152	6	the	the	DET
biomedich-346	152	7	sars	sar	NOUN
biomedich-346	152	8	-	-	PUNCT
biomedich-346	152	9	cov-2	cov-2	NOUN
biomedich-346	152	10	variant	variant	NOUN
biomedich-346	152	11	of	of	ADP
biomedich-346	152	12	concern	concern	NOUN
biomedich-346	152	13	b.1.351	b.1.351	NOUN
biomedich-346	152	14	(	(	PUNCT
biomedich-346	152	15	or	or	CCONJ
biomedich-346	152	16	beta	beta	NOUN
biomedich-346	152	17	)	)	PUNCT
biomedich-346	152	18	was	be	AUX
biomedich-346	152	19	predominant	predominant	ADJ
biomedich-346	152	20	,	,	PUNCT
biomedich-346	152	21	a	a	DET
biomedich-346	152	22	vaccine	vaccine	NOUN
biomedich-346	152	23	efficacy	efficacy	NOUN
biomedich-346	152	24	of	of	ADP
biomedich-346	152	25	100	100	NUM
biomedich-346	152	26	%	%	NOUN
biomedich-346	152	27	(	(	PUNCT
biomedich-346	152	28	95	95	NUM
biomedich-346	152	29	%	%	NOUN
biomedich-346	152	30	ci	ci	NOUN
biomedich-346	152	31	,	,	PUNCT
biomedich-346	152	32	53.5	53.5	NUM
biomedich-346	152	33	to	to	PART
biomedich-346	152	34	100	100	NUM
biomedich-346	152	35	)	)	PUNCT
biomedich-346	152	36	was	be	AUX
biomedich-346	152	37	observed	observe	VERB
biomedich-346	152	38	.	.	PUNCT
biomedich-346	153	1	348	348	NUM
biomedich-346	153	2	biology	biology	NOUN
biomedich-346	153	3	,	,	PUNCT
biomedich-346	153	4	medicine	medicine	NOUN
biomedich-346	153	5	,	,	PUNCT
biomedich-346	153	6	&	&	CCONJ
biomedich-346	153	7	natural	natural	ADJ
biomedich-346	153	8	product	product	NOUN
biomedich-346	153	9	chemistry	chemistry	NOUN
biomedich-346	153	10	12	12	NUM
biomedich-346	153	11	(	(	PUNCT
biomedich-346	153	12	1	1	NUM
biomedich-346	153	13	)	)	PUNCT
biomedich-346	153	14	,	,	PUNCT
biomedich-346	153	15	2023	2023	NUM
biomedich-346	153	16	:	:	PUNCT
biomedich-346	153	17	343	343	NUM
biomedich-346	153	18	-	-	SYM
biomedich-346	153	19	361	361	NUM
biomedich-346	153	20	table	table	NOUN
biomedich-346	153	21	1	1	NUM
biomedich-346	153	22	.	.	PUNCT
biomedich-346	153	23	cont	cont	NOUN
biomedich-346	153	24	.	.	PUNCT
biomedich-346	154	1	authors	author	NOUN
biomedich-346	154	2	title	title	VERB
biomedich-346	154	3	date	date	NOUN
biomedich-346	154	4	and	and	CCONJ
biomedich-346	154	5	type	type	NOUN
biomedich-346	154	6	of	of	ADP
biomedich-346	154	7	the	the	DET
biomedich-346	154	8	study	study	NOUN
biomedich-346	154	9	method	method	NOUN
biomedich-346	154	10	results	result	VERB
biomedich-346	154	11	heath	heath	PROPN
biomedich-346	154	12	et	et	PROPN
biomedich-346	154	13	al	al	PROPN
biomedich-346	154	14	.	.	PROPN
biomedich-346	154	15	safety	safety	NOUN
biomedich-346	154	16	and	and	CCONJ
biomedich-346	154	17	efficacy	efficacy	NOUN
biomedich-346	154	18	of	of	ADP
biomedich-346	154	19	nvx	nvx	PROPN
biomedich-346	154	20	-	-	PUNCT
biomedich-346	154	21	cov2373	cov2373	NOUN
biomedich-346	154	22	covid-19	covid-19	PROPN
biomedich-346	154	23	vaccine	vaccine	NOUN
biomedich-346	154	24	clinical	clinical	ADJ
biomedich-346	154	25	trial	trial	NOUN
biomedich-346	154	26	2021	2021	NUM
biomedich-346	154	27	in	in	ADP
biomedich-346	154	28	this	this	DET
biomedich-346	154	29	phase	phase	NOUN
biomedich-346	154	30	3	3	NUM
biomedich-346	154	31	,	,	PUNCT
biomedich-346	154	32	randomized	randomize	VERB
biomedich-346	154	33	,	,	PUNCT
biomedich-346	154	34	observer	observer	NOUN
biomedich-346	154	35	-	-	PUNCT
biomedich-346	154	36	blinded	blinded	ADJ
biomedich-346	154	37	,	,	PUNCT
biomedich-346	154	38	placebocontrolled	placebocontrolle	VERB
biomedich-346	154	39	trial	trial	NOUN
biomedich-346	154	40	conducted	conduct	VERB
biomedich-346	154	41	at	at	ADP
biomedich-346	154	42	33	33	NUM
biomedich-346	154	43	sites	site	NOUN
biomedich-346	154	44	in	in	ADP
biomedich-346	154	45	the	the	DET
biomedich-346	154	46	united	united	ADJ
biomedich-346	154	47	kingdom	kingdom	PROPN
biomedich-346	154	48	,	,	PUNCT
biomedich-346	154	49	we	we	PRON
biomedich-346	154	50	assigned	assign	VERB
biomedich-346	154	51	adults	adult	NOUN
biomedich-346	154	52	between	between	ADP
biomedich-346	154	53	the	the	DET
biomedich-346	154	54	ages	age	NOUN
biomedich-346	154	55	of	of	ADP
biomedich-346	154	56	18	18	NUM
biomedich-346	154	57	and	and	CCONJ
biomedich-346	154	58	84	84	NUM
biomedich-346	154	59	years	year	NOUN
biomedich-346	154	60	in	in	ADP
biomedich-346	154	61	a	a	DET
biomedich-346	154	62	1:1	1:1	NUM
biomedich-346	154	63	ratio	ratio	NOUN
biomedich-346	154	64	to	to	PART
biomedich-346	154	65	receive	receive	VERB
biomedich-346	154	66	two	two	NUM
biomedich-346	154	67	intramuscular	intramuscular	ADJ
biomedich-346	154	68	5μg	5μg	ADJ
biomedich-346	154	69	doses	dose	NOUN
biomedich-346	154	70	of	of	ADP
biomedich-346	154	71	nvx	nvx	NOUN
biomedich-346	154	72	-	-	PUNCT
biomedich-346	154	73	cov2373	cov2373	NOUN
biomedich-346	154	74	or	or	CCONJ
biomedich-346	154	75	placebo	placebo	NOUN
biomedich-346	154	76	administered	administer	VERB
biomedich-346	154	77	21	21	NUM
biomedich-346	154	78	days	day	NOUN
biomedich-346	154	79	apart	apart	ADV
biomedich-346	154	80	.	.	PUNCT
biomedich-346	155	1	the	the	DET
biomedich-346	155	2	primary	primary	ADJ
biomedich-346	155	3	efficacy	efficacy	NOUN
biomedich-346	155	4	endpoint	endpoint	NOUN
biomedich-346	155	5	was	be	AUX
biomedich-346	155	6	virologically	virologically	ADV
biomedich-346	155	7	confirmed	confirm	VERB
biomedich-346	155	8	mild	mild	ADJ
biomedich-346	155	9	,	,	PUNCT
biomedich-346	155	10	moderate	moderate	ADJ
biomedich-346	155	11	,	,	PUNCT
biomedich-346	155	12	or	or	CCONJ
biomedich-346	155	13	severe	severe	ADJ
biomedich-346	155	14	sars	sar	NOUN
biomedich-346	155	15	-	-	PUNCT
biomedich-346	155	16	cov-2	cov-2	NOUN
biomedich-346	155	17	infection	infection	NOUN
biomedich-346	155	18	with	with	ADP
biomedich-346	155	19	an	an	DET
biomedich-346	155	20	onset	onset	NOUN
biomedich-346	155	21	at	at	ADP
biomedich-346	155	22	least	least	ADV
biomedich-346	155	23	7	7	NUM
biomedich-346	155	24	days	day	NOUN
biomedich-346	155	25	after	after	ADP
biomedich-346	155	26	the	the	DET
biomedich-346	155	27	second	second	ADJ
biomedich-346	155	28	injection	injection	NOUN
biomedich-346	155	29	in	in	ADP
biomedich-346	155	30	participants	participant	NOUN
biomedich-346	155	31	who	who	PRON
biomedich-346	155	32	were	be	AUX
biomedich-346	155	33	serologically	serologically	ADV
biomedich-346	155	34	negative	negative	ADJ
biomedich-346	155	35	at	at	ADP
biomedich-346	155	36	baseline	baseline	NOUN
biomedich-346	155	37	.	.	PUNCT
biomedich-346	156	1	a	a	DET
biomedich-346	156	2	post	post	X
biomedich-346	156	3	hoc	hoc	X
biomedich-346	156	4	analysis	analysis	NOUN
biomedich-346	156	5	showed	show	VERB
biomedich-346	156	6	an	an	DET
biomedich-346	156	7	efficacy	efficacy	NOUN
biomedich-346	156	8	of	of	ADP
biomedich-346	156	9	86.3	86.3	NUM
biomedich-346	156	10	%	%	NOUN
biomedich-346	156	11	(	(	PUNCT
biomedich-346	156	12	95	95	NUM
biomedich-346	156	13	%	%	NOUN
biomedich-346	156	14	ci	ci	NOUN
biomedich-346	156	15	,	,	PUNCT
biomedich-346	156	16	71.3	71.3	NUM
biomedich-346	156	17	to	to	ADP
biomedich-346	156	18	93.5	93.5	NUM
biomedich-346	156	19	)	)	PUNCT
biomedich-346	156	20	against	against	ADP
biomedich-346	156	21	the	the	DET
biomedich-346	156	22	b.1.1.7	b.1.1.7	PROPN
biomedich-346	156	23	(	(	PUNCT
biomedich-346	156	24	or	or	CCONJ
biomedich-346	156	25	alpha	alpha	NOUN
biomedich-346	156	26	)	)	PUNCT
biomedich-346	156	27	variant	variant	NOUN
biomedich-346	156	28	and	and	CCONJ
biomedich-346	156	29	96.4	96.4	NUM
biomedich-346	156	30	%	%	NOUN
biomedich-346	156	31	(	(	PUNCT
biomedich-346	156	32	95	95	NUM
biomedich-346	156	33	%	%	NOUN
biomedich-346	156	34	ci	ci	NOUN
biomedich-346	156	35	,	,	PUNCT
biomedich-346	156	36	73.8	73.8	NUM
biomedich-346	156	37	to	to	PART
biomedich-346	156	38	99.5	99.5	NUM
biomedich-346	156	39	)	)	PUNCT
biomedich-346	156	40	against	against	ADP
biomedich-346	156	41	non	non	ADJ
biomedich-346	156	42	-	-	ADJ
biomedich-346	156	43	b.1.1.7	b.1.1.7	ADJ
biomedich-346	156	44	variants	variant	NOUN
biomedich-346	156	45	.	.	PUNCT
biomedich-346	157	1	reactogenicity	reactogenicity	NOUN
biomedich-346	157	2	was	be	AUX
biomedich-346	157	3	generally	generally	ADV
biomedich-346	157	4	mild	mild	ADJ
biomedich-346	157	5	and	and	CCONJ
biomedich-346	157	6	transient	transient	ADJ
biomedich-346	157	7	.	.	PUNCT
biomedich-346	158	1	the	the	DET
biomedich-346	158	2	incidence	incidence	NOUN
biomedich-346	158	3	of	of	ADP
biomedich-346	158	4	serious	serious	ADJ
biomedich-346	158	5	adverse	adverse	ADJ
biomedich-346	158	6	events	event	NOUN
biomedich-346	158	7	was	be	AUX
biomedich-346	158	8	low	low	ADJ
biomedich-346	158	9	and	and	CCONJ
biomedich-346	158	10	similar	similar	ADJ
biomedich-346	158	11	in	in	ADP
biomedich-346	158	12	the	the	DET
biomedich-346	158	13	two	two	NUM
biomedich-346	158	14	groups	group	NOUN
biomedich-346	158	15	.	.	PUNCT
biomedich-346	159	1	houser	houser	PROPN
biomedich-346	159	2	et	et	PROPN
biomedich-346	159	3	al	al	PROPN
biomedich-346	159	4	.	.	PROPN
biomedich-346	159	5	safety	safety	NOUN
biomedich-346	159	6	and	and	CCONJ
biomedich-346	159	7	immunogenicity	immunogenicity	NOUN
biomedich-346	159	8	of	of	ADP
biomedich-346	159	9	a	a	DET
biomedich-346	159	10	ferritin	ferritin	ADJ
biomedich-346	159	11	nanoparticle	nanoparticle	NOUN
biomedich-346	159	12	h2	h2	NOUN
biomedich-346	159	13	influenza	influenza	NOUN
biomedich-346	159	14	vaccine	vaccine	NOUN
biomedich-346	159	15	in	in	ADP
biomedich-346	159	16	healthy	healthy	ADJ
biomedich-346	159	17	adults	adult	NOUN
biomedich-346	159	18	:	:	PUNCT
biomedich-346	159	19	a	a	DET
biomedich-346	159	20	phase	phase	NOUN
biomedich-346	159	21	1	1	NUM
biomedich-346	159	22	trial	trial	NOUN
biomedich-346	159	23	clinical	clinical	ADJ
biomedich-346	159	24	trial	trial	NOUN
biomedich-346	159	25	2022	2022	NUM
biomedich-346	159	26	conducted	conduct	VERB
biomedich-346	159	27	a	a	DET
biomedich-346	159	28	first	first	ADJ
biomedich-346	159	29	-	-	PUNCT
biomedich-346	159	30	in	in	ADP
biomedich-346	159	31	-	-	PUNCT
biomedich-346	159	32	human	human	NOUN
biomedich-346	159	33	,	,	PUNCT
biomedich-346	159	34	randomized	randomize	VERB
biomedich-346	159	35	,	,	PUNCT
biomedich-346	159	36	open	open	ADJ
biomedich-346	159	37	-	-	PUNCT
biomedich-346	159	38	label	label	NOUN
biomedich-346	159	39	,	,	PUNCT
biomedich-346	159	40	phase	phase	NOUN
biomedich-346	159	41	1	1	NUM
biomedich-346	159	42	clinical	clinical	ADJ
biomedich-346	159	43	trial	trial	NOUN
biomedich-346	159	44	(	(	PUNCT
biomedich-346	159	45	nct03186781	nct03186781	PROPN
biomedich-346	159	46	)	)	PUNCT
biomedich-346	159	47	to	to	PART
biomedich-346	159	48	evaluate	evaluate	VERB
biomedich-346	159	49	a	a	DET
biomedich-346	159	50	novel	novel	NOUN
biomedich-346	159	51	ferritin	ferritin	ADJ
biomedich-346	159	52	(	(	PUNCT
biomedich-346	159	53	h2haferritin	h2haferritin	NOUN
biomedich-346	159	54	)	)	PUNCT
biomedich-346	159	55	nanoparticle	nanoparticle	NOUN
biomedich-346	159	56	influenza	influenza	ADJ
biomedich-346	159	57	vaccine	vaccine	NOUN
biomedich-346	159	58	platform	platform	NOUN
biomedich-346	159	59	.	.	PUNCT
biomedich-346	160	1	the	the	DET
biomedich-346	160	2	h2	h2	NOUN
biomedich-346	160	3	subtype	subtype	NOUN
biomedich-346	160	4	has	have	AUX
biomedich-346	160	5	not	not	PART
biomedich-346	160	6	circulated	circulate	VERB
biomedich-346	160	7	in	in	ADP
biomedich-346	160	8	humans	human	NOUN
biomedich-346	160	9	since	since	SCONJ
biomedich-346	160	10	1968	1968	NUM
biomedich-346	160	11	.	.	PUNCT
biomedich-346	161	1	adults	adult	NOUN
biomedich-346	161	2	born	bear	VERB
biomedich-346	161	3	after	after	ADP
biomedich-346	161	4	1968	1968	NUM
biomedich-346	161	5	have	have	AUX
biomedich-346	161	6	been	be	AUX
biomedich-346	161	7	exposed	expose	VERB
biomedich-346	161	8	to	to	ADP
biomedich-346	161	9	only	only	ADV
biomedich-346	161	10	the	the	DET
biomedich-346	161	11	h1	h1	ADJ
biomedich-346	161	12	subtype	subtype	NOUN
biomedich-346	161	13	of	of	ADP
biomedich-346	161	14	group	group	NOUN
biomedich-346	161	15	1	1	NUM
biomedich-346	161	16	influenza	influenza	NOUN
biomedich-346	161	17	viruses	virus	NOUN
biomedich-346	161	18	,	,	PUNCT
biomedich-346	161	19	which	which	PRON
biomedich-346	161	20	shares	share	VERB
biomedich-346	161	21	a	a	DET
biomedich-346	161	22	conserved	conserved	ADJ
biomedich-346	161	23	stem	stem	NOUN
biomedich-346	161	24	with	with	ADP
biomedich-346	161	25	h2	h2	NOUN
biomedich-346	161	26	.	.	PUNCT
biomedich-346	162	1	including	include	VERB
biomedich-346	162	2	both	both	CCONJ
biomedich-346	162	3	h2	h2	NOUN
biomedich-346	162	4	-	-	PUNCT
biomedich-346	162	5	naive	naive	ADJ
biomedich-346	162	6	and	and	CCONJ
biomedich-346	162	7	h2	h2	NOUN
biomedich-346	162	8	-	-	PUNCT
biomedich-346	162	9	exposed	expose	VERB
biomedich-346	162	10	adults	adult	NOUN
biomedich-346	162	11	in	in	ADP
biomedich-346	162	12	the	the	DET
biomedich-346	162	13	trial	trial	NOUN
biomedich-346	162	14	allowed	allow	VERB
biomedich-346	162	15	us	we	PRON
biomedich-346	162	16	to	to	PART
biomedich-346	162	17	evaluate	evaluate	VERB
biomedich-346	162	18	memory	memory	NOUN
biomedich-346	162	19	responses	response	NOUN
biomedich-346	162	20	against	against	ADP
biomedich-346	162	21	the	the	DET
biomedich-346	162	22	conserved	conserve	VERB
biomedich-346	162	23	stem	stem	NOUN
biomedich-346	162	24	domain	domain	NOUN
biomedich-346	162	25	in	in	ADP
biomedich-346	162	26	the	the	DET
biomedich-346	162	27	presence	presence	NOUN
biomedich-346	162	28	or	or	CCONJ
biomedich-346	162	29	absence	absence	NOUN
biomedich-346	162	30	of	of	ADP
biomedich-346	162	31	pre	pre	ADJ
biomedich-346	162	32	-	-	ADJ
biomedich-346	162	33	existing	existing	ADJ
biomedich-346	162	34	responses	response	NOUN
biomedich-346	162	35	against	against	ADP
biomedich-346	162	36	the	the	DET
biomedich-346	162	37	immunodominant	immunodominant	ADJ
biomedich-346	162	38	ha	ha	INTJ
biomedich-346	162	39	head	head	NOUN
biomedich-346	162	40	domain	domain	NOUN
biomedich-346	162	41	.	.	PUNCT
biomedich-346	163	1	exploratory	exploratory	ADJ
biomedich-346	163	2	analyses	analysis	NOUN
biomedich-346	163	3	identified	identify	VERB
biomedich-346	163	4	neutralizing	neutralize	VERB
biomedich-346	163	5	antibody	antibody	NOUN
biomedich-346	163	6	responses	response	NOUN
biomedich-346	163	7	elicited	elicit	VERB
biomedich-346	163	8	by	by	ADP
biomedich-346	163	9	the	the	DET
biomedich-346	163	10	h2ha	h2ha	NOUN
biomedich-346	163	11	-	-	PUNCT
biomedich-346	163	12	ferritin	ferritin	ADJ
biomedich-346	163	13	vaccine	vaccine	NOUN
biomedich-346	163	14	in	in	ADP
biomedich-346	163	15	both	both	DET
biomedich-346	163	16	h2	h2	NOUN
biomedich-346	163	17	-	-	PUNCT
biomedich-346	163	18	naive	naive	ADJ
biomedich-346	163	19	and	and	CCONJ
biomedich-346	163	20	h2	h2	NOUN
biomedich-346	163	21	-	-	PUNCT
biomedich-346	163	22	exposed	expose	VERB
biomedich-346	163	23	populations	population	NOUN
biomedich-346	163	24	.	.	PUNCT
biomedich-346	164	1	furthermore	furthermore	ADV
biomedich-346	164	2	,	,	PUNCT
biomedich-346	164	3	broadly	broadly	ADV
biomedich-346	164	4	neutralizing	neutralize	VERB
biomedich-346	164	5	antibody	antibody	NOUN
biomedich-346	164	6	responses	response	NOUN
biomedich-346	164	7	against	against	ADP
biomedich-346	164	8	group	group	NOUN
biomedich-346	164	9	1	1	NUM
biomedich-346	164	10	influenza	influenza	NOUN
biomedich-346	164	11	viruses	virus	NOUN
biomedich-346	164	12	,	,	PUNCT
biomedich-346	164	13	including	include	VERB
biomedich-346	164	14	both	both	CCONJ
biomedich-346	164	15	seasonal	seasonal	ADJ
biomedich-346	164	16	h1	h1	NOUN
biomedich-346	164	17	and	and	CCONJ
biomedich-346	164	18	avian	avian	ADJ
biomedich-346	164	19	h5	h5	NOUN
biomedich-346	164	20	subtypes	subtype	NOUN
biomedich-346	164	21	,	,	PUNCT
biomedich-346	164	22	were	be	AUX
biomedich-346	164	23	induced	induce	VERB
biomedich-346	164	24	in	in	ADP
biomedich-346	164	25	the	the	DET
biomedich-346	164	26	h2naive	h2naive	ADJ
biomedich-346	164	27	population	population	NOUN
biomedich-346	164	28	by	by	ADP
biomedich-346	164	29	targeting	target	VERB
biomedich-346	164	30	the	the	DET
biomedich-346	164	31	ha	ha	NOUN
biomedich-346	164	32	stem	stem	NOUN
biomedich-346	164	33	.	.	PUNCT
biomedich-346	165	1	this	this	DET
biomedich-346	165	2	ferritin	ferritin	ADJ
biomedich-346	165	3	nanoparticle	nanoparticle	NOUN
biomedich-346	165	4	vaccine	vaccine	NOUN
biomedich-346	165	5	technology	technology	NOUN
biomedich-346	165	6	represents	represent	VERB
biomedich-346	165	7	a	a	DET
biomedich-346	165	8	novel	novel	NOUN
biomedich-346	165	9	,	,	PUNCT
biomedich-346	165	10	safe	safe	ADJ
biomedich-346	165	11	and	and	CCONJ
biomedich-346	165	12	immunogenic	immunogenic	ADJ
biomedich-346	165	13	platform	platform	NOUN
biomedich-346	165	14	with	with	ADP
biomedich-346	165	15	potential	potential	ADJ
biomedich-346	165	16	application	application	NOUN
biomedich-346	165	17	for	for	ADP
biomedich-346	165	18	pandemic	pandemic	ADJ
biomedich-346	165	19	preparedness	preparedness	NOUN
biomedich-346	165	20	and	and	CCONJ
biomedich-346	165	21	universal	universal	ADJ
biomedich-346	165	22	influenza	influenza	ADJ
biomedich-346	165	23	vaccine	vaccine	NOUN
biomedich-346	165	24	development	development	NOUN
biomedich-346	165	25	.	.	PUNCT
biomedich-346	166	1	shinde	shinde	PROPN
biomedich-346	166	2	et	et	PROPN
biomedich-346	166	3	al	al	PROPN
biomedich-346	166	4	.	.	PROPN
biomedich-346	166	5	efficacy	efficacy	NOUN
biomedich-346	166	6	of	of	ADP
biomedich-346	166	7	nvxcov2373	nvxcov2373	PROPN
biomedich-346	166	8	covid-19	covid-19	PROPN
biomedich-346	166	9	vaccine	vaccine	NOUN
biomedich-346	166	10	against	against	ADP
biomedich-346	166	11	the	the	DET
biomedich-346	166	12	b.1.351	b.1.351	NOUN
biomedich-346	166	13	variant	variant	ADJ
biomedich-346	166	14	clinical	clinical	ADJ
biomedich-346	166	15	trial	trial	NOUN
biomedich-346	166	16	2021	2021	NUM
biomedich-346	166	17	in	in	ADP
biomedich-346	166	18	this	this	DET
biomedich-346	166	19	phase	phase	NOUN
biomedich-346	166	20	2a	2a	NUM
biomedich-346	166	21	-	-	PUNCT
biomedich-346	166	22	b	b	NOUN
biomedich-346	166	23	trial	trial	NOUN
biomedich-346	166	24	in	in	ADP
biomedich-346	166	25	south	south	PROPN
biomedich-346	166	26	africa	africa	PROPN
biomedich-346	166	27	,	,	PUNCT
biomedich-346	166	28	we	we	PRON
biomedich-346	166	29	randomly	randomly	VERB
biomedich-346	166	30	assigned	assign	VERB
biomedich-346	166	31	human	human	ADJ
biomedich-346	166	32	immunodeficiency	immunodeficiency	NOUN
biomedich-346	166	33	virus	virus	NOUN
biomedich-346	166	34	(	(	PUNCT
biomedich-346	166	35	hiv)-negative	hiv)-negative	ADJ
biomedich-346	166	36	adults	adult	NOUN
biomedich-346	166	37	between	between	ADP
biomedich-346	166	38	the	the	DET
biomedich-346	166	39	ages	age	NOUN
biomedich-346	166	40	of	of	ADP
biomedich-346	166	41	18	18	NUM
biomedich-346	166	42	and	and	CCONJ
biomedich-346	166	43	84	84	NUM
biomedich-346	166	44	years	year	NOUN
biomedich-346	166	45	or	or	CCONJ
biomedich-346	166	46	medically	medically	ADV
biomedich-346	166	47	stable	stable	ADJ
biomedich-346	166	48	hiv	hiv	NOUN
biomedich-346	166	49	-	-	PUNCT
biomedich-346	166	50	positive	positive	ADJ
biomedich-346	166	51	participants	participant	NOUN
biomedich-346	166	52	between	between	ADP
biomedich-346	166	53	the	the	DET
biomedich-346	166	54	ages	age	NOUN
biomedich-346	166	55	of	of	ADP
biomedich-346	166	56	18	18	NUM
biomedich-346	166	57	and	and	CCONJ
biomedich-346	166	58	64	64	NUM
biomedich-346	166	59	years	year	NOUN
biomedich-346	166	60	in	in	ADP
biomedich-346	166	61	a	a	DET
biomedich-346	166	62	1:1	1:1	NUM
biomedich-346	166	63	ratio	ratio	NOUN
biomedich-346	166	64	to	to	PART
biomedich-346	166	65	receive	receive	VERB
biomedich-346	166	66	two	two	NUM
biomedich-346	166	67	doses	dose	NOUN
biomedich-346	166	68	of	of	ADP
biomedich-346	166	69	either	either	CCONJ
biomedich-346	166	70	the	the	DET
biomedich-346	166	71	nvx	nvx	PROPN
biomedich-346	166	72	-	-	PUNCT
biomedich-346	166	73	cov2373	cov2373	NOUN
biomedich-346	166	74	vaccine	vaccine	NOUN
biomedich-346	166	75	(	(	PUNCT
biomedich-346	166	76	5	5	NUM
biomedich-346	166	77	μg	μg	NOUN
biomedich-346	166	78	of	of	ADP
biomedich-346	166	79	recombinant	recombinant	ADJ
biomedich-346	166	80	spike	spike	ADJ
biomedich-346	166	81	protein	protein	NOUN
biomedich-346	166	82	with	with	ADP
biomedich-346	166	83	50	50	NUM
biomedich-346	166	84	μg	μg	NOUN
biomedich-346	166	85	of	of	ADP
biomedich-346	166	86	matrix	matrix	NOUN
biomedich-346	166	87	-	-	PUNCT
biomedich-346	166	88	m1	m1	NOUN
biomedich-346	166	89	adjuvant	adjuvant	NOUN
biomedich-346	166	90	)	)	PUNCT
biomedich-346	166	91	or	or	CCONJ
biomedich-346	166	92	placebo	placebo	NOUN
biomedich-346	166	93	.	.	PUNCT
biomedich-346	167	1	the	the	DET
biomedich-346	167	2	primary	primary	ADJ
biomedich-346	167	3	endpoints	endpoint	NOUN
biomedich-346	167	4	were	be	AUX
biomedich-346	167	5	safety	safety	NOUN
biomedich-346	167	6	and	and	CCONJ
biomedich-346	167	7	vaccine	vaccine	NOUN
biomedich-346	167	8	efficacy	efficacy	NOUN
biomedich-346	167	9	against	against	ADP
biomedich-346	167	10	laboratory	laboratory	NOUN
biomedich-346	167	11	-	-	PUNCT
biomedich-346	167	12	confirmed	confirm	VERB
biomedich-346	167	13	symptomatic	symptomatic	ADJ
biomedich-346	167	14	covid-19	covid-19	PROPN
biomedich-346	167	15	at	at	ADP
biomedich-346	167	16	7	7	NUM
biomedich-346	167	17	days	day	NOUN
biomedich-346	167	18	or	or	CCONJ
biomedich-346	167	19	more	more	ADJ
biomedich-346	167	20	after	after	ADP
biomedich-346	167	21	the	the	DET
biomedich-346	167	22	second	second	ADJ
biomedich-346	167	23	dose	dose	NOUN
biomedich-346	167	24	among	among	ADP
biomedich-346	167	25	participants	participant	NOUN
biomedich-346	167	26	without	without	ADP
biomedich-346	167	27	previous	previous	ADJ
biomedich-346	167	28	sars	sar	NOUN
biomedich-346	167	29	-	-	PUNCT
biomedich-346	167	30	cov-2	cov-2	NOUN
biomedich-346	167	31	infection	infection	NOUN
biomedich-346	167	32	.	.	PUNCT
biomedich-346	168	1	of	of	ADP
biomedich-346	168	2	41	41	NUM
biomedich-346	168	3	sequenced	sequence	VERB
biomedich-346	168	4	isolates	isolate	NOUN
biomedich-346	168	5	,	,	PUNCT
biomedich-346	168	6	38	38	NUM
biomedich-346	168	7	(	(	PUNCT
biomedich-346	168	8	92.7	92.7	NUM
biomedich-346	168	9	%	%	NOUN
biomedich-346	168	10	)	)	PUNCT
biomedich-346	168	11	were	be	AUX
biomedich-346	168	12	the	the	DET
biomedich-346	168	13	b.1.351	b.1.351	NOUN
biomedich-346	168	14	variant	variant	NOUN
biomedich-346	168	15	.	.	PUNCT
biomedich-346	169	1	post	post	VERB
biomedich-346	169	2	hoc	hoc	X
biomedich-346	169	3	vaccine	vaccine	NOUN
biomedich-346	169	4	efficacy	efficacy	NOUN
biomedich-346	169	5	against	against	ADP
biomedich-346	169	6	b.1.351	b.1.351	NOUN
biomedich-346	169	7	was	be	AUX
biomedich-346	169	8	51.0	51.0	NUM
biomedich-346	169	9	%	%	NOUN
biomedich-346	169	10	(	(	PUNCT
biomedich-346	169	11	95	95	NUM
biomedich-346	169	12	%	%	NOUN
biomedich-346	169	13	ci	ci	NOUN
biomedich-346	169	14	,	,	PUNCT
biomedich-346	169	15	-0.6	-0.6	NOUN
biomedich-346	169	16	to	to	ADP
biomedich-346	169	17	76.2	76.2	NUM
biomedich-346	169	18	)	)	PUNCT
biomedich-346	169	19	among	among	ADP
biomedich-346	169	20	the	the	DET
biomedich-346	169	21	hiv	hiv	PROPN
biomedich-346	169	22	-	-	PUNCT
biomedich-346	169	23	negative	negative	ADJ
biomedich-346	169	24	participants	participant	NOUN
biomedich-346	169	25	.	.	PUNCT
biomedich-346	170	1	preliminary	preliminary	ADJ
biomedich-346	170	2	local	local	ADJ
biomedich-346	170	3	and	and	CCONJ
biomedich-346	170	4	systemic	systemic	ADJ
biomedich-346	170	5	reactogenicity	reactogenicity	NOUN
biomedich-346	170	6	events	event	NOUN
biomedich-346	170	7	were	be	AUX
biomedich-346	170	8	more	more	ADV
biomedich-346	170	9	common	common	ADJ
biomedich-346	170	10	in	in	ADP
biomedich-346	170	11	the	the	DET
biomedich-346	170	12	vaccine	vaccine	NOUN
biomedich-346	170	13	group	group	NOUN
biomedich-346	170	14	;	;	PUNCT
biomedich-346	170	15	serious	serious	ADJ
biomedich-346	170	16	adverse	adverse	ADJ
biomedich-346	170	17	events	event	NOUN
biomedich-346	170	18	were	be	AUX
biomedich-346	170	19	rare	rare	ADJ
biomedich-346	170	20	in	in	ADP
biomedich-346	170	21	both	both	DET
biomedich-346	170	22	groups	group	NOUN
biomedich-346	170	23	.	.	PUNCT
biomedich-346	171	1	dunkle	dunkle	PROPN
biomedich-346	171	2	et	et	PROPN
biomedich-346	171	3	al	al	PROPN
biomedich-346	171	4	.	.	PROPN
biomedich-346	171	5	efficacy	efficacy	NOUN
biomedich-346	171	6	and	and	CCONJ
biomedich-346	171	7	safety	safety	NOUN
biomedich-346	171	8	of	of	ADP
biomedich-346	171	9	nvx	nvx	NOUN
biomedich-346	171	10	-	-	PUNCT
biomedich-346	171	11	cov2373	cov2373	NOUN
biomedich-346	171	12	in	in	ADP
biomedich-346	171	13	adults	adult	NOUN
biomedich-346	171	14	in	in	ADP
biomedich-346	171	15	the	the	DET
biomedich-346	171	16	united	united	ADJ
biomedich-346	171	17	clinical	clinical	ADJ
biomedich-346	171	18	trial	trial	NOUN
biomedich-346	171	19	2022	2022	NUM
biomedich-346	171	20	conducted	conduct	VERB
biomedich-346	171	21	a	a	DET
biomedich-346	171	22	phase	phase	NOUN
biomedich-346	171	23	3	3	NUM
biomedich-346	171	24	,	,	PUNCT
biomedich-346	171	25	randomized	randomize	VERB
biomedich-346	171	26	,	,	PUNCT
biomedich-346	171	27	observer	observer	NOUN
biomedich-346	171	28	-	-	PUNCT
biomedich-346	171	29	blinded	blinded	ADJ
biomedich-346	171	30	,	,	PUNCT
biomedich-346	171	31	placebo	placebo	NOUN
biomedich-346	171	32	-	-	PUNCT
biomedich-346	171	33	controlled	control	VERB
biomedich-346	171	34	trial	trial	NOUN
biomedich-346	171	35	in	in	ADP
biomedich-346	171	36	the	the	DET
biomedich-346	171	37	ten	ten	NUM
biomedich-346	171	38	moderate	moderate	ADJ
biomedich-346	171	39	and	and	CCONJ
biomedich-346	171	40	4	4	NUM
biomedich-346	171	41	severe	severe	ADJ
biomedich-346	171	42	cases	case	NOUN
biomedich-346	171	43	occurred	occur	VERB
biomedich-346	171	44	,	,	PUNCT
biomedich-346	171	45	all	all	PRON
biomedich-346	171	46	in	in	ADP
biomedich-346	171	47	placebo	placebo	NOUN
biomedich-346	171	48	recipients	recipient	NOUN
biomedich-346	171	49	,	,	PUNCT
biomedich-346	171	50	yielding	yield	VERB
biomedich-346	171	51	vaccine	vaccine	NOUN
biomedich-346	171	52	efficacy	efficacy	NOUN
biomedich-346	171	53	against	against	ADP
biomedich-346	171	54	the	the	DET
biomedich-346	171	55	hussein	hussein	PROPN
biomedich-346	171	56	et	et	PROPN
biomedich-346	171	57	al	al	PROPN
biomedich-346	171	58	.	.	PROPN
biomedich-346	171	59	–	–	PUNCT
biomedich-346	171	60	nanotechnology	nanotechnology	NOUN
biomedich-346	171	61	-	-	PUNCT
biomedich-346	171	62	based	base	VERB
biomedich-346	171	63	vaccines	vaccine	NOUN
biomedich-346	171	64	349	349	NUM
biomedich-346	171	65	authors	author	NOUN
biomedich-346	171	66	title	title	VERB
biomedich-346	171	67	date	date	NOUN
biomedich-346	171	68	and	and	CCONJ
biomedich-346	171	69	type	type	NOUN
biomedich-346	171	70	of	of	ADP
biomedich-346	171	71	the	the	DET
biomedich-346	171	72	study	study	NOUN
biomedich-346	171	73	method	method	NOUN
biomedich-346	171	74	results	result	VERB
biomedich-346	171	75	states	state	NOUN
biomedich-346	171	76	and	and	CCONJ
biomedich-346	171	77	mexico	mexico	PROPN
biomedich-346	171	78	united	unite	VERB
biomedich-346	171	79	states	states	PROPN
biomedich-346	171	80	and	and	CCONJ
biomedich-346	171	81	mexico	mexico	PROPN
biomedich-346	171	82	during	during	ADP
biomedich-346	171	83	the	the	DET
biomedich-346	171	84	first	first	ADJ
biomedich-346	171	85	half	half	NOUN
biomedich-346	171	86	of	of	ADP
biomedich-346	171	87	2021	2021	NUM
biomedich-346	171	88	to	to	PART
biomedich-346	171	89	evaluate	evaluate	VERB
biomedich-346	171	90	the	the	DET
biomedich-346	171	91	efficacy	efficacy	NOUN
biomedich-346	171	92	and	and	CCONJ
biomedich-346	171	93	safety	safety	NOUN
biomedich-346	171	94	of	of	ADP
biomedich-346	171	95	nvxcov2373	nvxcov2373	NOUN
biomedich-346	171	96	in	in	ADP
biomedich-346	171	97	adults	adult	NOUN
biomedich-346	171	98	(	(	PUNCT
biomedich-346	171	99	≥18	≥18	NUM
biomedich-346	171	100	years	year	NOUN
biomedich-346	171	101	of	of	ADP
biomedich-346	171	102	age	age	NOUN
biomedich-346	171	103	)	)	PUNCT
biomedich-346	171	104	who	who	PRON
biomedich-346	171	105	had	have	AUX
biomedich-346	171	106	not	not	PART
biomedich-346	171	107	had	have	VERB
biomedich-346	171	108	severe	severe	ADJ
biomedich-346	171	109	acute	acute	ADJ
biomedich-346	171	110	respiratory	respiratory	ADJ
biomedich-346	171	111	syndrome	syndrome	NOUN
biomedich-346	171	112	coronavirus	coronavirus	NOUN
biomedich-346	171	113	2	2	NUM
biomedich-346	171	114	(	(	PUNCT
biomedich-346	171	115	sars	sar	NOUN
biomedich-346	171	116	-	-	PUNCT
biomedich-346	171	117	cov-2	cov-2	NOUN
biomedich-346	171	118	)	)	PUNCT
biomedich-346	171	119	infection	infection	NOUN
biomedich-346	171	120	.	.	PUNCT
biomedich-346	172	1	participants	participant	NOUN
biomedich-346	172	2	were	be	AUX
biomedich-346	172	3	randomly	randomly	ADV
biomedich-346	172	4	assigned	assign	VERB
biomedich-346	172	5	in	in	ADP
biomedich-346	172	6	a	a	DET
biomedich-346	172	7	2:1	2:1	NUM
biomedich-346	172	8	ratio	ratio	NOUN
biomedich-346	172	9	to	to	PART
biomedich-346	172	10	receive	receive	VERB
biomedich-346	172	11	two	two	NUM
biomedich-346	172	12	doses	dose	NOUN
biomedich-346	172	13	of	of	ADP
biomedich-346	172	14	nvxcov2373	nvxcov2373	NOUN
biomedich-346	172	15	or	or	CCONJ
biomedich-346	172	16	placebo	placebo	NOUN
biomedich-346	172	17	21	21	NUM
biomedich-346	172	18	days	day	NOUN
biomedich-346	172	19	apart	apart	ADV
biomedich-346	172	20	.	.	PUNCT
biomedich-346	173	1	the	the	DET
biomedich-346	173	2	primary	primary	ADJ
biomedich-346	173	3	objective	objective	NOUN
biomedich-346	173	4	was	be	AUX
biomedich-346	173	5	to	to	PART
biomedich-346	173	6	determine	determine	VERB
biomedich-346	173	7	vaccine	vaccine	NOUN
biomedich-346	173	8	efficacy	efficacy	NOUN
biomedich-346	173	9	against	against	ADP
biomedich-346	173	10	reverse	reverse	NOUN
biomedich-346	173	11	-	-	PUNCT
biomedich-346	173	12	transcriptasepolymerase	transcriptasepolymerase	NOUN
biomedich-346	173	13	-	-	PUNCT
biomedich-346	173	14	chain	chain	NOUN
biomedich-346	173	15	-	-	PUNCT
biomedich-346	173	16	reactionconfirmed	reactionconfirme	VERB
biomedich-346	173	17	covid-19	covid-19	PROPN
biomedich-346	173	18	occurring	occur	VERB
biomedich-346	173	19	at	at	ADV
biomedich-346	173	20	least	least	ADV
biomedich-346	173	21	7	7	NUM
biomedich-346	173	22	days	day	NOUN
biomedich-346	173	23	after	after	ADP
biomedich-346	173	24	the	the	DET
biomedich-346	173	25	second	second	ADJ
biomedich-346	173	26	dose	dose	PROPN
biomedich-346	173	27	.	.	PUNCT
biomedich-346	174	1	vaccine	vaccine	NOUN
biomedich-346	174	2	efficacy	efficacy	NOUN
biomedich-346	174	3	against	against	ADP
biomedich-346	174	4	moderate	moderate	ADJ
biomedich-346	174	5	-	-	PUNCT
biomedich-346	174	6	to	to	ADP
biomedich-346	174	7	-	-	PUNCT
biomedich-346	174	8	severe	severe	ADJ
biomedich-346	174	9	disease	disease	NOUN
biomedich-346	174	10	and	and	CCONJ
biomedich-346	174	11	against	against	ADP
biomedich-346	174	12	different	different	ADJ
biomedich-346	174	13	variants	variant	NOUN
biomedich-346	174	14	was	be	AUX
biomedich-346	174	15	also	also	ADV
biomedich-346	174	16	assessed	assess	VERB
biomedich-346	174	17	.	.	PUNCT
biomedich-346	175	1	moderate	moderate	ADJ
biomedich-346	175	2	-	-	PUNCT
biomedich-346	175	3	to	to	ADP
biomedich-346	175	4	-	-	PUNCT
biomedich-346	175	5	severe	severe	ADJ
biomedich-346	175	6	disease	disease	NOUN
biomedich-346	175	7	of	of	ADP
biomedich-346	175	8	100	100	NUM
biomedich-346	175	9	%	%	NOUN
biomedich-346	175	10	(	(	PUNCT
biomedich-346	175	11	95	95	NUM
biomedich-346	175	12	%	%	NOUN
biomedich-346	175	13	ci	ci	NOUN
biomedich-346	175	14	,	,	PUNCT
biomedich-346	175	15	87.0	87.0	NUM
biomedich-346	175	16	to	to	PART
biomedich-346	175	17	100	100	NUM
biomedich-346	175	18	)	)	PUNCT
biomedich-346	175	19	.	.	PUNCT
biomedich-346	176	1	most	most	ADV
biomedich-346	176	2	sequenced	sequence	VERB
biomedich-346	176	3	viral	viral	ADJ
biomedich-346	176	4	genomes	genome	NOUN
biomedich-346	176	5	(	(	PUNCT
biomedich-346	176	6	48	48	NUM
biomedich-346	176	7	of	of	ADP
biomedich-346	176	8	61	61	NUM
biomedich-346	176	9	,	,	PUNCT
biomedich-346	176	10	79	79	NUM
biomedich-346	176	11	%	%	NOUN
biomedich-346	176	12	)	)	PUNCT
biomedich-346	176	13	were	be	AUX
biomedich-346	176	14	variants	variant	NOUN
biomedich-346	176	15	of	of	ADP
biomedich-346	176	16	concern	concern	NOUN
biomedich-346	176	17	or	or	CCONJ
biomedich-346	176	18	interest	interest	NOUN
biomedich-346	176	19	largely	largely	ADV
biomedich-346	176	20	b.1.1.7	b.1.1.7	CCONJ
biomedich-346	176	21	(	(	PUNCT
biomedich-346	176	22	alpha	alpha	NOUN
biomedich-346	176	23	)	)	PUNCT
biomedich-346	176	24	(	(	PUNCT
biomedich-346	176	25	31	31	NUM
biomedich-346	176	26	of	of	ADP
biomedich-346	176	27	the	the	DET
biomedich-346	176	28	35	35	NUM
biomedich-346	176	29	genomes	genome	NOUN
biomedich-346	176	30	for	for	ADP
biomedich-346	176	31	variants	variant	NOUN
biomedich-346	176	32	of	of	ADP
biomedich-346	176	33	concern	concern	NOUN
biomedich-346	176	34	,	,	PUNCT
biomedich-346	176	35	89	89	NUM
biomedich-346	176	36	%	%	NOUN
biomedich-346	176	37	)	)	PUNCT
biomedich-346	176	38	.	.	PUNCT
biomedich-346	177	1	vaccine	vaccine	NOUN
biomedich-346	177	2	efficacy	efficacy	NOUN
biomedich-346	177	3	against	against	ADP
biomedich-346	177	4	any	any	DET
biomedich-346	177	5	variant	variant	NOUN
biomedich-346	177	6	of	of	ADP
biomedich-346	177	7	concern	concern	NOUN
biomedich-346	177	8	or	or	CCONJ
biomedich-346	177	9	interest	interest	NOUN
biomedich-346	177	10	was	be	AUX
biomedich-346	177	11	92.6	92.6	NUM
biomedich-346	177	12	%	%	NOUN
biomedich-346	177	13	(	(	PUNCT
biomedich-346	177	14	95	95	NUM
biomedich-346	177	15	%	%	NOUN
biomedich-346	177	16	ci	ci	NOUN
biomedich-346	177	17	,	,	PUNCT
biomedich-346	177	18	83.6	83.6	NUM
biomedich-346	177	19	to	to	ADP
biomedich-346	177	20	96.7	96.7	NUM
biomedich-346	177	21	)	)	PUNCT
biomedich-346	177	22	.	.	PUNCT
biomedich-346	178	1	reactogenicity	reactogenicity	NOUN
biomedich-346	178	2	was	be	AUX
biomedich-346	178	3	mostly	mostly	ADV
biomedich-346	178	4	mild	mild	ADJ
biomedich-346	178	5	to	to	AUX
biomedich-346	178	6	moderate	moderate	ADJ
biomedich-346	178	7	and	and	CCONJ
biomedich-346	178	8	transient	transient	ADJ
biomedich-346	178	9	but	but	CCONJ
biomedich-346	178	10	was	be	AUX
biomedich-346	178	11	more	more	ADV
biomedich-346	178	12	frequent	frequent	ADJ
biomedich-346	178	13	among	among	ADP
biomedich-346	178	14	nvx	nvx	NOUN
biomedich-346	178	15	-	-	PUNCT
biomedich-346	178	16	cov2373	cov2373	NOUN
biomedich-346	178	17	recipients	recipient	NOUN
biomedich-346	178	18	than	than	ADP
biomedich-346	178	19	among	among	ADP
biomedich-346	178	20	placebo	placebo	NOUN
biomedich-346	178	21	recipients	recipient	NOUN
biomedich-346	178	22	and	and	CCONJ
biomedich-346	178	23	was	be	AUX
biomedich-346	178	24	more	more	ADV
biomedich-346	178	25	frequent	frequent	ADJ
biomedich-346	178	26	after	after	ADP
biomedich-346	178	27	the	the	DET
biomedich-346	178	28	second	second	ADJ
biomedich-346	178	29	dose	dose	NOUN
biomedich-346	178	30	than	than	ADP
biomedich-346	178	31	after	after	ADP
biomedich-346	178	32	the	the	DET
biomedich-346	178	33	first	first	ADJ
biomedich-346	178	34	dose	dose	NOUN
biomedich-346	178	35	.	.	PUNCT
biomedich-346	179	1	wei	wei	PROPN
biomedich-346	179	2	et	et	PROPN
biomedich-346	179	3	al	al	PROPN
biomedich-346	179	4	.	.	PROPN
biomedich-346	179	5	efficacy	efficacy	NOUN
biomedich-346	179	6	and	and	CCONJ
biomedich-346	179	7	safety	safety	NOUN
biomedich-346	179	8	of	of	ADP
biomedich-346	179	9	a	a	DET
biomedich-346	179	10	nanoparticle	nanoparticle	NOUN
biomedich-346	179	11	therapeutic	therapeutic	ADJ
biomedich-346	179	12	vaccine	vaccine	NOUN
biomedich-346	179	13	in	in	ADP
biomedich-346	179	14	patients	patient	NOUN
biomedich-346	179	15	with	with	ADP
biomedich-346	179	16	chronic	chronic	ADJ
biomedich-346	179	17	hepatitis	hepatitis	NOUN
biomedich-346	179	18	b	b	NOUN
biomedich-346	179	19	:	:	PUNCT
biomedich-346	179	20	a	a	DET
biomedich-346	179	21	randomized	randomized	ADJ
biomedich-346	179	22	clinical	clinical	ADJ
biomedich-346	179	23	trial	trial	NOUN
biomedich-346	179	24	clinical	clinical	ADJ
biomedich-346	179	25	trial	trial	NOUN
biomedich-346	179	26	2022	2022	NUM
biomedich-346	179	27	a	a	DET
biomedich-346	179	28	two	two	NUM
biomedich-346	179	29	-	-	PUNCT
biomedich-346	179	30	stage	stage	NOUN
biomedich-346	179	31	phase	phase	NOUN
biomedich-346	179	32	2	2	NUM
biomedich-346	179	33	trial	trial	NOUN
biomedich-346	179	34	,	,	PUNCT
biomedich-346	179	35	which	which	PRON
biomedich-346	179	36	included	include	VERB
biomedich-346	179	37	a	a	DET
biomedich-346	179	38	76	76	NUM
biomedich-346	179	39	-	-	PUNCT
biomedich-346	179	40	week	week	NOUN
biomedich-346	179	41	,	,	PUNCT
biomedich-346	179	42	randomized	randomize	VERB
biomedich-346	179	43	,	,	PUNCT
biomedich-346	179	44	double	double	ADJ
biomedich-346	179	45	-	-	PUNCT
biomedich-346	179	46	blind	blind	ADJ
biomedich-346	179	47	,	,	PUNCT
biomedich-346	179	48	placebo	placebo	NOUN
biomedich-346	179	49	-	-	PUNCT
biomedich-346	179	50	controlled	control	VERB
biomedich-346	179	51	trial	trial	NOUN
biomedich-346	179	52	(	(	PUNCT
biomedich-346	179	53	stage	stage	NOUN
biomedich-346	179	54	1	1	NUM
biomedich-346	179	55	)	)	PUNCT
biomedich-346	179	56	and	and	CCONJ
biomedich-346	179	57	a	a	DET
biomedich-346	179	58	68	68	NUM
biomedich-346	179	59	-	-	PUNCT
biomedich-346	179	60	week	week	NOUN
biomedich-346	179	61	open	open	ADJ
biomedich-346	179	62	-	-	PUNCT
biomedich-346	179	63	label	label	NOUN
biomedich-346	179	64	extension	extension	NOUN
biomedich-346	179	65	(	(	PUNCT
biomedich-346	179	66	stage	stage	NOUN
biomedich-346	179	67	2	2	NUM
biomedich-346	179	68	)	)	PUNCT
biomedich-346	179	69	,	,	PUNCT
biomedich-346	179	70	was	be	AUX
biomedich-346	179	71	conducted	conduct	VERB
biomedich-346	179	72	in	in	ADP
biomedich-346	179	73	15	15	NUM
biomedich-346	179	74	centers	center	NOUN
biomedich-346	179	75	across	across	ADP
biomedich-346	179	76	china	china	PROPN
biomedich-346	179	77	.	.	PUNCT
biomedich-346	180	1	with	with	ADP
biomedich-346	180	2	a	a	DET
biomedich-346	180	3	combined	combine	VERB
biomedich-346	180	4	endpoint	endpoint	NOUN
biomedich-346	180	5	of	of	ADP
biomedich-346	180	6	hbeag	hbeag	ADJ
biomedich-346	180	7	seroconversion	seroconversion	NOUN
biomedich-346	180	8	,	,	PUNCT
biomedich-346	180	9	alanine	alanine	NOUN
biomedich-346	180	10	aminotransferase	aminotransferase	PROPN
biomedich-346	180	11	normalization	normalization	NOUN
biomedich-346	180	12	and	and	CCONJ
biomedich-346	180	13	hbv	hbv	NOUN
biomedich-346	180	14	dna	dna	PROPN
biomedich-346	180	15	<	<	X
biomedich-346	180	16	2,000	2,000	NUM
biomedich-346	180	17	iu	iu	NOUN
biomedich-346	180	18	/	/	SYM
biomedich-346	180	19	ml	ml	NOUN
biomedich-346	180	20	,	,	PUNCT
biomedich-346	180	21	both	both	DET
biomedich-346	180	22	900	900	NUM
biomedich-346	180	23	µg	µg	ADP
biomedich-346	180	24	(	(	PUNCT
biomedich-346	180	25	18.1	18.1	NUM
biomedich-346	180	26	%	%	NOUN
biomedich-346	180	27	)	)	PUNCT
biomedich-346	180	28	and	and	CCONJ
biomedich-346	180	29	600	600	NUM
biomedich-346	180	30	µg	µg	ADV
biomedich-346	180	31	(	(	PUNCT
biomedich-346	180	32	14.3	14.3	NUM
biomedich-346	180	33	%	%	NOUN
biomedich-346	180	34	)	)	PUNCT
biomedich-346	180	35	,	,	PUNCT
biomedich-346	180	36	resulted	result	VERB
biomedich-346	180	37	in	in	ADP
biomedich-346	180	38	significantly	significantly	ADV
biomedich-346	180	39	higher	high	ADJ
biomedich-346	180	40	rate	rate	NOUN
biomedich-346	180	41	versus	versus	ADP
biomedich-346	180	42	placebo	placebo	NOUN
biomedich-346	180	43	(	(	PUNCT
biomedich-346	180	44	5.0	5.0	NUM
biomedich-346	180	45	%	%	NOUN
biomedich-346	180	46	)	)	PUNCT
biomedich-346	180	47	(	(	PUNCT
biomedich-346	180	48	p	p	X
biomedich-346	180	49	=	=	PUNCT
biomedich-346	180	50	0.002	0.002	NUM
biomedich-346	180	51	and	and	CCONJ
biomedich-346	180	52	p	p	NOUN
biomedich-346	180	53	=	=	NOUN
biomedich-346	180	54	0.02	0.02	NUM
biomedich-346	180	55	,	,	PUNCT
biomedich-346	180	56	respectively	respectively	ADV
biomedich-346	180	57	)	)	PUNCT
biomedich-346	180	58	at	at	ADP
biomedich-346	180	59	week	week	NOUN
biomedich-346	180	60	76	76	NUM
biomedich-346	180	61	.	.	PUNCT
biomedich-346	181	1	in	in	ADP
biomedich-346	181	2	stage	stage	NOUN
biomedich-346	181	3	2	2	NUM
biomedich-346	181	4	,	,	PUNCT
biomedich-346	181	5	none	none	NOUN
biomedich-346	181	6	(	(	PUNCT
biomedich-346	181	7	0	0	NUM
biomedich-346	181	8	of	of	ADP
biomedich-346	181	9	20	20	NUM
biomedich-346	181	10	)	)	PUNCT
biomedich-346	181	11	of	of	ADP
biomedich-346	181	12	900	900	NUM
biomedich-346	181	13	µg	µg	ADV
biomedich-346	181	14	εpa44	εpa44	NOUN
biomedich-346	181	15	-	-	PUNCT
biomedich-346	181	16	treated	treat	VERB
biomedich-346	181	17	patients	patient	NOUN
biomedich-346	181	18	experienced	experience	VERB
biomedich-346	181	19	a	a	DET
biomedich-346	181	20	serologic	serologic	ADJ
biomedich-346	181	21	relapse	relapse	NOUN
biomedich-346	181	22	.	.	PUNCT
biomedich-346	182	1	the	the	DET
biomedich-346	182	2	safety	safety	NOUN
biomedich-346	182	3	profile	profile	NOUN
biomedich-346	182	4	of	of	ADP
biomedich-346	182	5	εpa-44	εpa-44	NUM
biomedich-346	182	6	was	be	AUX
biomedich-346	182	7	comparable	comparable	ADJ
biomedich-346	182	8	to	to	ADP
biomedich-346	182	9	that	that	PRON
biomedich-346	182	10	of	of	ADP
biomedich-346	182	11	the	the	DET
biomedich-346	182	12	placebo	placebo	NOUN
biomedich-346	182	13	.	.	PUNCT
biomedich-346	183	1	sahin	sahin	PROPN
biomedich-346	183	2	et	et	PROPN
biomedich-346	183	3	al	al	PROPN
biomedich-346	183	4	.	.	PUNCT
biomedich-346	184	1	bnt162b2	bnt162b2	PROPN
biomedich-346	184	2	vaccine	vaccine	NOUN
biomedich-346	184	3	induces	induce	VERB
biomedich-346	184	4	neutralizing	neutralize	VERB
biomedich-346	184	5	antibodies	antibody	NOUN
biomedich-346	184	6	and	and	CCONJ
biomedich-346	184	7	polyspecific	polyspecific	NOUN
biomedich-346	184	8	t	t	NOUN
biomedich-346	184	9	cells	cell	NOUN
biomedich-346	184	10	in	in	ADP
biomedich-346	184	11	humans	human	NOUN
biomedich-346	184	12	clinical	clinical	ADJ
biomedich-346	184	13	trial	trial	NOUN
biomedich-346	184	14	2021	2021	NUM
biomedich-346	184	15	extend	extend	VERB
biomedich-346	184	16	a	a	DET
biomedich-346	184	17	previous	previous	ADJ
biomedich-346	184	18	phase	phase	NOUN
biomedich-346	184	19	-	-	PUNCT
biomedich-346	184	20	i	i	NOUN
biomedich-346	184	21	/	/	SYM
biomedich-346	184	22	ii	ii	PROPN
biomedich-346	184	23	trial	trial	NOUN
biomedich-346	184	24	report2	report2	VERB
biomedich-346	184	25	by	by	ADP
biomedich-346	184	26	presenting	present	VERB
biomedich-346	184	27	data	datum	NOUN
biomedich-346	184	28	on	on	ADP
biomedich-346	184	29	the	the	DET
biomedich-346	184	30	immune	immune	ADJ
biomedich-346	184	31	response	response	NOUN
biomedich-346	184	32	induced	induce	VERB
biomedich-346	184	33	by	by	ADP
biomedich-346	184	34	bnt162b2	bnt162b2	ADJ
biomedich-346	184	35	prime	prime	ADJ
biomedich-346	184	36	-	-	PUNCT
biomedich-346	184	37	boost	boost	NOUN
biomedich-346	184	38	vaccination	vaccination	NOUN
biomedich-346	184	39	from	from	ADP
biomedich-346	184	40	an	an	DET
biomedich-346	184	41	additional	additional	ADJ
biomedich-346	184	42	phase	phase	NOUN
biomedich-346	184	43	-	-	PUNCT
biomedich-346	184	44	i	i	NOUN
biomedich-346	184	45	/	/	SYM
biomedich-346	184	46	ii	ii	PROPN
biomedich-346	184	47	trial	trial	NOUN
biomedich-346	184	48	in	in	ADP
biomedich-346	184	49	healthy	healthy	ADJ
biomedich-346	184	50	adults	adult	NOUN
biomedich-346	184	51	(	(	PUNCT
biomedich-346	184	52	18	18	NUM
biomedich-346	184	53	-	-	SYM
biomedich-346	184	54	55	55	NUM
biomedich-346	184	55	years	year	NOUN
biomedich-346	184	56	old	old	ADJ
biomedich-346	184	57	)	)	PUNCT
biomedich-346	184	58	.	.	PUNCT
biomedich-346	185	1	most	most	ADJ
biomedich-346	185	2	participants	participant	NOUN
biomedich-346	185	3	had	have	VERB
biomedich-346	185	4	a	a	DET
biomedich-346	185	5	strong	strong	ADJ
biomedich-346	185	6	response	response	NOUN
biomedich-346	185	7	of	of	ADP
biomedich-346	185	8	ifnγ+	ifnγ+	NOUN
biomedich-346	185	9	or	or	CCONJ
biomedich-346	185	10	il-2	il-2	PROPN
biomedich-346	185	11	+	+	PROPN
biomedich-346	185	12	cd8	cd8	PROPN
biomedich-346	185	13	+	+	PROPN
biomedich-346	185	14	and	and	CCONJ
biomedich-346	185	15	cd4	cd4	PROPN
biomedich-346	185	16	+	+	PROPN
biomedich-346	185	17	t	t	PROPN
biomedich-346	185	18	helper	helper	NOUN
biomedich-346	185	19	type	type	NOUN
biomedich-346	185	20	1	1	NUM
biomedich-346	185	21	cell	cell	NOUN
biomedich-346	185	22	,	,	PUNCT
biomedich-346	185	23	which	which	PRON
biomedich-346	185	24	was	be	AUX
biomedich-346	185	25	detectable	detectable	ADJ
biomedich-346	185	26	throughout	throughout	ADP
biomedich-346	185	27	the	the	DET
biomedich-346	185	28	full	full	ADJ
biomedich-346	185	29	observation	observation	NOUN
biomedich-346	185	30	period	period	NOUN
biomedich-346	185	31	of	of	ADP
biomedich-346	185	32	nine	nine	NUM
biomedich-346	185	33	weeks	week	NOUN
biomedich-346	185	34	following	follow	VERB
biomedich-346	185	35	the	the	DET
biomedich-346	185	36	boost	boost	NOUN
biomedich-346	185	37	.	.	PUNCT
biomedich-346	186	1	using	use	VERB
biomedich-346	186	2	peptidemhc	peptidemhc	NOUN
biomedich-346	186	3	multimer	multimer	NOUN
biomedich-346	186	4	technology	technology	NOUN
biomedich-346	186	5	,	,	PUNCT
biomedich-346	186	6	we	we	PRON
biomedich-346	186	7	identified	identify	VERB
biomedich-346	186	8	several	several	ADJ
biomedich-346	186	9	bnt162b2	bnt162b2	NOUN
biomedich-346	186	10	-	-	PUNCT
biomedich-346	186	11	induced	induce	VERB
biomedich-346	186	12	epitopes	epitope	NOUN
biomedich-346	186	13	that	that	PRON
biomedich-346	186	14	were	be	AUX
biomedich-346	186	15	presented	present	VERB
biomedich-346	186	16	by	by	ADP
biomedich-346	186	17	frequent	frequent	ADJ
biomedich-346	186	18	mhc	mhc	PROPN
biomedich-346	186	19	alleles	allele	NOUN
biomedich-346	186	20	and	and	CCONJ
biomedich-346	186	21	conserved	conserve	VERB
biomedich-346	186	22	in	in	ADP
biomedich-346	186	23	mutant	mutant	ADJ
biomedich-346	186	24	strains	strain	NOUN
biomedich-346	186	25	.	.	PUNCT
biomedich-346	187	1	one	one	NUM
biomedich-346	187	2	week	week	NOUN
biomedich-346	187	3	after	after	ADP
biomedich-346	187	4	the	the	DET
biomedich-346	187	5	boost	boost	NOUN
biomedich-346	187	6	,	,	PUNCT
biomedich-346	187	7	epitope	epitope	NOUN
biomedich-346	187	8	-	-	PUNCT
biomedich-346	187	9	specific	specific	ADJ
biomedich-346	187	10	cd8	cd8	PROPN
biomedich-346	187	11	+	+	PROPN
biomedich-346	187	12	t	t	NOUN
biomedich-346	187	13	cells	cell	NOUN
biomedich-346	187	14	of	of	ADP
biomedich-346	187	15	the	the	DET
biomedich-346	187	16	early	early	ADV
biomedich-346	187	17	-	-	PUNCT
biomedich-346	187	18	differentiated	differentiate	VERB
biomedich-346	187	19	effectormemory	effectormemory	ADJ
biomedich-346	187	20	phenotype	phenotype	NOUN
biomedich-346	187	21	comprised	comprise	VERB
biomedich-346	187	22	0.022.92	0.022.92	NUM
biomedich-346	187	23	%	%	NOUN
biomedich-346	187	24	of	of	ADP
biomedich-346	187	25	total	total	ADJ
biomedich-346	187	26	circulating	circulating	PROPN
biomedich-346	187	27	cd8	cd8	PROPN
biomedich-346	187	28	+	+	PROPN
biomedich-346	187	29	t	t	NOUN
biomedich-346	187	30	cells	cell	NOUN
biomedich-346	187	31	and	and	CCONJ
biomedich-346	187	32	were	be	AUX
biomedich-346	187	33	detectable	detectable	ADJ
biomedich-346	187	34	(	(	PUNCT
biomedich-346	187	35	0.01	0.01	NUM
biomedich-346	187	36	-	-	PUNCT
biomedich-346	187	37	0.28	0.28	NUM
biomedich-346	187	38	%	%	NOUN
biomedich-346	187	39	)	)	PUNCT
biomedich-346	187	40	eight	eight	NUM
biomedich-346	187	41	weeks	week	NOUN
biomedich-346	187	42	later	later	ADV
biomedich-346	187	43	.	.	PUNCT
biomedich-346	188	1	in	in	ADP
biomedich-346	188	2	summary	summary	NOUN
biomedich-346	188	3	,	,	PUNCT
biomedich-346	188	4	bnt162b2	bnt162b2	PROPN
biomedich-346	188	5	elicits	elicit	VERB
biomedich-346	188	6	an	an	DET
biomedich-346	188	7	adaptive	adaptive	ADJ
biomedich-346	188	8	humoral	humoral	ADJ
biomedich-346	188	9	and	and	CCONJ
biomedich-346	188	10	poly	poly	ADJ
biomedich-346	188	11	-	-	PUNCT
biomedich-346	188	12	specific	specific	ADJ
biomedich-346	188	13	cellular	cellular	ADJ
biomedich-346	188	14	immune	immune	ADJ
biomedich-346	188	15	response	response	NOUN
biomedich-346	188	16	against	against	ADP
biomedich-346	188	17	epitopes	epitope	NOUN
biomedich-346	188	18	that	that	PRON
biomedich-346	188	19	are	be	AUX
biomedich-346	188	20	conserved	conserve	VERB
biomedich-346	188	21	in	in	ADP
biomedich-346	188	22	a	a	DET
biomedich-346	188	23	broad	broad	ADJ
biomedich-346	188	24	range	range	NOUN
biomedich-346	188	25	of	of	ADP
biomedich-346	188	26	variants	variant	NOUN
biomedich-346	188	27	,	,	PUNCT
biomedich-346	188	28	at	at	ADP
biomedich-346	188	29	well	well	ADV
biomedich-346	188	30	-	-	PUNCT
biomedich-346	188	31	tolerated	tolerate	VERB
biomedich-346	188	32	doses	dose	NOUN
biomedich-346	188	33	.	.	PUNCT
biomedich-346	189	1	datoo	datoo	PROPN
biomedich-346	189	2	et	et	PROPN
biomedich-346	189	3	al	al	PROPN
biomedich-346	189	4	.	.	PROPN
biomedich-346	189	5	efficacy	efficacy	NOUN
biomedich-346	189	6	of	of	ADP
biomedich-346	189	7	a	a	DET
biomedich-346	189	8	lowdose	lowdose	ADJ
biomedich-346	189	9	candidate	candidate	NOUN
biomedich-346	189	10	malaria	malaria	NOUN
biomedich-346	189	11	vaccine	vaccine	NOUN
biomedich-346	189	12	,	,	PUNCT
biomedich-346	189	13	r21	r21	NOUN
biomedich-346	189	14	in	in	ADP
biomedich-346	189	15	adjuvant	adjuvant	ADJ
biomedich-346	189	16	matrixm	matrixm	NOUN
biomedich-346	189	17	,	,	PUNCT
biomedich-346	189	18	with	with	ADP
biomedich-346	189	19	seasonal	seasonal	ADJ
biomedich-346	189	20	administration	administration	NOUN
biomedich-346	189	21	to	to	ADP
biomedich-346	189	22	children	child	NOUN
biomedich-346	189	23	in	in	ADP
biomedich-346	189	24	burkina	burkina	PROPN
biomedich-346	189	25	faso	faso	PROPN
biomedich-346	189	26	:	:	PUNCT
biomedich-346	189	27	a	a	DET
biomedich-346	189	28	randomised	randomised	ADJ
biomedich-346	189	29	clinical	clinical	ADJ
biomedich-346	189	30	trial	trial	NOUN
biomedich-346	189	31	2021	2021	NUM
biomedich-346	189	32	in	in	ADP
biomedich-346	189	33	this	this	DET
biomedich-346	189	34	double	double	ADJ
biomedich-346	189	35	-	-	PUNCT
biomedich-346	189	36	blind	blind	ADJ
biomedich-346	189	37	,	,	PUNCT
biomedich-346	189	38	randomized	randomize	VERB
biomedich-346	189	39	,	,	PUNCT
biomedich-346	189	40	controlled	control	VERB
biomedich-346	189	41	,	,	PUNCT
biomedich-346	189	42	phase	phase	NOUN
biomedich-346	189	43	2b	2b	NUM
biomedich-346	189	44	trial	trial	NOUN
biomedich-346	189	45	,	,	PUNCT
biomedich-346	189	46	the	the	DET
biomedich-346	189	47	low	low	ADV
biomedich-346	189	48	-	-	PUNCT
biomedich-346	189	49	dose	dose	NOUN
biomedich-346	189	50	circumsporozoite	circumsporozoite	NOUN
biomedich-346	189	51	protein	protein	NOUN
biomedich-346	189	52	-	-	PUNCT
biomedich-346	189	53	based	base	VERB
biomedich-346	189	54	vaccine	vaccine	NOUN
biomedich-346	189	55	r21	r21	NOUN
biomedich-346	189	56	,	,	PUNCT
biomedich-346	189	57	with	with	ADP
biomedich-346	189	58	two	two	NUM
biomedich-346	189	59	different	different	ADJ
biomedich-346	189	60	doses	dose	NOUN
biomedich-346	189	61	of	of	ADP
biomedich-346	189	62	adjuvant	adjuvant	ADJ
biomedich-346	189	63	matrix	matrix	NOUN
biomedich-346	189	64	-	-	PUNCT
biomedich-346	189	65	m	m	PROPN
biomedich-346	189	66	(	(	PUNCT
biomedich-346	189	67	mm	mm	PROPN
biomedich-346	189	68	)	)	PUNCT
biomedich-346	189	69	,	,	PUNCT
biomedich-346	189	70	was	be	AUX
biomedich-346	189	71	given	give	VERB
biomedich-346	189	72	to	to	ADP
biomedich-346	189	73	children	child	NOUN
biomedich-346	189	74	aged	age	VERB
biomedich-346	189	75	5	5	NUM
biomedich-346	189	76	-	-	SYM
biomedich-346	189	77	17	17	NUM
biomedich-346	189	78	months	month	NOUN
biomedich-346	189	79	in	in	ADP
biomedich-346	189	80	nanoro	nanoro	ADV
biomedich-346	189	81	,	,	PUNCT
biomedich-346	189	82	participants	participant	NOUN
biomedich-346	189	83	vaccinated	vaccinate	VERB
biomedich-346	189	84	with	with	ADP
biomedich-346	189	85	r21	r21	NOUN
biomedich-346	189	86	/	/	SYM
biomedich-346	189	87	mm	mm	PROPN
biomedich-346	189	88	showed	show	VERB
biomedich-346	189	89	high	high	ADJ
biomedich-346	189	90	titres	titre	NOUN
biomedich-346	189	91	of	of	ADP
biomedich-346	189	92	malaria	malaria	NOUN
biomedich-346	189	93	-	-	PUNCT
biomedich-346	189	94	specific	specific	ADJ
biomedich-346	189	95	anti	anti	ADJ
biomedich-346	189	96	-	-	ADJ
biomedich-346	189	97	asn	asn	ADJ
biomedich-346	189	98	-	-	PUNCT
biomedich-346	189	99	ala	ala	PROPN
biomedich-346	189	100	-	-	PUNCT
biomedich-346	189	101	asn	asn	NOUN
biomedich-346	189	102	-	-	PUNCT
biomedich-346	189	103	pro	pro	ADJ
biomedich-346	189	104	(	(	PUNCT
biomedich-346	189	105	nanp	nanp	ADJ
biomedich-346	189	106	)	)	PUNCT
biomedich-346	189	107	antibodies	antibodie	VERB
biomedich-346	189	108	28	28	NUM
biomedich-346	189	109	days	day	NOUN
biomedich-346	189	110	after	after	ADP
biomedich-346	189	111	the	the	DET
biomedich-346	189	112	third	third	ADJ
biomedich-346	189	113	vaccination	vaccination	NOUN
biomedich-346	189	114	,	,	PUNCT
biomedich-346	189	115	which	which	PRON
biomedich-346	189	116	were	be	AUX
biomedich-346	189	117	almost	almost	ADV
biomedich-346	189	118	doubled	double	VERB
biomedich-346	189	119	with	with	ADP
biomedich-346	189	120	the	the	DET
biomedich-346	189	121	higher	high	ADJ
biomedich-346	189	122	adjuvant	adjuvant	ADJ
biomedich-346	189	123	dose	dose	PROPN
biomedich-346	189	124	.	.	PUNCT
biomedich-346	190	1	titres	titre	NOUN
biomedich-346	190	2	waned	wane	VERB
biomedich-346	190	3	but	but	CCONJ
biomedich-346	190	4	were	be	AUX
biomedich-346	190	5	boosted	boost	VERB
biomedich-346	190	6	to	to	ADP
biomedich-346	190	7	levels	level	NOUN
biomedich-346	190	8	similar	similar	ADJ
biomedich-346	190	9	to	to	AUX
biomedich-346	190	10	peak	peak	VERB
biomedich-346	190	11	titres	titre	NOUN
biomedich-346	190	12	after	after	ADP
biomedich-346	190	13	the	the	DET
biomedich-346	190	14	350	350	NUM
biomedich-346	190	15	biology	biology	NOUN
biomedich-346	190	16	,	,	PUNCT
biomedich-346	190	17	medicine	medicine	NOUN
biomedich-346	190	18	,	,	PUNCT
biomedich-346	190	19	&	&	CCONJ
biomedich-346	190	20	natural	natural	ADJ
biomedich-346	190	21	product	product	NOUN
biomedich-346	190	22	chemistry	chemistry	NOUN
biomedich-346	190	23	12	12	NUM
biomedich-346	190	24	(	(	PUNCT
biomedich-346	190	25	1	1	NUM
biomedich-346	190	26	)	)	PUNCT
biomedich-346	190	27	,	,	PUNCT
biomedich-346	190	28	2023	2023	NUM
biomedich-346	190	29	:	:	PUNCT
biomedich-346	190	30	343	343	NUM
biomedich-346	190	31	-	-	SYM
biomedich-346	190	32	361	361	NUM
biomedich-346	190	33	authors	author	NOUN
biomedich-346	190	34	title	title	NOUN
biomedich-346	190	35	date	date	NOUN
biomedich-346	190	36	and	and	CCONJ
biomedich-346	190	37	type	type	NOUN
biomedich-346	190	38	of	of	ADP
biomedich-346	190	39	the	the	DET
biomedich-346	190	40	study	study	NOUN
biomedich-346	190	41	method	method	NOUN
biomedich-346	190	42	results	result	NOUN
biomedich-346	190	43	controlled	control	VERB
biomedich-346	190	44	trial	trial	NOUN
biomedich-346	190	45	burkina	burkina	PROPN
biomedich-346	190	46	faso	faso	PROPN
biomedich-346	190	47	-	-	PUNCT
biomedich-346	190	48	a	a	DET
biomedich-346	190	49	highly	highly	ADV
biomedich-346	190	50	seasonal	seasonal	ADJ
biomedich-346	190	51	malaria	malaria	NOUN
biomedich-346	190	52	transmission	transmission	NOUN
biomedich-346	190	53	setting	setting	NOUN
biomedich-346	190	54	.	.	PUNCT
biomedich-346	191	1	three	three	NUM
biomedich-346	191	2	vaccinations	vaccination	NOUN
biomedich-346	191	3	were	be	AUX
biomedich-346	191	4	administered	administer	VERB
biomedich-346	191	5	at	at	ADP
biomedich-346	191	6	4	4	NUM
biomedich-346	191	7	-	-	PUNCT
biomedich-346	191	8	week	week	NOUN
biomedich-346	191	9	intervals	interval	NOUN
biomedich-346	191	10	before	before	ADP
biomedich-346	191	11	the	the	DET
biomedich-346	191	12	malaria	malaria	NOUN
biomedich-346	191	13	season	season	NOUN
biomedich-346	191	14	,	,	PUNCT
biomedich-346	191	15	with	with	ADP
biomedich-346	191	16	a	a	DET
biomedich-346	191	17	fourth	fourth	ADJ
biomedich-346	191	18	dose	dose	NOUN
biomedich-346	191	19	1	1	NUM
biomedich-346	191	20	year	year	NOUN
biomedich-346	191	21	later	later	ADV
biomedich-346	191	22	.	.	PUNCT
biomedich-346	192	1	all	all	DET
biomedich-346	192	2	vaccines	vaccine	NOUN
biomedich-346	192	3	were	be	AUX
biomedich-346	192	4	administered	administer	VERB
biomedich-346	192	5	intramuscularly	intramuscularly	ADV
biomedich-346	192	6	into	into	ADP
biomedich-346	192	7	the	the	DET
biomedich-346	192	8	thigh	thigh	NOUN
biomedich-346	192	9	.	.	PUNCT
biomedich-346	193	1	group	group	NOUN
biomedich-346	193	2	1	1	NUM
biomedich-346	193	3	received	receive	VERB
biomedich-346	193	4	5	5	NUM
biomedich-346	193	5	μg	μg	PROPN
biomedich-346	193	6	r21	r21	NOUN
biomedich-346	193	7	plus	plus	CCONJ
biomedich-346	193	8	25	25	NUM
biomedich-346	193	9	μg	μg	PROPN
biomedich-346	193	10	mm	mm	PROPN
biomedich-346	193	11	,	,	PUNCT
biomedich-346	193	12	group	group	NOUN
biomedich-346	193	13	2	2	NUM
biomedich-346	193	14	received	receive	VERB
biomedich-346	193	15	5	5	NUM
biomedich-346	193	16	μg	μg	PROPN
biomedich-346	193	17	r21	r21	NOUN
biomedich-346	193	18	plus	plus	CCONJ
biomedich-346	193	19	50	50	NUM
biomedich-346	193	20	μg	μg	NOUN
biomedich-346	193	21	mm	mm	PROPN
biomedich-346	193	22	,	,	PUNCT
biomedich-346	193	23	and	and	CCONJ
biomedich-346	193	24	group	group	NOUN
biomedich-346	193	25	3	3	NUM
biomedich-346	193	26	,	,	PUNCT
biomedich-346	193	27	the	the	DET
biomedich-346	193	28	control	control	NOUN
biomedich-346	193	29	group	group	NOUN
biomedich-346	193	30	,	,	PUNCT
biomedich-346	193	31	received	receive	VERB
biomedich-346	193	32	rabies	rabie	NOUN
biomedich-346	193	33	vaccinations	vaccination	NOUN
biomedich-346	193	34	.	.	PUNCT
biomedich-346	194	1	children	child	NOUN
biomedich-346	194	2	were	be	AUX
biomedich-346	194	3	randomly	randomly	ADV
biomedich-346	194	4	assigned	assign	VERB
biomedich-346	194	5	(	(	PUNCT
biomedich-346	194	6	1:1:1	1:1:1	NOUN
biomedich-346	194	7	)	)	PUNCT
biomedich-346	194	8	to	to	ADP
biomedich-346	194	9	groups	group	NOUN
biomedich-346	194	10	1	1	NUM
biomedich-346	194	11	-	-	SYM
biomedich-346	194	12	3	3	NUM
biomedich-346	194	13	.	.	PUNCT
biomedich-346	195	1	an	an	DET
biomedich-346	195	2	independent	independent	ADJ
biomedich-346	195	3	statistician	statistician	NOUN
biomedich-346	195	4	generated	generate	VERB
biomedich-346	195	5	a	a	DET
biomedich-346	195	6	random	random	ADJ
biomedich-346	195	7	allocation	allocation	NOUN
biomedich-346	195	8	list	list	NOUN
biomedich-346	195	9	,	,	PUNCT
biomedich-346	195	10	using	use	VERB
biomedich-346	195	11	block	block	NOUN
biomedich-346	195	12	randomisation	randomisation	NOUN
biomedich-346	195	13	with	with	ADP
biomedich-346	195	14	variable	variable	ADJ
biomedich-346	195	15	block	block	NOUN
biomedich-346	195	16	sizes	size	NOUN
biomedich-346	195	17	,	,	PUNCT
biomedich-346	195	18	which	which	PRON
biomedich-346	195	19	was	be	AUX
biomedich-346	195	20	used	use	VERB
biomedich-346	195	21	to	to	PART
biomedich-346	195	22	assign	assign	VERB
biomedich-346	195	23	participants	participant	NOUN
biomedich-346	195	24	.	.	PUNCT
biomedich-346	196	1	participants	participant	NOUN
biomedich-346	196	2	,	,	PUNCT
biomedich-346	196	3	their	their	PRON
biomedich-346	196	4	families	family	NOUN
biomedich-346	196	5	,	,	PUNCT
biomedich-346	196	6	and	and	CCONJ
biomedich-346	196	7	the	the	DET
biomedich-346	196	8	local	local	ADJ
biomedich-346	196	9	study	study	NOUN
biomedich-346	196	10	team	team	NOUN
biomedich-346	196	11	were	be	AUX
biomedich-346	196	12	all	all	PRON
biomedich-346	196	13	masked	mask	VERB
biomedich-346	196	14	to	to	ADP
biomedich-346	196	15	group	group	NOUN
biomedich-346	196	16	allocation	allocation	NOUN
biomedich-346	196	17	.	.	PUNCT
biomedich-346	197	1	only	only	ADV
biomedich-346	197	2	the	the	DET
biomedich-346	197	3	pharmacists	pharmacist	NOUN
biomedich-346	197	4	preparing	prepare	VERB
biomedich-346	197	5	the	the	DET
biomedich-346	197	6	vaccine	vaccine	NOUN
biomedich-346	197	7	were	be	AUX
biomedich-346	197	8	unmasked	unmasked	ADJ
biomedich-346	197	9	to	to	ADP
biomedich-346	197	10	group	group	NOUN
biomedich-346	197	11	allocation	allocation	NOUN
biomedich-346	197	12	.	.	PUNCT
biomedich-346	198	1	vaccine	vaccine	NOUN
biomedich-346	198	2	safety	safety	NOUN
biomedich-346	198	3	,	,	PUNCT
biomedich-346	198	4	immunogenicity	immunogenicity	NOUN
biomedich-346	198	5	,	,	PUNCT
biomedich-346	198	6	and	and	CCONJ
biomedich-346	198	7	efficacy	efficacy	NOUN
biomedich-346	198	8	were	be	AUX
biomedich-346	198	9	evaluated	evaluate	VERB
biomedich-346	198	10	over	over	ADP
biomedich-346	198	11	1	1	NUM
biomedich-346	198	12	year	year	NOUN
biomedich-346	198	13	.	.	PUNCT
biomedich-346	199	1	the	the	DET
biomedich-346	199	2	primary	primary	ADJ
biomedich-346	199	3	objective	objective	NOUN
biomedich-346	199	4	assessed	assess	VERB
biomedich-346	199	5	the	the	DET
biomedich-346	199	6	protective	protective	ADJ
biomedich-346	199	7	efficacy	efficacy	NOUN
biomedich-346	199	8	of	of	ADP
biomedich-346	199	9	r21	r21	NOUN
biomedich-346	199	10	plus	plus	CCONJ
biomedich-346	199	11	mm	mm	PROPN
biomedich-346	199	12	(	(	PUNCT
biomedich-346	199	13	r21	r21	PROPN
biomedich-346	199	14	/	/	SYM
biomedich-346	199	15	mm	mm	NOUN
biomedich-346	199	16	)	)	PUNCT
biomedich-346	199	17	from	from	ADP
biomedich-346	199	18	14	14	NUM
biomedich-346	199	19	days	day	NOUN
biomedich-346	199	20	after	after	ADP
biomedich-346	199	21	the	the	DET
biomedich-346	199	22	third	third	ADJ
biomedich-346	199	23	vaccination	vaccination	NOUN
biomedich-346	199	24	to	to	ADP
biomedich-346	199	25	6	6	NUM
biomedich-346	199	26	months	month	NOUN
biomedich-346	199	27	.	.	PUNCT
biomedich-346	200	1	primary	primary	ADJ
biomedich-346	200	2	analyses	analysis	NOUN
biomedich-346	200	3	of	of	ADP
biomedich-346	200	4	vaccine	vaccine	NOUN
biomedich-346	200	5	efficacy	efficacy	NOUN
biomedich-346	200	6	were	be	AUX
biomedich-346	200	7	based	base	VERB
biomedich-346	200	8	on	on	ADP
biomedich-346	200	9	a	a	DET
biomedich-346	200	10	modified	modify	VERB
biomedich-346	200	11	intention	intention	NOUN
biomedich-346	200	12	-	-	PUNCT
biomedich-346	200	13	to	to	ADP
biomedich-346	200	14	-	-	PUNCT
biomedich-346	200	15	treat	treat	VERB
biomedich-346	200	16	population	population	NOUN
biomedich-346	200	17	,	,	PUNCT
biomedich-346	200	18	which	which	PRON
biomedich-346	200	19	included	include	VERB
biomedich-346	200	20	all	all	DET
biomedich-346	200	21	participants	participant	NOUN
biomedich-346	200	22	who	who	PRON
biomedich-346	200	23	received	receive	VERB
biomedich-346	200	24	three	three	NUM
biomedich-346	200	25	vaccinations	vaccination	NOUN
biomedich-346	200	26	,	,	PUNCT
biomedich-346	200	27	allowing	allow	VERB
biomedich-346	200	28	for	for	ADP
biomedich-346	200	29	the	the	DET
biomedich-346	200	30	inclusion	inclusion	NOUN
biomedich-346	200	31	of	of	ADP
biomedich-346	200	32	participants	participant	NOUN
biomedich-346	200	33	who	who	PRON
biomedich-346	200	34	received	receive	VERB
biomedich-346	200	35	the	the	DET
biomedich-346	200	36	wrong	wrong	ADJ
biomedich-346	200	37	vaccine	vaccine	NOUN
biomedich-346	200	38	at	at	ADP
biomedich-346	200	39	any	any	DET
biomedich-346	200	40	time	time	NOUN
biomedich-346	200	41	point	point	NOUN
biomedich-346	200	42	.	.	PUNCT
biomedich-346	201	1	primary	primary	ADJ
biomedich-346	201	2	series	series	NOUN
biomedich-346	201	3	of	of	ADP
biomedich-346	201	4	vaccinations	vaccination	NOUN
biomedich-346	201	5	after	after	SCONJ
biomedich-346	201	6	a	a	DET
biomedich-346	201	7	fourth	fourth	ADJ
biomedich-346	201	8	dose	dose	NOUN
biomedich-346	201	9	administered	administer	VERB
biomedich-346	201	10	1	1	NUM
biomedich-346	201	11	year	year	NOUN
biomedich-346	201	12	later	later	ADV
biomedich-346	201	13	.	.	PUNCT
biomedich-346	202	1	toback	toback	VERB
biomedich-346	202	2	et	et	PROPN
biomedich-346	202	3	al	al	PROPN
biomedich-346	202	4	.	.	PROPN
biomedich-346	202	5	safety	safety	PROPN
biomedich-346	202	6	,	,	PUNCT
biomedich-346	202	7	immunogenicity	immunogenicity	NOUN
biomedich-346	202	8	,	,	PUNCT
biomedich-346	202	9	and	and	CCONJ
biomedich-346	202	10	efficacy	efficacy	NOUN
biomedich-346	202	11	of	of	ADP
biomedich-346	202	12	a	a	DET
biomedich-346	202	13	covid19	covid19	NOUN
biomedich-346	202	14	vaccine	vaccine	NOUN
biomedich-346	202	15	(	(	PUNCT
biomedich-346	202	16	nvxcov2373	nvxcov2373	PROPN
biomedich-346	202	17	)	)	PUNCT
biomedich-346	202	18	coadministered	coadministere	VERB
biomedich-346	202	19	with	with	ADP
biomedich-346	202	20	seasonal	seasonal	ADJ
biomedich-346	202	21	influenza	influenza	NOUN
biomedich-346	202	22	vaccines	vaccine	NOUN
biomedich-346	202	23	:	:	PUNCT
biomedich-346	202	24	an	an	DET
biomedich-346	202	25	exploratory	exploratory	ADJ
biomedich-346	202	26	substudy	substudy	NOUN
biomedich-346	202	27	of	of	ADP
biomedich-346	202	28	a	a	DET
biomedich-346	202	29	randomized	randomize	VERB
biomedich-346	202	30	,	,	PUNCT
biomedich-346	202	31	observer	observer	NOUN
biomedich-346	202	32	-	-	PUNCT
biomedich-346	202	33	blinded	blinded	ADJ
biomedich-346	202	34	,	,	PUNCT
biomedich-346	202	35	placebo	placebo	NOUN
biomedich-346	202	36	-	-	PUNCT
biomedich-346	202	37	controlled	control	VERB
biomedich-346	202	38	,	,	PUNCT
biomedich-346	202	39	phase	phase	NOUN
biomedich-346	202	40	3	3	NUM
biomedich-346	202	41	trial	trial	NOUN
biomedich-346	202	42	clinical	clinical	ADJ
biomedich-346	202	43	trial	trial	NOUN
biomedich-346	202	44	2022	2022	NUM
biomedich-346	202	45	a	a	DET
biomedich-346	202	46	planned	plan	VERB
biomedich-346	202	47	exploratory	exploratory	ADJ
biomedich-346	202	48	substudy	substudy	NOUN
biomedich-346	202	49	as	as	ADP
biomedich-346	202	50	part	part	NOUN
biomedich-346	202	51	of	of	ADP
biomedich-346	202	52	the	the	DET
biomedich-346	202	53	randomized	randomize	VERB
biomedich-346	202	54	,	,	PUNCT
biomedich-346	202	55	observer	observer	NOUN
biomedich-346	202	56	-	-	PUNCT
biomedich-346	202	57	blinded	blinded	ADJ
biomedich-346	202	58	,	,	PUNCT
biomedich-346	202	59	placebocontrolled	placebocontrolle	VERB
biomedich-346	202	60	,	,	PUNCT
biomedich-346	202	61	phase	phase	NOUN
biomedich-346	202	62	3	3	NUM
biomedich-346	202	63	trial	trial	NOUN
biomedich-346	202	64	of	of	ADP
biomedich-346	202	65	the	the	DET
biomedich-346	202	66	safety	safety	NOUN
biomedich-346	202	67	and	and	CCONJ
biomedich-346	202	68	efficacy	efficacy	NOUN
biomedich-346	202	69	of	of	ADP
biomedich-346	202	70	the	the	DET
biomedich-346	202	71	covid-19	covid-19	PROPN
biomedich-346	202	72	vaccine	vaccine	NOUN
biomedich-346	202	73	(	(	PUNCT
biomedich-346	202	74	nvxcov2373	nvxcov2373	PROPN
biomedich-346	202	75	)	)	PUNCT
biomedich-346	202	76	by	by	ADP
biomedich-346	202	77	co	co	VERB
biomedich-346	202	78	-	-	VERB
biomedich-346	202	79	administrating	administrate	VERB
biomedich-346	202	80	the	the	DET
biomedich-346	202	81	influenza	influenza	NOUN
biomedich-346	202	82	vaccine	vaccine	NOUN
biomedich-346	202	83	at	at	ADP
biomedich-346	202	84	four	four	NUM
biomedich-346	202	85	study	study	NOUN
biomedich-346	202	86	hospitals	hospital	NOUN
biomedich-346	202	87	in	in	ADP
biomedich-346	202	88	the	the	DET
biomedich-346	202	89	uk	uk	PROPN
biomedich-346	202	90	.	.	PUNCT
biomedich-346	202	91	approximately	approximately	ADV
biomedich-346	202	92	,	,	PUNCT
biomedich-346	202	93	the	the	DET
biomedich-346	202	94	first	first	ADJ
biomedich-346	202	95	400	400	NUM
biomedich-346	202	96	participants	participant	NOUN
biomedich-346	202	97	meeting	meet	VERB
biomedich-346	202	98	the	the	DET
biomedich-346	202	99	main	main	ADJ
biomedich-346	202	100	study	study	NOUN
biomedich-346	202	101	entry	entry	NOUN
biomedich-346	202	102	criteria	criterion	NOUN
biomedich-346	202	103	-	-	PUNCT
biomedich-346	202	104	with	with	ADP
biomedich-346	202	105	no	no	DET
biomedich-346	202	106	contraindications	contraindication	NOUN
biomedich-346	202	107	to	to	ADP
biomedich-346	202	108	influenza	influenza	NOUN
biomedich-346	202	109	vaccination	vaccination	NOUN
biomedich-346	202	110	-	-	PUNCT
biomedich-346	202	111	were	be	AUX
biomedich-346	202	112	invited	invite	VERB
biomedich-346	202	113	to	to	PART
biomedich-346	202	114	join	join	VERB
biomedich-346	202	115	the	the	DET
biomedich-346	202	116	substudy	substudy	NOUN
biomedich-346	202	117	.	.	PUNCT
biomedich-346	203	1	participants	participant	NOUN
biomedich-346	203	2	of	of	ADP
biomedich-346	203	3	the	the	DET
biomedich-346	203	4	main	main	ADJ
biomedich-346	203	5	study	study	NOUN
biomedich-346	203	6	were	be	AUX
biomedich-346	203	7	randomly	randomly	ADV
biomedich-346	203	8	assigned	assign	VERB
biomedich-346	203	9	(	(	PUNCT
biomedich-346	203	10	1:1	1:1	NUM
biomedich-346	203	11	)	)	PUNCT
biomedich-346	203	12	to	to	PART
biomedich-346	203	13	receive	receive	VERB
biomedich-346	203	14	two	two	NUM
biomedich-346	203	15	intramuscular	intramuscular	ADJ
biomedich-346	203	16	injections	injection	NOUN
biomedich-346	203	17	of	of	ADP
biomedich-346	203	18	either	either	CCONJ
biomedich-346	203	19	nvx	nvx	NOUN
biomedich-346	203	20	-	-	PUNCT
biomedich-346	203	21	cov2373	cov2373	NOUN
biomedich-346	203	22	(	(	PUNCT
biomedich-346	203	23	5	5	NUM
biomedich-346	203	24	μg	μg	NOUN
biomedich-346	203	25	)	)	PUNCT
biomedich-346	203	26	or	or	CCONJ
biomedich-346	203	27	placebo	placebo	NOUN
biomedich-346	203	28	(	(	PUNCT
biomedich-346	203	29	normal	normal	ADJ
biomedich-346	203	30	saline	saline	NOUN
biomedich-346	203	31	)	)	PUNCT
biomedich-346	203	32	21	21	NUM
biomedich-346	203	33	days	day	NOUN
biomedich-346	203	34	apart	apart	ADV
biomedich-346	203	35	;	;	PUNCT
biomedich-346	203	36	participants	participant	NOUN
biomedich-346	203	37	enrolled	enrol	VERB
biomedich-346	203	38	into	into	ADP
biomedich-346	203	39	the	the	DET
biomedich-346	203	40	substudy	substudy	NOUN
biomedich-346	203	41	were	be	AUX
biomedich-346	203	42	co	co	VERB
biomedich-346	203	43	-	-	VERB
biomedich-346	203	44	vaccinated	vaccinate	VERB
biomedich-346	203	45	with	with	ADP
biomedich-346	203	46	a	a	DET
biomedich-346	203	47	single	single	ADJ
biomedich-346	203	48	(	(	PUNCT
biomedich-346	203	49	0·5	0·5	NUM
biomedich-346	203	50	ml	ml	NOUN
biomedich-346	203	51	)	)	PUNCT
biomedich-346	203	52	no	no	DET
biomedich-346	203	53	episodes	episode	NOUN
biomedich-346	203	54	of	of	ADP
biomedich-346	203	55	anaphylaxis	anaphylaxis	ADJ
biomedich-346	203	56	or	or	CCONJ
biomedich-346	203	57	deaths	death	NOUN
biomedich-346	203	58	were	be	AUX
biomedich-346	203	59	reported	report	VERB
biomedich-346	203	60	within	within	ADP
biomedich-346	203	61	the	the	DET
biomedich-346	203	62	substudy	substudy	NOUN
biomedich-346	203	63	.	.	PUNCT
biomedich-346	204	1	coadministration	coadministration	NOUN
biomedich-346	204	2	resulted	result	VERB
biomedich-346	204	3	in	in	ADP
biomedich-346	204	4	no	no	DET
biomedich-346	204	5	change	change	NOUN
biomedich-346	204	6	to	to	ADP
biomedich-346	204	7	influenza	influenza	ADJ
biomedich-346	204	8	vaccine	vaccine	NOUN
biomedich-346	204	9	immune	immune	ADJ
biomedich-346	204	10	response	response	NOUN
biomedich-346	204	11	although	although	SCONJ
biomedich-346	204	12	a	a	DET
biomedich-346	204	13	reduction	reduction	NOUN
biomedich-346	204	14	in	in	ADP
biomedich-346	204	15	antibody	antibody	NOUN
biomedich-346	204	16	responses	response	NOUN
biomedich-346	204	17	to	to	ADP
biomedich-346	204	18	the	the	DET
biomedich-346	204	19	nvx	nvx	NOUN
biomedich-346	204	20	-	-	PUNCT
biomedich-346	204	21	cov2373	cov2373	NOUN
biomedich-346	204	22	vaccine	vaccine	NOUN
biomedich-346	204	23	was	be	AUX
biomedich-346	204	24	noted	note	VERB
biomedich-346	204	25	.	.	PUNCT
biomedich-346	205	1	nvx	nvx	PROPN
biomedich-346	205	2	-	-	PUNCT
biomedich-346	205	3	cov2373	cov2373	PROPN
biomedich-346	205	4	vaccine	vaccine	NOUN
biomedich-346	205	5	efficacy	efficacy	NOUN
biomedich-346	205	6	in	in	ADP
biomedich-346	205	7	the	the	DET
biomedich-346	205	8	substudy	substudy	NOUN
biomedich-346	205	9	(	(	PUNCT
biomedich-346	205	10	ie	ie	X
biomedich-346	205	11	,	,	PUNCT
biomedich-346	205	12	participants	participant	NOUN
biomedich-346	205	13	aged	age	VERB
biomedich-346	205	14	18	18	NUM
biomedich-346	205	15	to	to	ADP
biomedich-346	205	16	<	<	X
biomedich-346	205	17	65	65	NUM
biomedich-346	205	18	years	year	NOUN
biomedich-346	205	19	)	)	PUNCT
biomedich-346	205	20	was	be	AUX
biomedich-346	205	21	87·5	87·5	NOUN
biomedich-346	205	22	%	%	NOUN
biomedich-346	205	23	(	(	PUNCT
biomedich-346	205	24	95	95	NUM
biomedich-346	205	25	%	%	NOUN
biomedich-346	205	26	ci	ci	PROPN
biomedich-346	205	27	-0·2	-0·2	PROPN
biomedich-346	205	28	to	to	ADP
biomedich-346	205	29	98·4	98·4	NOUN
biomedich-346	205	30	)	)	PUNCT
biomedich-346	205	31	and	and	CCONJ
biomedich-346	205	32	in	in	ADP
biomedich-346	205	33	the	the	DET
biomedich-346	205	34	main	main	ADJ
biomedich-346	205	35	study	study	NOUN
biomedich-346	205	36	was	be	AUX
biomedich-346	205	37	89·8	89·8	NUM
biomedich-346	205	38	%	%	NOUN
biomedich-346	205	39	(	(	PUNCT
biomedich-346	205	40	95	95	NUM
biomedich-346	205	41	%	%	NOUN
biomedich-346	205	42	ci	ci	NOUN
biomedich-346	205	43	79·7	79·7	NUM
biomedich-346	205	44	-	-	PUNCT
biomedich-346	205	45	95·5	95·5	NUM
biomedich-346	205	46	)	)	PUNCT
biomedich-346	205	47	.	.	PUNCT
biomedich-346	206	1	hussein	hussein	PROPN
biomedich-346	206	2	et	et	PROPN
biomedich-346	206	3	al	al	PROPN
biomedich-346	206	4	.	.	PROPN
biomedich-346	206	5	–	–	PUNCT
biomedich-346	206	6	nanotechnology	nanotechnology	NOUN
biomedich-346	206	7	-	-	PUNCT
biomedich-346	206	8	based	base	VERB
biomedich-346	206	9	vaccines	vaccine	NOUN
biomedich-346	206	10	351	351	NUM
biomedich-346	206	11	authors	author	NOUN
biomedich-346	206	12	title	title	VERB
biomedich-346	206	13	date	date	NOUN
biomedich-346	206	14	and	and	CCONJ
biomedich-346	206	15	type	type	NOUN
biomedich-346	206	16	of	of	ADP
biomedich-346	206	17	the	the	DET
biomedich-346	206	18	study	study	NOUN
biomedich-346	206	19	method	method	NOUN
biomedich-346	206	20	results	result	NOUN
biomedich-346	206	21	intramuscular	intramuscular	ADJ
biomedich-346	206	22	,	,	PUNCT
biomedich-346	206	23	age	age	NOUN
biomedich-346	206	24	-	-	PUNCT
biomedich-346	206	25	appropriate	appropriate	ADJ
biomedich-346	206	26	(	(	PUNCT
biomedich-346	206	27	quadrivalent	quadrivalent	NOUN
biomedich-346	206	28	influenza	influenza	NOUN
biomedich-346	206	29	cellbased	cellbase	VERB
biomedich-346	206	30	vaccine	vaccine	NOUN
biomedich-346	206	31	[	[	X
biomedich-346	206	32	flucelvax	flucelvax	X
biomedich-346	206	33	quadrivalent	quadrivalent	NOUN
biomedich-346	206	34	;	;	PUNCT
biomedich-346	206	35	seqirus	seqirus	PROPN
biomedich-346	206	36	uk	uk	PROPN
biomedich-346	206	37	,	,	PUNCT
biomedich-346	206	38	maidenhead	maidenhead	NOUN
biomedich-346	206	39	]	]	PUNCT
biomedich-346	206	40	for	for	ADP
biomedich-346	206	41	those	those	DET
biomedich-346	206	42	aged	aged	ADJ
biomedich-346	206	43	1864	1864	NUM
biomedich-346	206	44	years	year	NOUN
biomedich-346	206	45	and	and	CCONJ
biomedich-346	206	46	adjuvanted	adjuvante	VERB
biomedich-346	206	47	trivalent	trivalent	NOUN
biomedich-346	206	48	influenza	influenza	NOUN
biomedich-346	206	49	vaccine	vaccine	NOUN
biomedich-346	206	50	[	[	X
biomedich-346	206	51	fluad	fluad	ADV
biomedich-346	206	52	;	;	PUNCT
biomedich-346	206	53	seqirus	seqirus	PROPN
biomedich-346	206	54	uk	uk	PROPN
biomedich-346	206	55	,	,	PUNCT
biomedich-346	206	56	maidenhead	maidenhead	NOUN
biomedich-346	206	57	]	]	PUNCT
biomedich-346	206	58	for	for	ADP
biomedich-346	206	59	those	those	DET
biomedich-346	206	60	≥65	≥65	NUM
biomedich-346	206	61	years	year	NOUN
biomedich-346	206	62	)	)	PUNCT
biomedich-346	206	63	,	,	PUNCT
biomedich-346	206	64	licensed	license	VERB
biomedich-346	206	65	,	,	PUNCT
biomedich-346	206	66	influenza	influenza	ADJ
biomedich-346	206	67	vaccine	vaccine	NOUN
biomedich-346	206	68	on	on	ADP
biomedich-346	206	69	the	the	DET
biomedich-346	206	70	opposite	opposite	ADJ
biomedich-346	206	71	deltoid	deltoid	NOUN
biomedich-346	206	72	to	to	ADP
biomedich-346	206	73	that	that	PRON
biomedich-346	206	74	of	of	ADP
biomedich-346	206	75	the	the	DET
biomedich-346	206	76	first	first	ADJ
biomedich-346	206	77	study	study	NOUN
biomedich-346	206	78	vaccine	vaccine	NOUN
biomedich-346	206	79	dose	dose	VERB
biomedich-346	206	80	or	or	CCONJ
biomedich-346	206	81	placebo	placebo	NOUN
biomedich-346	206	82	.	.	PUNCT
biomedich-346	207	1	the	the	DET
biomedich-346	207	2	influenza	influenza	NOUN
biomedich-346	207	3	vaccine	vaccine	NOUN
biomedich-346	207	4	was	be	AUX
biomedich-346	207	5	administered	administer	VERB
biomedich-346	207	6	in	in	ADP
biomedich-346	207	7	an	an	DET
biomedich-346	207	8	open	open	ADJ
biomedich-346	207	9	-	-	PUNCT
biomedich-346	207	10	label	label	NOUN
biomedich-346	207	11	manner	manner	NOUN
biomedich-346	207	12	and	and	CCONJ
biomedich-346	207	13	at	at	ADP
biomedich-346	207	14	the	the	DET
biomedich-346	207	15	same	same	ADJ
biomedich-346	207	16	time	time	NOUN
biomedich-346	207	17	as	as	ADP
biomedich-346	207	18	the	the	DET
biomedich-346	207	19	first	first	ADJ
biomedich-346	207	20	study	study	NOUN
biomedich-346	207	21	injection	injection	NOUN
biomedich-346	207	22	.	.	PUNCT
biomedich-346	208	1	reactogenicity	reactogenicity	NOUN
biomedich-346	208	2	was	be	AUX
biomedich-346	208	3	evaluated	evaluate	VERB
biomedich-346	208	4	via	via	ADP
biomedich-346	208	5	an	an	DET
biomedich-346	208	6	electronic	electronic	ADJ
biomedich-346	208	7	diary	diary	NOUN
biomedich-346	208	8	for	for	ADP
biomedich-346	208	9	7	7	NUM
biomedich-346	208	10	days	day	NOUN
biomedich-346	208	11	after	after	ADP
biomedich-346	208	12	vaccination	vaccination	NOUN
biomedich-346	208	13	in	in	ADP
biomedich-346	208	14	addition	addition	NOUN
biomedich-346	208	15	to	to	ADP
biomedich-346	208	16	monitoring	monitor	VERB
biomedich-346	208	17	for	for	ADP
biomedich-346	208	18	unsolicited	unsolicited	ADJ
biomedich-346	208	19	adverse	adverse	ADJ
biomedich-346	208	20	events	event	NOUN
biomedich-346	208	21	,	,	PUNCT
biomedich-346	208	22	medically	medically	ADV
biomedich-346	208	23	attended	attend	VERB
biomedich-346	208	24	adverse	adverse	ADJ
biomedich-346	208	25	events	event	NOUN
biomedich-346	208	26	and	and	CCONJ
biomedich-346	208	27	serious	serious	ADJ
biomedich-346	208	28	adverse	adverse	ADJ
biomedich-346	208	29	events	event	NOUN
biomedich-346	208	30	.	.	PUNCT
biomedich-346	209	1	immunogenicity	immunogenicity	NOUN
biomedich-346	209	2	was	be	AUX
biomedich-346	209	3	assessed	assess	VERB
biomedich-346	209	4	with	with	ADP
biomedich-346	209	5	influenza	influenza	NOUN
biomedich-346	209	6	haemagglutination	haemagglutination	NOUN
biomedich-346	209	7	inhibition	inhibition	NOUN
biomedich-346	209	8	and	and	CCONJ
biomedich-346	209	9	sars	sar	NOUN
biomedich-346	209	10	-	-	PUNCT
biomedich-346	209	11	cov-2	cov-2	PART
biomedich-346	209	12	anti	anti	ADJ
biomedich-346	209	13	-	-	ADJ
biomedich-346	209	14	spike	spike	ADJ
biomedich-346	209	15	protein	protein	NOUN
biomedich-346	209	16	igg	igg	NOUN
biomedich-346	209	17	assays	assay	NOUN
biomedich-346	209	18	.	.	PUNCT
biomedich-346	210	1	vaccine	vaccine	NOUN
biomedich-346	210	2	efficacy	efficacy	NOUN
biomedich-346	210	3	against	against	ADP
biomedich-346	210	4	pcr	pcr	NOUN
biomedich-346	210	5	-	-	PUNCT
biomedich-346	210	6	confirmed	confirm	VERB
biomedich-346	210	7	,	,	PUNCT
biomedich-346	210	8	symptomatic	symptomatic	ADJ
biomedich-346	210	9	covid-19	covid-19	PROPN
biomedich-346	210	10	was	be	AUX
biomedich-346	210	11	assessed	assess	VERB
biomedich-346	210	12	in	in	ADP
biomedich-346	210	13	participants	participant	NOUN
biomedich-346	210	14	who	who	PRON
biomedich-346	210	15	were	be	AUX
biomedich-346	210	16	seronegative	seronegative	ADJ
biomedich-346	210	17	at	at	ADP
biomedich-346	210	18	baseline	baseline	NOUN
biomedich-346	210	19	,	,	PUNCT
biomedich-346	210	20	received	receive	VERB
biomedich-346	210	21	both	both	DET
biomedich-346	210	22	doses	dose	NOUN
biomedich-346	210	23	of	of	ADP
biomedich-346	210	24	the	the	DET
biomedich-346	210	25	study	study	NOUN
biomedich-346	210	26	vaccine	vaccine	NOUN
biomedich-346	210	27	or	or	CCONJ
biomedich-346	210	28	placebo	placebo	NOUN
biomedich-346	210	29	,	,	PUNCT
biomedich-346	210	30	had	have	VERB
biomedich-346	210	31	no	no	DET
biomedich-346	210	32	major	major	ADJ
biomedich-346	210	33	protocol	protocol	NOUN
biomedich-346	210	34	deviations	deviation	NOUN
biomedich-346	210	35	affecting	affect	VERB
biomedich-346	210	36	the	the	DET
biomedich-346	210	37	primary	primary	ADJ
biomedich-346	210	38	endpoint	endpoint	NOUN
biomedich-346	210	39	,	,	PUNCT
biomedich-346	210	40	and	and	CCONJ
biomedich-346	210	41	had	have	VERB
biomedich-346	210	42	no	no	DET
biomedich-346	210	43	confirmed	confirm	VERB
biomedich-346	210	44	cases	case	NOUN
biomedich-346	210	45	of	of	ADP
biomedich-346	210	46	symptomatic	symptomatic	ADJ
biomedich-346	210	47	covid-19	covid-19	PROPN
biomedich-346	210	48	from	from	ADP
biomedich-346	210	49	the	the	DET
biomedich-346	210	50	first	first	ADJ
biomedich-346	210	51	dose	dose	NOUN
biomedich-346	210	52	until	until	ADP
biomedich-346	210	53	6	6	NUM
biomedich-346	210	54	days	day	NOUN
biomedich-346	210	55	after	after	ADP
biomedich-346	210	56	the	the	DET
biomedich-346	210	57	second	second	ADJ
biomedich-346	210	58	dose	dose	NOUN
biomedich-346	210	59	(	(	PUNCT
biomedich-346	210	60	per	per	ADP
biomedich-346	210	61	-	-	PUNCT
biomedich-346	210	62	protocol	protocol	NOUN
biomedich-346	210	63	efficacy	efficacy	NOUN
biomedich-346	210	64	population	population	NOUN
biomedich-346	210	65	)	)	PUNCT
biomedich-346	210	66	.	.	PUNCT
biomedich-346	211	1	immunogenicity	immunogenicity	NOUN
biomedich-346	211	2	was	be	AUX
biomedich-346	211	3	assessed	assess	VERB
biomedich-346	211	4	in	in	ADP
biomedich-346	211	5	participants	participant	NOUN
biomedich-346	211	6	who	who	PRON
biomedich-346	211	7	received	receive	VERB
biomedich-346	211	8	scheduled	schedule	VERB
biomedich-346	211	9	two	two	NUM
biomedich-346	211	10	doses	dose	NOUN
biomedich-346	211	11	of	of	ADP
biomedich-346	211	12	the	the	DET
biomedich-346	211	13	study	study	NOUN
biomedich-346	211	14	vaccine	vaccine	NOUN
biomedich-346	211	15	,	,	PUNCT
biomedich-346	211	16	had	have	VERB
biomedich-346	211	17	a	a	DET
biomedich-346	211	18	baseline	baseline	ADJ
biomedich-346	211	19	sample	sample	NOUN
biomedich-346	211	20	and	and	CCONJ
biomedich-346	211	21	at	at	ADV
biomedich-346	211	22	least	least	ADJ
biomedich-346	211	23	one	one	NUM
biomedich-346	211	24	post	post	ADJ
biomedich-346	211	25	-	-	ADJ
biomedich-346	211	26	vaccination	vaccination	ADJ
biomedich-346	211	27	sample	sample	NOUN
biomedich-346	211	28	,	,	PUNCT
biomedich-346	211	29	and	and	CCONJ
biomedich-346	211	30	had	have	VERB
biomedich-346	211	31	no	no	DET
biomedich-346	211	32	major	major	ADJ
biomedich-346	211	33	protocol	protocol	NOUN
biomedich-346	211	34	violations	violation	NOUN
biomedich-346	211	35	before	before	ADP
biomedich-346	211	36	unmasking	unmask	VERB
biomedich-346	211	37	(	(	PUNCT
biomedich-346	211	38	per	per	ADP
biomedich-346	211	39	-	-	PUNCT
biomedich-346	211	40	protocol	protocol	NOUN
biomedich-346	211	41	immunogenicity	immunogenicity	NOUN
biomedich-346	211	42	population	population	NOUN
biomedich-346	211	43	)	)	PUNCT
biomedich-346	211	44	.	.	PUNCT
biomedich-346	212	1	reactogenicity	reactogenicity	NOUN
biomedich-346	212	2	was	be	AUX
biomedich-346	212	3	analyzed	analyze	VERB
biomedich-346	212	4	in	in	ADP
biomedich-346	212	5	all	all	DET
biomedich-346	212	6	participants	participant	NOUN
biomedich-346	212	7	who	who	PRON
biomedich-346	212	8	received	receive	VERB
biomedich-346	212	9	at	at	ADV
biomedich-346	212	10	least	least	ADV
biomedich-346	212	11	one	one	NUM
biomedich-346	212	12	dose	dose	NOUN
biomedich-346	212	13	of	of	ADP
biomedich-346	212	14	nvxcov2373	nvxcov2373	NOUN
biomedich-346	212	15	or	or	CCONJ
biomedich-346	212	16	placebo	placebo	NOUN
biomedich-346	212	17	and	and	CCONJ
biomedich-346	212	18	had	have	VERB
biomedich-346	212	19	data	datum	NOUN
biomedich-346	212	20	collected	collect	VERB
biomedich-346	212	21	for	for	ADP
biomedich-346	212	22	reactogenicity	reactogenicity	NOUN
biomedich-346	212	23	events	event	NOUN
biomedich-346	212	24	.	.	PUNCT
biomedich-346	213	1	safety	safety	NOUN
biomedich-346	213	2	was	be	AUX
biomedich-346	213	3	analyzed	analyze	VERB
biomedich-346	213	4	in	in	ADP
biomedich-346	213	5	all	all	DET
biomedich-346	213	6	participants	participant	NOUN
biomedich-346	213	7	who	who	PRON
biomedich-346	213	8	received	receive	VERB
biomedich-346	213	9	at	at	ADV
biomedich-346	213	10	least	least	ADV
biomedich-346	213	11	one	one	NUM
biomedich-346	213	12	dose	dose	NOUN
biomedich-346	213	13	of	of	ADP
biomedich-346	213	14	nvxcov2373	nvxcov2373	NOUN
biomedich-346	213	15	or	or	CCONJ
biomedich-346	213	16	placebo	placebo	NOUN
biomedich-346	213	17	.	.	PUNCT
biomedich-346	214	1	comparisons	comparison	NOUN
biomedich-346	214	2	were	be	AUX
biomedich-346	214	3	made	make	VERB
biomedich-346	214	4	between	between	ADP
biomedich-346	214	5	participants	participant	NOUN
biomedich-346	214	6	of	of	ADP
biomedich-346	214	7	the	the	DET
biomedich-346	214	8	substudy	substudy	NOUN
biomedich-346	214	9	and	and	CCONJ
biomedich-346	214	10	the	the	DET
biomedich-346	214	11	main	main	ADJ
biomedich-346	214	12	study	study	NOUN
biomedich-346	214	13	(	(	PUNCT
biomedich-346	214	14	who	who	PRON
biomedich-346	214	15	were	be	AUX
biomedich-346	214	16	not	not	PART
biomedich-346	214	17	co	co	VERB
biomedich-346	214	18	-	-	VERB
biomedich-346	214	19	vaccinated	vaccinate	VERB
biomedich-346	214	20	for	for	ADP
biomedich-346	214	21	influenza	influenza	NOUN
biomedich-346	214	22	)	)	PUNCT
biomedich-346	214	23	.	.	PUNCT
biomedich-346	215	1	352	352	NUM
biomedich-346	215	2	biology	biology	NOUN
biomedich-346	215	3	,	,	PUNCT
biomedich-346	215	4	medicine	medicine	NOUN
biomedich-346	215	5	,	,	PUNCT
biomedich-346	215	6	&	&	CCONJ
biomedich-346	215	7	natural	natural	ADJ
biomedich-346	215	8	product	product	NOUN
biomedich-346	215	9	chemistry	chemistry	NOUN
biomedich-346	215	10	12	12	NUM
biomedich-346	215	11	(	(	PUNCT
biomedich-346	215	12	1	1	NUM
biomedich-346	215	13	)	)	PUNCT
biomedich-346	215	14	,	,	PUNCT
biomedich-346	215	15	2023	2023	NUM
biomedich-346	215	16	:	:	PUNCT
biomedich-346	215	17	343	343	NUM
biomedich-346	215	18	-	-	SYM
biomedich-346	215	19	361	361	NUM
biomedich-346	215	20	authors	author	NOUN
biomedich-346	215	21	title	title	NOUN
biomedich-346	215	22	date	date	NOUN
biomedich-346	215	23	and	and	CCONJ
biomedich-346	215	24	type	type	NOUN
biomedich-346	215	25	of	of	ADP
biomedich-346	215	26	the	the	DET
biomedich-346	215	27	study	study	NOUN
biomedich-346	215	28	method	method	NOUN
biomedich-346	215	29	results	result	VERB
biomedich-346	215	30	maruggi	maruggi	NOUN
biomedich-346	215	31	et	et	PROPN
biomedich-346	215	32	al	al	PROPN
biomedich-346	215	33	.	.	PUNCT
biomedich-346	216	1	a	a	DET
biomedich-346	216	2	self	self	NOUN
biomedich-346	216	3	-	-	PUNCT
biomedich-346	216	4	amplifying	amplifying	ADJ
biomedich-346	216	5	mrna	mrna	PROPN
biomedich-346	216	6	sars	sar	NOUN
biomedich-346	216	7	-	-	PUNCT
biomedich-346	216	8	cov-2	cov-2	PART
biomedich-346	216	9	vaccine	vaccine	NOUN
biomedich-346	216	10	candidate	candidate	NOUN
biomedich-346	216	11	induces	induce	VERB
biomedich-346	216	12	safe	safe	ADJ
biomedich-346	216	13	and	and	CCONJ
biomedich-346	216	14	robust	robust	ADJ
biomedich-346	216	15	protective	protective	ADJ
biomedich-346	216	16	immunity	immunity	NOUN
biomedich-346	216	17	in	in	ADP
biomedich-346	216	18	preclinical	preclinical	ADJ
biomedich-346	216	19	models	model	NOUN
biomedich-346	216	20	clinical	clinical	ADJ
biomedich-346	216	21	trial	trial	NOUN
biomedich-346	216	22	2022	2022	NUM
biomedich-346	216	23	assessed	assess	VERB
biomedich-346	216	24	immunogenicity	immunogenicity	NOUN
biomedich-346	216	25	and	and	CCONJ
biomedich-346	216	26	,	,	PUNCT
biomedich-346	216	27	for	for	ADP
biomedich-346	216	28	the	the	DET
biomedich-346	216	29	first	first	ADJ
biomedich-346	216	30	time	time	NOUN
biomedich-346	216	31	,	,	PUNCT
biomedich-346	216	32	toxicity	toxicity	NOUN
biomedich-346	216	33	,	,	PUNCT
biomedich-346	216	34	biodistribution	biodistribution	NOUN
biomedich-346	216	35	,	,	PUNCT
biomedich-346	216	36	and	and	CCONJ
biomedich-346	216	37	protective	protective	ADJ
biomedich-346	216	38	efficacy	efficacy	NOUN
biomedich-346	216	39	in	in	ADP
biomedich-346	216	40	preclinical	preclinical	ADJ
biomedich-346	216	41	models	model	NOUN
biomedich-346	216	42	of	of	ADP
biomedich-346	216	43	a	a	DET
biomedich-346	216	44	two	two	NUM
biomedich-346	216	45	-	-	PUNCT
biomedich-346	216	46	dose	dose	NOUN
biomedich-346	216	47	self	self	NOUN
biomedich-346	216	48	-	-	PUNCT
biomedich-346	216	49	amplifying	amplify	VERB
biomedich-346	216	50	messenger	messenger	NOUN
biomedich-346	216	51	rna	rna	NOUN
biomedich-346	216	52	(	(	PUNCT
biomedich-346	216	53	sam	sam	PROPN
biomedich-346	216	54	)	)	PUNCT
biomedich-346	216	55	vaccine	vaccine	NOUN
biomedich-346	216	56	,	,	PUNCT
biomedich-346	216	57	encoding	encode	VERB
biomedich-346	216	58	a	a	DET
biomedich-346	216	59	prefusion	prefusion	NOUN
biomedich-346	216	60	-	-	PUNCT
biomedich-346	216	61	stabilized	stabilize	VERB
biomedich-346	216	62	spike	spike	ADJ
biomedich-346	216	63	antigen	antigen	NOUN
biomedich-346	216	64	of	of	ADP
biomedich-346	216	65	sars	sar	NOUN
biomedich-346	216	66	-	-	PUNCT
biomedich-346	216	67	cov-2	cov-2	NOUN
biomedich-346	216	68	wuhan	wuhan	PROPN
biomedich-346	216	69	-	-	PUNCT
biomedich-346	216	70	hu-1	hu-1	VERB
biomedich-346	216	71	strain	strain	NOUN
biomedich-346	216	72	and	and	CCONJ
biomedich-346	216	73	delivered	deliver	VERB
biomedich-346	216	74	by	by	ADP
biomedich-346	216	75	lipid	lipid	ADJ
biomedich-346	216	76	nanoparticles	nanoparticle	NOUN
biomedich-346	216	77	(	(	PUNCT
biomedich-346	216	78	lnps	lnps	PROPN
biomedich-346	216	79	)	)	PUNCT
biomedich-346	216	80	.	.	PUNCT
biomedich-346	217	1	in	in	ADP
biomedich-346	217	2	mice	mouse	NOUN
biomedich-346	217	3	,	,	PUNCT
biomedich-346	217	4	one	one	NUM
biomedich-346	217	5	immunization	immunization	NOUN
biomedich-346	217	6	with	with	ADP
biomedich-346	217	7	the	the	DET
biomedich-346	217	8	sam	sam	PROPN
biomedich-346	217	9	vaccine	vaccine	NOUN
biomedich-346	217	10	elicited	elicit	VERB
biomedich-346	217	11	a	a	DET
biomedich-346	217	12	robust	robust	ADJ
biomedich-346	217	13	spikespecific	spikespecific	ADJ
biomedich-346	217	14	antibody	antibody	NOUN
biomedich-346	217	15	response	response	NOUN
biomedich-346	217	16	,	,	PUNCT
biomedich-346	217	17	which	which	PRON
biomedich-346	217	18	was	be	AUX
biomedich-346	217	19	further	far	ADV
biomedich-346	217	20	boosted	boost	VERB
biomedich-346	217	21	by	by	ADP
biomedich-346	217	22	a	a	DET
biomedich-346	217	23	second	second	ADJ
biomedich-346	217	24	immunization	immunization	NOUN
biomedich-346	217	25	,	,	PUNCT
biomedich-346	217	26	and	and	CCONJ
biomedich-346	217	27	effectively	effectively	ADV
biomedich-346	217	28	neutralized	neutralize	VERB
biomedich-346	217	29	the	the	DET
biomedich-346	217	30	matched	match	VERB
biomedich-346	217	31	sars	sar	NOUN
biomedich-346	217	32	-	-	PUNCT
biomedich-346	217	33	cov-2	cov-2	NOUN
biomedich-346	217	34	wuhan	wuhan	PROPN
biomedich-346	217	35	strain	strain	NOUN
biomedich-346	217	36	as	as	ADV
biomedich-346	217	37	well	well	ADV
biomedich-346	217	38	as	as	ADP
biomedich-346	217	39	b.1.1.7	b.1.1.7	PROPN
biomedich-346	217	40	(	(	PUNCT
biomedich-346	217	41	alpha	alpha	NOUN
biomedich-346	217	42	)	)	PUNCT
biomedich-346	217	43	,	,	PUNCT
biomedich-346	217	44	b.1.351	b.1.351	NOUN
biomedich-346	217	45	(	(	PUNCT
biomedich-346	217	46	beta	beta	NOUN
biomedich-346	217	47	)	)	PUNCT
biomedich-346	217	48	and	and	CCONJ
biomedich-346	217	49	b.1.617.2	b.1.617.2	PROPN
biomedich-346	217	50	(	(	PUNCT
biomedich-346	217	51	delta	delta	NOUN
biomedich-346	217	52	)	)	PUNCT
biomedich-346	217	53	variants	variant	NOUN
biomedich-346	217	54	.	.	PUNCT
biomedich-346	218	1	high	high	ADJ
biomedich-346	218	2	frequencies	frequency	NOUN
biomedich-346	218	3	of	of	ADP
biomedich-346	218	4	spike	spike	ADJ
biomedich-346	218	5	-	-	PUNCT
biomedich-346	218	6	specific	specific	ADJ
biomedich-346	218	7	germinal	germinal	ADJ
biomedich-346	218	8	center	center	NOUN
biomedich-346	218	9	b	b	NOUN
biomedich-346	218	10	,	,	PUNCT
biomedich-346	218	11	th0	th0	PROPN
biomedich-346	218	12	/	/	SYM
biomedich-346	218	13	th1	th1	PROPN
biomedich-346	218	14	cd4	cd4	PROPN
biomedich-346	218	15	,	,	PUNCT
biomedich-346	218	16	and	and	CCONJ
biomedich-346	218	17	cd8	cd8	PROPN
biomedich-346	218	18	t	t	PROPN
biomedich-346	218	19	cell	cell	NOUN
biomedich-346	218	20	responses	response	NOUN
biomedich-346	218	21	were	be	AUX
biomedich-346	218	22	observed	observe	VERB
biomedich-346	218	23	in	in	ADP
biomedich-346	218	24	mice	mouse	NOUN
biomedich-346	218	25	.	.	PUNCT
biomedich-346	219	1	local	local	ADJ
biomedich-346	219	2	tolerance	tolerance	NOUN
biomedich-346	219	3	,	,	PUNCT
biomedich-346	219	4	potential	potential	ADJ
biomedich-346	219	5	systemic	systemic	ADJ
biomedich-346	219	6	toxicity	toxicity	NOUN
biomedich-346	219	7	,	,	PUNCT
biomedich-346	219	8	and	and	CCONJ
biomedich-346	219	9	biodistribution	biodistribution	NOUN
biomedich-346	219	10	of	of	ADP
biomedich-346	219	11	the	the	DET
biomedich-346	219	12	vaccine	vaccine	NOUN
biomedich-346	219	13	were	be	AUX
biomedich-346	219	14	characterized	characterize	VERB
biomedich-346	219	15	in	in	ADP
biomedich-346	219	16	rats	rat	NOUN
biomedich-346	219	17	.	.	PUNCT
biomedich-346	220	1	in	in	ADP
biomedich-346	220	2	hamsters	hamster	NOUN
biomedich-346	220	3	,	,	PUNCT
biomedich-346	220	4	the	the	DET
biomedich-346	220	5	vaccine	vaccine	NOUN
biomedich-346	220	6	candidate	candidate	NOUN
biomedich-346	220	7	was	be	AUX
biomedich-346	220	8	well	well	ADV
biomedich-346	220	9	-	-	PUNCT
biomedich-346	220	10	tolerated	tolerate	VERB
biomedich-346	220	11	,	,	PUNCT
biomedich-346	220	12	markedly	markedly	ADV
biomedich-346	220	13	reduced	reduce	VERB
biomedich-346	220	14	viral	viral	ADJ
biomedich-346	220	15	load	load	NOUN
biomedich-346	220	16	in	in	ADP
biomedich-346	220	17	the	the	DET
biomedich-346	220	18	upper	upper	ADJ
biomedich-346	220	19	and	and	CCONJ
biomedich-346	220	20	lower	low	ADJ
biomedich-346	220	21	airways	airway	NOUN
biomedich-346	220	22	,	,	PUNCT
biomedich-346	220	23	and	and	CCONJ
biomedich-346	220	24	protected	protect	VERB
biomedich-346	220	25	animals	animal	NOUN
biomedich-346	220	26	against	against	ADP
biomedich-346	220	27	disease	disease	NOUN
biomedich-346	220	28	in	in	ADP
biomedich-346	220	29	a	a	DET
biomedich-346	220	30	dose	dose	NOUN
biomedich-346	220	31	-	-	PUNCT
biomedich-346	220	32	dependent	dependent	ADJ
biomedich-346	220	33	manner	manner	NOUN
biomedich-346	220	34	,	,	PUNCT
biomedich-346	220	35	with	with	ADP
biomedich-346	220	36	no	no	DET
biomedich-346	220	37	evidence	evidence	NOUN
biomedich-346	220	38	of	of	ADP
biomedich-346	220	39	disease	disease	NOUN
biomedich-346	220	40	enhancement	enhancement	NOUN
biomedich-346	220	41	following	follow	VERB
biomedich-346	220	42	the	the	DET
biomedich-346	220	43	sarscov-2	sarscov-2	NUM
biomedich-346	220	44	challenge	challenge	NOUN
biomedich-346	220	45	.	.	PUNCT
biomedich-346	221	1	therefore	therefore	ADV
biomedich-346	221	2	,	,	PUNCT
biomedich-346	221	3	the	the	DET
biomedich-346	221	4	sars	sar	NOUN
biomedich-346	221	5	-	-	PUNCT
biomedich-346	221	6	cov-2	cov-2	NOUN
biomedich-346	221	7	sam	sam	PROPN
biomedich-346	221	8	(	(	PUNCT
biomedich-346	221	9	lnp	lnp	PROPN
biomedich-346	221	10	)	)	PUNCT
biomedich-346	221	11	vaccine	vaccine	NOUN
biomedich-346	221	12	candidate	candidate	NOUN
biomedich-346	221	13	has	have	VERB
biomedich-346	221	14	a	a	DET
biomedich-346	221	15	favorable	favorable	ADJ
biomedich-346	221	16	safety	safety	NOUN
biomedich-346	221	17	profile	profile	NOUN
biomedich-346	221	18	,	,	PUNCT
biomedich-346	221	19	elicits	elicit	VERB
biomedich-346	221	20	robust	robust	ADJ
biomedich-346	221	21	protective	protective	ADJ
biomedich-346	221	22	immune	immune	ADJ
biomedich-346	221	23	responses	response	NOUN
biomedich-346	221	24	against	against	ADP
biomedich-346	221	25	multiple	multiple	ADJ
biomedich-346	221	26	sars	sar	NOUN
biomedich-346	221	27	-	-	PUNCT
biomedich-346	221	28	cov-2	cov-2	NOUN
biomedich-346	221	29	variants	variant	NOUN
biomedich-346	221	30	,	,	PUNCT
biomedich-346	221	31	and	and	CCONJ
biomedich-346	221	32	has	have	AUX
biomedich-346	221	33	been	be	AUX
biomedich-346	221	34	advanced	advanced	ADJ
biomedich-346	221	35	to	to	PART
biomedich-346	221	36	phase	phase	VERB
biomedich-346	221	37	1	1	NUM
biomedich-346	221	38	clinical	clinical	ADJ
biomedich-346	221	39	evaluation	evaluation	NOUN
biomedich-346	221	40	madhi	madhi	NOUN
biomedich-346	221	41	et	et	PROPN
biomedich-346	221	42	al	al	PROPN
biomedich-346	221	43	.	.	PROPN
biomedich-346	221	44	immunogenicity	immunogenicity	NOUN
biomedich-346	221	45	and	and	CCONJ
biomedich-346	221	46	safety	safety	NOUN
biomedich-346	221	47	of	of	ADP
biomedich-346	221	48	a	a	DET
biomedich-346	221	49	sarscov-2	sarscov-2	NUM
biomedich-346	221	50	recombinant	recombinant	ADJ
biomedich-346	221	51	spike	spike	ADJ
biomedich-346	221	52	protein	protein	NOUN
biomedich-346	221	53	nanoparticle	nanoparticle	NOUN
biomedich-346	221	54	vaccine	vaccine	NOUN
biomedich-346	221	55	in	in	ADP
biomedich-346	221	56	people	people	NOUN
biomedich-346	221	57	living	live	VERB
biomedich-346	221	58	with	with	ADP
biomedich-346	221	59	and	and	CCONJ
biomedich-346	221	60	without	without	ADP
biomedich-346	221	61	hiv-1	hiv-1	ADJ
biomedich-346	221	62	infection	infection	NOUN
biomedich-346	221	63	:	:	PUNCT
biomedich-346	221	64	a	a	DET
biomedich-346	221	65	randomized	randomized	ADJ
biomedich-346	221	66	,	,	PUNCT
biomedich-346	221	67	controlled	control	VERB
biomedich-346	221	68	,	,	PUNCT
biomedich-346	221	69	phase	phase	NOUN
biomedich-346	221	70	2a/2b	2a/2b	NUM
biomedich-346	221	71	trial	trial	NOUN
biomedich-346	221	72	clinical	clinical	ADJ
biomedich-346	221	73	trial	trial	NOUN
biomedich-346	221	74	2022	2022	NUM
biomedich-346	221	75	in	in	ADP
biomedich-346	221	76	this	this	PRON
biomedich-346	221	77	randomized	randomize	VERB
biomedich-346	221	78	,	,	PUNCT
biomedich-346	221	79	observerblinded	observerblinded	ADJ
biomedich-346	221	80	,	,	PUNCT
biomedich-346	221	81	multicentre	multicentre	PROPN
biomedich-346	221	82	,	,	PUNCT
biomedich-346	221	83	placebocontrolled	placebocontrolle	VERB
biomedich-346	221	84	phase	phase	NOUN
biomedich-346	221	85	2a	2a	NUM
biomedich-346	221	86	/	/	SYM
biomedich-346	221	87	b	b	NOUN
biomedich-346	221	88	trial	trial	NOUN
biomedich-346	221	89	in	in	ADP
biomedich-346	221	90	south	south	PROPN
biomedich-346	221	91	africa	africa	PROPN
biomedich-346	221	92	,	,	PUNCT
biomedich-346	221	93	participants	participant	NOUN
biomedich-346	221	94	aged	age	VERB
biomedich-346	221	95	18	18	NUM
biomedich-346	221	96	-	-	SYM
biomedich-346	221	97	84	84	NUM
biomedich-346	221	98	years	year	NOUN
biomedich-346	221	99	,	,	PUNCT
biomedich-346	221	100	with	with	ADP
biomedich-346	221	101	and	and	CCONJ
biomedich-346	221	102	without	without	ADP
biomedich-346	221	103	underlying	underlie	VERB
biomedich-346	221	104	hiv-1	hiv-1	ADV
biomedich-346	221	105	,	,	PUNCT
biomedich-346	221	106	were	be	AUX
biomedich-346	221	107	enrolled	enrol	VERB
biomedich-346	221	108	from	from	ADP
biomedich-346	221	109	16	16	NUM
biomedich-346	221	110	sites	site	NOUN
biomedich-346	221	111	and	and	CCONJ
biomedich-346	221	112	randomly	randomly	ADV
biomedich-346	221	113	assigned	assign	VERB
biomedich-346	221	114	(	(	PUNCT
biomedich-346	221	115	1:1	1:1	NUM
biomedich-346	221	116	)	)	PUNCT
biomedich-346	221	117	to	to	PART
biomedich-346	221	118	receive	receive	VERB
biomedich-346	221	119	two	two	NUM
biomedich-346	221	120	intramuscular	intramuscular	ADJ
biomedich-346	221	121	injections	injection	NOUN
biomedich-346	221	122	of	of	ADP
biomedich-346	221	123	nvx	nvx	NOUN
biomedich-346	221	124	-	-	PUNCT
biomedich-346	221	125	cov2373	cov2373	NOUN
biomedich-346	221	126	or	or	CCONJ
biomedich-346	221	127	placebo	placebo	NOUN
biomedich-346	221	128	,	,	PUNCT
biomedich-346	221	129	21	21	NUM
biomedich-346	221	130	days	day	NOUN
biomedich-346	221	131	apart	apart	ADV
biomedich-346	221	132	.	.	PUNCT
biomedich-346	222	1	people	people	NOUN
biomedich-346	222	2	living	live	VERB
biomedich-346	222	3	with	with	ADP
biomedich-346	222	4	hiv-1	hiv-1	PUNCT
biomedich-346	222	5	were	be	AUX
biomedich-346	222	6	on	on	ADP
biomedich-346	222	7	stable	stable	ADJ
biomedich-346	222	8	antiretroviral	antiretroviral	ADJ
biomedich-346	222	9	therapy	therapy	NOUN
biomedich-346	222	10	and	and	CCONJ
biomedich-346	222	11	had	have	VERB
biomedich-346	222	12	an	an	DET
biomedich-346	222	13	hiv-1	hiv-1	ADJ
biomedich-346	222	14	viral	viral	ADJ
biomedich-346	222	15	load	load	NOUN
biomedich-346	222	16	of	of	ADP
biomedich-346	222	17	few	few	ADJ
biomedich-346	222	18	than	than	ADP
biomedich-346	222	19	1000	1000	NUM
biomedich-346	222	20	copies	copy	NOUN
biomedich-346	222	21	per	per	ADP
biomedich-346	222	22	ml	ml	PROPN
biomedich-346	222	23	.	.	PUNCT
biomedich-346	223	1	vacc	vacc	PROPN
biomedich-346	223	2	ine	ine	PROPN
biomedich-346	223	3	dosage	dosage	NOUN
biomedich-346	223	4	was	be	AUX
biomedich-346	223	5	5	5	NUM
biomedich-346	223	6	μg	μg	PROPN
biomedich-346	223	7	sars	sar	NOUN
biomedich-346	223	8	-	-	PUNCT
biomedich-346	223	9	cov-2	cov-2	NOUN
biomedich-346	223	10	recombinant	recombinant	ADJ
biomedich-346	223	11	spike	spike	ADJ
biomedich-346	223	12	protein	protein	NOUN
biomedich-346	223	13	with	with	ADP
biomedich-346	223	14	50	50	NUM
biomedich-346	223	15	μg	μg	NOUN
biomedich-346	223	16	matrix	matrix	NOUN
biomedich-346	223	17	-	-	PUNCT
biomedich-346	223	18	m	m	NOUN
biomedich-346	223	19	adjuvant	adjuvant	NOUN
biomedich-346	223	20	,	,	PUNCT
biomedich-346	223	21	whereas	whereas	SCONJ
biomedich-346	223	22	0·9	0·9	NUM
biomedich-346	223	23	%	%	NOUN
biomedich-346	223	24	saline	saline	NOUN
biomedich-346	223	25	was	be	AUX
biomedich-346	223	26	used	use	VERB
biomedich-346	223	27	as	as	ADP
biomedich-346	223	28	a	a	DET
biomedich-346	223	29	placebo	placebo	NOUN
biomedich-346	223	30	injection	injection	NOUN
biomedich-346	223	31	(	(	PUNCT
biomedich-346	223	32	volume	volume	NOUN
biomedich-346	223	33	0·5	0·5	NUM
biomedich-346	223	34	ml	ml	ADP
biomedich-346	223	35	each	each	PRON
biomedich-346	223	36	)	)	PUNCT
biomedich-346	223	37	.	.	PUNCT
biomedich-346	224	1	all	all	DET
biomedich-346	224	2	study	study	NOUN
biomedich-346	224	3	staff	staff	NOUN
biomedich-346	224	4	and	and	CCONJ
biomedich-346	224	5	participants	participant	NOUN
biomedich-346	224	6	remained	remain	VERB
biomedich-346	224	7	masked	mask	VERB
biomedich-346	224	8	to	to	PART
biomedich-346	224	9	study	study	VERB
biomedich-346	224	10	group	group	NOUN
biomedich-346	224	11	assignment	assignment	NOUN
biomedich-346	224	12	.	.	PUNCT
biomedich-346	225	1	we	we	PRON
biomedich-346	225	2	previously	previously	ADV
biomedich-346	225	3	reported	report	VERB
biomedich-346	225	4	an	an	DET
biomedich-346	225	5	interim	interim	ADJ
biomedich-346	225	6	analysis	analysis	NOUN
biomedich-346	225	7	on	on	ADP
biomedich-346	225	8	the	the	DET
biomedich-346	225	9	efficacy	efficacy	NOUN
biomedich-346	225	10	and	and	CCONJ
biomedich-346	225	11	safety	safety	NOUN
biomedich-346	225	12	of	of	ADP
biomedich-346	225	13	the	the	DET
biomedich-346	225	14	nvx	nvx	ADJ
biomedich-346	225	15	-	-	PUNCT
biomedich-346	225	16	cov2373	cov2373	NOUN
biomedich-346	225	17	vaccine	vaccine	NOUN
biomedich-346	225	18	(	(	PUNCT
biomedich-346	225	19	coprimary	coprimary	ADJ
biomedich-346	225	20	endpoints	endpoint	NOUN
biomedich-346	225	21	)	)	PUNCT
biomedich-346	225	22	.	.	PUNCT
biomedich-346	226	1	in	in	ADP
biomedich-346	226	2	this	this	DET
biomedich-346	226	3	article	article	NOUN
biomedich-346	226	4	,	,	PUNCT
biomedich-346	226	5	we	we	PRON
biomedich-346	226	6	present	present	VERB
biomedich-346	226	7	an	an	DET
biomedich-346	226	8	expanded	expand	VERB
biomedich-346	226	9	safety	safety	NOUN
biomedich-346	226	10	analysis	analysis	NOUN
biomedich-346	226	11	for	for	ADP
biomedich-346	226	12	the	the	DET
biomedich-346	226	13	full	full	ADJ
biomedich-346	226	14	cohort	cohort	NOUN
biomedich-346	226	15	of	of	ADP
biomedich-346	226	16	participants	participant	NOUN
biomedich-346	226	17	and	and	CCONJ
biomedich-346	226	18	report	report	VERB
biomedich-346	226	19	on	on	ADP
biomedich-346	226	20	the	the	DET
biomedich-346	226	21	secondary	secondary	ADJ
biomedich-346	226	22	objective	objective	NOUN
biomedich-346	226	23	of	of	ADP
biomedich-346	226	24	vaccine	vaccine	NOUN
biomedich-346	226	25	immunogenicity	immunogenicity	NOUN
biomedich-346	226	26	in	in	ADP
biomedich-346	226	27	the	the	DET
biomedich-346	226	28	full	full	ADJ
biomedich-346	226	29	cohort	cohort	NOUN
biomedich-346	226	30	of	of	ADP
biomedich-346	226	31	people	people	NOUN
biomedich-346	226	32	living	live	VERB
biomedich-346	226	33	with	with	ADP
biomedich-346	226	34	hiv-1	hiv-1	PUNCT
biomedich-346	226	35	and	and	CCONJ
biomedich-346	226	36	in	in	ADP
biomedich-346	226	37	hiv	hiv	PROPN
biomedich-346	226	38	-	-	PUNCT
biomedich-346	226	39	negative	negative	ADJ
biomedich-346	226	40	individuals	individual	NOUN
biomedich-346	226	41	overall	overall	ADJ
biomedich-346	226	42	and	and	CCONJ
biomedich-346	226	43	stratified	stratify	VERB
biomedich-346	226	44	by	by	ADP
biomedich-346	226	45	baseline	baseline	PROPN
biomedich-346	226	46	sars	sar	NOUN
biomedich-346	226	47	-	-	PUNCT
biomedich-346	226	48	cov-2	cov-2	NOUN
biomedich-346	226	49	serostatus	serostatus	NOUN
biomedich-346	226	50	.	.	PUNCT
biomedich-346	227	1	of	of	ADP
biomedich-346	227	2	the	the	DET
biomedich-346	227	3	serious	serious	ADJ
biomedich-346	227	4	adverse	adverse	ADJ
biomedich-346	227	5	events	event	NOUN
biomedich-346	227	6	that	that	PRON
biomedich-346	227	7	occurred	occur	VERB
biomedich-346	227	8	among	among	ADP
biomedich-346	227	9	hiv	hiv	PROPN
biomedich-346	227	10	-	-	PUNCT
biomedich-346	227	11	negative	negative	ADJ
biomedich-346	227	12	people	people	NOUN
biomedich-346	227	13	(	(	PUNCT
biomedich-346	227	14	of	of	ADP
biomedich-346	227	15	whom	whom	PRON
biomedich-346	227	16	,	,	PUNCT
biomedich-346	227	17	two	two	NUM
biomedich-346	227	18	[	[	NOUN
biomedich-346	227	19	0·1	0·1	NUM
biomedich-346	227	20	%	%	NOUN
biomedich-346	227	21	]	]	PUNCT
biomedich-346	227	22	were	be	AUX
biomedich-346	228	1	baseline	baseline	ADJ
biomedich-346	228	2	sars	sar	NOUN
biomedich-346	228	3	-	-	PUNCT
biomedich-346	228	4	cov-2	cov-2	NOUN
biomedich-346	228	5	-	-	PUNCT
biomedich-346	228	6	negative	negative	ADJ
biomedich-346	228	7	and	and	CCONJ
biomedich-346	228	8	four	four	NUM
biomedich-346	229	1	[	[	X
biomedich-346	229	2	0·6	0·6	X
biomedich-346	229	3	%	%	NOUN
biomedich-346	229	4	]	]	PUNCT
biomedich-346	229	5	were	be	AUX
biomedich-346	229	6	baseline	baseline	ADJ
biomedich-346	229	7	sars	sar	NOUN
biomedich-346	229	8	-	-	PUNCT
biomedich-346	229	9	cov-2positive	cov-2positive	NOUN
biomedich-346	229	10	)	)	PUNCT
biomedich-346	229	11	and	and	CCONJ
biomedich-346	229	12	people	people	NOUN
biomedich-346	229	13	living	live	VERB
biomedich-346	229	14	with	with	ADP
biomedich-346	229	15	hiv-1	hiv-1	X
biomedich-346	229	16	(	(	PUNCT
biomedich-346	229	17	for	for	ADP
biomedich-346	229	18	whom	whom	PRON
biomedich-346	229	19	there	there	PRON
biomedich-346	229	20	were	be	VERB
biomedich-346	229	21	no	no	DET
biomedich-346	229	22	serious	serious	ADJ
biomedich-346	229	23	adverse	adverse	ADJ
biomedich-346	229	24	events	event	NOUN
biomedich-346	229	25	)	)	PUNCT
biomedich-346	229	26	in	in	ADP
biomedich-346	229	27	the	the	DET
biomedich-346	229	28	nvx	nvx	PROPN
biomedich-346	229	29	-	-	PUNCT
biomedich-346	229	30	cov2373	cov2373	NOUN
biomedich-346	229	31	group	group	NOUN
biomedich-346	229	32	,	,	PUNCT
biomedich-346	229	33	none	none	NOUN
biomedich-346	229	34	were	be	AUX
biomedich-346	229	35	assessed	assess	VERB
biomedich-346	229	36	as	as	ADP
biomedich-346	229	37	related	relate	VERB
biomedich-346	229	38	to	to	ADP
biomedich-346	229	39	the	the	DET
biomedich-346	229	40	vaccine	vaccine	NOUN
biomedich-346	229	41	.	.	PUNCT
biomedich-346	230	1	among	among	ADP
biomedich-346	230	2	participants	participant	NOUN
biomedich-346	230	3	who	who	PRON
biomedich-346	230	4	were	be	AUX
biomedich-346	230	5	baseline	baseline	PROPN
biomedich-346	230	6	sars	sar	NOUN
biomedich-346	230	7	-	-	PUNCT
biomedich-346	230	8	cov-2	cov-2	NOUN
biomedich-346	230	9	-	-	PUNCT
biomedich-346	230	10	negative	negative	ADJ
biomedich-346	230	11	in	in	ADP
biomedich-346	230	12	the	the	DET
biomedich-346	230	13	nvx	nvx	PROPN
biomedich-346	230	14	-	-	PUNCT
biomedich-346	230	15	cov2373	cov2373	NOUN
biomedich-346	230	16	group	group	NOUN
biomedich-346	230	17	,	,	PUNCT
biomedich-346	230	18	the	the	DET
biomedich-346	230	19	antispike	antispike	ADJ
biomedich-346	230	20	igg	igg	PROPN
biomedich-346	230	21	geometric	geometric	ADJ
biomedich-346	230	22	mean	mean	NOUN
biomedich-346	230	23	titres	titre	NOUN
biomedich-346	230	24	(	(	PUNCT
biomedich-346	230	25	gmts	gmts	NOUN
biomedich-346	230	26	)	)	PUNCT
biomedich-346	230	27	and	and	CCONJ
biomedich-346	230	28	seroconversion	seroconversion	NOUN
biomedich-346	230	29	rates	rate	NOUN
biomedich-346	230	30	(	(	PUNCT
biomedich-346	230	31	scrs	scrs	PROPN
biomedich-346	230	32	)	)	PUNCT
biomedich-346	230	33	were	be	AUX
biomedich-346	230	34	lower	low	ADJ
biomedich-346	230	35	in	in	ADP
biomedich-346	230	36	people	people	NOUN
biomedich-346	230	37	living	live	VERB
biomedich-346	230	38	with	with	ADP
biomedich-346	230	39	hiv-1	hiv-1	PUNCT
biomedich-346	230	40	(	(	PUNCT
biomedich-346	230	41	n=62	n=62	ADV
biomedich-346	230	42	)	)	PUNCT
biomedich-346	230	43	than	than	ADP
biomedich-346	230	44	in	in	ADP
biomedich-346	230	45	hivnegative	hivnegative	ADJ
biomedich-346	230	46	people	people	NOUN
biomedich-346	230	47	(	(	PUNCT
biomedich-346	230	48	n=1234	n=1234	NOUN
biomedich-346	230	49	)	)	PUNCT
biomedich-346	230	50	following	follow	VERB
biomedich-346	230	51	the	the	DET
biomedich-346	230	52	first	first	ADJ
biomedich-346	230	53	vaccination	vaccination	NOUN
biomedich-346	230	54	(	(	PUNCT
biomedich-346	230	55	gmt	gmt	NOUN
biomedich-346	230	56	:	:	PUNCT
biomedich-346	230	57	508·6	508·6	NOUN
biomedich-346	230	58	vs	vs	ADP
biomedich-346	230	59	1195·3	1195·3	PROPN
biomedich-346	230	60	elisa	elisa	NOUN
biomedich-346	230	61	units	unit	NOUN
biomedich-346	230	62	[	[	X
biomedich-346	230	63	eu]/ml	eu]/ml	ADJ
biomedich-346	230	64	;	;	PUNCT
biomedich-346	230	65	scr	scr	NOUN
biomedich-346	230	66	:	:	PUNCT
biomedich-346	230	67	51·6	51·6	NUM
biomedich-346	230	68	%	%	NOUN
biomedich-346	230	69	vs	vs	ADP
biomedich-346	230	70	81·3	81·3	NUM
biomedich-346	230	71	%	%	NOUN
biomedich-346	230	72	)	)	PUNCT
biomedich-346	230	73	;	;	PUNCT
biomedich-346	230	74	and	and	CCONJ
biomedich-346	230	75	similarly	similarly	ADV
biomedich-346	230	76	so	so	ADV
biomedich-346	230	77	14	14	NUM
biomedich-346	230	78	days	day	NOUN
biomedich-346	230	79	after	after	ADP
biomedich-346	230	80	the	the	DET
biomedich-346	230	81	second	second	ADJ
biomedich-346	230	82	vaccination	vaccination	NOUN
biomedich-346	230	83	for	for	ADP
biomedich-346	230	84	gmts	gmts	NOUN
biomedich-346	230	85	(	(	PUNCT
biomedich-346	230	86	14	14	NUM
biomedich-346	230	87	420·5	420·5	NUM
biomedich-346	230	88	vs	vs	ADP
biomedich-346	230	89	31	31	NUM
biomedich-346	230	90	631·8	631·8	NUM
biomedich-346	230	91	eu	eu	PROPN
biomedich-346	230	92	/	/	SYM
biomedich-346	230	93	ml	ml	PROPN
biomedich-346	230	94	)	)	PUNCT
biomedich-346	230	95	,	,	PUNCT
biomedich-346	230	96	whereas	whereas	SCONJ
biomedich-346	230	97	the	the	DET
biomedich-346	230	98	scr	scr	NOUN
biomedich-346	230	99	was	be	AUX
biomedich-346	230	100	similar	similar	ADJ
biomedich-346	230	101	at	at	ADP
biomedich-346	230	102	this	this	DET
biomedich-346	230	103	point	point	NOUN
biomedich-346	230	104	(	(	PUNCT
biomedich-346	230	105	100·0	100·0	NUM
biomedich-346	230	106	%	%	NOUN
biomedich-346	230	107	vs	vs	ADP
biomedich-346	230	108	99·3	99·3	NUM
biomedich-346	230	109	%	%	NOUN
biomedich-346	230	110	)	)	PUNCT
biomedich-346	230	111	.	.	PUNCT
biomedich-346	231	1	in	in	ADP
biomedich-346	231	2	the	the	DET
biomedich-346	231	3	nvxcov2373	nvxcov2373	PROPN
biomedich-346	231	4	group	group	NOUN
biomedich-346	231	5	,	,	PUNCT
biomedich-346	231	6	anti	anti	ADJ
biomedich-346	231	7	-	-	ADJ
biomedich-346	231	8	spike	spike	ADJ
biomedich-346	231	9	igg	igg	NOUN
biomedich-346	231	10	gmts	gmts	VERB
biomedich-346	231	11	14	14	NUM
biomedich-346	231	12	days	day	NOUN
biomedich-346	231	13	after	after	SCONJ
biomedich-346	231	14	the	the	DET
biomedich-346	231	15	second	second	ADJ
biomedich-346	231	16	vaccination	vaccination	NOUN
biomedich-346	231	17	were	be	AUX
biomedich-346	231	18	substantially	substantially	ADV
biomedich-346	231	19	higher	high	ADJ
biomedich-346	231	20	in	in	ADP
biomedich-346	231	21	those	those	PRON
biomedich-346	231	22	who	who	PRON
biomedich-346	231	23	were	be	AUX
biomedich-346	231	24	baseline	baseline	PROPN
biomedich-346	231	25	sars	sar	NOUN
biomedich-346	231	26	-	-	PUNCT
biomedich-346	231	27	cov-2	cov-2	NOUN
biomedich-346	231	28	-	-	ADJ
biomedich-346	231	29	positive	positive	ADJ
biomedich-346	231	30	than	than	ADP
biomedich-346	231	31	in	in	ADP
biomedich-346	231	32	those	those	PRON
biomedich-346	231	33	who	who	PRON
biomedich-346	231	34	were	be	AUX
biomedich-346	231	35	baseline	baseline	PROPN
biomedich-346	231	36	sars	sar	NOUN
biomedich-346	231	37	-	-	PUNCT
biomedich-346	231	38	cov-2	cov-2	NOUN
biomedich-346	231	39	-	-	ADJ
biomedich-346	231	40	seronegative	seronegative	ADJ
biomedich-346	231	41	for	for	ADP
biomedich-346	231	42	hivnegative	hivnegative	ADJ
biomedich-346	231	43	participants	participant	NOUN
biomedich-346	231	44	(	(	PUNCT
biomedich-346	231	45	100	100	NUM
biomedich-346	231	46	666·1	666·1	NOUN
biomedich-346	231	47	vs	vs	ADP
biomedich-346	231	48	31	31	NUM
biomedich-346	231	49	631·8	631·8	NUM
biomedich-346	231	50	eu	eu	PROPN
biomedich-346	231	51	/	/	SYM
biomedich-346	231	52	ml	ml	PROPN
biomedich-346	231	53	)	)	PUNCT
biomedich-346	231	54	and	and	CCONJ
biomedich-346	231	55	for	for	ADP
biomedich-346	231	56	people	people	NOUN
biomedich-346	231	57	living	live	VERB
biomedich-346	231	58	with	with	ADP
biomedich-346	231	59	hiv-1	hiv-1	PUNCT
biomedich-346	231	60	(	(	PUNCT
biomedich-346	231	61	98	98	NUM
biomedich-346	231	62	399·5	399·5	NUM
biomedich-346	231	63	vs	vs	ADP
biomedich-346	231	64	14	14	NUM
biomedich-346	231	65	420·5	420·5	NUM
biomedich-346	231	66	eu	eu	PROPN
biomedich-346	231	67	/	/	SYM
biomedich-346	231	68	ml	ml	VERB
biomedich-346	231	69	)	)	PUNCT
biomedich-346	231	70	.	.	PUNCT
biomedich-346	232	1	this	this	PRON
biomedich-346	232	2	was	be	AUX
biomedich-346	232	3	also	also	ADV
biomedich-346	232	4	the	the	DET
biomedich-346	232	5	case	case	NOUN
biomedich-346	232	6	for	for	ADP
biomedich-346	232	7	angiotensin	angiotensin	NOUN
biomedich-346	232	8	-	-	PUNCT
biomedich-346	232	9	converting	convert	VERB
biomedich-346	232	10	enzyme	enzyme	NOUN
biomedich-346	232	11	2	2	NUM
biomedich-346	232	12	receptor	receptor	NOUN
biomedich-346	232	13	-	-	PUNCT
biomedich-346	232	14	binding	bind	VERB
biomedich-346	232	15	antibodies	antibody	NOUN
biomedich-346	232	16	and	and	CCONJ
biomedich-346	232	17	neutralizing	neutralize	VERB
biomedich-346	232	18	antibody.titers	antibody.titer	NOUN
biomedich-346	232	19	.	.	PUNCT
biomedich-346	233	1	stuart	stuart	PROPN
biomedich-346	233	2	et	et	PROPN
biomedich-346	233	3	al	al	PROPN
biomedich-346	233	4	.	.	PROPN
biomedich-346	233	5	immunogenicity	immunogenicity	PROPN
biomedich-346	233	6	,	,	PUNCT
biomedich-346	233	7	safety	safety	NOUN
biomedich-346	233	8	,	,	PUNCT
biomedich-346	233	9	and	and	CCONJ
biomedich-346	233	10	reactogenicity	reactogenicity	NOUN
biomedich-346	233	11	of	of	ADP
biomedich-346	233	12	heterologous	heterologous	ADJ
biomedich-346	233	13	covid-19	covid-19	PROPN
biomedich-346	233	14	primary	primary	ADJ
biomedich-346	233	15	clinical	clinical	ADJ
biomedich-346	233	16	trial	trial	NOUN
biomedich-346	233	17	2022	2022	NUM
biomedich-346	233	18	com	com	NOUN
biomedich-346	233	19	-	-	PUNCT
biomedich-346	233	20	cov2	cov2	PROPN
biomedich-346	233	21	is	be	AUX
biomedich-346	233	22	a	a	DET
biomedich-346	233	23	single	single	ADJ
biomedich-346	233	24	-	-	PUNCT
biomedich-346	233	25	blind	blind	ADJ
biomedich-346	233	26	,	,	PUNCT
biomedich-346	233	27	randomized	randomize	VERB
biomedich-346	233	28	,	,	PUNCT
biomedich-346	233	29	non	non	ADJ
biomedich-346	233	30	-	-	ADJ
biomedich-346	233	31	inferiority	inferiority	ADJ
biomedich-346	233	32	trial	trial	NOUN
biomedich-346	233	33	in	in	ADP
biomedich-346	233	34	which	which	PRON
biomedich-346	233	35	adults	adult	NOUN
biomedich-346	233	36	aged	age	VERB
biomedich-346	233	37	50	50	NUM
biomedich-346	233	38	years	year	NOUN
biomedich-346	233	39	and	and	CCONJ
biomedich-346	233	40	older	old	ADJ
biomedich-346	233	41	,	,	PUNCT
biomedich-346	233	42	previously	previously	ADV
biomedich-346	233	43	immunised	immunise	VERB
biomedich-346	233	44	with	with	ADP
biomedich-346	233	45	a	a	DET
biomedich-346	233	46	single	single	ADJ
biomedich-346	233	47	dose	dose	NOUN
biomedich-346	233	48	of	of	ADP
biomedich-346	233	49	chad	chad	PROPN
biomedich-346	233	50	or	or	CCONJ
biomedich-346	233	51	between	between	ADP
biomedich-346	233	52	april	april	PROPN
biomedich-346	233	53	19	19	NUM
biomedich-346	233	54	and	and	CCONJ
biomedich-346	233	55	may	may	PROPN
biomedich-346	233	56	14	14	NUM
biomedich-346	233	57	,	,	PUNCT
biomedich-346	233	58	2021	2021	NUM
biomedich-346	233	59	,	,	PUNCT
biomedich-346	233	60	1072	1072	NUM
biomedich-346	233	61	participants	participant	NOUN
biomedich-346	233	62	were	be	AUX
biomedich-346	233	63	enrolled	enrol	VERB
biomedich-346	233	64	at	at	ADP
biomedich-346	233	65	a	a	DET
biomedich-346	233	66	median	median	NOUN
biomedich-346	233	67	of	of	ADP
biomedich-346	233	68	9·4	9·4	NUM
biomedich-346	233	69	weeks	week	NOUN
biomedich-346	233	70	after	after	ADP
biomedich-346	233	71	receipt	receipt	NOUN
biomedich-346	233	72	of	of	ADP
biomedich-346	233	73	a	a	DET
biomedich-346	233	74	single	single	ADJ
biomedich-346	233	75	dose	dose	NOUN
biomedich-346	233	76	of	of	ADP
biomedich-346	233	77	chad	chad	PROPN
biomedich-346	233	78	(	(	PUNCT
biomedich-346	233	79	n=540	n=540	PROPN
biomedich-346	233	80	,	,	PUNCT
biomedich-346	233	81	47	47	NUM
biomedich-346	233	82	%	%	NOUN
biomedich-346	233	83	female	female	NOUN
biomedich-346	233	84	)	)	PUNCT
biomedich-346	233	85	or	or	CCONJ
biomedich-346	233	86	bnt	bnt	PROPN
biomedich-346	233	87	(	(	PUNCT
biomedich-346	233	88	n=532	n=532	PROPN
biomedich-346	233	89	,	,	PUNCT
biomedich-346	233	90	40	40	NUM
biomedich-346	233	91	%	%	NOUN
biomedich-346	233	92	female	female	NOUN
biomedich-346	233	93	)	)	PUNCT
biomedich-346	233	94	.	.	PUNCT
biomedich-346	234	1	hussein	hussein	PROPN
biomedich-346	234	2	et	et	PROPN
biomedich-346	234	3	al	al	PROPN
biomedich-346	234	4	.	.	PROPN
biomedich-346	234	5	–	–	PUNCT
biomedich-346	234	6	nanotechnology	nanotechnology	NOUN
biomedich-346	234	7	-	-	PUNCT
biomedich-346	234	8	based	base	VERB
biomedich-346	234	9	vaccines	vaccine	NOUN
biomedich-346	234	10	353	353	NUM
biomedich-346	234	11	authors	author	NOUN
biomedich-346	234	12	title	title	VERB
biomedich-346	234	13	date	date	NOUN
biomedich-346	234	14	and	and	CCONJ
biomedich-346	234	15	type	type	NOUN
biomedich-346	234	16	of	of	ADP
biomedich-346	234	17	the	the	DET
biomedich-346	234	18	study	study	NOUN
biomedich-346	234	19	method	method	NOUN
biomedich-346	234	20	results	result	VERB
biomedich-346	234	21	vaccination	vaccination	NOUN
biomedich-346	234	22	incorporating	incorporate	VERB
biomedich-346	234	23	mrna	mrna	PROPN
biomedich-346	234	24	,	,	PUNCT
biomedich-346	234	25	viral	viral	ADJ
biomedich-346	234	26	-	-	PUNCT
biomedich-346	234	27	vector	vector	NOUN
biomedich-346	234	28	,	,	PUNCT
biomedich-346	234	29	and	and	CCONJ
biomedich-346	234	30	protein	protein	NOUN
biomedich-346	234	31	-	-	PUNCT
biomedich-346	234	32	adjuvant	adjuvant	ADJ
biomedich-346	234	33	vaccines	vaccine	NOUN
biomedich-346	234	34	in	in	ADP
biomedich-346	234	35	the	the	DET
biomedich-346	234	36	uk	uk	PROPN
biomedich-346	234	37	(	(	PUNCT
biomedich-346	234	38	com	com	NOUN
biomedich-346	234	39	-	-	PUNCT
biomedich-346	234	40	cov2	cov2	PROPN
biomedich-346	234	41	):	):	PUNCT
biomedich-346	234	42	a	a	DET
biomedich-346	234	43	single	single	ADJ
biomedich-346	234	44	-	-	PUNCT
biomedich-346	234	45	blind	blind	ADJ
biomedich-346	234	46	,	,	PUNCT
biomedich-346	234	47	randomised	randomise	VERB
biomedich-346	234	48	,	,	PUNCT
biomedich-346	234	49	phase	phase	NOUN
biomedich-346	234	50	2	2	NUM
biomedich-346	234	51	,	,	PUNCT
biomedich-346	234	52	non	non	ADJ
biomedich-346	234	53	-	-	ADJ
biomedich-346	234	54	inferiority	inferiority	ADJ
biomedich-346	234	55	trial	trial	NOUN
biomedich-346	234	56	bnt	bnt	PROPN
biomedich-346	234	57	in	in	ADP
biomedich-346	234	58	the	the	DET
biomedich-346	234	59	community	community	NOUN
biomedich-346	234	60	,	,	PUNCT
biomedich-346	234	61	were	be	AUX
biomedich-346	234	62	randomly	randomly	ADV
biomedich-346	234	63	assigned	assign	VERB
biomedich-346	234	64	(	(	PUNCT
biomedich-346	234	65	in	in	ADP
biomedich-346	234	66	random	random	ADJ
biomedich-346	234	67	blocks	block	NOUN
biomedich-346	234	68	of	of	ADP
biomedich-346	234	69	three	three	NUM
biomedich-346	234	70	and	and	CCONJ
biomedich-346	234	71	six	six	NUM
biomedich-346	234	72	)	)	PUNCT
biomedich-346	234	73	within	within	ADP
biomedich-346	234	74	these	these	DET
biomedich-346	234	75	cohorts	cohort	NOUN
biomedich-346	234	76	in	in	ADP
biomedich-346	234	77	a	a	DET
biomedich-346	234	78	1:1:1	1:1:1	PROPN
biomedich-346	234	79	ratio	ratio	NOUN
biomedich-346	234	80	to	to	PART
biomedich-346	234	81	receive	receive	VERB
biomedich-346	234	82	a	a	DET
biomedich-346	234	83	second	second	ADJ
biomedich-346	234	84	dose	dose	NOUN
biomedich-346	234	85	intramuscularly	intramuscularly	ADV
biomedich-346	234	86	(	(	PUNCT
biomedich-346	234	87	8	8	NUM
biomedich-346	234	88	-	-	SYM
biomedich-346	234	89	12	12	NUM
biomedich-346	234	90	weeks	week	NOUN
biomedich-346	234	91	after	after	ADP
biomedich-346	234	92	the	the	DET
biomedich-346	234	93	first	first	ADJ
biomedich-346	234	94	dose	dose	NOUN
biomedich-346	234	95	)	)	PUNCT
biomedich-346	234	96	with	with	ADP
biomedich-346	234	97	the	the	DET
biomedich-346	234	98	homologous	homologous	ADJ
biomedich-346	234	99	vaccine	vaccine	NOUN
biomedich-346	234	100	,	,	PUNCT
biomedich-346	234	101	m1273	m1273	PROPN
biomedich-346	234	102	,	,	PUNCT
biomedich-346	234	103	or	or	CCONJ
biomedich-346	234	104	nvx	nvx	NOUN
biomedich-346	234	105	.	.	PUNCT
biomedich-346	235	1	the	the	DET
biomedich-346	235	2	primary	primary	ADJ
biomedich-346	235	3	endpoint	endpoint	NOUN
biomedich-346	235	4	was	be	AUX
biomedich-346	235	5	the	the	DET
biomedich-346	235	6	geometric	geometric	ADJ
biomedich-346	235	7	mean	mean	NOUN
biomedich-346	235	8	ratio	ratio	NOUN
biomedich-346	235	9	(	(	PUNCT
biomedich-346	235	10	gmr	gmr	PROPN
biomedich-346	235	11	)	)	PUNCT
biomedich-346	235	12	of	of	ADP
biomedich-346	235	13	serum	serum	NOUN
biomedich-346	235	14	sars	sar	NOUN
biomedich-346	235	15	-	-	PUNCT
biomedich-346	235	16	cov-2	cov-2	NOUN
biomedich-346	235	17	antispike	antispike	PROPN
biomedich-346	235	18	igg	igg	NOUN
biomedich-346	235	19	concentrations	concentration	NOUN
biomedich-346	235	20	measured	measure	VERB
biomedich-346	235	21	by	by	ADP
biomedich-346	235	22	elisa	elisa	NOUN
biomedich-346	235	23	in	in	ADP
biomedich-346	235	24	heterologous	heterologous	ADJ
biomedich-346	235	25	versus	versus	ADP
biomedich-346	235	26	homologous	homologous	ADJ
biomedich-346	235	27	schedules	schedule	NOUN
biomedich-346	235	28	at	at	ADP
biomedich-346	235	29	28	28	NUM
biomedich-346	235	30	days	day	NOUN
biomedich-346	235	31	after	after	ADP
biomedich-346	235	32	the	the	DET
biomedich-346	235	33	second	second	ADJ
biomedich-346	235	34	dose	dose	NOUN
biomedich-346	235	35	,	,	PUNCT
biomedich-346	235	36	with	with	ADP
biomedich-346	235	37	a	a	DET
biomedich-346	235	38	noninferiority	noninferiority	NOUN
biomedich-346	235	39	criterion	criterion	NOUN
biomedich-346	235	40	of	of	ADP
biomedich-346	235	41	the	the	DET
biomedich-346	235	42	gmr	gmr	NOUN
biomedich-346	235	43	above	above	ADP
biomedich-346	235	44	0·63	0·63	PRON
biomedich-346	235	45	for	for	ADP
biomedich-346	235	46	the	the	DET
biomedich-346	235	47	one	one	NUM
biomedich-346	235	48	-	-	PUNCT
biomedich-346	235	49	sided	sided	ADJ
biomedich-346	235	50	98·75	98·75	NUM
biomedich-346	235	51	%	%	NOUN
biomedich-346	235	52	ci	ci	NOUN
biomedich-346	235	53	.	.	PUNCT
biomedich-346	236	1	the	the	DET
biomedich-346	236	2	primary	primary	ADJ
biomedich-346	236	3	analysis	analysis	NOUN
biomedich-346	236	4	was	be	AUX
biomedich-346	236	5	on	on	ADP
biomedich-346	236	6	the	the	DET
biomedich-346	236	7	per	per	ADP
biomedich-346	236	8	-	-	PUNCT
biomedich-346	236	9	protocol	protocol	NOUN
biomedich-346	236	10	population	population	NOUN
biomedich-346	236	11	,	,	PUNCT
biomedich-346	236	12	who	who	PRON
biomedich-346	236	13	were	be	AUX
biomedich-346	236	14	seronegative	seronegative	ADJ
biomedich-346	236	15	at	at	ADP
biomedich-346	236	16	baseline	baseline	NOUN
biomedich-346	236	17	.	.	PUNCT
biomedich-346	237	1	safety	safety	NOUN
biomedich-346	237	2	analyses	analysis	NOUN
biomedich-346	237	3	were	be	AUX
biomedich-346	237	4	done	do	VERB
biomedich-346	237	5	for	for	ADP
biomedich-346	237	6	all	all	DET
biomedich-346	237	7	participants	participant	NOUN
biomedich-346	237	8	who	who	PRON
biomedich-346	237	9	received	receive	VERB
biomedich-346	237	10	a	a	DET
biomedich-346	237	11	dose	dose	NOUN
biomedich-346	237	12	of	of	ADP
biomedich-346	237	13	the	the	DET
biomedich-346	237	14	study	study	NOUN
biomedich-346	237	15	vaccine	vaccine	NOUN
biomedich-346	237	16	.	.	PUNCT
biomedich-346	238	1	in	in	ADP
biomedich-346	238	2	chad	chad	PROPN
biomedich-346	238	3	-	-	PUNCT
biomedich-346	238	4	primed	prime	VERB
biomedich-346	238	5	participants	participant	NOUN
biomedich-346	238	6	,	,	PUNCT
biomedich-346	238	7	geometric	geometric	ADJ
biomedich-346	238	8	mean	mean	NOUN
biomedich-346	238	9	concentration	concentration	NOUN
biomedich-346	238	10	(	(	PUNCT
biomedich-346	238	11	gmc	gmc	NOUN
biomedich-346	238	12	)	)	PUNCT
biomedich-346	238	13	28	28	NUM
biomedich-346	238	14	days	day	NOUN
biomedich-346	238	15	after	after	ADP
biomedich-346	238	16	a	a	DET
biomedich-346	238	17	boost	boost	NOUN
biomedich-346	238	18	of	of	ADP
biomedich-346	238	19	sars	sar	NOUN
biomedich-346	238	20	-	-	PUNCT
biomedich-346	238	21	cov-2	cov-2	NOUN
biomedich-346	238	22	anti	anti	ADJ
biomedich-346	238	23	-	-	ADJ
biomedich-346	238	24	spike	spike	ADJ
biomedich-346	238	25	igg	igg	NOUN
biomedich-346	238	26	in	in	ADP
biomedich-346	238	27	recipients	recipient	NOUN
biomedich-346	238	28	of	of	ADP
biomedich-346	238	29	chad	chad	PROPN
biomedich-346	238	30	/	/	SYM
biomedich-346	238	31	m1273	m1273	PROPN
biomedich-346	238	32	(	(	PUNCT
biomedich-346	238	33	20	20	NUM
biomedich-346	238	34	114	114	NUM
biomedich-346	238	35	elisa	elisa	NOUN
biomedich-346	238	36	laboratory	laboratory	NOUN
biomedich-346	238	37	units	unit	NOUN
biomedich-346	238	38	[	[	X
biomedich-346	238	39	elu]/ml	elu]/ml	NOUN
biomedich-346	238	40	[	[	PUNCT
biomedich-346	238	41	95	95	NUM
biomedich-346	238	42	%	%	NOUN
biomedich-346	238	43	ci	ci	NOUN
biomedich-346	238	44	18	18	NUM
biomedich-346	238	45	160	160	NUM
biomedich-346	238	46	to	to	ADP
biomedich-346	238	47	22	22	NUM
biomedich-346	238	48	279	279	NUM
biomedich-346	238	49	]	]	PUNCT
biomedich-346	238	50	)	)	PUNCT
biomedich-346	238	51	and	and	CCONJ
biomedich-346	238	52	chad	chad	PROPN
biomedich-346	238	53	/	/	SYM
biomedich-346	238	54	nvx	nvx	PROPN
biomedich-346	238	55	(	(	PUNCT
biomedich-346	238	56	5597	5597	NUM
biomedich-346	238	57	elu	elu	NOUN
biomedich-346	238	58	/	/	SYM
biomedich-346	238	59	ml	ml	PROPN
biomedich-346	238	60	[	[	X
biomedich-346	238	61	4756	4756	NUM
biomedich-346	238	62	to	to	ADP
biomedich-346	238	63	6586	6586	NUM
biomedich-346	238	64	]	]	PUNCT
biomedich-346	238	65	)	)	PUNCT
biomedich-346	238	66	was	be	AUX
biomedich-346	238	67	noninferior	noninferior	ADJ
biomedich-346	238	68	to	to	ADP
biomedich-346	238	69	that	that	PRON
biomedich-346	238	70	of	of	ADP
biomedich-346	238	71	chad	chad	PROPN
biomedich-346	238	72	/	/	SYM
biomedich-346	238	73	chad	chad	PROPN
biomedich-346	238	74	recipients	recipient	NOUN
biomedich-346	238	75	(	(	PUNCT
biomedich-346	238	76	1971	1971	NUM
biomedich-346	238	77	elu	elu	NOUN
biomedich-346	238	78	/	/	SYM
biomedich-346	238	79	ml	ml	X
biomedich-346	239	1	[	[	X
biomedich-346	239	2	1718	1718	NUM
biomedich-346	239	3	to	to	ADP
biomedich-346	239	4	2262	2262	NUM
biomedich-346	239	5	]	]	PUNCT
biomedich-346	239	6	)	)	PUNCT
biomedich-346	239	7	with	with	ADP
biomedich-346	239	8	a	a	DET
biomedich-346	239	9	gmr	gmr	NOUN
biomedich-346	239	10	of	of	ADP
biomedich-346	239	11	10·2	10·2	NUM
biomedich-346	239	12	(	(	PUNCT
biomedich-346	239	13	one	one	NUM
biomedich-346	239	14	-	-	PUNCT
biomedich-346	239	15	sided	sided	ADJ
biomedich-346	239	16	98·75	98·75	NUM
biomedich-346	239	17	%	%	NOUN
biomedich-346	239	18	ci	ci	NOUN
biomedich-346	239	19	8·4	8·4	NUM
biomedich-346	239	20	to	to	ADP
biomedich-346	239	21	∞	∞	NUM
biomedich-346	239	22	)	)	PUNCT
biomedich-346	239	23	for	for	ADP
biomedich-346	239	24	chad	chad	PROPN
biomedich-346	239	25	/	/	SYM
biomedich-346	239	26	m1273	m1273	PROPN
biomedich-346	239	27	and	and	CCONJ
biomedich-346	239	28	2·8	2·8	NUM
biomedich-346	239	29	(	(	PUNCT
biomedich-346	239	30	2·2	2·2	NUM
biomedich-346	239	31	to	to	ADP
biomedich-346	239	32	∞	∞	NUM
biomedich-346	239	33	)	)	PUNCT
biomedich-346	239	34	for	for	ADP
biomedich-346	239	35	chad	chad	PROPN
biomedich-346	239	36	/	/	SYM
biomedich-346	239	37	nvx	nvx	PROPN
biomedich-346	239	38	,	,	PUNCT
biomedich-346	239	39	compared	compare	VERB
biomedich-346	239	40	with	with	ADP
biomedich-346	239	41	chad	chad	PROPN
biomedich-346	239	42	/	/	SYM
biomedich-346	239	43	chad	chad	PROPN
biomedich-346	239	44	.	.	PUNCT
biomedich-346	240	1	in	in	ADP
biomedich-346	240	2	bntprimed	bntprimed	ADJ
biomedich-346	240	3	participants	participant	NOUN
biomedich-346	240	4	,	,	PUNCT
biomedich-346	240	5	non	non	ADJ
biomedich-346	240	6	-	-	ADJ
biomedich-346	240	7	inferiority	inferiority	NOUN
biomedich-346	240	8	was	be	AUX
biomedich-346	240	9	shown	show	VERB
biomedich-346	240	10	for	for	ADP
biomedich-346	240	11	bnt	bnt	PROPN
biomedich-346	240	12	/	/	SYM
biomedich-346	240	13	m1273	m1273	PROPN
biomedich-346	240	14	(	(	PUNCT
biomedich-346	240	15	gmc	gmc	PROPN
biomedich-346	240	16	22	22	NUM
biomedich-346	240	17	978	978	NUM
biomedich-346	240	18	elu	elu	NOUN
biomedich-346	240	19	/	/	SYM
biomedich-346	240	20	ml	ml	X
biomedich-346	241	1	[	[	X
biomedich-346	241	2	95	95	NUM
biomedich-346	241	3	%	%	NOUN
biomedich-346	241	4	ci	ci	NOUN
biomedich-346	241	5	20	20	NUM
biomedich-346	241	6	597	597	NUM
biomedich-346	241	7	to	to	PART
biomedich-346	241	8	25	25	NUM
biomedich-346	241	9	636	636	NUM
biomedich-346	241	10	]	]	PUNCT
biomedich-346	241	11	)	)	PUNCT
biomedich-346	241	12	but	but	CCONJ
biomedich-346	241	13	not	not	PART
biomedich-346	241	14	for	for	ADP
biomedich-346	241	15	bnt	bnt	PROPN
biomedich-346	241	16	/	/	SYM
biomedich-346	241	17	nvx	nvx	PROPN
biomedich-346	241	18	(	(	PUNCT
biomedich-346	241	19	8874	8874	NUM
biomedich-346	241	20	elu	elu	NOUN
biomedich-346	241	21	/	/	SYM
biomedich-346	241	22	ml	ml	X
biomedich-346	242	1	[	[	X
biomedich-346	242	2	7391	7391	NUM
biomedich-346	242	3	to	to	ADP
biomedich-346	242	4	10	10	NUM
biomedich-346	242	5	654	654	NUM
biomedich-346	242	6	]	]	PUNCT
biomedich-346	242	7	)	)	PUNCT
biomedich-346	243	1	,	,	PUNCT
biomedich-346	243	2	compared	compare	VERB
biomedich-346	243	3	with	with	ADP
biomedich-346	243	4	bnt	bnt	PROPN
biomedich-346	243	5	/	/	SYM
biomedich-346	243	6	bnt	bnt	PROPN
biomedich-346	243	7	(	(	PUNCT
biomedich-346	243	8	16	16	NUM
biomedich-346	243	9	929	929	NUM
biomedich-346	243	10	elu	elu	NOUN
biomedich-346	243	11	/	/	SYM
biomedich-346	243	12	ml	ml	X
biomedich-346	244	1	[	[	X
biomedich-346	244	2	15	15	NUM
biomedich-346	244	3	025	025	NUM
biomedich-346	244	4	to	to	PART
biomedich-346	244	5	19	19	NUM
biomedich-346	244	6	075	075	NUM
biomedich-346	244	7	]	]	PUNCT
biomedich-346	244	8	)	)	PUNCT
biomedich-346	244	9	with	with	ADP
biomedich-346	244	10	a	a	DET
biomedich-346	244	11	gmr	gmr	NOUN
biomedich-346	244	12	of	of	ADP
biomedich-346	244	13	1·3	1·3	NUM
biomedich-346	244	14	(	(	PUNCT
biomedich-346	244	15	one	one	NUM
biomedich-346	244	16	-	-	PUNCT
biomedich-346	244	17	sided	sided	ADJ
biomedich-346	244	18	98·75	98·75	NUM
biomedich-346	244	19	%	%	NOUN
biomedich-346	244	20	ci	ci	NOUN
biomedich-346	244	21	1·1	1·1	NUM
biomedich-346	244	22	to	to	ADP
biomedich-346	244	23	∞	∞	NUM
biomedich-346	244	24	)	)	PUNCT
biomedich-346	244	25	for	for	ADP
biomedich-346	244	26	bnt	bnt	PROPN
biomedich-346	244	27	/	/	SYM
biomedich-346	244	28	m1273	m1273	PROPN
biomedich-346	244	29	and	and	CCONJ
biomedich-346	244	30	0·5	0·5	NUM
biomedich-346	244	31	(	(	PUNCT
biomedich-346	244	32	0·4	0·4	NUM
biomedich-346	244	33	to	to	ADP
biomedich-346	244	34	∞	∞	NUM
biomedich-346	244	35	)	)	PUNCT
biomedich-346	244	36	for	for	ADP
biomedich-346	244	37	bnt	bnt	PROPN
biomedich-346	244	38	/	/	SYM
biomedich-346	244	39	nvx	nvx	PROPN
biomedich-346	244	40	,	,	PUNCT
biomedich-346	244	41	compared	compare	VERB
biomedich-346	244	42	with	with	ADP
biomedich-346	244	43	bnt	bnt	PROPN
biomedich-346	244	44	/	/	SYM
biomedich-346	244	45	bnt	bnt	PROPN
biomedich-346	244	46	;	;	PUNCT
biomedich-346	244	47	however	however	ADV
biomedich-346	244	48	,	,	PUNCT
biomedich-346	244	49	nvx	nvx	PROPN
biomedich-346	244	50	still	still	ADV
biomedich-346	244	51	induced	induce	VERB
biomedich-346	244	52	an	an	DET
biomedich-346	244	53	18	18	NUM
biomedich-346	244	54	-	-	ADJ
biomedich-346	244	55	fold	fold	ADJ
biomedich-346	244	56	rise	rise	NOUN
biomedich-346	244	57	in	in	ADP
biomedich-346	244	58	gmc	gmc	ADJ
biomedich-346	244	59	28	28	NUM
biomedich-346	244	60	days	day	NOUN
biomedich-346	244	61	after	after	ADP
biomedich-346	244	62	vaccination	vaccination	NOUN
biomedich-346	244	63	.	.	PUNCT
biomedich-346	245	1	there	there	PRON
biomedich-346	245	2	were	be	VERB
biomedich-346	245	3	15	15	NUM
biomedich-346	245	4	serious	serious	ADJ
biomedich-346	245	5	adverse	adverse	ADJ
biomedich-346	245	6	events	event	NOUN
biomedich-346	245	7	,	,	PUNCT
biomedich-346	245	8	none	none	NOUN
biomedich-346	245	9	considered	consider	VERB
biomedich-346	245	10	related	related	ADJ
biomedich-346	245	11	to	to	ADP
biomedich-346	245	12	immunization	immunization	NOUN
biomedich-346	245	13	.	.	PUNCT
biomedich-346	246	1	aldrich	aldrich	PROPN
biomedich-346	246	2	et	et	PROPN
biomedich-346	246	3	al	al	PROPN
biomedich-346	246	4	.	.	PUNCT
biomedich-346	247	1	proof	proof	NOUN
biomedich-346	247	2	-	-	PUNCT
biomedich-346	247	3	of	of	ADP
biomedich-346	247	4	-	-	PUNCT
biomedich-346	247	5	concept	concept	NOUN
biomedich-346	247	6	of	of	ADP
biomedich-346	247	7	a	a	DET
biomedich-346	247	8	low	low	ADV
biomedich-346	247	9	-	-	PUNCT
biomedich-346	247	10	dose	dose	NOUN
biomedich-346	247	11	unmodified	unmodified	ADJ
biomedich-346	247	12	mrna	mrna	PROPN
biomedich-346	247	13	-	-	PUNCT
biomedich-346	247	14	based	base	VERB
biomedich-346	247	15	rabies	rabie	NOUN
biomedich-346	247	16	vaccine	vaccine	NOUN
biomedich-346	247	17	formulated	formulate	VERB
biomedich-346	247	18	with	with	ADP
biomedich-346	247	19	lipid	lipid	ADJ
biomedich-346	247	20	nanoparticles	nanoparticle	NOUN
biomedich-346	247	21	in	in	ADP
biomedich-346	247	22	human	human	ADJ
biomedich-346	247	23	volunteers	volunteer	NOUN
biomedich-346	247	24	:	:	PUNCT
biomedich-346	247	25	a	a	DET
biomedich-346	247	26	phase	phase	NOUN
biomedich-346	247	27	1	1	NUM
biomedich-346	247	28	trial	trial	NOUN
biomedich-346	247	29	clinical	clinical	ADJ
biomedich-346	247	30	trial	trial	NOUN
biomedich-346	247	31	2021	2021	NUM
biomedich-346	247	32	in	in	ADP
biomedich-346	247	33	this	this	DET
biomedich-346	247	34	phase	phase	NOUN
biomedich-346	247	35	1	1	NUM
biomedich-346	247	36	,	,	PUNCT
biomedich-346	247	37	multi	multi	ADJ
biomedich-346	247	38	-	-	ADJ
biomedich-346	247	39	center	center	ADJ
biomedich-346	247	40	,	,	PUNCT
biomedich-346	247	41	controlled	control	VERB
biomedich-346	247	42	study	study	NOUN
biomedich-346	247	43	in	in	ADP
biomedich-346	247	44	belgium	belgium	PROPN
biomedich-346	247	45	and	and	CCONJ
biomedich-346	247	46	germany	germany	PROPN
biomedich-346	247	47	we	we	PRON
biomedich-346	247	48	enrolled	enrol	VERB
biomedich-346	247	49	55	55	NUM
biomedich-346	247	50	healthy	healthy	ADJ
biomedich-346	247	51	18	18	NUM
biomedich-346	247	52	-	-	SYM
biomedich-346	247	53	40	40	NUM
biomedich-346	247	54	-	-	PUNCT
biomedich-346	247	55	year	year	NOUN
biomedich-346	247	56	-	-	PUNCT
biomedich-346	247	57	olds	old	NOUN
biomedich-346	247	58	to	to	PART
biomedich-346	247	59	receive	receive	VERB
biomedich-346	247	60	intramuscular	intramuscular	ADJ
biomedich-346	247	61	injections	injection	NOUN
biomedich-346	247	62	of	of	ADP
biomedich-346	247	63	5	5	NUM
biomedich-346	247	64	μg	μg	NOUN
biomedich-346	247	65	(	(	PUNCT
biomedich-346	247	66	n	n	NOUN
biomedich-346	247	67	=	=	NUM
biomedich-346	247	68	10	10	NUM
biomedich-346	247	69	)	)	PUNCT
biomedich-346	247	70	,	,	PUNCT
biomedich-346	247	71	1	1	NUM
biomedich-346	247	72	μg	μg	X
biomedich-346	247	73	(	(	PUNCT
biomedich-346	247	74	n	n	NOUN
biomedich-346	247	75	=	=	SYM
biomedich-346	247	76	16	16	NUM
biomedich-346	247	77	)	)	PUNCT
biomedich-346	247	78	,	,	PUNCT
biomedich-346	247	79	or	or	CCONJ
biomedich-346	247	80	2	2	NUM
biomedich-346	247	81	μg	μg	NOUN
biomedich-346	247	82	(	(	PUNCT
biomedich-346	247	83	n	n	NOUN
biomedich-346	247	84	=	=	SYM
biomedich-346	247	85	16	16	NUM
biomedich-346	247	86	)	)	PUNCT
biomedich-346	247	87	cv7202	cv7202	NOUN
biomedich-346	247	88	on	on	ADP
biomedich-346	247	89	day	day	NOUN
biomedich-346	247	90	1	1	NUM
biomedich-346	247	91	;	;	PUNCT
biomedich-346	247	92	subsets	subset	NOUN
biomedich-346	247	93	(	(	PUNCT
biomedich-346	247	94	n	n	NOUN
biomedich-346	247	95	=	=	SYM
biomedich-346	247	96	8)	8)	NUM
biomedich-346	247	97	of	of	ADP
biomedich-346	247	98	1	1	NUM
biomedich-346	247	99	μg	μg	PROPN
biomedich-346	247	100	an	an	DET
biomedich-346	247	101	nd	nd	NOUN
biomedich-346	247	102	2	2	NUM
biomedich-346	247	103	μg	μg	NOUN
biomedich-346	247	104	groups	group	NOUN
biomedich-346	247	105	received	receive	VERB
biomedich-346	247	106	second	second	ADJ
biomedich-346	247	107	doses	dose	NOUN
biomedich-346	247	108	on	on	ADP
biomedich-346	247	109	day	day	NOUN
biomedich-346	247	110	29	29	NUM
biomedich-346	247	111	.	.	PUNCT
biomedich-346	248	1	controls	control	NOUN
biomedich-346	248	2	(	(	PUNCT
biomedich-346	248	3	n	n	NOUN
biomedich-346	248	4	=	=	SYM
biomedich-346	248	5	10	10	NUM
biomedich-346	248	6	)	)	PUNCT
biomedich-346	248	7	received	receive	VERB
biomedich-346	248	8	the	the	DET
biomedich-346	248	9	rabies	rabie	NOUN
biomedich-346	248	10	vaccine	vaccine	NOUN
biomedich-346	248	11	,	,	PUNCT
biomedich-346	248	12	rabipur	rabipur	ADJ
biomedich-346	248	13	,	,	PUNCT
biomedich-346	248	14	on	on	ADP
biomedich-346	248	15	days	day	NOUN
biomedich-346	248	16	1	1	NUM
biomedich-346	248	17	,	,	PUNCT
biomedich-346	248	18	8	8	NUM
biomedich-346	248	19	,	,	PUNCT
biomedich-346	248	20	and	and	CCONJ
biomedich-346	248	21	29	29	NUM
biomedich-346	248	22	.	.	PUNCT
biomedich-346	249	1	safety	safety	NOUN
biomedich-346	249	2	and	and	CCONJ
biomedich-346	249	3	reactogenicity	reactogenicity	NOUN
biomedich-346	249	4	were	be	AUX
biomedich-346	249	5	assessed	assess	VERB
biomedich-346	249	6	up	up	ADP
biomedich-346	249	7	to	to	PART
biomedich-346	249	8	28	28	NUM
biomedich-346	249	9	days	day	NOUN
biomedich-346	249	10	postvaccination	postvaccination	NOUN
biomedich-346	249	11	using	use	VERB
biomedich-346	249	12	diary	diary	ADJ
biomedich-346	249	13	cards	card	NOUN
biomedich-346	249	14	;	;	PUNCT
biomedich-346	249	15	immunogenicity	immunogenicity	NOUN
biomedich-346	249	16	was	be	AUX
biomedich-346	249	17	measured	measure	VERB
biomedich-346	249	18	as	as	ADP
biomedich-346	249	19	rabv	rabv	NOUN
biomedich-346	249	20	-	-	PUNCT
biomedich-346	249	21	g	g	NOUN
biomedich-346	249	22	-	-	PUNCT
biomedich-346	249	23	specific	specific	ADJ
biomedich-346	249	24	neutralizing	neutralize	VERB
biomedich-346	249	25	titers	titer	NOUN
biomedich-346	249	26	(	(	PUNCT
biomedich-346	249	27	vnt	vnt	PROPN
biomedich-346	249	28	)	)	PUNCT
biomedich-346	249	29	by	by	ADP
biomedich-346	249	30	rffit	rffit	NOUN
biomedich-346	249	31	and	and	CCONJ
biomedich-346	249	32	igg	igg	PROPN
biomedich-346	249	33	by	by	ADP
biomedich-346	249	34	elisa	elisa	PROPN
biomedich-346	249	35	.	.	PUNCT
biomedich-346	250	1	as	as	ADP
biomedich-346	250	2	initially	initially	ADV
biomedich-346	250	3	tested	test	VERB
biomedich-346	250	4	doses	dose	NOUN
biomedich-346	250	5	of	of	ADP
biomedich-346	250	6	5	5	NUM
biomedich-346	250	7	μg	μg	NOUN
biomedich-346	250	8	cv7202	cv7202	PROPN
biomedich-346	250	9	elicited	elicit	VERB
biomedich-346	250	10	unacceptably	unacceptably	ADV
biomedich-346	250	11	high	high	ADJ
biomedich-346	250	12	reactogenicity	reactogenicity	NOUN
biomedich-346	250	13	we	we	PRON
biomedich-346	250	14	subsequently	subsequently	ADV
biomedich-346	250	15	tested	test	VERB
biomedich-346	250	16	1	1	NUM
biomedich-346	250	17	and	and	CCONJ
biomedich-346	250	18	2	2	NUM
biomedich-346	250	19	μg	μg	PROPN
biomedich-346	250	20	doses	dose	NOUN
biomedich-346	250	21	which	which	PRON
biomedich-346	250	22	were	be	AUX
biomedich-346	250	23	better	well	ADV
biomedich-346	250	24	tolerated	tolerate	VERB
biomedich-346	250	25	.	.	PUNCT
biomedich-346	251	1	no	no	DET
biomedich-346	251	2	vaccine	vaccine	NOUN
biomedich-346	251	3	-	-	PUNCT
biomedich-346	251	4	related	relate	VERB
biomedich-346	251	5	serious	serious	ADJ
biomedich-346	251	6	adverse	adverse	ADJ
biomedich-346	251	7	events	event	NOUN
biomedich-346	251	8	or	or	CCONJ
biomedich-346	251	9	withdrawals	withdrawal	NOUN
biomedich-346	251	10	occurred	occur	VERB
biomedich-346	251	11	.	.	PUNCT
biomedich-346	252	1	low	low	ADJ
biomedich-346	252	2	,	,	PUNCT
biomedich-346	252	3	dose	dose	NOUN
biomedich-346	252	4	-	-	PUNCT
biomedich-346	252	5	dependent	dependent	ADJ
biomedich-346	252	6	vnt	vnt	PROPN
biomedich-346	252	7	responses	response	NOUN
biomedich-346	252	8	were	be	AUX
biomedich-346	252	9	detectable	detectable	ADJ
biomedich-346	252	10	from	from	ADP
biomedich-346	252	11	day	day	NOUN
biomedich-346	252	12	15	15	NUM
biomedich-346	252	13	,	,	PUNCT
biomedich-346	252	14	and	and	CCONJ
biomedich-346	252	15	by	by	ADP
biomedich-346	252	16	day	day	NOUN
biomedich-346	252	17	29	29	NUM
biomedich-346	252	18	%	%	NOUN
biomedich-346	252	19	,	,	PUNCT
biomedich-346	252	20	31	31	NUM
biomedich-346	252	21	%	%	NOUN
biomedich-346	252	22	,	,	PUNCT
biomedich-346	252	23	and	and	CCONJ
biomedich-346	252	24	22	22	NUM
biomedich-346	252	25	%	%	NOUN
biomedich-346	252	26	of	of	ADP
biomedich-346	252	27	1	1	NUM
biomedich-346	252	28	,	,	PUNCT
biomedich-346	252	29	2	2	NUM
biomedich-346	252	30	and	and	CCONJ
biomedich-346	252	31	5	5	NUM
biomedich-346	252	32	μg	μg	PROPN
biomedich-346	252	33	groups	group	NOUN
biomedich-346	252	34	,	,	PUNCT
biomedich-346	252	35	respectively	respectively	ADV
biomedich-346	252	36	,	,	PUNCT
biomedich-346	252	37	had	have	AUX
biomedich-346	252	38	vnts	vnt	NOUN
biomedich-346	252	39	≥	≥	PRON
biomedich-346	252	40	0·5	0·5	NUM
biomedich-346	252	41	iu	iu	ADP
biomedich-346	252	42	/	/	SYM
biomedich-346	252	43	ml	ml	NOUN
biomedich-346	252	44	,	,	PUNCT
biomedich-346	252	45	considered	consider	VERB
biomedich-346	252	46	an	an	DET
biomedich-346	252	47	adequate	adequate	ADJ
biomedich-346	252	48	response	response	NOUN
biomedich-346	252	49	by	by	ADP
biomedich-346	252	50	the	the	DET
biomedich-346	252	51	who	who	PRON
biomedich-346	252	52	.	.	PUNCT
biomedich-346	253	1	after	after	ADP
biomedich-346	253	2	two	two	NUM
biomedich-346	253	3	1	1	NUM
biomedich-346	253	4	or	or	CCONJ
biomedich-346	253	5	2	2	NUM
biomedich-346	253	6	μg	μg	NOUN
biomedich-346	253	7	doses	dose	NOUN
biomedich-346	253	8	all	all	DET
biomedich-346	253	9	recipients	recipient	NOUN
biomedich-346	253	10	had	have	VERB
biomedich-346	253	11	titers	titer	NOUN
biomedich-346	253	12	≥	≥	NUM
biomedich-346	253	13	0.5	0.5	NUM
biomedich-346	253	14	iu	iu	NOUN
biomedich-346	253	15	/	/	SYM
biomedich-346	253	16	ml	ml	VERB
biomedich-346	253	17	by	by	ADP
biomedich-346	253	18	day	day	NOUN
biomedich-346	253	19	43	43	NUM
biomedich-346	253	20	.	.	PUNCT
biomedich-346	254	1	day	day	NOUN
biomedich-346	254	2	57	57	NUM
biomedich-346	254	3	gmts	gmts	NOUN
biomedich-346	254	4	were	be	AUX
biomedich-346	254	5	not	not	PART
biomedich-346	254	6	significantly	significantly	ADV
biomedich-346	254	7	lower	low	ADJ
biomedich-346	254	8	than	than	ADP
biomedich-346	254	9	those	those	PRON
biomedich-346	254	10	with	with	ADP
biomedich-346	254	11	rabipur	rabipur	NOUN
biomedich-346	254	12	,	,	PUNCT
biomedich-346	254	13	which	which	PRON
biomedich-346	254	14	elicited	elicit	VERB
biomedich-346	254	15	adequate	adequate	ADJ
biomedich-346	254	16	responses	response	NOUN
biomedich-346	254	17	in	in	ADP
biomedich-346	254	18	all	all	DET
biomedich-346	254	19	vaccinees	vaccinee	NOUN
biomedich-346	254	20	after	after	ADP
biomedich-346	254	21	two	two	NUM
biomedich-346	254	22	doses	dose	NOUN
biomedich-346	254	23	.	.	PUNCT
biomedich-346	255	1	cv7202	cv7202	PROPN
biomedich-346	255	2	-	-	PUNCT
biomedich-346	255	3	elicited	elicit	VERB
biomedich-346	255	4	vnt	vnt	PROPN
biomedich-346	255	5	was	be	AUX
biomedich-346	255	6	significantly	significantly	ADV
biomedich-346	255	7	correlated	correlate	VERB
biomedich-346	255	8	with	with	ADP
biomedich-346	255	9	rabv	rabv	VERB
biomedich-346	255	10	-	-	PUNCT
biomedich-346	255	11	g	g	NOUN
biomedich-346	255	12	-	-	PUNCT
biomedich-346	255	13	specific	specific	ADJ
biomedich-346	255	14	igg	igg	NOUN
biomedich-346	255	15	antibodies	antibodie	VERB
biomedich-346	255	16	(	(	PUNCT
biomedich-346	255	17	r2	r2	PROPN
biomedich-346	255	18	=	=	SYM
biomedich-346	255	19	0.8319	0.8319	NUM
biomedich-346	255	20	,	,	PUNCT
biomedich-346	255	21	p	p	X
biomedich-346	255	22	<	<	X
biomedich-346	255	23	0.0001	0.0001	NUM
biomedich-346	255	24	)	)	PUNCT
biomedich-346	255	25	.	.	PUNCT
biomedich-346	256	1	shinde	shinde	PROPN
biomedich-346	256	2	et	et	PROPN
biomedich-346	256	3	al	al	PROPN
biomedich-346	256	4	.	.	PROPN
biomedich-346	256	5	comparison	comparison	NOUN
biomedich-346	256	6	of	of	ADP
biomedich-346	256	7	the	the	DET
biomedich-346	256	8	safety	safety	NOUN
biomedich-346	256	9	and	and	CCONJ
biomedich-346	256	10	immunogenicity	immunogenicity	NOUN
biomedich-346	256	11	of	of	ADP
biomedich-346	256	12	a	a	DET
biomedich-346	256	13	novel	novel	ADJ
biomedich-346	256	14	matrix	matrix	NOUN
biomedich-346	256	15	-	-	PUNCT
biomedich-346	256	16	madjuvanted	madjuvante	VERB
biomedich-346	256	17	nanoparticle	nanoparticle	NOUN
biomedich-346	256	18	influenza	influenza	NOUN
biomedich-346	256	19	vaccine	vaccine	NOUN
biomedich-346	256	20	with	with	ADP
biomedich-346	256	21	a	a	DET
biomedich-346	256	22	quadrivalent	quadrivalent	ADJ
biomedich-346	256	23	seasonal	seasonal	ADJ
biomedich-346	256	24	influenza	influenza	NOUN
biomedich-346	256	25	vaccine	vaccine	NOUN
biomedich-346	256	26	in	in	ADP
biomedich-346	256	27	older	old	ADJ
biomedich-346	256	28	adults	adult	NOUN
biomedich-346	256	29	:	:	PUNCT
biomedich-346	256	30	a	a	DET
biomedich-346	256	31	phase	phase	NOUN
biomedich-346	256	32	3	3	NUM
biomedich-346	256	33	randomized	randomize	VERB
biomedich-346	256	34	controlled	control	VERB
biomedich-346	256	35	trial	trial	NOUN
biomedich-346	256	36	clinical	clinical	ADJ
biomedich-346	256	37	trial	trial	NOUN
biomedich-346	256	38	2022	2022	NUM
biomedich-346	256	39	this	this	PRON
biomedich-346	256	40	was	be	AUX
biomedich-346	256	41	phase	phase	NOUN
biomedich-346	256	42	3	3	NUM
biomedich-346	256	43	randomized	randomize	VERB
biomedich-346	256	44	,	,	PUNCT
biomedich-346	256	45	observer	observer	NOUN
biomedich-346	256	46	-	-	PUNCT
biomedich-346	256	47	blinded	blinded	ADJ
biomedich-346	256	48	,	,	PUNCT
biomedich-346	256	49	activecomparator	activecomparator	PROPN
biomedich-346	256	50	controlled	control	VERB
biomedich-346	256	51	trial	trial	NOUN
biomedich-346	256	52	done	do	VERB
biomedich-346	256	53	across	across	ADP
biomedich-346	256	54	19	19	NUM
biomedich-346	256	55	us	us	PROPN
biomedich-346	256	56	community	community	NOUN
biomedich-346	256	57	-	-	PUNCT
biomedich-346	256	58	based	base	VERB
biomedich-346	256	59	clinical	clinical	ADJ
biomedich-346	256	60	research	research	NOUN
biomedich-346	256	61	sites	site	NOUN
biomedich-346	256	62	during	during	ADP
biomedich-346	256	63	the	the	DET
biomedich-346	256	64	2019	2019	NUM
biomedich-346	256	65	-	-	SYM
biomedich-346	256	66	20	20	NUM
biomedich-346	256	67	influenza	influenza	NOUN
biomedich-346	256	68	season	season	NOUN
biomedich-346	256	69	.	.	PUNCT
biomedich-346	257	1	participants	participant	NOUN
biomedich-346	257	2	were	be	AUX
biomedich-346	257	3	clinically	clinically	ADV
biomedich-346	257	4	stable	stable	ADJ
biomedich-346	257	5	and	and	CCONJ
biomedich-346	257	6	community	community	NOUN
biomedich-346	257	7	-	-	PUNCT
biomedich-346	257	8	dwelling	dwelling	NOUN
biomedich-346	257	9	,	,	PUNCT
biomedich-346	257	10	aged	age	VERB
biomedich-346	257	11	at	at	ADP
biomedich-346	257	12	least	least	ADV
biomedich-346	257	13	65	65	NUM
biomedich-346	257	14	years	year	NOUN
biomedich-346	257	15	and	and	CCONJ
biomedich-346	257	16	were	be	AUX
biomedich-346	257	17	randomisedin	randomisedin	VERB
biomedich-346	257	18	a	a	DET
biomedich-346	257	19	1:1	1:1	NUM
biomedich-346	257	20	ratio	ratio	NOUN
biomedich-346	257	21	using	use	VERB
biomedich-346	257	22	an	an	DET
biomedich-346	257	23	interactive	interactive	ADJ
biomedich-346	257	24	web	web	NOUN
biomedich-346	257	25	response	response	NOUN
biomedich-346	257	26	system	system	NOUN
biomedich-346	257	27	to	to	PART
biomedich-346	257	28	receive	receive	VERB
biomedich-346	257	29	a	a	DET
biomedich-346	257	30	single	single	ADJ
biomedich-346	257	31	intramuscular	intramuscular	ADJ
biomedich-346	257	32	dose	dose	NOUN
biomedich-346	257	33	of	of	ADP
biomedich-346	257	34	qniv	qniv	PROPN
biomedich-346	257	35	or	or	CCONJ
biomedich-346	257	36	iiv4	iiv4	NOUN
biomedich-346	257	37	.	.	PUNCT
biomedich-346	258	1	the	the	DET
biomedich-346	258	2	primary	primary	ADJ
biomedich-346	258	3	objective	objective	NOUN
biomedich-346	258	4	was	be	AUX
biomedich-346	258	5	more	more	ADV
biomedich-346	258	6	solicited	solicited	ADJ
biomedich-346	258	7	adverse	adverse	ADJ
biomedich-346	258	8	events	event	NOUN
biomedich-346	258	9	were	be	AUX
biomedich-346	258	10	reported	report	VERB
biomedich-346	258	11	by	by	ADP
biomedich-346	258	12	participants	participant	NOUN
biomedich-346	258	13	in	in	ADP
biomedich-346	258	14	the	the	DET
biomedich-346	258	15	qniv	qniv	ADJ
biomedich-346	258	16	group	group	NOUN
biomedich-346	258	17	(	(	PUNCT
biomedich-346	258	18	551	551	NUM
biomedich-346	258	19	[	[	X
biomedich-346	258	20	41·3	41·3	NUM
biomedich-346	258	21	%	%	NOUN
biomedich-346	258	22	]	]	PUNCT
biomedich-346	258	23	of	of	ADP
biomedich-346	258	24	1333	1333	NUM
biomedich-346	258	25	)	)	PUNCT
biomedich-346	258	26	than	than	ADP
biomedich-346	258	27	in	in	ADP
biomedich-346	258	28	the	the	DET
biomedich-346	258	29	iiv4	iiv4	PROPN
biomedich-346	258	30	group	group	NOUN
biomedich-346	258	31	(	(	PUNCT
biomedich-346	258	32	420	420	NUM
biomedich-346	258	33	[	[	X
biomedich-346	258	34	31·8	31·8	NUM
biomedich-346	258	35	%	%	NOUN
biomedich-346	258	36	]	]	PUNCT
biomedich-346	258	37	of	of	ADP
biomedich-346	258	38	1319	1319	NUM
biomedich-346	258	39	)	)	PUNCT
biomedich-346	258	40	,	,	PUNCT
biomedich-346	258	41	and	and	CCONJ
biomedich-346	258	42	were	be	AUX
biomedich-346	258	43	comprised	comprise	VERB
biomedich-346	258	44	primarily	primarily	ADV
biomedich-346	258	45	of	of	ADP
biomedich-346	258	46	mild	mild	ADJ
biomedich-346	258	47	to	to	ADP
biomedich-346	258	48	moderate	moderate	ADJ
biomedich-346	258	49	transient	transient	ADJ
biomedich-346	258	50	injection	injection	NOUN
biomedich-346	258	51	site	site	NOUN
biomedich-346	258	52	pain	pain	NOUN
biomedich-346	258	53	(	(	PUNCT
biomedich-346	258	54	341	341	NUM
biomedich-346	258	55	[	[	X
biomedich-346	258	56	25·6	25·6	NUM
biomedich-346	258	57	%	%	NOUN
biomedich-346	258	58	]	]	PUNCT
biomedich-346	258	59	in	in	ADP
biomedich-346	258	60	the	the	DET
biomedich-346	258	61	qniv	qniv	ADJ
biomedich-346	258	62	group	group	NOUN
biomedich-346	258	63	vs	vs	ADP
biomedich-346	258	64	212	212	NUM
biomedich-346	258	65	[	[	X
biomedich-346	258	66	16·1	16·1	NUM
biomedich-346	258	67	%	%	NOUN
biomedich-346	258	68	]	]	PUNCT
biomedich-346	258	69	in	in	ADP
biomedich-346	258	70	the	the	DET
biomedich-346	258	71	iiv4	iiv4	PROPN
biomedich-346	258	72	group	group	NOUN
biomedich-346	258	73	)	)	PUNCT
biomedich-346	258	74	.	.	PUNCT
biomedich-346	259	1	354	354	NUM
biomedich-346	259	2	biology	biology	NOUN
biomedich-346	259	3	,	,	PUNCT
biomedich-346	259	4	medicine	medicine	NOUN
biomedich-346	259	5	,	,	PUNCT
biomedich-346	259	6	&	&	CCONJ
biomedich-346	259	7	natural	natural	ADJ
biomedich-346	259	8	product	product	NOUN
biomedich-346	259	9	chemistry	chemistry	NOUN
biomedich-346	259	10	12	12	NUM
biomedich-346	259	11	(	(	PUNCT
biomedich-346	259	12	1	1	NUM
biomedich-346	259	13	)	)	PUNCT
biomedich-346	259	14	,	,	PUNCT
biomedich-346	259	15	2023	2023	NUM
biomedich-346	259	16	:	:	PUNCT
biomedich-346	259	17	343	343	NUM
biomedich-346	259	18	-	-	SYM
biomedich-346	259	19	361	361	NUM
biomedich-346	259	20	authors	author	NOUN
biomedich-346	259	21	title	title	NOUN
biomedich-346	259	22	date	date	NOUN
biomedich-346	259	23	and	and	CCONJ
biomedich-346	259	24	type	type	NOUN
biomedich-346	259	25	of	of	ADP
biomedich-346	259	26	the	the	DET
biomedich-346	259	27	study	study	NOUN
biomedich-346	259	28	method	method	NOUN
biomedich-346	259	29	results	result	NOUN
biomedich-346	259	30	to	to	PART
biomedich-346	259	31	describe	describe	VERB
biomedich-346	259	32	the	the	DET
biomedich-346	259	33	safety	safety	NOUN
biomedich-346	259	34	and	and	CCONJ
biomedich-346	259	35	show	show	VERB
biomedich-346	259	36	that	that	SCONJ
biomedich-346	259	37	qniv	qniv	PROPN
biomedich-346	259	38	was	be	AUX
biomedich-346	259	39	immunologically	immunologically	ADV
biomedich-346	259	40	non	non	ADJ
biomedich-346	259	41	-	-	ADJ
biomedich-346	259	42	inferior	inferior	ADJ
biomedich-346	259	43	to	to	ADP
biomedich-346	259	44	iiv4	iiv4	PROPN
biomedich-346	259	45	.	.	PUNCT
biomedich-346	260	1	the	the	DET
biomedich-346	260	2	primary	primary	ADJ
biomedich-346	260	3	outcomes	outcome	NOUN
biomedich-346	260	4	were	be	AUX
biomedich-346	260	5	adverse	adverse	ADJ
biomedich-346	260	6	events	event	NOUN
biomedich-346	260	7	by	by	ADP
biomedich-346	260	8	treatment	treatment	NOUN
biomedich-346	260	9	group	group	NOUN
biomedich-346	260	10	and	and	CCONJ
biomedich-346	260	11	comparative	comparative	ADJ
biomedich-346	260	12	haemagglutinationinhibiting	haemagglutinationinhibiting	NOUN
biomedich-346	260	13	antibody	antibody	NOUN
biomedich-346	260	14	responses	response	NOUN
biomedich-346	260	15	(	(	PUNCT
biomedich-346	260	16	assayed	assayed	ADJ
biomedich-346	260	17	with	with	ADP
biomedich-346	260	18	egg	egg	NOUN
biomedich-346	260	19	-	-	PUNCT
biomedich-346	260	20	propagated	propagate	VERB
biomedich-346	260	21	virus	virus	NOUN
biomedich-346	260	22	)	)	PUNCT
biomedich-346	260	23	on	on	ADP
biomedich-346	260	24	day	day	NOUN
biomedich-346	260	25	28	28	NUM
biomedich-346	260	26	,	,	PUNCT
biomedich-346	260	27	summarised	summarise	VERB
biomedich-346	260	28	in	in	ADP
biomedich-346	260	29	terms	term	NOUN
biomedich-346	260	30	of	of	ADP
biomedich-346	260	31	the	the	DET
biomedich-346	260	32	ratio	ratio	NOUN
biomedich-346	260	33	of	of	ADP
biomedich-346	260	34	geometric	geometric	ADJ
biomedich-346	260	35	mean	mean	NOUN
biomedich-346	260	36	titres	titre	NOUN
biomedich-346	260	37	(	(	PUNCT
biomedich-346	260	38	gmtrqniv	gmtrqniv	NOUN
biomedich-346	260	39	/	/	SYM
biomedich-346	260	40	iiv4	iiv4	PROPN
biomedich-346	260	41	)	)	PUNCT
biomedich-346	260	42	and	and	CCONJ
biomedich-346	260	43	seroconversion	seroconversion	NOUN
biomedich-346	260	44	rate	rate	NOUN
biomedich-346	260	45	(	(	PUNCT
biomedich-346	260	46	scr	scr	NOUN
biomedich-346	260	47	)	)	PUNCT
biomedich-346	260	48	difference	difference	NOUN
biomedich-346	260	49	between	between	ADP
biomedich-346	260	50	participants	participant	NOUN
biomedich-346	260	51	receiving	receive	VERB
biomedich-346	260	52	qniv	qniv	NOUN
biomedich-346	260	53	or	or	CCONJ
biomedich-346	260	54	iiv4	iiv4	NOUN
biomedich-346	260	55	for	for	ADP
biomedich-346	260	56	all	all	DET
biomedich-346	260	57	four	four	NUM
biomedich-346	260	58	vaccine	vaccine	NOUN
biomedich-346	260	59	homologous	homologous	ADJ
biomedich-346	260	60	influenza	influenza	NOUN
biomedich-346	260	61	strains	strain	VERB
biomedich-346	260	62	.	.	PUNCT
biomedich-346	261	1	the	the	DET
biomedich-346	261	2	immunogenicity	immunogenicity	NOUN
biomedich-346	261	3	outcome	outcome	NOUN
biomedich-346	261	4	was	be	AUX
biomedich-346	261	5	measured	measure	VERB
biomedich-346	261	6	in	in	ADP
biomedich-346	261	7	the	the	DET
biomedich-346	261	8	per	per	ADP
biomedich-346	261	9	-	-	PUNCT
biomedich-346	261	10	protocol	protocol	NOUN
biomedich-346	261	11	population	population	NOUN
biomedich-346	261	12	.	.	PUNCT
biomedich-346	262	1	non	non	ADJ
biomedich-346	262	2	-	-	ADJ
biomedich-346	262	3	inferiority	inferiority	NOUN
biomedich-346	262	4	was	be	AUX
biomedich-346	262	5	shown	show	VERB
biomedich-346	262	6	if	if	SCONJ
biomedich-346	262	7	the	the	DET
biomedich-346	262	8	lower	low	ADJ
biomedich-346	262	9	bound	bind	VERB
biomedich-346	262	10	of	of	ADP
biomedich-346	262	11	the	the	DET
biomedich-346	262	12	two	two	NUM
biomedich-346	262	13	-	-	PUNCT
biomedich-346	262	14	sided	sided	ADJ
biomedich-346	262	15	95	95	NUM
biomedich-346	262	16	%	%	NOUN
biomedich-346	262	17	ci	ci	NOUN
biomedich-346	262	18	on	on	ADP
biomedich-346	262	19	the	the	DET
biomedich-346	262	20	gmtrqniv	gmtrqniv	NOUN
biomedich-346	262	21	/	/	SYM
biomedich-346	262	22	iiv4	iiv4	PROPN
biomedich-346	262	23	was	be	AUX
biomedich-346	262	24	at	at	ADV
biomedich-346	262	25	least	least	ADJ
biomedich-346	262	26	0·67	0·67	NOUN
biomedich-346	262	27	and	and	CCONJ
biomedich-346	262	28	the	the	DET
biomedich-346	262	29	lower	lower	ADV
biomedich-346	262	30	bound	bind	VERB
biomedich-346	262	31	of	of	ADP
biomedich-346	262	32	the	the	DET
biomedich-346	262	33	two	two	NUM
biomedich-346	262	34	-	-	PUNCT
biomedich-346	262	35	sided	sided	ADJ
biomedich-346	262	36	95	95	NUM
biomedich-346	262	37	%	%	NOUN
biomedich-346	262	38	ci	ci	NOUN
biomedich-346	262	39	on	on	ADP
biomedich-346	262	40	the	the	DET
biomedich-346	262	41	scr	scr	NOUN
biomedich-346	262	42	difference	difference	NOUN
biomedich-346	262	43	-was	-wa	VERB
biomedich-346	262	44	at	at	ADV
biomedich-346	262	45	least	least	ADJ
biomedich-346	262	46	-10	-10	NUM
biomedich-346	262	47	%	%	NOUN
biomedich-346	262	48	.	.	PUNCT
biomedich-346	263	1	formica	formica	NOUN
biomedich-346	263	2	et	et	PROPN
biomedich-346	263	3	al	al	PROPN
biomedich-346	263	4	.	.	PUNCT
biomedich-346	264	1	different	different	ADJ
biomedich-346	264	2	dose	dose	NOUN
biomedich-346	264	3	regimens	regimen	NOUN
biomedich-346	264	4	of	of	ADP
biomedich-346	264	5	a	a	DET
biomedich-346	264	6	sarscov-2	sarscov-2	NUM
biomedich-346	264	7	recombinant	recombinant	ADJ
biomedich-346	264	8	spike	spike	ADJ
biomedich-346	264	9	protein	protein	NOUN
biomedich-346	264	10	vaccine	vaccine	NOUN
biomedich-346	264	11	(	(	PUNCT
biomedich-346	264	12	nvx	nvx	NOUN
biomedich-346	264	13	-	-	PUNCT
biomedich-346	264	14	cov2373	cov2373	NOUN
biomedich-346	264	15	)	)	PUNCT
biomedich-346	264	16	in	in	ADP
biomedich-346	264	17	younger	young	ADJ
biomedich-346	264	18	and	and	CCONJ
biomedich-346	264	19	older	old	ADJ
biomedich-346	264	20	adults	adult	NOUN
biomedich-346	264	21	:	:	PUNCT
biomedich-346	264	22	a	a	DET
biomedich-346	264	23	phase	phase	NOUN
biomedich-346	264	24	2	2	NUM
biomedich-346	264	25	randomized	randomize	VERB
biomedich-346	264	26	placebocontrolled	placebocontrolle	VERB
biomedich-346	264	27	trial	trial	NOUN
biomedich-346	264	28	clinical	clinical	ADJ
biomedich-346	264	29	trial	trial	NOUN
biomedich-346	264	30	2021	2021	NUM
biomedich-346	264	31	the	the	DET
biomedich-346	264	32	phase	phase	NOUN
biomedich-346	264	33	2	2	NUM
biomedich-346	264	34	component	component	NOUN
biomedich-346	264	35	of	of	ADP
biomedich-346	264	36	our	our	PRON
biomedich-346	264	37	randomized	randomized	ADJ
biomedich-346	264	38	,	,	PUNCT
biomedich-346	264	39	placebo	placebo	NOUN
biomedich-346	264	40	-	-	PUNCT
biomedich-346	264	41	controlled	control	VERB
biomedich-346	264	42	,	,	PUNCT
biomedich-346	264	43	phase	phase	NOUN
biomedich-346	264	44	1	1	NUM
biomedich-346	264	45	to	to	PART
biomedich-346	264	46	2	2	NUM
biomedich-346	264	47	trial	trial	NOUN
biomedich-346	264	48	was	be	AUX
biomedich-346	264	49	designed	design	VERB
biomedich-346	264	50	to	to	PART
biomedich-346	264	51	identify	identify	VERB
biomedich-346	264	52	which	which	PRON
biomedich-346	264	53	dosing	dose	VERB
biomedich-346	264	54	regimen	regiman	NOUN
biomedich-346	264	55	of	of	ADP
biomedich-346	264	56	nvx	nvx	NOUN
biomedich-346	264	57	-	-	PUNCT
biomedich-346	264	58	cov2373	cov2373	NOUN
biomedich-346	264	59	should	should	AUX
biomedich-346	264	60	move	move	VERB
biomedich-346	264	61	forward	forward	ADV
biomedich-346	264	62	into	into	ADP
biomedich-346	264	63	latephase	latephase	ADJ
biomedich-346	264	64	studies	study	NOUN
biomedich-346	264	65	and	and	CCONJ
biomedich-346	264	66	was	be	AUX
biomedich-346	264	67	based	base	VERB
biomedich-346	264	68	on	on	ADP
biomedich-346	264	69	immunogenicity	immunogenicity	NOUN
biomedich-346	264	70	and	and	CCONJ
biomedich-346	264	71	safety	safety	NOUN
biomedich-346	264	72	data	datum	NOUN
biomedich-346	264	73	through	through	ADP
biomedich-346	264	74	day	day	NOUN
biomedich-346	264	75	35	35	NUM
biomedich-346	264	76	(	(	PUNCT
biomedich-346	264	77	14	14	NUM
biomedich-346	264	78	days	day	NOUN
biomedich-346	264	79	after	after	ADP
biomedich-346	264	80	the	the	DET
biomedich-346	264	81	second	second	ADJ
biomedich-346	264	82	dose	dose	NOUN
biomedich-346	264	83	)	)	PUNCT
biomedich-346	264	84	.	.	PUNCT
biomedich-346	265	1	the	the	DET
biomedich-346	265	2	trial	trial	NOUN
biomedich-346	265	3	was	be	AUX
biomedich-346	265	4	conducted	conduct	VERB
biomedich-346	265	5	at	at	ADP
biomedich-346	265	6	9	9	NUM
biomedich-346	265	7	sites	site	NOUN
biomedich-346	265	8	in	in	ADP
biomedich-346	265	9	australia	australia	PROPN
biomedich-346	265	10	and	and	CCONJ
biomedich-346	265	11	8	8	NUM
biomedich-346	265	12	sites	site	NOUN
biomedich-346	265	13	in	in	ADP
biomedich-346	265	14	the	the	DET
biomedich-346	265	15	united	united	PROPN
biomedich-346	265	16	states	states	PROPN
biomedich-346	265	17	.	.	PUNCT
biomedich-346	266	1	participants	participant	NOUN
biomedich-346	266	2	in	in	ADP
biomedich-346	266	3	2	2	NUM
biomedich-346	266	4	age	age	NOUN
biomedich-346	266	5	groups	group	NOUN
biomedich-346	266	6	(	(	PUNCT
biomedich-346	266	7	aged	aged	ADJ
biomedich-346	266	8	18	18	NUM
biomedich-346	266	9	to	to	ADP
biomedich-346	266	10	59	59	NUM
biomedich-346	266	11	and	and	CCONJ
biomedich-346	266	12	60	60	NUM
biomedich-346	266	13	to	to	PART
biomedich-346	266	14	84	84	NUM
biomedich-346	266	15	years	year	NOUN
biomedich-346	266	16	)	)	PUNCT
biomedich-346	266	17	were	be	AUX
biomedich-346	266	18	randomly	randomly	ADV
biomedich-346	266	19	assigned	assign	VERB
biomedich-346	266	20	to	to	PART
biomedich-346	266	21	receive	receive	VERB
biomedich-346	266	22	either	either	PRON
biomedich-346	266	23	1	1	NUM
biomedich-346	266	24	or	or	CCONJ
biomedich-346	266	25	2	2	NUM
biomedich-346	266	26	intramuscular	intramuscular	ADJ
biomedich-346	266	27	doses	dose	NOUN
biomedich-346	266	28	of	of	ADP
biomedich-346	266	29	5	5	NUM
biomedich-346	266	30	-	-	PUNCT
biomedich-346	266	31	μg	μg	NOUN
biomedich-346	266	32	or	or	CCONJ
biomedich-346	266	33	25	25	NUM
biomedich-346	266	34	-	-	PUNCT
biomedich-346	266	35	μg	μg	PROPN
biomedich-346	266	36	nvx	nvx	PROPN
biomedich-346	266	37	-	-	PUNCT
biomedich-346	266	38	cov2373	cov2373	PROPN
biomedich-346	266	39	or	or	CCONJ
biomedich-346	266	40	placebo	placebo	NOUN
biomedich-346	266	41	,	,	PUNCT
biomedich-346	266	42	21	21	NUM
biomedich-346	266	43	days	day	NOUN
biomedich-346	266	44	apart	apart	ADV
biomedich-346	266	45	.	.	PUNCT
biomedich-346	267	1	primary	primary	ADJ
biomedich-346	267	2	endpoints	endpoint	NOUN
biomedich-346	267	3	were	be	AUX
biomedich-346	267	4	immunoglobulin	immunoglobulin	NOUN
biomedich-346	267	5	g	g	PROPN
biomedich-346	267	6	(	(	PUNCT
biomedich-346	267	7	igg	igg	PROPN
biomedich-346	267	8	)	)	PUNCT
biomedich-346	267	9	anti	anti	ADJ
biomedich-346	267	10	-	-	ADJ
biomedich-346	267	11	spike	spike	ADJ
biomedich-346	267	12	protein	protein	NOUN
biomedich-346	267	13	response	response	NOUN
biomedich-346	267	14	,	,	PUNCT
biomedich-346	267	15	7	7	NUM
biomedich-346	267	16	-	-	PUNCT
biomedich-346	267	17	day	day	NOUN
biomedich-346	267	18	solicited	solicited	ADJ
biomedich-346	267	19	reactogenicity	reactogenicity	NOUN
biomedich-346	267	20	and	and	CCONJ
biomedich-346	267	21	unsolicited	unsolicited	ADJ
biomedich-346	267	22	adverse	adverse	ADJ
biomedich-346	267	23	events	event	NOUN
biomedich-346	267	24	.	.	PUNCT
biomedich-346	268	1	a	a	DET
biomedich-346	268	2	key	key	ADJ
biomedich-346	268	3	secondary	secondary	ADJ
biomedich-346	268	4	endpoint	endpoint	NOUN
biomedich-346	268	5	was	be	AUX
biomedich-346	268	6	a	a	DET
biomedich-346	268	7	wild	wild	ADJ
biomedich-346	268	8	-	-	PUNCT
biomedich-346	268	9	type	type	NOUN
biomedich-346	268	10	virusneutralizing	virusneutralize	VERB
biomedich-346	268	11	antibody	antibody	NOUN
biomedich-346	268	12	response	response	NOUN
biomedich-346	268	13	.	.	PUNCT
biomedich-346	269	1	after	after	ADP
biomedich-346	269	2	enrollment	enrollment	NOUN
biomedich-346	269	3	,	,	PUNCT
biomedich-346	269	4	1,288	1,288	NUM
biomedich-346	269	5	participants	participant	NOUN
biomedich-346	269	6	were	be	AUX
biomedich-346	269	7	randomly	randomly	ADV
biomedich-346	269	8	assigned	assign	VERB
biomedich-346	269	9	to	to	ADP
biomedich-346	269	10	1	1	NUM
biomedich-346	269	11	of	of	ADP
biomedich-346	269	12	4	4	NUM
biomedich-346	269	13	vaccine	vaccine	NOUN
biomedich-346	269	14	groups	group	NOUN
biomedich-346	269	15	or	or	CCONJ
biomedich-346	269	16	placebo	placebo	NOUN
biomedich-346	269	17	,	,	PUNCT
biomedich-346	269	18	with	with	ADP
biomedich-346	269	19	1,283	1,283	NUM
biomedich-346	269	20	participants	participant	NOUN
biomedich-346	269	21	administered	administer	VERB
biomedich-346	269	22	at	at	ADV
biomedich-346	269	23	least	least	ADJ
biomedich-346	269	24	1	1	NUM
biomedich-346	269	25	study	study	NOUN
biomedich-346	269	26	treatment	treatment	NOUN
biomedich-346	269	27	.	.	PUNCT
biomedich-346	270	1	neutralizing	neutralize	VERB
biomedich-346	270	2	antibody	antibody	NOUN
biomedich-346	270	3	responses	response	NOUN
biomedich-346	270	4	exceeded	exceed	VERB
biomedich-346	270	5	those	those	PRON
biomedich-346	270	6	seen	see	VERB
biomedich-346	270	7	in	in	ADP
biomedich-346	270	8	a	a	DET
biomedich-346	270	9	panel	panel	NOUN
biomedich-346	270	10	of	of	ADP
biomedich-346	270	11	convalescent	convalescent	NOUN
biomedich-346	270	12	sera	sera	NOUN
biomedich-346	270	13	for	for	ADP
biomedich-346	270	14	both	both	DET
biomedich-346	270	15	age	age	NOUN
biomedich-346	270	16	groups	group	NOUN
biomedich-346	270	17	.	.	PUNCT
biomedich-346	271	1	study	study	NOUN
biomedich-346	271	2	limitations	limitation	NOUN
biomedich-346	271	3	include	include	VERB
biomedich-346	271	4	the	the	DET
biomedich-346	271	5	relatively	relatively	ADV
biomedich-346	271	6	short	short	ADJ
biomedich-346	271	7	duration	duration	NOUN
biomedich-346	271	8	of	of	ADP
biomedich-346	271	9	safety	safety	NOUN
biomedich-346	271	10	follow	follow	NOUN
biomedich-346	271	11	-	-	PUNCT
biomedich-346	271	12	up	up	NOUN
biomedich-346	271	13	to	to	ADP
biomedich-346	271	14	date	date	NOUN
biomedich-346	271	15	and	and	CCONJ
biomedich-346	271	16	the	the	DET
biomedich-346	271	17	current	current	ADJ
biomedich-346	271	18	lack	lack	NOUN
biomedich-346	271	19	of	of	ADP
biomedich-346	271	20	immune	immune	ADJ
biomedich-346	271	21	persistence	persistence	NOUN
biomedich-346	271	22	data	datum	NOUN
biomedich-346	271	23	beyond	beyond	ADP
biomedich-346	271	24	the	the	DET
biomedich-346	271	25	primary	primary	ADJ
biomedich-346	271	26	vaccination	vaccination	NOUN
biomedich-346	271	27	regimen	regimen	NOUN
biomedich-346	271	28	time	time	NOUN
biomedich-346	271	29	point	point	NOUN
biomedich-346	271	30	assessments	assessment	NOUN
biomedich-346	271	31	,	,	PUNCT
biomedich-346	271	32	but	but	CCONJ
biomedich-346	271	33	these	these	DET
biomedich-346	271	34	data	datum	NOUN
biomedich-346	271	35	will	will	AUX
biomedich-346	271	36	accumulate	accumulate	VERB
biomedich-346	271	37	over	over	ADP
biomedich-346	271	38	time	time	NOUN
biomedich-346	271	39	.	.	PUNCT
biomedich-346	272	1	khobragade	khobragade	PROPN
biomedich-346	272	2	et	et	PROPN
biomedich-346	272	3	al	al	PROPN
biomedich-346	272	4	.	.	PROPN
biomedich-346	272	5	safety	safety	NOUN
biomedich-346	272	6	and	and	CCONJ
biomedich-346	272	7	immunogenicity	immunogenicity	NOUN
biomedich-346	272	8	of	of	ADP
biomedich-346	272	9	a	a	DET
biomedich-346	272	10	novel	novel	ADJ
biomedich-346	272	11	three	three	NUM
biomedich-346	272	12	-	-	PUNCT
biomedich-346	272	13	dose	dose	NOUN
biomedich-346	272	14	recombinant	recombinant	ADJ
biomedich-346	272	15	nanoparticle	nanoparticle	NOUN
biomedich-346	272	16	rabies	rabie	NOUN
biomedich-346	272	17	g	g	NOUN
biomedich-346	272	18	protein	protein	NOUN
biomedich-346	272	19	vaccine	vaccine	NOUN
biomedich-346	272	20	administered	administer	VERB
biomedich-346	272	21	as	as	ADP
biomedich-346	272	22	clinical	clinical	ADJ
biomedich-346	272	23	trial	trial	NOUN
biomedich-346	272	24	2021	2021	NUM
biomedich-346	272	25	a	a	DET
biomedich-346	272	26	multi	multi	ADJ
biomedich-346	272	27	-	-	ADJ
biomedich-346	272	28	centric	centric	ADJ
biomedich-346	272	29	,	,	PUNCT
biomedich-346	272	30	open	open	ADJ
biomedich-346	272	31	-	-	PUNCT
biomedich-346	272	32	label	label	NOUN
biomedich-346	272	33	,	,	PUNCT
biomedich-346	272	34	assessor	assessor	NOUN
biomedich-346	272	35	-	-	PUNCT
biomedich-346	272	36	blind	blind	ADJ
biomedich-346	272	37	,	,	PUNCT
biomedich-346	272	38	center	center	NOUN
biomedich-346	272	39	-	-	PUNCT
biomedich-346	272	40	specific	specific	ADJ
biomedich-346	272	41	block	block	NOUN
biomedich-346	272	42	randomized	randomize	VERB
biomedich-346	272	43	,	,	PUNCT
biomedich-346	272	44	parallel	parallel	ADJ
biomedich-346	272	45	design	design	NOUN
biomedich-346	272	46	,	,	PUNCT
biomedich-346	272	47	phase	phase	NOUN
biomedich-346	272	48	iii	iii	NUM
biomedich-346	272	49	clinical	clinical	ADJ
biomedich-346	272	50	study	study	NOUN
biomedich-346	272	51	was	be	AUX
biomedich-346	272	52	conducted	conduct	VERB
biomedich-346	272	53	among	among	ADP
biomedich-346	272	54	800	800	NUM
biomedich-346	272	55	subjects	subject	NOUN
biomedich-346	272	56	.	.	PUNCT
biomedich-346	273	1	the	the	DET
biomedich-346	273	2	eligible	eligible	ADJ
biomedich-346	273	3	subjects	subject	NOUN
biomedich-346	273	4	were	be	AUX
biomedich-346	273	5	randomized	randomize	VERB
biomedich-346	273	6	in	in	ADP
biomedich-346	273	7	a	a	DET
biomedich-346	273	8	2:1	2:1	NUM
biomedich-346	273	9	ratio	ratio	NOUN
biomedich-346	273	10	the	the	DET
biomedich-346	273	11	socio	socio	NOUN
biomedich-346	273	12	-	-	ADJ
biomedich-346	273	13	demographic	demographic	ADJ
biomedich-346	273	14	characteristics	characteristic	NOUN
biomedich-346	273	15	of	of	ADP
biomedich-346	273	16	the	the	DET
biomedich-346	273	17	two	two	NUM
biomedich-346	273	18	arms	arm	NOUN
biomedich-346	273	19	were	be	AUX
biomedich-346	273	20	comparable	comparable	ADJ
biomedich-346	273	21	.	.	PUNCT
biomedich-346	274	1	about	about	ADV
biomedich-346	274	2	9.9	9.9	NUM
biomedich-346	274	3	%	%	NOUN
biomedich-346	274	4	of	of	ADP
biomedich-346	274	5	subjects	subject	NOUN
biomedich-346	274	6	in	in	ADP
biomedich-346	274	7	the	the	DET
biomedich-346	274	8	recombinant	recombinant	ADJ
biomedich-346	274	9	rabies	rabie	NOUN
biomedich-346	274	10	g	g	NOUN
biomedich-346	274	11	protein	protein	NOUN
biomedich-346	274	12	vaccine	vaccine	NOUN
biomedich-346	274	13	arm	arm	NOUN
biomedich-346	274	14	and	and	CCONJ
biomedich-346	274	15	17.2	17.2	NUM
biomedich-346	274	16	%	%	NOUN
biomedich-346	274	17	of	of	ADP
biomedich-346	274	18	subjects	subject	NOUN
biomedich-346	274	19	in	in	ADP
biomedich-346	274	20	the	the	DET
biomedich-346	274	21	reference	reference	NOUN
biomedich-346	274	22	arm	arm	NOUN
biomedich-346	274	23	reported	report	VERB
biomedich-346	274	24	adverse	adverse	ADJ
biomedich-346	274	25	events	event	NOUN
biomedich-346	274	26	.	.	PUNCT
biomedich-346	275	1	the	the	DET
biomedich-346	275	2	seroprotection	seroprotection	NOUN
biomedich-346	275	3	on	on	ADP
biomedich-346	275	4	day	day	NOUN
biomedich-346	275	5	14	14	NUM
biomedich-346	275	6	was	be	AUX
biomedich-346	275	7	hussein	hussein	PROPN
biomedich-346	275	8	et	et	PROPN
biomedich-346	275	9	al	al	PROPN
biomedich-346	275	10	.	.	PROPN
biomedich-346	275	11	–	–	PUNCT
biomedich-346	275	12	nanotechnology	nanotechnology	NOUN
biomedich-346	275	13	-	-	PUNCT
biomedich-346	275	14	based	base	VERB
biomedich-346	275	15	vaccines	vaccine	NOUN
biomedich-346	275	16	355	355	NUM
biomedich-346	275	17	authors	author	NOUN
biomedich-346	275	18	title	title	VERB
biomedich-346	275	19	date	date	NOUN
biomedich-346	275	20	and	and	CCONJ
biomedich-346	275	21	type	type	NOUN
biomedich-346	275	22	of	of	ADP
biomedich-346	275	23	the	the	DET
biomedich-346	275	24	study	study	NOUN
biomedich-346	275	25	method	method	NOUN
biomedich-346	275	26	results	result	VERB
biomedich-346	275	27	simulated	simulate	VERB
biomedich-346	275	28	postexposure	postexposure	ADJ
biomedich-346	275	29	immunization	immunization	NOUN
biomedich-346	275	30	:	:	PUNCT
biomedich-346	275	31	a	a	DET
biomedich-346	275	32	randomized	randomized	ADJ
biomedich-346	275	33	,	,	PUNCT
biomedich-346	275	34	comparatorcontrolled	comparatorcontrolle	VERB
biomedich-346	275	35	,	,	PUNCT
biomedich-346	275	36	multicenter	multicenter	NOUN
biomedich-346	275	37	,	,	PUNCT
biomedich-346	275	38	phase	phase	NOUN
biomedich-346	275	39	iii	iii	NUM
biomedich-346	275	40	clinical	clinical	ADJ
biomedich-346	275	41	study	study	NOUN
biomedich-346	275	42	for	for	ADP
biomedich-346	275	43	the	the	DET
biomedich-346	275	44	recombinant	recombinant	ADJ
biomedich-346	275	45	rabies	rabie	NOUN
biomedich-346	275	46	g	g	NOUN
biomedich-346	275	47	protein	protein	NOUN
biomedich-346	275	48	vaccine	vaccine	NOUN
biomedich-346	275	49	and	and	CCONJ
biomedich-346	275	50	the	the	DET
biomedich-346	275	51	reference	reference	NOUN
biomedich-346	275	52	vaccine	vaccine	NOUN
biomedich-346	275	53	.	.	PUNCT
biomedich-346	276	1	subjects	subject	NOUN
biomedich-346	276	2	in	in	ADP
biomedich-346	276	3	the	the	DET
biomedich-346	276	4	recombinant	recombinant	ADJ
biomedich-346	276	5	rabies	rabie	NOUN
biomedich-346	276	6	g	g	NOUN
biomedich-346	276	7	protein	protein	NOUN
biomedich-346	276	8	vaccine	vaccine	NOUN
biomedich-346	276	9	arm	arm	NOUN
biomedich-346	276	10	received	receive	VERB
biomedich-346	276	11	three	three	NUM
biomedich-346	276	12	doses	dose	NOUN
biomedich-346	276	13	of	of	ADP
biomedich-346	276	14	vaccine	vaccine	NOUN
biomedich-346	276	15	on	on	ADP
biomedich-346	276	16	days	day	NOUN
biomedich-346	276	17	0	0	NUM
biomedich-346	276	18	,	,	PUNCT
biomedich-346	276	19	3	3	NUM
biomedich-346	276	20	,	,	PUNCT
biomedich-346	276	21	and	and	CCONJ
biomedich-346	276	22	7	7	NUM
biomedich-346	276	23	,	,	PUNCT
biomedich-346	276	24	while	while	SCONJ
biomedich-346	276	25	subjects	subject	NOUN
biomedich-346	276	26	in	in	ADP
biomedich-346	276	27	the	the	DET
biomedich-346	276	28	reference	reference	NOUN
biomedich-346	276	29	vaccine	vaccine	NOUN
biomedich-346	276	30	arm	arm	NOUN
biomedich-346	276	31	received	receive	VERB
biomedich-346	276	32	five	five	NUM
biomedich-346	276	33	doses	dose	NOUN
biomedich-346	276	34	of	of	ADP
biomedich-346	276	35	who	who	PRON
biomedich-346	276	36	-	-	PUNCT
biomedich-346	276	37	prequalified	prequalifie	VERB
biomedich-346	276	38	vaccine	vaccine	NOUN
biomedich-346	276	39	on	on	ADP
biomedich-346	276	40	days	day	NOUN
biomedich-346	276	41	0	0	NUM
biomedich-346	276	42	,	,	PUNCT
biomedich-346	276	43	3	3	NUM
biomedich-346	276	44	,	,	PUNCT
biomedich-346	276	45	7	7	NUM
biomedich-346	276	46	,	,	PUNCT
biomedich-346	276	47	14	14	NUM
biomedich-346	276	48	,	,	PUNCT
biomedich-346	276	49	and	and	CCONJ
biomedich-346	276	50	28	28	NUM
biomedich-346	276	51	.	.	PUNCT
biomedich-346	276	52	found	find	VERB
biomedich-346	276	53	to	to	PART
biomedich-346	276	54	be	be	AUX
biomedich-346	276	55	99.24	99.24	NUM
biomedich-346	276	56	%	%	NOUN
biomedich-346	276	57	and	and	CCONJ
biomedich-346	276	58	97.72	97.72	NUM
biomedich-346	276	59	%	%	NOUN
biomedich-346	276	60	in	in	ADP
biomedich-346	276	61	the	the	DET
biomedich-346	276	62	recombinant	recombinant	ADJ
biomedich-346	276	63	rabies	rabie	NOUN
biomedich-346	276	64	g	g	NOUN
biomedich-346	276	65	protein	protein	NOUN
biomedich-346	276	66	vaccine	vaccine	NOUN
biomedich-346	276	67	arm	arm	NOUN
biomedich-346	276	68	and	and	CCONJ
biomedich-346	276	69	reference	reference	NOUN
biomedich-346	276	70	vaccine	vaccine	NOUN
biomedich-346	276	71	arm	arm	VERB
biomedich-346	276	72	respectively	respectively	ADV
biomedich-346	276	73	and	and	CCONJ
biomedich-346	276	74	the	the	DET
biomedich-346	276	75	difference	difference	NOUN
biomedich-346	276	76	was	be	AUX
biomedich-346	276	77	statistically	statistically	ADV
biomedich-346	276	78	nonsignificant	nonsignificant	ADJ
biomedich-346	276	79	.	.	PUNCT
biomedich-346	277	1	august	august	PROPN
biomedich-346	277	2	et	et	PROPN
biomedich-346	277	3	al	al	PROPN
biomedich-346	277	4	.	.	PUNCT
biomedich-346	278	1	a	a	DET
biomedich-346	278	2	phase	phase	NOUN
biomedich-346	278	3	1	1	NUM
biomedich-346	278	4	trial	trial	NOUN
biomedich-346	278	5	of	of	ADP
biomedich-346	278	6	lipid	lipid	NOUN
biomedich-346	278	7	-	-	PUNCT
biomedich-346	278	8	encapsulated	encapsulate	VERB
biomedich-346	278	9	mrna	mrna	NOUN
biomedich-346	278	10	encoding	encode	VERB
biomedich-346	278	11	a	a	DET
biomedich-346	278	12	monoclonal	monoclonal	NOUN
biomedich-346	278	13	antibody	antibody	NOUN
biomedich-346	278	14	with	with	ADP
biomedich-346	278	15	neutralizing	neutralizing	ADJ
biomedich-346	278	16	activity	activity	NOUN
biomedich-346	278	17	against	against	ADP
biomedich-346	278	18	chikungunya	chikungunya	NOUN
biomedich-346	278	19	virus	virus	NOUN
biomedich-346	278	20	clinical	clinical	ADJ
biomedich-346	278	21	trial	trial	NOUN
biomedich-346	278	22	2021	2021	NUM
biomedich-346	278	23	this	this	DET
biomedich-346	278	24	phase	phase	NOUN
biomedich-346	278	25	1	1	NUM
biomedich-346	278	26	,	,	PUNCT
biomedich-346	278	27	first	first	ADJ
biomedich-346	278	28	-	-	PUNCT
biomedich-346	278	29	in	in	ADP
biomedich-346	278	30	-	-	PUNCT
biomedich-346	278	31	human	human	NOUN
biomedich-346	278	32	,	,	PUNCT
biomedich-346	278	33	randomized	randomize	VERB
biomedich-346	278	34	,	,	PUNCT
biomedich-346	278	35	placebo	placebo	NOUN
biomedich-346	278	36	-	-	PUNCT
biomedich-346	278	37	controlled	control	VERB
biomedich-346	278	38	,	,	PUNCT
biomedich-346	278	39	proof	proof	NOUN
biomedich-346	278	40	-	-	PUNCT
biomedich-346	278	41	of	of	ADP
biomedich-346	278	42	-	-	PUNCT
biomedich-346	278	43	concept	concept	NOUN
biomedich-346	278	44	trial	trial	NOUN
biomedich-346	278	45	conducted	conduct	VERB
biomedich-346	278	46	from	from	ADP
biomedich-346	278	47	january	january	PROPN
biomedich-346	278	48	2019	2019	NUM
biomedich-346	278	49	to	to	ADP
biomedich-346	278	50	june	june	PROPN
biomedich-346	278	51	2020	2020	NUM
biomedich-346	278	52	evaluated	evaluate	VERB
biomedich-346	278	53	the	the	DET
biomedich-346	278	54	safety	safety	NOUN
biomedich-346	278	55	and	and	CCONJ
biomedich-346	278	56	pharmacology	pharmacology	NOUN
biomedich-346	278	57	of	of	ADP
biomedich-346	278	58	mrna-1944	mrna-1944	NOUN
biomedich-346	278	59	,	,	PUNCT
biomedich-346	278	60	a	a	DET
biomedich-346	278	61	lipid	lipid	NOUN
biomedich-346	278	62	nanoparticle	nanoparticle	NOUN
biomedich-346	278	63	-	-	PUNCT
biomedich-346	278	64	encapsulated	encapsulate	VERB
biomedich-346	278	65	messenger	messenger	NOUN
biomedich-346	278	66	rna	rna	NOUN
biomedich-346	278	67	encoding	encode	VERB
biomedich-346	278	68	the	the	DET
biomedich-346	278	69	heavy	heavy	ADJ
biomedich-346	278	70	and	and	CCONJ
biomedich-346	278	71	light	light	ADJ
biomedich-346	278	72	chains	chain	NOUN
biomedich-346	278	73	of	of	ADP
biomedich-346	278	74	a	a	DET
biomedich-346	278	75	chikv	chikv	NOUN
biomedich-346	278	76	-	-	PUNCT
biomedich-346	278	77	specific	specific	ADJ
biomedich-346	278	78	monoclonal	monoclonal	NOUN
biomedich-346	278	79	neutralizing	neutralize	VERB
biomedich-346	278	80	antibody	antibody	NOUN
biomedich-346	278	81	,	,	PUNCT
biomedich-346	278	82	chkv-24	chkv-24	VERB
biomedich-346	278	83	further	further	ADJ
biomedich-346	278	84	evaluation	evaluation	NOUN
biomedich-346	278	85	of	of	ADP
biomedich-346	278	86	the	the	DET
biomedich-346	278	87	potential	potential	ADJ
biomedich-346	278	88	therapeutic	therapeutic	ADJ
biomedich-346	278	89	use	use	NOUN
biomedich-346	278	90	of	of	ADP
biomedich-346	278	91	mrna-1944	mrna-1944	NOUN
biomedich-346	278	92	in	in	ADP
biomedich-346	278	93	clinical	clinical	ADJ
biomedich-346	278	94	trials	trial	NOUN
biomedich-346	278	95	for	for	ADP
biomedich-346	278	96	the	the	DET
biomedich-346	278	97	treatment	treatment	NOUN
biomedich-346	278	98	of	of	ADP
biomedich-346	278	99	chikv	chikv	ADJ
biomedich-346	278	100	infection	infection	NOUN
biomedich-346	278	101	is	be	AUX
biomedich-346	278	102	warranted	warrant	VERB
biomedich-346	278	103	.	.	PUNCT
biomedich-346	279	1	shinde	shinde	PROPN
biomedich-346	279	2	et	et	PROPN
biomedich-346	279	3	al	al	PROPN
biomedich-346	279	4	.	.	PROPN
biomedich-346	279	5	induction	induction	NOUN
biomedich-346	279	6	of	of	ADP
biomedich-346	279	7	crossreactive	crossreactive	ADJ
biomedich-346	279	8	hemagglutination	hemagglutination	NOUN
biomedich-346	279	9	inhibiting	inhibit	VERB
biomedich-346	279	10	antibody	antibody	NOUN
biomedich-346	279	11	and	and	CCONJ
biomedich-346	279	12	polyfunctional	polyfunctional	ADJ
biomedich-346	279	13	cd4	cd4	PROPN
biomedich-346	279	14	+	+	PROPN
biomedich-346	279	15	t	t	PROPN
biomedich-346	279	16	-	-	PUNCT
biomedich-346	279	17	cell	cell	NOUN
biomedich-346	279	18	responses	response	NOUN
biomedich-346	279	19	by	by	ADP
biomedich-346	279	20	a	a	DET
biomedich-346	279	21	recombinant	recombinant	ADJ
biomedich-346	279	22	matrixm	matrixm	NOUN
biomedich-346	279	23	-	-	PUNCT
biomedich-346	279	24	adjuvanted	adjuvante	VERB
biomedich-346	279	25	hemagglutinin	hemagglutinin	ADJ
biomedich-346	279	26	nanoparticle	nanoparticle	NOUN
biomedich-346	279	27	influenza	influenza	NOUN
biomedich-346	279	28	vaccine	vaccine	NOUN
biomedich-346	279	29	randomized	randomize	VERB
biomedich-346	279	30	controlled	control	VERB
biomedich-346	279	31	trial	trial	NOUN
biomedich-346	279	32	2021	2021	NUM
biomedich-346	279	33	a	a	DET
biomedich-346	279	34	randomized	randomize	VERB
biomedich-346	279	35	,	,	PUNCT
biomedich-346	279	36	observer	observer	NOUN
biomedich-346	279	37	-	-	PUNCT
biomedich-346	279	38	blind	blind	ADJ
biomedich-346	279	39	,	,	PUNCT
biomedich-346	279	40	comparator	comparator	NOUN
biomedich-346	279	41	-	-	PUNCT
biomedich-346	279	42	controlled	control	VERB
biomedich-346	279	43	(	(	PUNCT
biomedich-346	279	44	trivalent	trivalent	NOUN
biomedich-346	279	45	high	high	ADJ
biomedich-346	279	46	-	-	PUNCT
biomedich-346	279	47	dose	dose	VERB
biomedich-346	279	48	inactivated	inactivated	ADJ
biomedich-346	279	49	influenza	influenza	NOUN
biomedich-346	279	50	vaccine	vaccine	NOUN
biomedich-346	279	51	[	[	X
biomedich-346	279	52	iiv3	iiv3	PROPN
biomedich-346	279	53	-	-	PUNCT
biomedich-346	279	54	hd	hd	VERB
biomedich-346	279	55	]	]	PUNCT
biomedich-346	279	56	or	or	CCONJ
biomedich-346	279	57	quadrivalent	quadrivalent	NOUN
biomedich-346	279	58	recombinant	recombinant	ADJ
biomedich-346	279	59	influenza	influenza	ADJ
biomedich-346	279	60	vaccine	vaccine	NOUN
biomedich-346	279	61	[	[	X
biomedich-346	279	62	riv4	riv4	PROPN
biomedich-346	279	63	]	]	X
biomedich-346	279	64	)	)	PUNCT
biomedich-346	279	65	,	,	PUNCT
biomedich-346	279	66	safety	safety	NOUN
biomedich-346	279	67	and	and	CCONJ
biomedich-346	279	68	immunogenicity	immunogenicity	NOUN
biomedich-346	279	69	trial	trial	NOUN
biomedich-346	279	70	of	of	ADP
biomedich-346	279	71	qniv	qniv	NOUN
biomedich-346	279	72	(	(	PUNCT
biomedich-346	279	73	5	5	NUM
biomedich-346	279	74	doses	dose	NOUN
biomedich-346	279	75	/	/	SYM
biomedich-346	279	76	formulations	formulation	NOUN
biomedich-346	279	77	)	)	PUNCT
biomedich-346	279	78	in	in	ADP
biomedich-346	279	79	healthy	healthy	ADJ
biomedich-346	279	80	adults	adult	NOUN
biomedich-346	279	81	≥65	≥65	NUM
biomedich-346	279	82	years	year	NOUN
biomedich-346	279	83	.	.	PUNCT
biomedich-346	280	1	vaccine	vaccine	NOUN
biomedich-346	280	2	immunogenicity	immunogenicity	NOUN
biomedich-346	280	3	was	be	AUX
biomedich-346	280	4	measured	measure	VERB
biomedich-346	280	5	by	by	ADP
biomedich-346	280	6	hemagglutinationinhibition	hemagglutinationinhibition	NOUN
biomedich-346	280	7	assays	assay	NOUN
biomedich-346	280	8	using	use	VERB
biomedich-346	280	9	reagents	reagent	NOUN
biomedich-346	280	10	that	that	PRON
biomedich-346	280	11	express	express	VERB
biomedich-346	280	12	wild	wild	ADJ
biomedich-346	280	13	-	-	PUNCT
biomedich-346	280	14	type	type	NOUN
biomedich-346	280	15	hemagglutination	hemagglutination	NOUN
biomedich-346	280	16	inhibition	inhibition	NOUN
biomedich-346	280	17	(	(	PUNCT
biomedich-346	280	18	wthai	wthai	ADJ
biomedich-346	280	19	)	)	PUNCT
biomedich-346	280	20	sequences	sequence	NOUN
biomedich-346	280	21	and	and	CCONJ
biomedich-346	280	22	cellmediated	cellmediated	ADJ
biomedich-346	280	23	immune	immune	ADJ
biomedich-346	280	24	responses	response	NOUN
biomedich-346	280	25	.	.	PUNCT
biomedich-346	281	1	overall	overall	ADJ
biomedich-346	281	2	,	,	PUNCT
biomedich-346	281	3	similar	similar	ADJ
biomedich-346	281	4	frequencies	frequency	NOUN
biomedich-346	281	5	of	of	ADP
biomedich-346	281	6	solicited	solicited	ADJ
biomedich-346	281	7	and	and	CCONJ
biomedich-346	281	8	unsolicited	unsolicited	ADJ
biomedich-346	281	9	adverse	adverse	ADJ
biomedich-346	281	10	events	event	NOUN
biomedich-346	281	11	were	be	AUX
biomedich-346	281	12	reported	report	VERB
biomedich-346	281	13	in	in	ADP
biomedich-346	281	14	all	all	DET
biomedich-346	281	15	treatment	treatment	NOUN
biomedich-346	281	16	groups	group	NOUN
biomedich-346	281	17	.	.	PUNCT
biomedich-346	282	1	kremsner	kremsner	PROPN
biomedich-346	282	2	et	et	PROPN
biomedich-346	282	3	al	al	PROPN
biomedich-346	282	4	.	.	PROPN
biomedich-346	282	5	safety	safety	NOUN
biomedich-346	282	6	and	and	CCONJ
biomedich-346	282	7	immunogenicity	immunogenicity	NOUN
biomedich-346	282	8	of	of	ADP
biomedich-346	282	9	an	an	DET
biomedich-346	282	10	mrna	mrna	NOUN
biomedich-346	282	11	-	-	PUNCT
biomedich-346	282	12	lipid	lipid	NOUN
biomedich-346	282	13	nanoparticle	nanoparticle	NOUN
biomedich-346	282	14	vaccine	vaccine	NOUN
biomedich-346	282	15	candidate	candidate	NOUN
biomedich-346	282	16	against	against	ADP
biomedich-346	282	17	sars	sar	NOUN
biomedich-346	282	18	-	-	PUNCT
biomedich-346	282	19	cov-2	cov-2	PUNCT
biomedich-346	282	20	:	:	PUNCT
biomedich-346	282	21	a	a	DET
biomedich-346	282	22	phase	phase	NOUN
biomedich-346	282	23	1	1	NUM
biomedich-346	282	24	randomized	randomize	VERB
biomedich-346	282	25	clinical	clinical	ADJ
biomedich-346	282	26	trial	trial	NOUN
biomedich-346	282	27	clinical	clinical	ADJ
biomedich-346	282	28	trial	trial	NOUN
biomedich-346	282	29	2021	2021	NUM
biomedich-346	282	30	this	this	PRON
biomedich-346	282	31	is	be	AUX
biomedich-346	282	32	an	an	DET
biomedich-346	282	33	interim	interim	ADJ
biomedich-346	282	34	analysis	analysis	NOUN
biomedich-346	282	35	of	of	ADP
biomedich-346	282	36	a	a	DET
biomedich-346	282	37	dosage	dosage	NOUN
biomedich-346	282	38	escalation	escalation	NOUN
biomedich-346	282	39	phase	phase	NOUN
biomedich-346	282	40	1	1	NUM
biomedich-346	282	41	study	study	NOUN
biomedich-346	282	42	in	in	ADP
biomedich-346	282	43	healthy	healthy	ADJ
biomedich-346	282	44	18	18	NUM
biomedich-346	282	45	-	-	SYM
biomedich-346	282	46	60	60	NUM
biomedich-346	282	47	-	-	PUNCT
biomedich-346	282	48	year	year	NOUN
biomedich-346	282	49	-	-	PUNCT
biomedich-346	282	50	old	old	ADJ
biomedich-346	282	51	volunteers	volunteer	NOUN
biomedich-346	282	52	in	in	ADP
biomedich-346	282	53	hannover	hannover	PROPN
biomedich-346	282	54	,	,	PUNCT
biomedich-346	282	55	munich	munich	PROPN
biomedich-346	282	56	,	,	PUNCT
biomedich-346	282	57	and	and	CCONJ
biomedich-346	282	58	tübingen	tübingen	PROPN
biomedich-346	282	59	,	,	PUNCT
biomedich-346	282	60	germany	germany	PROPN
biomedich-346	282	61	,	,	PUNCT
biomedich-346	282	62	and	and	CCONJ
biomedich-346	282	63	ghent	ghent	NOUN
biomedich-346	282	64	,	,	PUNCT
biomedich-346	282	65	belgium	belgium	PROPN
biomedich-346	282	66	.	.	PUNCT
biomedich-346	283	1	after	after	ADP
biomedich-346	283	2	giving	give	VERB
biomedich-346	283	3	2	2	NUM
biomedich-346	283	4	intramuscular	intramuscular	ADJ
biomedich-346	283	5	doses	dose	NOUN
biomedich-346	283	6	of	of	ADP
biomedich-346	283	7	cvncov	cvncov	ADJ
biomedich-346	283	8	or	or	CCONJ
biomedich-346	283	9	placebo	placebo	NOUN
biomedich-346	283	10	28	28	NUM
biomedich-346	283	11	days	day	NOUN
biomedich-346	283	12	apart	apart	ADV
biomedich-346	283	13	we	we	PRON
biomedich-346	283	14	assessed	assess	VERB
biomedich-346	283	15	solicited	solicited	ADJ
biomedich-346	283	16	local	local	ADJ
biomedich-346	283	17	and	and	CCONJ
biomedich-346	283	18	systemic	systemic	ADJ
biomedich-346	283	19	adverse	adverse	ADJ
biomedich-346	283	20	events	event	NOUN
biomedich-346	283	21	(	(	PUNCT
biomedich-346	283	22	ae	ae	PROPN
biomedich-346	283	23	)	)	PUNCT
biomedich-346	283	24	for	for	ADP
biomedich-346	283	25	7	7	NUM
biomedich-346	283	26	days	day	NOUN
biomedich-346	283	27	and	and	CCONJ
biomedich-346	283	28	unsolicited	unsolicited	ADJ
biomedich-346	283	29	aes	aes	NOUN
biomedich-346	283	30	for	for	ADP
biomedich-346	283	31	28	28	NUM
biomedich-346	283	32	days	day	NOUN
biomedich-346	283	33	after	after	ADP
biomedich-346	283	34	each	each	DET
biomedich-346	283	35	vaccination	vaccination	NOUN
biomedich-346	283	36	.	.	PUNCT
biomedich-346	284	1	immunogenicity	immunogenicity	NOUN
biomedich-346	284	2	was	be	AUX
biomedich-346	284	3	measured	measure	VERB
biomedich-346	284	4	as	as	ADP
biomedich-346	284	5	enzyme	enzyme	NOUN
biomedich-346	284	6	-	-	PUNCT
biomedich-346	284	7	linked	link	VERB
biomedich-346	284	8	immunosorbent	immunosorbent	NOUN
biomedich-346	284	9	assay	assay	PROPN
biomedich-346	284	10	(	(	PUNCT
biomedich-346	284	11	elisa	elisa	NOUN
biomedich-346	284	12	)	)	PUNCT
biomedich-346	284	13	igg	igg	PROPN
biomedich-346	284	14	antibodies	antibodie	VERB
biomedich-346	284	15	to	to	ADP
biomedich-346	284	16	sars	sars	PROPN
biomedich-346	284	17	-	-	PUNCT
biomedich-346	284	18	cov‑2	cov‑2	NOUN
biomedich-346	284	19	s‑protein	s‑protein	PROPN
biomedich-346	284	20	and	and	CCONJ
biomedich-346	284	21	receptor	receptor	NOUN
biomedich-346	284	22	binding	bind	VERB
biomedich-346	284	23	domain	domain	NOUN
biomedich-346	284	24	(	(	PUNCT
biomedich-346	284	25	rbd	rbd	NOUN
biomedich-346	284	26	)	)	PUNCT
biomedich-346	284	27	,	,	PUNCT
biomedich-346	284	28	and	and	CCONJ
biomedich-346	284	29	sarscov‑2	sarscov‑2	VERB
biomedich-346	284	30	neutralizing	neutralize	VERB
biomedich-346	284	31	titers	titer	NOUN
biomedich-346	284	32	(	(	PUNCT
biomedich-346	284	33	mn50	mn50	PROPN
biomedich-346	284	34	)	)	PUNCT
biomedich-346	284	35	.	.	PUNCT
biomedich-346	285	1	responses	response	NOUN
biomedich-346	285	2	to	to	ADP
biomedich-346	285	3	12	12	NUM
biomedich-346	285	4	μg	μg	NOUN
biomedich-346	285	5	were	be	AUX
biomedich-346	285	6	comparable	comparable	ADJ
biomedich-346	285	7	to	to	ADP
biomedich-346	285	8	those	those	PRON
biomedich-346	285	9	observed	observe	VERB
biomedich-346	285	10	in	in	ADP
biomedich-346	285	11	convalescent	convalescent	NOUN
biomedich-346	285	12	sera	sera	NOUN
biomedich-346	285	13	from	from	ADP
biomedich-346	285	14	known	know	VERB
biomedich-346	285	15	covid-19	covid-19	PROPN
biomedich-346	285	16	patients	patient	NOUN
biomedich-346	285	17	.	.	PUNCT
biomedich-346	286	1	mallory	mallory	PROPN
biomedich-346	286	2	et	et	PROPN
biomedich-346	286	3	al	al	PROPN
biomedich-346	286	4	.	.	PROPN
biomedich-346	286	5	safety	safety	NOUN
biomedich-346	286	6	and	and	CCONJ
biomedich-346	286	7	immunogenicity	immunogenicity	NOUN
biomedich-346	286	8	following	follow	VERB
biomedich-346	286	9	a	a	DET
biomedich-346	286	10	homologous	homologous	ADJ
biomedich-346	286	11	booster	booster	NOUN
biomedich-346	286	12	dose	dose	NOUN
biomedich-346	286	13	of	of	ADP
biomedich-346	286	14	a	a	DET
biomedich-346	286	15	sarscov-2	sarscov-2	NUM
biomedich-346	286	16	recombinant	recombinant	ADJ
biomedich-346	286	17	clinical	clinical	ADJ
biomedich-346	286	18	trial	trial	NOUN
biomedich-346	286	19	2022	2022	NUM
biomedich-346	286	20	this	this	DET
biomedich-346	286	21	secondary	secondary	ADJ
biomedich-346	286	22	analysis	analysis	NOUN
biomedich-346	286	23	of	of	ADP
biomedich-346	286	24	phase	phase	NOUN
biomedich-346	286	25	2	2	NUM
biomedich-346	286	26	,	,	PUNCT
biomedich-346	286	27	randomised	randomised	ADJ
biomedich-346	286	28	study	study	NOUN
biomedich-346	286	29	assessed	assess	VERB
biomedich-346	286	30	a	a	DET
biomedich-346	286	31	single	single	ADJ
biomedich-346	286	32	booster	booster	NOUN
biomedich-346	286	33	dose	dose	NOUN
biomedich-346	286	34	of	of	ADP
biomedich-346	286	35	a	a	DET
biomedich-346	286	36	sarscov-2	sarscov-2	NUM
biomedich-346	286	37	recombinant	recombinant	ADJ
biomedich-346	286	38	spike	spike	ADJ
biomedich-346	286	39	protein	protein	NOUN
biomedich-346	286	40	vaccine	vaccine	NOUN
biomedich-346	286	41	with	with	ADP
biomedich-346	286	42	matrix	matrix	NOUN
biomedich-346	286	43	-	-	PUNCT
biomedich-346	286	44	m	m	NOUN
biomedich-346	286	45	adjuvant	adjuvant	ADJ
biomedich-346	286	46	(	(	PUNCT
biomedich-346	286	47	nvx	nvx	NOUN
biomedich-346	286	48	-	-	PUNCT
biomedich-346	286	49	cov2373	cov2373	NOUN
biomedich-346	286	50	)	)	PUNCT
biomedich-346	286	51	in	in	ADP
biomedich-346	286	52	1610	1610	NUM
biomedich-346	286	53	participants	participant	NOUN
biomedich-346	286	54	were	be	AUX
biomedich-346	286	55	screened	screen	VERB
biomedich-346	286	56	from	from	ADP
biomedich-346	286	57	aug	aug	PROPN
biomedich-346	286	58	24	24	NUM
biomedich-346	286	59	,	,	PUNCT
biomedich-346	286	60	2020	2020	NUM
biomedich-346	286	61	,	,	PUNCT
biomedich-346	286	62	to	to	PART
biomedich-346	286	63	sept	sept	PROPN
biomedich-346	286	64	25	25	NUM
biomedich-346	286	65	,	,	PUNCT
biomedich-346	286	66	2020	2020	NUM
biomedich-346	286	67	.	.	PUNCT
biomedich-346	287	1	1282	1282	NUM
biomedich-346	287	2	participants	participant	NOUN
biomedich-346	287	3	were	be	AUX
biomedich-346	287	4	enrolled	enrol	VERB
biomedich-346	287	5	,	,	PUNCT
biomedich-346	287	6	of	of	ADP
biomedich-346	287	7	whom	whom	PRON
biomedich-346	287	8	173	173	NUM
biomedich-346	287	9	were	be	AUX
biomedich-346	287	10	assigned	assign	VERB
biomedich-346	287	11	again	again	ADV
biomedich-346	287	12	to	to	ADP
biomedich-346	287	13	placebo	placebo	NOUN
biomedich-346	287	14	(	(	PUNCT
biomedich-346	287	15	group	group	NOUN
biomedich-346	287	16	a	a	NOUN
biomedich-346	287	17	)	)	PUNCT
biomedich-346	287	18	,	,	PUNCT
biomedich-346	287	19	106	106	NUM
biomedich-346	287	20	were	be	AUX
biomedich-346	287	21	re	re	VERB
biomedich-346	287	22	-	-	VERB
biomedich-346	287	23	randomized	randomize	VERB
biomedich-346	287	24	to	to	ADP
biomedich-346	287	25	nvx	nvx	NOUN
biomedich-346	287	26	-	-	PUNCT
biomedich-346	287	27	cov2373	cov2373	NOUN
biomedich-346	287	28	-	-	PUNCT
biomedich-346	287	29	placebo	placebo	NOUN
biomedich-346	287	30	(	(	PUNCT
biomedich-346	287	31	group	group	NOUN
biomedich-346	287	32	b1	b1	PROPN
biomedich-346	287	33	)	)	PUNCT
biomedich-346	287	34	,	,	PUNCT
biomedich-346	287	35	356	356	NUM
biomedich-346	287	36	biology	biology	NOUN
biomedich-346	287	37	,	,	PUNCT
biomedich-346	287	38	medicine	medicine	NOUN
biomedich-346	287	39	,	,	PUNCT
biomedich-346	287	40	&	&	CCONJ
biomedich-346	287	41	natural	natural	ADJ
biomedich-346	287	42	product	product	NOUN
biomedich-346	287	43	chemistry	chemistry	NOUN
biomedich-346	287	44	12	12	NUM
biomedich-346	287	45	(	(	PUNCT
biomedich-346	287	46	1	1	NUM
biomedich-346	287	47	)	)	PUNCT
biomedich-346	287	48	,	,	PUNCT
biomedich-346	287	49	2023	2023	NUM
biomedich-346	287	50	:	:	PUNCT
biomedich-346	287	51	343	343	NUM
biomedich-346	287	52	-	-	SYM
biomedich-346	287	53	361	361	NUM
biomedich-346	287	54	authors	author	NOUN
biomedich-346	287	55	title	title	NOUN
biomedich-346	287	56	date	date	NOUN
biomedich-346	287	57	and	and	CCONJ
biomedich-346	287	58	type	type	NOUN
biomedich-346	287	59	of	of	ADP
biomedich-346	287	60	the	the	DET
biomedich-346	287	61	study	study	NOUN
biomedich-346	287	62	method	method	NOUN
biomedich-346	287	63	results	result	VERB
biomedich-346	287	64	spike	spike	ADJ
biomedich-346	287	65	protein	protein	NOUN
biomedich-346	287	66	vaccine	vaccine	NOUN
biomedich-346	287	67	(	(	PUNCT
biomedich-346	287	68	nvx	nvx	NOUN
biomedich-346	287	69	-	-	PUNCT
biomedich-346	287	70	cov2373	cov2373	PROPN
biomedich-346	287	71	):	):	PUNCT
biomedich-346	287	72	a	a	DET
biomedich-346	287	73	secondary	secondary	ADJ
biomedich-346	287	74	analysis	analysis	NOUN
biomedich-346	287	75	of	of	ADP
biomedich-346	287	76	a	a	DET
biomedich-346	287	77	randomised	randomise	VERB
biomedich-346	287	78	,	,	PUNCT
biomedich-346	287	79	placebo	placebo	NOUN
biomedich-346	287	80	-	-	PUNCT
biomedich-346	287	81	controlled	control	VERB
biomedich-346	287	82	,	,	PUNCT
biomedich-346	287	83	phase	phase	NOUN
biomedich-346	287	84	2	2	NUM
biomedich-346	287	85	trial	trial	NOUN
biomedich-346	287	86	healthy	healthy	ADJ
biomedich-346	287	87	adults	adult	NOUN
biomedich-346	287	88	aged	age	VERB
biomedich-346	287	89	18	18	NUM
biomedich-346	287	90	-	-	SYM
biomedich-346	287	91	84	84	NUM
biomedich-346	287	92	years	year	NOUN
biomedich-346	287	93	,	,	PUNCT
biomedich-346	287	94	recruited	recruit	VERB
biomedich-346	287	95	from	from	ADP
biomedich-346	287	96	17	17	NUM
biomedich-346	287	97	clinical	clinical	ADJ
biomedich-346	287	98	centres	centre	NOUN
biomedich-346	287	99	in	in	ADP
biomedich-346	287	100	the	the	DET
biomedich-346	287	101	usa	usa	PROPN
biomedich-346	287	102	and	and	CCONJ
biomedich-346	287	103	australia	australia	PROPN
biomedich-346	287	104	.	.	PUNCT
biomedich-346	288	1	and	and	CCONJ
biomedich-346	288	2	104	104	NUM
biomedich-346	288	3	were	be	AUX
biomedich-346	288	4	re	re	VERB
biomedich-346	288	5	-	-	VERB
biomedich-346	288	6	randomized	randomize	VERB
biomedich-346	288	7	to	to	ADP
biomedich-346	288	8	nvxcov2373	nvxcov2373	PROPN
biomedich-346	288	9	-	-	PUNCT
biomedich-346	288	10	nvx	nvx	NOUN
biomedich-346	288	11	-	-	PUNCT
biomedich-346	288	12	cov2373	cov2373	NOUN
biomedich-346	288	13	(	(	PUNCT
biomedich-346	288	14	group	group	NOUN
biomedich-346	288	15	b2	b2	PROPN
biomedich-346	288	16	)	)	PUNCT
biomedich-346	288	17	;	;	PUNCT
biomedich-346	288	18	after	after	ADP
biomedich-346	288	19	accounting	account	VERB
biomedich-346	288	20	for	for	ADP
biomedich-346	288	21	exclusions	exclusion	NOUN
biomedich-346	288	22	and	and	CCONJ
biomedich-346	288	23	incorrect	incorrect	ADJ
biomedich-346	288	24	administration	administration	NOUN
biomedich-346	288	25	,	,	PUNCT
biomedich-346	288	26	172	172	NUM
biomedich-346	288	27	participants	participant	NOUN
biomedich-346	288	28	in	in	ADP
biomedich-346	288	29	group	group	PROPN
biomedich-346	288	30	a	a	PROPN
biomedich-346	288	31	,	,	PUNCT
biomedich-346	288	32	102	102	NUM
biomedich-346	288	33	in	in	ADP
biomedich-346	288	34	group	group	NOUN
biomedich-346	288	35	b1	b1	NOUN
biomedich-346	288	36	,	,	PUNCT
biomedich-346	288	37	and	and	CCONJ
biomedich-346	288	38	105	105	NUM
biomedich-346	288	39	in	in	ADP
biomedich-346	288	40	group	group	NOUN
biomedich-346	288	41	b2	b2	NOUN
biomedich-346	288	42	were	be	AUX
biomedich-346	288	43	analyzed	analyze	VERB
biomedich-346	288	44	for	for	ADP
biomedich-346	288	45	safety	safety	NOUN
biomedich-346	288	46	.	.	PUNCT
biomedich-346	289	1	following	follow	VERB
biomedich-346	289	2	the	the	DET
biomedich-346	289	3	active	active	ADJ
biomedich-346	289	4	booster	booster	NOUN
biomedich-346	289	5	,	,	PUNCT
biomedich-346	289	6	the	the	DET
biomedich-346	289	7	proportion	proportion	NOUN
biomedich-346	289	8	of	of	ADP
biomedich-346	289	9	participants	participant	NOUN
biomedich-346	289	10	with	with	ADP
biomedich-346	289	11	available	available	ADJ
biomedich-346	289	12	data	datum	NOUN
biomedich-346	289	13	reporting	report	VERB
biomedich-346	289	14	local	local	ADJ
biomedich-346	289	15	(	(	PUNCT
biomedich-346	289	16	80	80	NUM
biomedich-346	289	17	[	[	SYM
biomedich-346	289	18	82	82	NUM
biomedich-346	289	19	%	%	NOUN
biomedich-346	289	20	]	]	PUNCT
biomedich-346	289	21	of	of	ADP
biomedich-346	289	22	97	97	NUM
biomedich-346	289	23	participants	participant	NOUN
biomedich-346	289	24	had	have	VERB
biomedich-346	289	25	any	any	DET
biomedich-346	289	26	adverse	adverse	ADJ
biomedich-346	289	27	event	event	NOUN
biomedich-346	289	28	;	;	PUNCT
biomedich-346	289	29	13	13	NUM
biomedich-346	290	1	[	[	SYM
biomedich-346	290	2	13	13	NUM
biomedich-346	290	3	%	%	NOUN
biomedich-346	290	4	]	]	PUNCT
biomedich-346	290	5	had	have	VERB
biomedich-346	290	6	a	a	DET
biomedich-346	290	7	grade	grade	NOUN
biomedich-346	290	8	≥3	≥3	NOUN
biomedich-346	290	9	events	event	NOUN
biomedich-346	290	10	)	)	PUNCT
biomedich-346	290	11	and	and	CCONJ
biomedich-346	290	12	systemic	systemic	ADJ
biomedich-346	290	13	(	(	PUNCT
biomedich-346	290	14	75	75	NUM
biomedich-346	290	15	[	[	X
biomedich-346	290	16	77	77	NUM
biomedich-346	290	17	%	%	NOUN
biomedich-346	290	18	]	]	PUNCT
biomedich-346	290	19	of	of	ADP
biomedich-346	290	20	98	98	NUM
biomedich-346	290	21	participants	participant	NOUN
biomedich-346	290	22	had	have	VERB
biomedich-346	290	23	any	any	DET
biomedich-346	290	24	adverse	adverse	ADJ
biomedich-346	290	25	event	event	NOUN
biomedich-346	290	26	;	;	PUNCT
biomedich-346	291	1	15	15	NUM
biomedich-346	291	2	[	[	SYM
biomedich-346	291	3	15	15	NUM
biomedich-346	291	4	%	%	NOUN
biomedich-346	291	5	]	]	PUNCT
biomedich-346	291	6	had	have	VERB
biomedich-346	291	7	a	a	DET
biomedich-346	291	8	grade	grade	NOUN
biomedich-346	291	9	≥3	≥3	PROPN
biomedich-346	291	10	events	event	NOUN
biomedich-346	291	11	)	)	PUNCT
biomedich-346	291	12	reactions	reaction	NOUN
biomedich-346	291	13	was	be	AUX
biomedich-346	291	14	higher	high	ADJ
biomedich-346	291	15	than	than	ADP
biomedich-346	291	16	after	after	ADP
biomedich-346	291	17	primary	primary	ADJ
biomedich-346	291	18	vaccination	vaccination	NOUN
biomedich-346	291	19	(	(	PUNCT
biomedich-346	291	20	175	175	NUM
biomedich-346	292	1	[	[	X
biomedich-346	292	2	70	70	NUM
biomedich-346	292	3	%	%	NOUN
biomedich-346	292	4	]	]	PUNCT
biomedich-346	292	5	of	of	ADP
biomedich-346	292	6	250	250	NUM
biomedich-346	292	7	participants	participant	NOUN
biomedich-346	292	8	had	have	VERB
biomedich-346	292	9	any	any	DET
biomedich-346	292	10	local	local	ADJ
biomedich-346	292	11	adverse	adverse	ADJ
biomedich-346	292	12	event	event	NOUN
biomedich-346	292	13	,	,	PUNCT
biomedich-346	292	14	13	13	NUM
biomedich-346	292	15	[	[	SYM
biomedich-346	292	16	5	5	NUM
biomedich-346	292	17	%	%	NOUN
biomedich-346	292	18	]	]	PUNCT
biomedich-346	292	19	had	have	VERB
biomedich-346	292	20	a	a	DET
biomedich-346	292	21	grade	grade	NOUN
biomedich-346	292	22	≥3	≥3	NOUN
biomedich-346	292	23	events	event	NOUN
biomedich-346	292	24	;	;	PUNCT
biomedich-346	292	25	132	132	NUM
biomedich-346	292	26	[	[	SYM
biomedich-346	292	27	53	53	NUM
biomedich-346	292	28	%	%	NOUN
biomedich-346	292	29	]	]	PUNCT
biomedich-346	292	30	of	of	ADP
biomedich-346	292	31	250	250	NUM
biomedich-346	292	32	had	have	VERB
biomedich-346	292	33	any	any	DET
biomedich-346	292	34	systemic	systemic	ADJ
biomedich-346	292	35	adverse	adverse	ADJ
biomedich-346	292	36	event	event	NOUN
biomedich-346	292	37	,	,	PUNCT
biomedich-346	292	38	14	14	NUM
biomedich-346	292	39	[	[	SYM
biomedich-346	292	40	6	6	NUM
biomedich-346	292	41	%	%	NOUN
biomedich-346	292	42	]	]	PUNCT
biomedich-346	292	43	had	have	VERB
biomedich-346	292	44	a	a	DET
biomedich-346	292	45	grade	grade	NOUN
biomedich-346	292	46	≥3events	≥3event	NOUN
biomedich-346	292	47	)	)	PUNCT
biomedich-346	292	48	.	.	PUNCT
biomedich-346	293	1	local	local	ADJ
biomedich-346	293	2	and	and	CCONJ
biomedich-346	293	3	systemic	systemic	ADJ
biomedich-346	293	4	events	event	NOUN
biomedich-346	293	5	were	be	AUX
biomedich-346	293	6	transient	transient	ADJ
biomedich-346	293	7	in	in	ADP
biomedich-346	293	8	nature	nature	NOUN
biomedich-346	293	9	(	(	PUNCT
biomedich-346	293	10	median	median	ADJ
biomedich-346	293	11	duration	duration	NOUN
biomedich-346	293	12	1·0	1·0	NUM
biomedich-346	293	13	-	-	SYM
biomedich-346	293	14	2·5	2·5	NUM
biomedich-346	293	15	days	day	NOUN
biomedich-346	293	16	)	)	PUNCT
biomedich-346	293	17	.	.	PUNCT
biomedich-346	294	1	in	in	ADP
biomedich-346	294	2	the	the	DET
biomedich-346	294	3	per	per	ADP
biomedich-346	294	4	-	-	PUNCT
biomedich-346	294	5	protocol	protocol	NOUN
biomedich-346	294	6	immunogenicity	immunogenicity	NOUN
biomedich-346	294	7	population	population	NOUN
biomedich-346	294	8	at	at	ADP
biomedich-346	294	9	day	day	NOUN
biomedich-346	294	10	217	217	NUM
biomedich-346	294	11	(	(	PUNCT
biomedich-346	294	12	167	167	NUM
biomedich-346	294	13	participants	participant	NOUN
biomedich-346	294	14	in	in	ADP
biomedich-346	294	15	group	group	PROPN
biomedich-346	294	16	a	a	PROPN
biomedich-346	294	17	,	,	PUNCT
biomedich-346	294	18	101	101	NUM
biomedich-346	294	19	participants	participant	NOUN
biomedich-346	294	20	in	in	ADP
biomedich-346	294	21	group	group	NOUN
biomedich-346	294	22	b1	b1	PROPN
biomedich-346	294	23	,	,	PUNCT
biomedich-346	294	24	101	101	NUM
biomedich-346	294	25	participants	participant	NOUN
biomedich-346	294	26	in	in	ADP
biomedich-346	294	27	group	group	NOUN
biomedich-346	294	28	b2	b2	NOUN
biomedich-346	294	29	)	)	PUNCT
biomedich-346	294	30	,	,	PUNCT
biomedich-346	294	31	igg	igg	PROPN
biomedich-346	294	32	geometric	geometric	ADJ
biomedich-346	294	33	mean	mean	NOUN
biomedich-346	294	34	titers	titer	NOUN
biomedich-346	294	35	(	(	PUNCT
biomedich-346	294	36	gmt	gmt	PROPN
biomedich-346	294	37	)	)	PUNCT
biomedich-346	294	38	had	have	AUX
biomedich-346	294	39	increased	increase	VERB
biomedich-346	294	40	by	by	ADP
biomedich-346	294	41	4·7	4·7	NOUN
biomedich-346	294	42	-	-	ADJ
biomedich-346	294	43	fold	fold	ADJ
biomedich-346	294	44	and	and	CCONJ
biomedich-346	294	45	mn50	mn50	PROPN
biomedich-346	294	46	gmt	gmt	PROPN
biomedich-346	294	47	by	by	ADP
biomedich-346	294	48	4·1	4·1	NOUN
biomedich-346	294	49	-	-	NOUN
biomedich-346	294	50	fold	fold	ADJ
biomedich-346	294	51	for	for	ADP
biomedich-346	294	52	the	the	DET
biomedich-346	294	53	ancestral	ancestral	ADJ
biomedich-346	294	54	sarscov-2	sarscov-2	NUM
biomedich-346	294	55	strain	strain	NOUN
biomedich-346	294	56	compared	compare	VERB
biomedich-346	294	57	with	with	ADP
biomedich-346	294	58	the	the	DET
biomedich-346	294	59	day	day	NOUN
biomedich-346	294	60	35	35	NUM
biomedich-346	294	61	titers	titer	NOUN
biomedich-346	294	62	.	.	PUNCT
biomedich-346	295	1	heath	heath	PROPN
biomedich-346	295	2	et	et	PROPN
biomedich-346	295	3	al	al	PROPN
biomedich-346	295	4	.	.	PROPN
biomedich-346	295	5	safety	safety	PROPN
biomedich-346	295	6	and	and	CCONJ
biomedich-346	295	7	efficacy	efficacy	NOUN
biomedich-346	295	8	of	of	ADP
biomedich-346	295	9	the	the	DET
biomedich-346	295	10	nvxcov2373	nvxcov2373	PROPN
biomedich-346	295	11	coronavirus	coronavirus	NOUN
biomedich-346	295	12	disease	disease	NOUN
biomedich-346	295	13	2019	2019	NUM
biomedich-346	295	14	vaccine	vaccine	NOUN
biomedich-346	295	15	at	at	ADP
biomedich-346	295	16	completion	completion	NOUN
biomedich-346	295	17	of	of	ADP
biomedich-346	295	18	the	the	DET
biomedich-346	295	19	placebo	placebo	NOUN
biomedich-346	295	20	-	-	PUNCT
biomedich-346	295	21	controlled	control	VERB
biomedich-346	295	22	phase	phase	NOUN
biomedich-346	295	23	of	of	ADP
biomedich-346	295	24	a	a	DET
biomedich-346	295	25	randomized	randomized	ADJ
biomedich-346	295	26	controlled	control	VERB
biomedich-346	295	27	trial	trial	NOUN
biomedich-346	295	28	clinical	clinical	ADJ
biomedich-346	295	29	trial	trial	NOUN
biomedich-346	295	30	2023	2023	NUM
biomedich-346	295	31	adults	adult	NOUN
biomedich-346	295	32	aged	age	VERB
biomedich-346	295	33	18	18	NUM
biomedich-346	295	34	-	-	SYM
biomedich-346	295	35	84	84	NUM
biomedich-346	295	36	years	year	NOUN
biomedich-346	295	37	received	receive	VERB
biomedich-346	295	38	2	2	NUM
biomedich-346	295	39	doses	dose	NOUN
biomedich-346	295	40	of	of	ADP
biomedich-346	295	41	nvxcov2373	nvxcov2373	NOUN
biomedich-346	295	42	or	or	CCONJ
biomedich-346	295	43	placebo	placebo	NOUN
biomedich-346	295	44	(	(	PUNCT
biomedich-346	295	45	1:1	1:1	NUM
biomedich-346	295	46	)	)	PUNCT
biomedich-346	295	47	and	and	CCONJ
biomedich-346	295	48	were	be	AUX
biomedich-346	295	49	monitored	monitor	VERB
biomedich-346	295	50	for	for	ADP
biomedich-346	295	51	virologically	virologically	ADV
biomedich-346	295	52	confirmed	confirm	VERB
biomedich-346	295	53	mild	mild	ADJ
biomedich-346	295	54	,	,	PUNCT
biomedich-346	295	55	moderate	moderate	ADJ
biomedich-346	295	56	,	,	PUNCT
biomedich-346	295	57	or	or	CCONJ
biomedich-346	295	58	severe	severe	ADJ
biomedich-346	295	59	covid-19	covid-19	PROPN
biomedich-346	295	60	(	(	PUNCT
biomedich-346	295	61	onset	onset	VERB
biomedich-346	295	62	from	from	ADP
biomedich-346	295	63	7	7	NUM
biomedich-346	295	64	days	day	NOUN
biomedich-346	295	65	after	after	ADP
biomedich-346	295	66	second	second	ADJ
biomedich-346	295	67	vaccination	vaccination	NOUN
biomedich-346	295	68	)	)	PUNCT
biomedich-346	295	69	.	.	PUNCT
biomedich-346	296	1	participants	participant	NOUN
biomedich-346	296	2	who	who	PRON
biomedich-346	296	3	developed	develop	VERB
biomedich-346	296	4	immunoglobulin	immunoglobulin	NOUN
biomedich-346	296	5	g	g	PROPN
biomedich-346	296	6	(	(	PUNCT
biomedich-346	296	7	igg	igg	PROPN
biomedich-346	296	8	)	)	PUNCT
biomedich-346	296	9	against	against	ADP
biomedich-346	296	10	nucleocapsid	nucleocapsid	ADJ
biomedich-346	296	11	protein	protein	NOUN
biomedich-346	296	12	but	but	CCONJ
biomedich-346	296	13	did	do	AUX
biomedich-346	296	14	not	not	PART
biomedich-346	296	15	show	show	VERB
biomedich-346	296	16	symptomatic	symptomatic	ADJ
biomedich-346	296	17	covid-19	covid-19	PROPN
biomedich-346	296	18	were	be	AUX
biomedich-346	296	19	considered	consider	VERB
biomedich-346	296	20	asymptomatic	asymptomatic	ADJ
biomedich-346	296	21	.	.	PUNCT
biomedich-346	297	1	secondary	secondary	ADJ
biomedich-346	297	2	outcomes	outcome	NOUN
biomedich-346	297	3	included	include	VERB
biomedich-346	297	4	anti	anti	ADJ
biomedich-346	297	5	-	-	ADJ
biomedich-346	297	6	spike	spike	ADJ
biomedich-346	297	7	(	(	PUNCT
biomedich-346	297	8	s	s	NOUN
biomedich-346	297	9	)	)	PUNCT
biomedich-346	297	10	igg	igg	NOUN
biomedich-346	297	11	responses	response	NOUN
biomedich-346	297	12	,	,	PUNCT
biomedich-346	297	13	wild	wild	ADJ
biomedich-346	297	14	-	-	PUNCT
biomedich-346	297	15	type	type	NOUN
biomedich-346	297	16	virus	virus	NOUN
biomedich-346	297	17	neutralization	neutralization	NOUN
biomedich-346	297	18	,	,	PUNCT
biomedich-346	297	19	and	and	CCONJ
biomedich-346	297	20	t	t	NOUN
biomedich-346	297	21	-	-	PUNCT
biomedich-346	297	22	cell	cell	NOUN
biomedich-346	297	23	responses	response	NOUN
biomedich-346	297	24	.	.	PUNCT
biomedich-346	298	1	incidence	incidence	NOUN
biomedich-346	298	2	of	of	ADP
biomedich-346	298	3	serious	serious	ADJ
biomedich-346	298	4	adverse	adverse	ADJ
biomedich-346	298	5	events	event	NOUN
biomedich-346	298	6	and	and	CCONJ
biomedich-346	298	7	adverse	adverse	ADJ
biomedich-346	298	8	events	event	NOUN
biomedich-346	298	9	of	of	ADP
biomedich-346	298	10	special	special	ADJ
biomedich-346	298	11	interest	interest	NOUN
biomedich-346	298	12	were	be	AUX
biomedich-346	298	13	similar	similar	ADJ
biomedich-346	298	14	between	between	ADP
biomedich-346	298	15	groups	group	NOUN
biomedich-346	298	16	.	.	PUNCT
biomedich-346	299	1	lovell	lovell	PROPN
biomedich-346	299	2	et	et	PROPN
biomedich-346	299	3	al	al	PROPN
biomedich-346	299	4	.	.	PROPN
biomedich-346	299	5	interim	interim	ADJ
biomedich-346	299	6	analysis	analysis	NOUN
biomedich-346	299	7	from	from	ADP
biomedich-346	299	8	a	a	DET
biomedich-346	299	9	phase	phase	NOUN
biomedich-346	299	10	2	2	NUM
biomedich-346	299	11	randomized	randomize	VERB
biomedich-346	299	12	trial	trial	NOUN
biomedich-346	299	13	of	of	ADP
biomedich-346	299	14	eucorvac19	eucorvac19	NOUN
biomedich-346	299	15	:	:	PUNCT
biomedich-346	299	16	a	a	DET
biomedich-346	299	17	recombinant	recombinant	ADJ
biomedich-346	299	18	protein	protein	NOUN
biomedich-346	299	19	sars	sar	NOUN
biomedich-346	299	20	-	-	PUNCT
biomedich-346	299	21	cov-2	cov-2	NOUN
biomedich-346	299	22	rbd	rbd	NOUN
biomedich-346	299	23	nanoliposome	nanoliposome	NOUN
biomedich-346	299	24	vaccine	vaccine	NOUN
biomedich-346	299	25	clinical	clinical	ADJ
biomedich-346	299	26	trial	trial	NOUN
biomedich-346	299	27	2022	2022	NUM
biomedich-346	299	28	an	an	DET
biomedich-346	299	29	initial	initial	ADJ
biomedich-346	299	30	study	study	NOUN
biomedich-346	299	31	of	of	ADP
biomedich-346	299	32	phase	phase	NOUN
biomedich-346	299	33	2	2	NUM
biomedich-346	299	34	randomized	randomize	VERB
biomedich-346	299	35	,	,	PUNCT
biomedich-346	299	36	observer	observer	NOUN
biomedich-346	299	37	-	-	PUNCT
biomedich-346	299	38	blind	blind	ADJ
biomedich-346	299	39	,	,	PUNCT
biomedich-346	299	40	placebo	placebo	NOUN
biomedich-346	299	41	-	-	PUNCT
biomedich-346	299	42	controlled	control	VERB
biomedich-346	299	43	trial	trial	NOUN
biomedich-346	299	44	to	to	PART
biomedich-346	299	45	assess	assess	VERB
biomedich-346	299	46	the	the	DET
biomedich-346	299	47	immunogenicity	immunogenicity	NOUN
biomedich-346	299	48	,	,	PUNCT
biomedich-346	299	49	safety	safety	NOUN
biomedich-346	299	50	,	,	PUNCT
biomedich-346	299	51	and	and	CCONJ
biomedich-346	299	52	tolerance	tolerance	NOUN
biomedich-346	299	53	of	of	ADP
biomedich-346	299	54	ecv19	ecv19	PROPN
biomedich-346	299	55	was	be	AUX
biomedich-346	299	56	carried	carry	VERB
biomedich-346	299	57	out	out	ADP
biomedich-346	299	58	between	between	ADP
biomedich-346	299	59	july	july	PROPN
biomedich-346	299	60	and	and	CCONJ
biomedich-346	299	61	october	october	PROPN
biomedich-346	299	62	2021	2021	NUM
biomedich-346	299	63	.	.	PUNCT
biomedich-346	300	1	two	two	NUM
biomedich-346	300	2	hundred	hundred	NUM
biomedich-346	300	3	twenty	twenty	NUM
biomedich-346	300	4	-	-	PUNCT
biomedich-346	300	5	nine	nine	NUM
biomedich-346	300	6	participants	participant	NOUN
biomedich-346	300	7	were	be	AUX
biomedich-346	300	8	enrolled	enrol	VERB
biomedich-346	300	9	at	at	ADP
biomedich-346	300	10	5	5	NUM
biomedich-346	300	11	hospital	hospital	NOUN
biomedich-346	300	12	sites	site	NOUN
biomedich-346	300	13	in	in	ADP
biomedich-346	300	14	south	south	PROPN
biomedich-346	300	15	korea	korea	PROPN
biomedich-346	300	16	.	.	PUNCT
biomedich-346	301	1	healthy	healthy	ADJ
biomedich-346	301	2	adults	adult	NOUN
biomedich-346	301	3	aged	age	VERB
biomedich-346	301	4	19	19	NUM
biomedich-346	301	5	-	-	SYM
biomedich-346	301	6	75	75	NUM
biomedich-346	301	7	without	without	ADP
biomedich-346	301	8	prior	prior	ADJ
biomedich-346	301	9	known	know	VERB
biomedich-346	301	10	exposure	exposure	NOUN
biomedich-346	301	11	to	to	ADP
biomedich-346	301	12	covid-19	covid-19	PROPN
biomedich-346	301	13	were	be	AUX
biomedich-346	301	14	vaccinated	vaccinate	VERB
biomedich-346	301	15	intramuscularly	intramuscularly	ADV
biomedich-346	301	16	on	on	ADP
biomedich-346	301	17	day	day	NOUN
biomedich-346	301	18	0	0	NUM
biomedich-346	301	19	and	and	CCONJ
biomedich-346	301	20	day	day	NOUN
biomedich-346	301	21	21	21	NUM
biomedich-346	301	22	.	.	PUNCT
biomedich-346	301	23	of	of	ADP
biomedich-346	301	24	the	the	DET
biomedich-346	301	25	participants	participant	NOUN
biomedich-346	301	26	who	who	PRON
biomedich-346	301	27	received	receive	VERB
biomedich-346	301	28	two	two	NUM
biomedich-346	301	29	vaccine	vaccine	NOUN
biomedich-346	301	30	doses	dose	NOUN
biomedich-346	301	31	according	accord	VERB
biomedich-346	301	32	to	to	ADP
biomedich-346	301	33	protocol	protocol	NOUN
biomedich-346	301	34	,	,	PUNCT
biomedich-346	301	35	100	100	NUM
biomedich-346	301	36	neutralizing	neutralize	VERB
biomedich-346	301	37	antibody	antibody	NOUN
biomedich-346	301	38	levels	level	NOUN
biomedich-346	301	39	of	of	ADP
biomedich-346	301	40	the	the	DET
biomedich-346	301	41	low	low	ADV
biomedich-346	301	42	-	-	PUNCT
biomedich-346	301	43	dose	dose	NOUN
biomedich-346	301	44	and	and	CCONJ
biomedich-346	301	45	high	high	ADV
biomedich-346	301	46	-	-	PUNCT
biomedich-346	301	47	dose	dose	VERB
biomedich-346	301	48	ecv19	ecv19	PROPN
biomedich-346	301	49	groups	group	NOUN
biomedich-346	301	50	had	have	VERB
biomedich-346	301	51	frnt50	frnt50	NOUN
biomedich-346	301	52	geometric	geometric	ADJ
biomedich-346	301	53	mean	mean	ADJ
biomedich-346	301	54	values	value	NOUN
biomedich-346	301	55	of	of	ADP
biomedich-346	301	56	129	129	NUM
biomedich-346	301	57	and	and	CCONJ
biomedich-346	301	58	316	316	NUM
biomedich-346	301	59	,	,	PUNCT
biomedich-346	301	60	respectively	respectively	ADV
biomedich-346	301	61	.	.	PUNCT
biomedich-346	302	1	boosting	boost	VERB
biomedich-346	302	2	responses	response	NOUN
biomedich-346	302	3	and	and	CCONJ
biomedich-346	302	4	dose	dose	NOUN
biomedich-346	302	5	responses	response	NOUN
biomedich-346	302	6	were	be	AUX
biomedich-346	302	7	observed	observe	VERB
biomedich-346	302	8	.	.	PUNCT
biomedich-346	303	1	antibodies	antibodie	VERB
biomedich-346	303	2	against	against	ADP
biomedich-346	303	3	the	the	DET
biomedich-346	303	4	rbd	rbd	NOUN
biomedich-346	303	5	correlated	correlate	VERB
biomedich-346	303	6	with	with	ADP
biomedich-346	303	7	antibodies	antibody	NOUN
biomedich-346	303	8	against	against	ADP
biomedich-346	303	9	the	the	DET
biomedich-346	303	10	spike	spike	NOUN
biomedich-346	303	11	and	and	CCONJ
biomedich-346	303	12	with	with	ADP
biomedich-346	303	13	virus	virus	NOUN
biomedich-346	303	14	neutralization	neutralization	NOUN
biomedich-346	303	15	.	.	PUNCT
biomedich-346	304	1	hussein	hussein	PROPN
biomedich-346	304	2	et	et	PROPN
biomedich-346	304	3	al	al	PROPN
biomedich-346	304	4	.	.	PROPN
biomedich-346	304	5	–	–	PUNCT
biomedich-346	304	6	nanotechnology	nanotechnology	NOUN
biomedich-346	304	7	-	-	PUNCT
biomedich-346	304	8	based	base	VERB
biomedich-346	304	9	vaccines	vaccine	NOUN
biomedich-346	304	10	357	357	NUM
biomedich-346	304	11	authors	author	NOUN
biomedich-346	304	12	title	title	VERB
biomedich-346	304	13	date	date	NOUN
biomedich-346	304	14	and	and	CCONJ
biomedich-346	304	15	type	type	NOUN
biomedich-346	304	16	of	of	ADP
biomedich-346	304	17	the	the	DET
biomedich-346	304	18	study	study	NOUN
biomedich-346	304	19	method	method	NOUN
biomedich-346	304	20	results	result	NOUN
biomedich-346	304	21	received	receive	VERB
biomedich-346	304	22	high	high	ADJ
biomedich-346	304	23	-	-	PUNCT
biomedich-346	304	24	dose	dose	NOUN
biomedich-346	304	25	ecv19	ecv19	PROPN
biomedich-346	304	26	(	(	PUNCT
biomedich-346	304	27	20	20	NUM
biomedich-346	304	28	μg	μg	PROPN
biomedich-346	304	29	rbd	rbd	PROPN
biomedich-346	304	30	)	)	PUNCT
biomedich-346	304	31	,	,	PUNCT
biomedich-346	304	32	96	96	NUM
biomedich-346	304	33	received	receive	VERB
biomedich-346	304	34	low	low	ADV
biomedich-346	304	35	-	-	PUNCT
biomedich-346	304	36	dose	dose	NOUN
biomedich-346	304	37	ecv19	ecv19	PROPN
biomedich-346	304	38	(	(	PUNCT
biomedich-346	304	39	10	10	NUM
biomedich-346	304	40	μg	μg	PROPN
biomedich-346	304	41	rbd	rbd	PROPN
biomedich-346	304	42	)	)	PUNCT
biomedich-346	304	43	,	,	PUNCT
biomedich-346	304	44	and	and	CCONJ
biomedich-346	304	45	27	27	NUM
biomedich-346	304	46	received	receive	VERB
biomedich-346	304	47	a	a	DET
biomedich-346	304	48	placebo	placebo	NOUN
biomedich-346	304	49	.	.	PUNCT
biomedich-346	305	1	local	local	ADJ
biomedich-346	305	2	and	and	CCONJ
biomedich-346	305	3	systemic	systemic	ADJ
biomedich-346	305	4	adverse	adverse	ADJ
biomedich-346	305	5	events	event	NOUN
biomedich-346	305	6	were	be	AUX
biomedich-346	305	7	monitored	monitor	VERB
biomedich-346	305	8	.	.	PUNCT
biomedich-346	306	1	serum	serum	PROPN
biomedich-346	306	2	was	be	AUX
biomedich-346	306	3	assessed	assess	VERB
biomedich-346	306	4	on	on	ADP
biomedich-346	306	5	days	day	NOUN
biomedich-346	306	6	0	0	NUM
biomedich-346	306	7	,	,	PUNCT
biomedich-346	306	8	21	21	NUM
biomedich-346	306	9	,	,	PUNCT
biomedich-346	306	10	and	and	CCONJ
biomedich-346	306	11	42	42	NUM
biomedich-346	306	12	for	for	ADP
biomedich-346	306	13	immunogenicity	immunogenicity	NOUN
biomedich-346	306	14	analysis	analysis	NOUN
biomedich-346	306	15	by	by	ADP
biomedich-346	306	16	elisa	elisa	NOUN
biomedich-346	306	17	and	and	CCONJ
biomedich-346	306	18	neutralizing	neutralize	VERB
biomedich-346	306	19	antibody	antibody	NOUN
biomedich-346	306	20	response	response	NOUN
biomedich-346	306	21	by	by	ADP
biomedich-346	306	22	focus	focus	NOUN
biomedich-346	306	23	reduction	reduction	NOUN
biomedich-346	306	24	neutralization	neutralization	NOUN
biomedich-346	306	25	test	test	NOUN
biomedich-346	306	26	(	(	PUNCT
biomedich-346	306	27	frnt	frnt	PROPN
biomedich-346	306	28	)	)	PUNCT
biomedich-346	306	29	.	.	PUNCT
biomedich-346	307	1	gatechompol	gatechompol	PROPN
biomedich-346	307	2	et	et	PROPN
biomedich-346	307	3	al	al	PROPN
biomedich-346	307	4	.	.	PROPN
biomedich-346	307	5	safety	safety	NOUN
biomedich-346	307	6	and	and	CCONJ
biomedich-346	307	7	immunogenicity	immunogenicity	NOUN
biomedich-346	307	8	of	of	ADP
biomedich-346	307	9	a	a	DET
biomedich-346	307	10	prefusion	prefusion	NOUN
biomedich-346	307	11	nonstabilized	nonstabilize	VERB
biomedich-346	307	12	spike	spike	ADJ
biomedich-346	307	13	protein	protein	NOUN
biomedich-346	307	14	mrna	mrna	PROPN
biomedich-346	307	15	covid-19	covid-19	PROPN
biomedich-346	307	16	vaccine	vaccine	NOUN
biomedich-346	307	17	:	:	PUNCT
biomedich-346	307	18	a	a	DET
biomedich-346	307	19	phase	phase	NOUN
biomedich-346	307	20	i	i	PRON
biomedich-346	307	21	trial	trial	VERB
biomedich-346	307	22	clinical	clinical	ADJ
biomedich-346	307	23	trial	trial	NOUN
biomedich-346	307	24	2022	2022	NUM
biomedich-346	307	25	seventy	seventy	NUM
biomedich-346	307	26	-	-	PUNCT
biomedich-346	307	27	two	two	NUM
biomedich-346	307	28	eligible	eligible	ADJ
biomedich-346	307	29	volunteers	volunteer	NOUN
biomedich-346	307	30	,	,	PUNCT
biomedich-346	307	31	36	36	NUM
biomedich-346	307	32	of	of	ADP
biomedich-346	307	33	whom	whom	PRON
biomedich-346	307	34	were	be	AUX
biomedich-346	307	35	aged	age	VERB
biomedich-346	307	36	18	18	NUM
biomedich-346	307	37	-	-	SYM
biomedich-346	307	38	55	55	NUM
biomedich-346	307	39	(	(	PUNCT
biomedich-346	307	40	adults	adult	NOUN
biomedich-346	307	41	)	)	PUNCT
biomedich-346	307	42	and	and	CCONJ
biomedich-346	307	43	36	36	NUM
biomedich-346	307	44	aged	aged	ADJ
biomedich-346	307	45	56	56	NUM
biomedich-346	307	46	-	-	SYM
biomedich-346	307	47	75	75	NUM
biomedich-346	307	48	(	(	PUNCT
biomedich-346	307	49	elderly	elderly	ADJ
biomedich-346	307	50	)	)	PUNCT
biomedich-346	307	51	,	,	PUNCT
biomedich-346	307	52	were	be	AUX
biomedich-346	307	53	enrolled	enrol	VERB
biomedich-346	307	54	.	.	PUNCT
biomedich-346	308	1	two	two	NUM
biomedich-346	308	2	doses	dose	NOUN
biomedich-346	308	3	of	of	ADP
biomedich-346	308	4	vaccine	vaccine	NOUN
biomedich-346	308	5	were	be	AUX
biomedich-346	308	6	administered	administer	VERB
biomedich-346	308	7	21	21	NUM
biomedich-346	308	8	d	d	NOUN
biomedich-346	308	9	apart	apart	ADV
biomedich-346	308	10	at	at	ADP
biomedich-346	308	11	10	10	NUM
biomedich-346	308	12	,	,	PUNCT
biomedich-346	308	13	25	25	NUM
biomedich-346	308	14	or	or	CCONJ
biomedich-346	308	15	50	50	NUM
biomedich-346	308	16	μg	μg	NOUN
biomedich-346	308	17	per	per	ADP
biomedich-346	308	18	dose	dose	PROPN
biomedich-346	308	19	(	(	PUNCT
biomedich-346	308	20	12	12	NUM
biomedich-346	308	21	per	per	ADP
biomedich-346	308	22	group	group	NOUN
biomedich-346	308	23	)	)	PUNCT
biomedich-346	308	24	.	.	PUNCT
biomedich-346	309	1	the	the	DET
biomedich-346	309	2	primary	primary	ADJ
biomedich-346	309	3	outcome	outcome	NOUN
biomedich-346	309	4	was	be	AUX
biomedich-346	309	5	safety	safety	NOUN
biomedich-346	309	6	,	,	PUNCT
biomedich-346	309	7	and	and	CCONJ
biomedich-346	309	8	the	the	DET
biomedich-346	309	9	secondary	secondary	ADJ
biomedich-346	309	10	outcome	outcome	NOUN
biomedich-346	309	11	was	be	AUX
biomedich-346	309	12	immunogenicity	immunogenicity	NOUN
biomedich-346	309	13	.	.	PUNCT
biomedich-346	310	1	all	all	DET
biomedich-346	310	2	three	three	NUM
biomedich-346	310	3	dosages	dosage	NOUN
biomedich-346	310	4	of	of	ADP
biomedich-346	310	5	chulacov19	chulacov19	NOUN
biomedich-346	310	6	were	be	AUX
biomedich-346	310	7	well	well	ADV
biomedich-346	310	8	tolerated	tolerate	VERB
biomedich-346	310	9	and	and	CCONJ
biomedich-346	310	10	elicited	elicit	VERB
biomedich-346	310	11	robust	robust	ADJ
biomedich-346	310	12	dosedependent	dosedependent	NOUN
biomedich-346	310	13	and	and	CCONJ
biomedich-346	310	14	age	age	NOUN
biomedich-346	310	15	-	-	PUNCT
biomedich-346	310	16	dependent	dependent	ADJ
biomedich-346	310	17	b	b	PROPN
biomedich-346	310	18	and	and	CCONJ
biomedich-346	310	19	t	t	PROPN
biomedich-346	310	20	-	-	PUNCT
biomedich-346	310	21	cell	cell	NOUN
biomedich-346	310	22	responses	response	NOUN
biomedich-346	310	23	mrna	mrna	PROPN
biomedich-346	310	24	vaccine	vaccine	NOUN
biomedich-346	310	25	expressing	express	VERB
biomedich-346	310	26	a	a	DET
biomedich-346	310	27	prefusion	prefusion	NOUN
biomedich-346	310	28	non	non	ADJ
biomedich-346	310	29	-	-	ADJ
biomedich-346	310	30	stabilized	stabilized	ADJ
biomedich-346	310	31	spike	spike	ADJ
biomedich-346	310	32	protein	protein	NOUN
biomedich-346	310	33	is	be	AUX
biomedich-346	310	34	safe	safe	ADJ
biomedich-346	310	35	and	and	CCONJ
biomedich-346	310	36	highly	highly	ADV
biomedich-346	310	37	immunogenic	immunogenic	ADJ
biomedich-346	310	38	.	.	PUNCT
biomedich-346	311	1	masuda	masuda	PROPN
biomedich-346	311	2	et	et	PROPN
biomedich-346	311	3	al	al	PROPN
biomedich-346	311	4	.	.	PROPN
biomedich-346	311	5	safety	safety	NOUN
biomedich-346	311	6	and	and	CCONJ
biomedich-346	311	7	immunogenicity	immunogenicity	NOUN
biomedich-346	311	8	of	of	ADP
biomedich-346	311	9	nvx	nvx	NOUN
biomedich-346	311	10	-	-	PUNCT
biomedich-346	311	11	cov2373	cov2373	PROPN
biomedich-346	311	12	(	(	PUNCT
biomedich-346	311	13	tak-019	tak-019	NOUN
biomedich-346	311	14	)	)	PUNCT
biomedich-346	311	15	vaccine	vaccine	NOUN
biomedich-346	311	16	in	in	ADP
biomedich-346	311	17	healthy	healthy	ADJ
biomedich-346	311	18	japanese	japanese	ADJ
biomedich-346	311	19	adults	adult	NOUN
biomedich-346	311	20	:	:	PUNCT
biomedich-346	311	21	interim	interim	ADJ
biomedich-346	311	22	report	report	NOUN
biomedich-346	311	23	of	of	ADP
biomedich-346	311	24	a	a	DET
biomedich-346	311	25	phase	phase	NOUN
biomedich-346	311	26	i	i	PRON
biomedich-346	311	27	/	/	SYM
biomedich-346	311	28	ii	ii	PROPN
biomedich-346	311	29	randomized	randomize	VERB
biomedich-346	311	30	controlled	control	VERB
biomedich-346	311	31	trial	trial	NOUN
biomedich-346	311	32	clinical	clinical	ADJ
biomedich-346	311	33	trial	trial	NOUN
biomedich-346	311	34	2022	2022	NUM
biomedich-346	311	35	this	this	DET
biomedich-346	311	36	phase	phase	NOUN
biomedich-346	311	37	1/2	1/2	NUM
biomedich-346	311	38	,	,	PUNCT
biomedich-346	311	39	randomized	randomize	VERB
biomedich-346	311	40	,	,	PUNCT
biomedich-346	311	41	observer	observer	NOUN
biomedich-346	311	42	-	-	PUNCT
biomedich-346	311	43	blind	blind	ADJ
biomedich-346	311	44	,	,	PUNCT
biomedich-346	311	45	placebocontrolled	placebocontrolle	VERB
biomedich-346	311	46	trial	trial	NOUN
biomedich-346	311	47	conducted	conduct	VERB
biomedich-346	311	48	in	in	ADP
biomedich-346	311	49	japan	japan	PROPN
biomedich-346	311	50	(	(	PUNCT
biomedich-346	311	51	two	two	NUM
biomedich-346	311	52	sites	site	NOUN
biomedich-346	311	53	)	)	PUNCT
biomedich-346	311	54	,	,	PUNCT
biomedich-346	311	55	enrolled	enrol	VERB
biomedich-346	311	56	healthy	healthy	ADJ
biomedich-346	311	57	japanese	japanese	ADJ
biomedich-346	311	58	adults	adult	NOUN
biomedich-346	311	59	aged	age	VERB
biomedich-346	311	60	≥	≥	NUM
biomedich-346	311	61	20	20	NUM
biomedich-346	311	62	years	year	NOUN
biomedich-346	311	63	with	with	ADP
biomedich-346	311	64	no	no	DET
biomedich-346	311	65	history	history	NOUN
biomedich-346	311	66	/	/	SYM
biomedich-346	311	67	risk	risk	NOUN
biomedich-346	311	68	of	of	ADP
biomedich-346	311	69	sars	sar	NOUN
biomedich-346	311	70	-	-	PUNCT
biomedich-346	311	71	cov-2	cov-2	PART
biomedich-346	311	72	infection	infection	NOUN
biomedich-346	311	73	and	and	CCONJ
biomedich-346	311	74	no	no	DET
biomedich-346	311	75	prior	prior	ADJ
biomedich-346	311	76	exposure	exposure	NOUN
biomedich-346	311	77	to	to	ADP
biomedich-346	311	78	other	other	ADJ
biomedich-346	311	79	approved	approve	VERB
biomedich-346	311	80	/	/	SYM
biomedich-346	311	81	investigational	investigational	ADJ
biomedich-346	311	82	sarscov-2	sarscov-2	NUM
biomedich-346	311	83	vaccines	vaccine	NOUN
biomedich-346	311	84	or	or	CCONJ
biomedich-346	311	85	treatments	treatment	NOUN
biomedich-346	311	86	.	.	PUNCT
biomedich-346	312	1	participants	participant	NOUN
biomedich-346	312	2	were	be	AUX
biomedich-346	312	3	stratified	stratify	VERB
biomedich-346	312	4	by	by	ADP
biomedich-346	312	5	age	age	NOUN
biomedich-346	312	6	(	(	PUNCT
biomedich-346	312	7	<	<	X
biomedich-346	312	8	65	65	NUM
biomedich-346	312	9	or	or	CCONJ
biomedich-346	312	10	≥	≥	NUM
biomedich-346	312	11	65	65	NUM
biomedich-346	312	12	years	year	NOUN
biomedich-346	312	13	)	)	PUNCT
biomedich-346	312	14	and	and	CCONJ
biomedich-346	312	15	randomized	randomize	VERB
biomedich-346	312	16	to	to	PART
biomedich-346	312	17	receive	receive	VERB
biomedich-346	312	18	two	two	NUM
biomedich-346	312	19	doses	dose	NOUN
biomedich-346	312	20	of	of	ADP
biomedich-346	312	21	either	either	CCONJ
biomedich-346	312	22	nvx	nvx	PROPN
biomedich-346	312	23	-	-	PUNCT
biomedich-346	312	24	cov2373	cov2373	NOUN
biomedich-346	312	25	(	(	PUNCT
biomedich-346	312	26	5	5	NUM
biomedich-346	312	27	μg	μg	PROPN
biomedich-346	312	28	sars	sars	PROPN
biomedich-346	312	29	-	-	PUNCT
biomedich-346	312	30	cov-2	cov-2	NOUN
biomedich-346	312	31	rs	rs	NOUN
biomedich-346	312	32	;	;	PUNCT
biomedich-346	312	33	50	50	NUM
biomedich-346	312	34	μg	μg	NOUN
biomedich-346	312	35	matrixm1	matrixm1	PROPN
biomedich-346	312	36	)	)	PUNCT
biomedich-346	312	37	or	or	CCONJ
biomedich-346	312	38	placebo	placebo	NOUN
biomedich-346	312	39	,	,	PUNCT
biomedich-346	312	40	21	21	NUM
biomedich-346	312	41	days	day	NOUN
biomedich-346	312	42	apart	apart	ADV
biomedich-346	312	43	.	.	PUNCT
biomedich-346	313	1	primary	primary	ADJ
biomedich-346	313	2	outcomes	outcome	NOUN
biomedich-346	313	3	were	be	AUX
biomedich-346	313	4	safety	safety	NOUN
biomedich-346	313	5	and	and	CCONJ
biomedich-346	313	6	immunogenicity	immunogenicity	NOUN
biomedich-346	313	7	assessed	assess	VERB
biomedich-346	313	8	by	by	ADP
biomedich-346	313	9	serum	serum	NOUN
biomedich-346	313	10	igg	igg	PROPN
biomedich-346	313	11	antibody	antibody	NOUN
biomedich-346	313	12	levels	level	NOUN
biomedich-346	313	13	against	against	ADP
biomedich-346	313	14	sars	sar	NOUN
biomedich-346	313	15	-	-	PUNCT
biomedich-346	313	16	cov-2	cov-2	NOUN
biomedich-346	313	17	rs	rs	ADJ
biomedich-346	313	18	protein	protein	NOUN
biomedich-346	313	19	on	on	ADP
biomedich-346	313	20	day	day	NOUN
biomedich-346	313	21	36	36	NUM
biomedich-346	313	22	.	.	PUNCT
biomedich-346	314	1	herein	herein	NOUN
biomedich-346	314	2	,	,	PUNCT
biomedich-346	314	3	we	we	PRON
biomedich-346	314	4	report	report	VERB
biomedich-346	314	5	the	the	DET
biomedich-346	314	6	primary	primary	ADJ
biomedich-346	314	7	data	datum	NOUN
biomedich-346	314	8	analysis	analysis	NOUN
biomedich-346	314	9	at	at	ADP
biomedich-346	314	10	4	4	NUM
biomedich-346	314	11	weeks	week	NOUN
biomedich-346	314	12	after	after	ADP
biomedich-346	314	13	the	the	DET
biomedich-346	314	14	second	second	ADJ
biomedich-346	314	15	dose	dose	NOUN
biomedich-346	314	16	,	,	PUNCT
biomedich-346	314	17	ahead	ahead	ADV
biomedich-346	314	18	of	of	ADP
biomedich-346	314	19	the	the	DET
biomedich-346	314	20	12	12	NUM
biomedich-346	314	21	-	-	PUNCT
biomedich-346	314	22	month	month	NOUN
biomedich-346	314	23	follow	follow	NOUN
biomedich-346	314	24	-	-	PUNCT
biomedich-346	314	25	up	up	ADP
biomedich-346	314	26	completion	completion	NOUN
biomedich-346	314	27	(	(	PUNCT
biomedich-346	314	28	data	datum	NOUN
biomedich-346	314	29	cut	cut	NOUN
biomedich-346	314	30	-	-	PUNCT
biomedich-346	314	31	off	off	NOUN
biomedich-346	314	32	:	:	PUNCT
biomedich-346	314	33	8	8	NUM
biomedich-346	314	34	may	may	PROPN
biomedich-346	314	35	2021	2021	NUM
biomedich-346	314	36	)	)	PUNCT
biomedich-346	314	37	.	.	PUNCT
biomedich-346	315	1	between	between	ADP
biomedich-346	315	2	12	12	NUM
biomedich-346	315	3	february	february	NOUN
biomedich-346	315	4	2021	2021	NUM
biomedich-346	315	5	and	and	CCONJ
biomedich-346	315	6	17	17	NUM
biomedich-346	315	7	march	march	NOUN
biomedich-346	315	8	2021	2021	NUM
biomedich-346	315	9	,	,	PUNCT
biomedich-346	315	10	326	326	NUM
biomedich-346	315	11	subjects	subject	NOUN
biomedich-346	315	12	were	be	AUX
biomedich-346	315	13	screened	screen	VERB
biomedich-346	315	14	,	,	PUNCT
biomedich-346	315	15	and	and	CCONJ
biomedich-346	315	16	200	200	NUM
biomedich-346	315	17	participants	participant	NOUN
biomedich-346	315	18	were	be	AUX
biomedich-346	315	19	enrolled	enrol	VERB
biomedich-346	315	20	and	and	CCONJ
biomedich-346	315	21	randomized	randomize	VERB
biomedich-346	315	22	:	:	PUNCT
biomedich-346	315	23	nvxcov2373	nvxcov2373	NOUN
biomedich-346	315	24	,	,	PUNCT
biomedich-346	315	25	n	n	NOUN
biomedich-346	315	26	=	=	SYM
biomedich-346	315	27	150	150	NUM
biomedich-346	315	28	;	;	PUNCT
biomedich-346	315	29	placebo	placebo	NOUN
biomedich-346	315	30	,	,	PUNCT
biomedich-346	315	31	n	n	NOUN
biomedich-346	315	32	=	=	SYM
biomedich-346	315	33	50	50	NUM
biomedich-346	315	34	.	.	PUNCT
biomedich-346	316	1	solicited	solicit	VERB
biomedich-346	316	2	adverse	adverse	ADJ
biomedich-346	316	3	events	event	NOUN
biomedich-346	316	4	(	(	PUNCT
biomedich-346	316	5	aes	aes	NOUN
biomedich-346	316	6	)	)	PUNCT
biomedich-346	316	7	through	through	ADP
biomedich-346	316	8	7	7	NUM
biomedich-346	316	9	days	day	NOUN
biomedich-346	316	10	after	after	SCONJ
biomedich-346	316	11	each	each	DET
biomedich-346	316	12	injection	injection	NOUN
biomedich-346	316	13	occurred	occur	VERB
biomedich-346	316	14	in	in	ADP
biomedich-346	316	15	121/150	121/150	PROPN
biomedich-346	316	16	(	(	PUNCT
biomedich-346	316	17	80.7	80.7	NUM
biomedich-346	316	18	%	%	NOUN
biomedich-346	316	19	)	)	PUNCT
biomedich-346	316	20	and	and	CCONJ
biomedich-346	316	21	11/50	11/50	NUM
biomedich-346	316	22	(	(	PUNCT
biomedich-346	316	23	22.0	22.0	NUM
biomedich-346	316	24	%	%	NOUN
biomedich-346	316	25	)	)	PUNCT
biomedich-346	316	26	participants	participant	NOUN
biomedich-346	316	27	in	in	ADP
biomedich-346	316	28	the	the	DET
biomedich-346	316	29	nvx	nvx	NOUN
biomedich-346	316	30	-	-	PUNCT
biomedich-346	316	31	cov2373	cov2373	PROPN
biomedich-346	316	32	and	and	CCONJ
biomedich-346	316	33	placebo	placebo	NOUN
biomedich-346	316	34	arms	arm	NOUN
biomedich-346	316	35	,	,	PUNCT
biomedich-346	316	36	respectively	respectively	ADV
biomedich-346	316	37	.	.	PUNCT
biomedich-346	317	1	in	in	ADP
biomedich-346	317	2	the	the	DET
biomedich-346	317	3	nvx	nvx	NOUN
biomedich-346	317	4	-	-	PUNCT
biomedich-346	317	5	cov2373	cov2373	NOUN
biomedich-346	317	6	arm	arm	NOUN
biomedich-346	317	7	,	,	PUNCT
biomedich-346	317	8	tenderness	tenderness	NOUN
biomedich-346	317	9	and	and	CCONJ
biomedich-346	317	10	injection	injection	NOUN
biomedich-346	317	11	site	site	NOUN
biomedich-346	317	12	pain	pain	NOUN
biomedich-346	317	13	were	be	AUX
biomedich-346	317	14	the	the	DET
biomedich-346	317	15	most	most	ADV
biomedich-346	317	16	frequently	frequently	ADV
biomedich-346	317	17	reported	report	VERB
biomedich-346	317	18	solicited	solicit	VERB
biomedich-346	317	19	aes	aes	NOUN
biomedich-346	317	20	after	after	ADP
biomedich-346	317	21	each	each	DET
biomedich-346	317	22	vaccination	vaccination	NOUN
biomedich-346	317	23	,	,	PUNCT
biomedich-346	317	24	irrespective	irrespective	ADV
biomedich-346	317	25	of	of	ADP
biomedich-346	317	26	age	age	NOUN
biomedich-346	317	27	.	.	PUNCT
biomedich-346	318	1	robust	robust	ADJ
biomedich-346	318	2	immune	immune	ADJ
biomedich-346	318	3	responses	response	NOUN
biomedich-346	318	4	occurred	occur	VERB
biomedich-346	318	5	with	with	ADP
biomedich-346	318	6	nvx	nvx	NOUN
biomedich-346	318	7	-	-	PUNCT
biomedich-346	318	8	cov2373	cov2373	NOUN
biomedich-346	318	9	(	(	PUNCT
biomedich-346	318	10	n	n	NOUN
biomedich-346	318	11	=	=	SYM
biomedich-346	318	12	150	150	NUM
biomedich-346	318	13	)	)	PUNCT
biomedich-346	318	14	by	by	ADP
biomedich-346	318	15	day	day	NOUN
biomedich-346	318	16	36	36	NUM
biomedich-346	318	17	:	:	PUNCT
biomedich-346	318	18	igg	igg	NOUN
biomedich-346	318	19	geometric	geometric	ADJ
biomedich-346	318	20	mean	mean	NOUN
biomedich-346	318	21	fold	fold	NOUN
biomedich-346	318	22	rise	rise	NOUN
biomedich-346	318	23	(	(	PUNCT
biomedich-346	318	24	95	95	NUM
biomedich-346	318	25	%	%	NOUN
biomedich-346	318	26	confidence	confidence	NOUN
biomedich-346	318	27	interval	interval	NOUN
biomedich-346	318	28	)	)	PUNCT
biomedich-346	318	29	259	259	NUM
biomedich-346	318	30	(	(	PUNCT
biomedich-346	318	31	219	219	NUM
biomedich-346	318	32	,	,	PUNCT
biomedich-346	318	33	306	306	NUM
biomedich-346	318	34	)	)	PUNCT
biomedich-346	318	35	;	;	PUNCT
biomedich-346	318	36	seroconversion	seroconversion	NOUN
biomedich-346	318	37	rate	rate	NOUN
biomedich-346	318	38	100	100	NUM
biomedich-346	318	39	%	%	NOUN
biomedich-346	318	40	(	(	PUNCT
biomedich-346	318	41	97.6	97.6	NUM
biomedich-346	318	42	,	,	PUNCT
biomedich-346	318	43	100	100	NUM
biomedich-346	318	44	)	)	PUNCT
biomedich-346	318	45	.	.	PUNCT
biomedich-346	319	1	no	no	DET
biomedich-346	319	2	such	such	ADJ
biomedich-346	319	3	response	response	NOUN
biomedich-346	319	4	occurred	occur	VERB
biomedich-346	319	5	with	with	ADP
biomedich-346	319	6	a	a	DET
biomedich-346	319	7	placebo	placebo	NOUN
biomedich-346	319	8	(	(	PUNCT
biomedich-346	319	9	n	n	NOUN
biomedich-346	319	10	=	=	NUM
biomedich-346	319	11	49	49	NUM
biomedich-346	319	12	)	)	PUNCT
biomedich-346	319	13	.	.	PUNCT
biomedich-346	320	1	ishikawa	ishikawa	PROPN
biomedich-346	320	2	et	et	PROPN
biomedich-346	320	3	al	al	PROPN
biomedich-346	320	4	.	.	PROPN
biomedich-346	320	5	safety	safety	NOUN
biomedich-346	320	6	and	and	CCONJ
biomedich-346	320	7	antibody	antibody	NOUN
biomedich-346	320	8	immune	immune	ADJ
biomedich-346	320	9	response	response	NOUN
biomedich-346	320	10	of	of	ADP
biomedich-346	320	11	chp	chp	PROPN
biomedich-346	320	12	-	-	PUNCT
biomedich-346	320	13	ny	ny	NOUN
biomedich-346	320	14	-	-	PUNCT
biomedich-346	320	15	eso-1	eso-1	NOUN
biomedich-346	320	16	vaccine	vaccine	NOUN
biomedich-346	320	17	combined	combine	VERB
biomedich-346	320	18	with	with	ADP
biomedich-346	320	19	poly	poly	ADJ
biomedich-346	320	20	-	-	PUNCT
biomedich-346	320	21	iclc	iclc	NOUN
biomedich-346	320	22	in	in	ADP
biomedich-346	320	23	advanced	advanced	ADJ
biomedich-346	320	24	or	or	CCONJ
biomedich-346	320	25	recurrent	recurrent	ADJ
biomedich-346	320	26	esophageal	esophageal	ADJ
biomedich-346	320	27	cancer	cancer	NOUN
biomedich-346	320	28	patients	patient	NOUN
biomedich-346	320	29	clinical	clinical	ADJ
biomedich-346	320	30	trial	trial	NOUN
biomedich-346	320	31	2021	2021	NUM
biomedich-346	320	32	conducted	conduct	VERB
biomedich-346	320	33	a	a	DET
biomedich-346	320	34	phase	phase	NOUN
biomedich-346	320	35	1	1	NUM
biomedich-346	320	36	clinical	clinical	ADJ
biomedich-346	320	37	trial	trial	NOUN
biomedich-346	320	38	of	of	ADP
biomedich-346	320	39	chp	chp	PROPN
biomedich-346	320	40	-	-	PUNCT
biomedich-346	320	41	ny	ny	NOUN
biomedich-346	320	42	-	-	PUNCT
biomedich-346	320	43	eso-1	eso-1	NOUN
biomedich-346	320	44	with	with	ADP
biomedich-346	320	45	poly	poly	ADJ
biomedich-346	320	46	-	-	PUNCT
biomedich-346	320	47	iclc	iclc	NOUN
biomedich-346	320	48	in	in	ADP
biomedich-346	320	49	patients	patient	NOUN
biomedich-346	320	50	with	with	ADP
biomedich-346	320	51	advanced	advanced	ADJ
biomedich-346	320	52	or	or	CCONJ
biomedich-346	320	53	recurrent	recurrent	ADJ
biomedich-346	320	54	esophageal	esophageal	ADJ
biomedich-346	320	55	cancer	cancer	NOUN
biomedich-346	320	56	.	.	PUNCT
biomedich-346	321	1	chp	chp	NOUN
biomedich-346	321	2	-	-	PUNCT
biomedich-346	321	3	nyeso-1	nyeso-1	NUM
biomedich-346	321	4	/	/	SYM
biomedich-346	321	5	poly	poly	NOUN
biomedich-346	321	6	-	-	PUNCT
biomedich-346	321	7	iclc	iclc	NOUN
biomedich-346	321	8	(	(	PUNCT
biomedich-346	321	9	μg	μg	PROPN
biomedich-346	321	10	/	/	SYM
biomedich-346	321	11	mg	mg	PROPN
biomedich-346	321	12	)	)	PUNCT
biomedich-346	321	13	was	be	AUX
biomedich-346	321	14	administered	administer	VERB
biomedich-346	321	15	at	at	ADP
biomedich-346	321	16	a	a	DET
biomedich-346	321	17	dose	dose	NOUN
biomedich-346	321	18	of	of	ADP
biomedich-346	321	19	200/0.5	200/0.5	NUM
biomedich-346	321	20	or	or	CCONJ
biomedich-346	321	21	200/1.0	200/1.0	NUM
biomedich-346	321	22	(	(	PUNCT
biomedich-346	321	23	cohorts	cohort	NOUN
biomedich-346	321	24	1	1	NUM
biomedich-346	321	25	and	and	CCONJ
biomedich-346	321	26	2	2	NUM
biomedich-346	321	27	,	,	PUNCT
biomedich-346	321	28	respectively	respectively	ADV
biomedich-346	321	29	)	)	PUNCT
biomedich-346	321	30	every	every	DET
biomedich-346	321	31	2	2	NUM
biomedich-346	321	32	weeks	week	NOUN
biomedich-346	321	33	for	for	ADP
biomedich-346	321	34	a	a	DET
biomedich-346	321	35	total	total	NOUN
biomedich-346	321	36	of	of	ADP
biomedich-346	321	37	six	six	NUM
biomedich-346	321	38	doses	dose	NOUN
biomedich-346	321	39	.	.	PUNCT
biomedich-346	322	1	the	the	DET
biomedich-346	322	2	primary	primary	ADJ
biomedich-346	322	3	endpoints	endpoint	NOUN
biomedich-346	322	4	were	be	AUX
biomedich-346	322	5	the	the	DET
biomedich-346	322	6	most	most	ADV
biomedich-346	322	7	common	common	ADJ
biomedich-346	322	8	adverse	adverse	ADJ
biomedich-346	322	9	event	event	NOUN
biomedich-346	322	10	(	(	PUNCT
biomedich-346	322	11	ae	ae	PROPN
biomedich-346	322	12	)	)	PUNCT
biomedich-346	322	13	was	be	AUX
biomedich-346	322	14	injection	injection	NOUN
biomedich-346	322	15	site	site	NOUN
biomedich-346	322	16	skin	skin	NOUN
biomedich-346	322	17	reaction	reaction	NOUN
biomedich-346	322	18	(	(	PUNCT
biomedich-346	322	19	86.7	86.7	NUM
biomedich-346	322	20	%	%	NOUN
biomedich-346	322	21	)	)	PUNCT
biomedich-346	322	22	.	.	PUNCT
biomedich-346	323	1	no	no	DET
biomedich-346	323	2	grade	grade	NOUN
biomedich-346	323	3	3	3	NUM
biomedich-346	323	4	or	or	CCONJ
biomedich-346	323	5	higher	high	ADJ
biomedich-346	323	6	drugrelated	drugrelated	ADJ
biomedich-346	323	7	aes	aes	PROPN
biomedich-346	323	8	were	be	AUX
biomedich-346	323	9	observed	observe	VERB
biomedich-346	323	10	.	.	PUNCT
biomedich-346	324	1	no	no	DET
biomedich-346	324	2	tumor	tumor	NOUN
biomedich-346	324	3	responses	response	NOUN
biomedich-346	324	4	were	be	AUX
biomedich-346	324	5	observed	observe	VERB
biomedich-346	324	6	,	,	PUNCT
biomedich-346	324	7	and	and	CCONJ
biomedich-346	324	8	three	three	NUM
biomedich-346	324	9	patients	patient	NOUN
biomedich-346	324	10	(	(	PUNCT
biomedich-346	324	11	30	30	NUM
biomedich-346	324	12	%	%	NOUN
biomedich-346	324	13	)	)	PUNCT
biomedich-346	324	14	had	have	VERB
biomedich-346	324	15	stable	stable	ADJ
biomedich-346	324	16	disease	disease	NOUN
biomedich-346	324	17	.	.	PUNCT
biomedich-346	325	1	the	the	DET
biomedich-346	325	2	immune	immune	ADJ
biomedich-346	325	3	response	response	NOUN
biomedich-346	325	4	was	be	AUX
biomedich-346	325	5	comparable	comparable	ADJ
biomedich-346	325	6	between	between	ADP
biomedich-346	325	7	the	the	DET
biomedich-346	325	8	two	two	NUM
biomedich-346	325	9	cohorts	cohort	NOUN
biomedich-346	325	10	,	,	PUNCT
biomedich-346	325	11	and	and	CCONJ
biomedich-346	325	12	all	all	DET
biomedich-346	325	13	patients	patient	NOUN
biomedich-346	325	14	(	(	PUNCT
biomedich-346	325	15	100	100	NUM
biomedich-346	325	16	%	%	NOUN
biomedich-346	325	17	)	)	PUNCT
biomedich-346	325	18	achieved	achieve	VERB
biomedich-346	325	19	antibody	antibody	NOUN
biomedich-346	325	20	responses	response	NOUN
biomedich-346	325	21	with	with	ADP
biomedich-346	325	22	a	a	DET
biomedich-346	325	23	median	median	NOUN
biomedich-346	325	24	of	of	ADP
biomedich-346	325	25	2.5	2.5	NUM
biomedich-346	325	26	vaccinations	vaccination	NOUN
biomedich-346	325	27	.	.	PUNCT
biomedich-346	326	1	comparing	compare	VERB
biomedich-346	326	2	chp	chp	NOUN
biomedich-346	326	3	-	-	PUNCT
biomedich-346	326	4	ny	ny	PROPN
biomedich-346	326	5	358	358	NUM
biomedich-346	326	6	biology	biology	NOUN
biomedich-346	326	7	,	,	PUNCT
biomedich-346	326	8	medicine	medicine	NOUN
biomedich-346	326	9	,	,	PUNCT
biomedich-346	326	10	&	&	CCONJ
biomedich-346	326	11	natural	natural	ADJ
biomedich-346	326	12	product	product	NOUN
biomedich-346	326	13	chemistry	chemistry	NOUN
biomedich-346	326	14	12	12	NUM
biomedich-346	326	15	(	(	PUNCT
biomedich-346	326	16	1	1	NUM
biomedich-346	326	17	)	)	PUNCT
biomedich-346	326	18	,	,	PUNCT
biomedich-346	326	19	2023	2023	NUM
biomedich-346	326	20	:	:	PUNCT
biomedich-346	326	21	343	343	NUM
biomedich-346	326	22	-	-	SYM
biomedich-346	326	23	361	361	NUM
biomedich-346	326	24	authors	author	NOUN
biomedich-346	326	25	title	title	NOUN
biomedich-346	326	26	date	date	NOUN
biomedich-346	326	27	and	and	CCONJ
biomedich-346	326	28	type	type	NOUN
biomedich-346	326	29	of	of	ADP
biomedich-346	326	30	the	the	DET
biomedich-346	326	31	study	study	NOUN
biomedich-346	326	32	method	method	NOUN
biomedich-346	326	33	results	result	VERB
biomedich-346	326	34	safety	safety	NOUN
biomedich-346	326	35	and	and	CCONJ
biomedich-346	326	36	immune	immune	ADJ
biomedich-346	326	37	response	response	NOUN
biomedich-346	326	38	.	.	PUNCT
biomedich-346	327	1	the	the	DET
biomedich-346	327	2	secondary	secondary	ADJ
biomedich-346	327	3	endpoint	endpoint	NOUN
biomedich-346	327	4	was	be	AUX
biomedich-346	327	5	tumor	tumor	NOUN
biomedich-346	327	6	response	response	NOUN
biomedich-346	327	7	.	.	PUNCT
biomedich-346	328	1	in	in	ADP
biomedich-346	328	2	total	total	NOUN
biomedich-346	328	3	,	,	PUNCT
biomedich-346	328	4	16	16	NUM
biomedich-346	328	5	patients	patient	NOUN
biomedich-346	328	6	were	be	AUX
biomedich-346	328	7	enrolled	enrol	VERB
biomedich-346	328	8	,	,	PUNCT
biomedich-346	328	9	and	and	CCONJ
biomedich-346	328	10	six	six	NUM
biomedich-346	328	11	patients	patient	NOUN
biomedich-346	328	12	in	in	ADP
biomedich-346	328	13	each	each	DET
biomedich-346	328	14	cohort	cohort	NOUN
biomedich-346	328	15	completed	complete	VERB
biomedich-346	328	16	the	the	DET
biomedich-346	328	17	trial	trial	NOUN
biomedich-346	328	18	.	.	PUNCT
biomedich-346	328	19	eso-1	eso-1	PUNCT
biomedich-346	328	20	alone	alone	ADV
biomedich-346	328	21	to	to	ADP
biomedich-346	328	22	the	the	DET
biomedich-346	328	23	poly	poly	ADJ
biomedich-346	328	24	-	-	PUNCT
biomedich-346	328	25	iclc	iclc	NOUN
biomedich-346	328	26	combination	combination	NOUN
biomedich-346	328	27	,	,	PUNCT
biomedich-346	328	28	all	all	DET
biomedich-346	328	29	patients	patient	NOUN
biomedich-346	328	30	in	in	ADP
biomedich-346	328	31	both	both	DET
biomedich-346	328	32	groups	group	NOUN
biomedich-346	328	33	exhibited	exhibit	VERB
biomedich-346	328	34	antibody	antibody	NOUN
biomedich-346	328	35	responses	response	NOUN
biomedich-346	328	36	,	,	PUNCT
biomedich-346	328	37	but	but	CCONJ
biomedich-346	328	38	the	the	DET
biomedich-346	328	39	titers	titer	NOUN
biomedich-346	328	40	were	be	AUX
biomedich-346	328	41	higher	high	ADJ
biomedich-346	328	42	in	in	ADP
biomedich-346	328	43	the	the	DET
biomedich-346	328	44	combination	combination	NOUN
biomedich-346	328	45	group	group	NOUN
biomedich-346	328	46	.	.	PUNCT
biomedich-346	329	1	in	in	ADP
biomedich-346	329	2	a	a	DET
biomedich-346	329	3	mouse	mouse	NOUN
biomedich-346	329	4	model	model	NOUN
biomedich-346	329	5	,	,	PUNCT
biomedich-346	329	6	adding	add	VERB
biomedich-346	329	7	an	an	DET
biomedich-346	329	8	anti	anti	ADJ
biomedich-346	329	9	-	-	ADJ
biomedich-346	329	10	pd-1	pd-1	ADJ
biomedich-346	329	11	antibody	antibody	NOUN
biomedich-346	329	12	to	to	ADP
biomedich-346	329	13	the	the	DET
biomedich-346	329	14	combination	combination	NOUN
biomedich-346	329	15	of	of	ADP
biomedich-346	329	16	chp	chp	NOUN
biomedich-346	329	17	-	-	PUNCT
biomedich-346	329	18	ny	ny	NOUN
biomedich-346	329	19	-	-	PUNCT
biomedich-346	329	20	eso-1	eso-1	NOUN
biomedich-346	329	21	/	/	SYM
biomedich-346	329	22	polyiclc	polyiclc	NOUN
biomedich-346	329	23	suppressed	suppress	VERB
biomedich-346	329	24	the	the	DET
biomedich-346	329	25	growth	growth	NOUN
biomedich-346	329	26	of	of	ADP
biomedich-346	329	27	nyeso-1	nyeso-1	NOUN
biomedich-346	329	28	-	-	PUNCT
biomedich-346	329	29	expressing	express	VERB
biomedich-346	329	30	tumors	tumor	NOUN
biomedich-346	329	31	.	.	PUNCT
biomedich-346	330	1	combining	combine	VERB
biomedich-346	330	2	the	the	DET
biomedich-346	330	3	vaccine	vaccine	NOUN
biomedich-346	330	4	with	with	ADP
biomedich-346	330	5	pd-1	pd-1	VERB
biomedich-346	330	6	blockade	blockade	NOUN
biomedich-346	330	7	holds	hold	VERB
biomedich-346	330	8	promise	promise	NOUN
biomedich-346	330	9	in	in	ADP
biomedich-346	330	10	human	human	ADJ
biomedich-346	330	11	trials	trial	NOUN
biomedich-346	330	12	.	.	PUNCT
biomedich-346	331	1	li	li	PROPN
biomedich-346	331	2	et	et	PROPN
biomedich-346	331	3	al	al	PROPN
biomedich-346	331	4	.	.	PROPN
biomedich-346	331	5	immune	immune	ADJ
biomedich-346	331	6	persistence	persistence	NOUN
biomedich-346	331	7	and	and	CCONJ
biomedich-346	331	8	safety	safety	NOUN
biomedich-346	331	9	after	after	ADP
biomedich-346	331	10	sars	sar	NOUN
biomedich-346	331	11	-	-	PUNCT
biomedich-346	331	12	cov-2	cov-2	NOUN
biomedich-346	331	13	bnt162b1	bnt162b1	NOUN
biomedich-346	331	14	mrna	mrna	NOUN
biomedich-346	331	15	vaccination	vaccination	NOUN
biomedich-346	331	16	in	in	ADP
biomedich-346	331	17	chinese	chinese	ADJ
biomedich-346	331	18	adults	adult	NOUN
biomedich-346	331	19	:	:	PUNCT
biomedich-346	331	20	a	a	DET
biomedich-346	331	21	randomized	randomized	ADJ
biomedich-346	331	22	,	,	PUNCT
biomedich-346	331	23	placebo	placebo	NOUN
biomedich-346	331	24	-	-	PUNCT
biomedich-346	331	25	controlled	control	VERB
biomedich-346	331	26	,	,	PUNCT
biomedich-346	331	27	double	double	ADJ
biomedich-346	331	28	-	-	PUNCT
biomedich-346	331	29	blind	blind	ADJ
biomedich-346	331	30	phase	phase	NOUN
biomedich-346	331	31	1	1	NUM
biomedich-346	331	32	trial	trial	NOUN
biomedich-346	331	33	clinical	clinical	ADJ
biomedich-346	331	34	trial	trial	NOUN
biomedich-346	331	35	2022	2022	NUM
biomedich-346	331	36	immune	immune	ADJ
biomedich-346	331	37	persistence	persistence	NOUN
biomedich-346	331	38	was	be	AUX
biomedich-346	331	39	determined	determine	VERB
biomedich-346	331	40	at	at	ADP
biomedich-346	331	41	month	month	NOUN
biomedich-346	331	42	3	3	NUM
biomedich-346	331	43	in	in	ADP
biomedich-346	331	44	72	72	NUM
biomedich-346	331	45	younger	young	ADJ
biomedich-346	331	46	participants	participant	NOUN
biomedich-346	331	47	(	(	PUNCT
biomedich-346	331	48	aged	aged	ADJ
biomedich-346	331	49	1855	1855	NUM
biomedich-346	331	50	years	year	NOUN
biomedich-346	331	51	)	)	PUNCT
biomedich-346	331	52	and	and	CCONJ
biomedich-346	331	53	at	at	ADP
biomedich-346	331	54	month	month	NOUN
biomedich-346	331	55	6	6	NUM
biomedich-346	331	56	in	in	ADP
biomedich-346	331	57	70	70	NUM
biomedich-346	331	58	younger	young	ADJ
biomedich-346	331	59	and	and	CCONJ
biomedich-346	331	60	69	69	NUM
biomedich-346	331	61	older	old	ADJ
biomedich-346	331	62	participants	participant	NOUN
biomedich-346	331	63	(	(	PUNCT
biomedich-346	331	64	aged	aged	ADJ
biomedich-346	331	65	65	65	NUM
biomedich-346	331	66	-	-	SYM
biomedich-346	331	67	85	85	NUM
biomedich-346	331	68	years	year	NOUN
biomedich-346	331	69	)	)	PUNCT
biomedich-346	331	70	.	.	PUNCT
biomedich-346	332	1	in	in	ADP
biomedich-346	332	2	younger	young	ADJ
biomedich-346	332	3	participants	participant	NOUN
biomedich-346	332	4	,	,	PUNCT
biomedich-346	332	5	neutralizing	neutralize	VERB
biomedich-346	332	6	antibody	antibody	NOUN
biomedich-346	332	7	(	(	PUNCT
biomedich-346	332	8	nab	nab	NOUN
biomedich-346	332	9	)	)	PUNCT
biomedich-346	332	10	geometric	geometric	ADJ
biomedich-346	332	11	mean	mean	NOUN
biomedich-346	332	12	titers	titer	NOUN
biomedich-346	332	13	(	(	PUNCT
biomedich-346	332	14	gmts	gmts	PROPN
biomedich-346	332	15	)	)	PUNCT
biomedich-346	332	16	for	for	ADP
biomedich-346	332	17	the	the	PRON
biomedich-346	332	18	10	10	NUM
biomedich-346	332	19	and	and	CCONJ
biomedich-346	332	20	30	30	NUM
biomedich-346	332	21	µg	µg	ADV
biomedich-346	332	22	dose	dose	NOUN
biomedich-346	332	23	levels	level	NOUN
biomedich-346	332	24	declined	decline	VERB
biomedich-346	332	25	from	from	ADP
biomedich-346	332	26	233	233	NUM
biomedich-346	332	27	and	and	CCONJ
biomedich-346	332	28	254	254	NUM
biomedich-346	332	29	(	(	PUNCT
biomedich-346	332	30	21	21	NUM
biomedich-346	332	31	days	day	NOUN
biomedich-346	332	32	after	after	ADP
biomedich-346	332	33	dose	dose	NOUN
biomedich-346	332	34	2	2	NUM
biomedich-346	332	35	)	)	PUNCT
biomedich-346	332	36	to	to	ADP
biomedich-346	332	37	55	55	NUM
biomedich-346	332	38	and	and	CCONJ
biomedich-346	332	39	87	87	NUM
biomedich-346	332	40	at	at	ADP
biomedich-346	332	41	month	month	NOUN
biomedich-346	332	42	3	3	NUM
biomedich-346	332	43	,	,	PUNCT
biomedich-346	332	44	respectively	respectively	ADV
biomedich-346	332	45	,	,	PUNCT
biomedich-346	332	46	and	and	CCONJ
biomedich-346	332	47	to	to	ADP
biomedich-346	332	48	16	16	NUM
biomedich-346	332	49	and	and	CCONJ
biomedich-346	332	50	27	27	NUM
biomedich-346	332	51	at	at	ADP
biomedich-346	332	52	month	month	NOUN
biomedich-346	332	53	6	6	NUM
biomedich-346	332	54	,	,	PUNCT
biomedich-346	332	55	respectively	respectively	ADV
biomedich-346	332	56	.	.	PUNCT
biomedich-346	333	1	in	in	ADP
biomedich-346	333	2	older	old	ADJ
biomedich-346	333	3	participants	participant	NOUN
biomedich-346	333	4	,	,	PUNCT
biomedich-346	333	5	nab	nab	ADJ
biomedich-346	333	6	gmts	gmts	NOUN
biomedich-346	333	7	declined	decline	VERB
biomedich-346	333	8	from	from	ADP
biomedich-346	333	9	80	80	NUM
biomedich-346	333	10	and	and	CCONJ
biomedich-346	333	11	160	160	NUM
biomedich-346	333	12	(	(	PUNCT
biomedich-346	333	13	21	21	NUM
biomedich-346	333	14	days	day	NOUN
biomedich-346	333	15	after	after	ADP
biomedich-346	333	16	dose	dose	NOUN
biomedich-346	333	17	2	2	NUM
biomedich-346	333	18	)	)	PUNCT
biomedich-346	333	19	to	to	ADP
biomedich-346	333	20	10	10	NUM
biomedich-346	333	21	and	and	CCONJ
biomedich-346	333	22	21	21	NUM
biomedich-346	333	23	at	at	ADP
biomedich-346	333	24	month	month	NOUN
biomedich-346	333	25	6	6	NUM
biomedich-346	333	26	.	.	PUNCT
biomedich-346	334	1	overall	overall	ADJ
biomedich-346	334	2	,	,	PUNCT
biomedich-346	334	3	higher	high	ADJ
biomedich-346	334	4	antibody	antibody	NOUN
biomedich-346	334	5	titers	titer	NOUN
biomedich-346	334	6	were	be	AUX
biomedich-346	334	7	observed	observe	VERB
biomedich-346	334	8	in	in	ADP
biomedich-346	334	9	younger	young	ADJ
biomedich-346	334	10	participants	participant	NOUN
biomedich-346	334	11	,	,	PUNCT
biomedich-346	334	12	and	and	CCONJ
biomedich-346	334	13	the	the	DET
biomedich-346	334	14	30	30	NUM
biomedich-346	334	15	µg	µg	NOUN
biomedich-346	334	16	dose	dose	NOUN
biomedich-346	334	17	induced	induce	VERB
biomedich-346	334	18	higher	high	ADJ
biomedich-346	334	19	levels	level	NOUN
biomedich-346	334	20	of	of	ADP
biomedich-346	334	21	nab	nab	NOUN
biomedich-346	334	22	,	,	PUNCT
biomedich-346	334	23	which	which	PRON
biomedich-346	334	24	declined	decline	VERB
biomedich-346	334	25	more	more	ADV
biomedich-346	334	26	slowly	slowly	ADV
biomedich-346	334	27	by	by	ADP
biomedich-346	334	28	month	month	NOUN
biomedich-346	334	29	6	6	NUM
biomedich-346	334	30	.	.	PUNCT
biomedich-346	335	1	no	no	DET
biomedich-346	335	2	serious	serious	ADJ
biomedich-346	335	3	adverse	adverse	ADJ
biomedich-346	335	4	events	event	NOUN
biomedich-346	335	5	were	be	AUX
biomedich-346	335	6	reported	report	VERB
biomedich-346	335	7	in	in	ADP
biomedich-346	335	8	the	the	DET
biomedich-346	335	9	vaccine	vaccine	NOUN
biomedich-346	335	10	group	group	NOUN
biomedich-346	335	11	.	.	PUNCT
biomedich-346	336	1	wei	wei	PROPN
biomedich-346	336	2	et	et	PROPN
biomedich-346	336	3	al	al	PROPN
biomedich-346	336	4	.	.	PROPN
biomedich-346	336	5	identification	identification	NOUN
biomedich-346	336	6	and	and	CCONJ
biomedich-346	336	7	application	application	NOUN
biomedich-346	336	8	of	of	ADP
biomedich-346	336	9	a	a	DET
biomedich-346	336	10	neutralizing	neutralizing	ADJ
biomedich-346	336	11	epitope	epitope	NOUN
biomedich-346	336	12	within	within	ADP
biomedich-346	336	13	alphahemolysin	alphahemolysin	NOUN
biomedich-346	336	14	using	use	VERB
biomedich-346	336	15	human	human	ADJ
biomedich-346	336	16	serum	serum	NOUN
biomedich-346	336	17	antibodies	antibody	NOUN
biomedich-346	336	18	elicited	elicit	VERB
biomedich-346	336	19	by	by	ADP
biomedich-346	336	20	vaccination	vaccination	NOUN
biomedich-346	336	21	clinical	clinical	ADJ
biomedich-346	336	22	trial	trial	NOUN
biomedich-346	336	23	2021	2021	NUM
biomedich-346	336	24	collected	collect	VERB
biomedich-346	336	25	sera	sera	NOUN
biomedich-346	336	26	from	from	ADP
biomedich-346	336	27	volunteers	volunteer	NOUN
biomedich-346	336	28	in	in	ADP
biomedich-346	336	29	a	a	DET
biomedich-346	336	30	phase	phase	NOUN
biomedich-346	336	31	1b	1b	NUM
biomedich-346	336	32	clinical	clinical	ADJ
biomedich-346	336	33	trial	trial	NOUN
biomedich-346	336	34	of	of	ADP
biomedich-346	336	35	a	a	DET
biomedich-346	336	36	novel	novel	NOUN
biomedich-346	336	37	recombinant	recombinant	ADJ
biomedich-346	336	38	five	five	NUM
biomedich-346	336	39	-	-	PUNCT
biomedich-346	336	40	antigen	antigen	NOUN
biomedich-346	336	41	sa	sa	NOUN
biomedich-346	336	42	vaccine	vaccine	NOUN
biomedich-346	336	43	(	(	PUNCT
biomedich-346	336	44	nct03966040	nct03966040	X
biomedich-346	336	45	)	)	PUNCT
biomedich-346	336	46	.	.	PUNCT
biomedich-346	337	1	using	use	VERB
biomedich-346	337	2	a	a	DET
biomedich-346	337	3	luminex	luminex	NOUN
biomedich-346	337	4	-	-	PUNCT
biomedich-346	337	5	based	base	VERB
biomedich-346	337	6	assay	assay	NOUN
biomedich-346	337	7	,	,	PUNCT
biomedich-346	337	8	we	we	PRON
biomedich-346	337	9	characterized	characterize	VERB
biomedich-346	337	10	the	the	DET
biomedich-346	337	11	human	human	ADJ
biomedich-346	337	12	serologic	serologic	ADJ
biomedich-346	337	13	response	response	NOUN
biomedich-346	337	14	against	against	ADP
biomedich-346	337	15	hla	hla	PROPN
biomedich-346	337	16	,	,	PUNCT
biomedich-346	337	17	and	and	CCONJ
biomedich-346	337	18	identified	identify	VERB
biomedich-346	337	19	hla121	hla121	PROPN
biomedich-346	337	20	-	-	PUNCT
biomedich-346	337	21	138	138	NUM
biomedich-346	337	22	as	as	ADP
biomedich-346	337	23	a	a	DET
biomedich-346	337	24	neutralizing	neutralizing	ADJ
biomedich-346	337	25	epitope	epitope	NOUN
biomedich-346	337	26	.	.	PUNCT
biomedich-346	338	1	in	in	ADP
biomedich-346	338	2	addition	addition	NOUN
biomedich-346	338	3	,	,	PUNCT
biomedich-346	338	4	we	we	PRON
biomedich-346	338	5	successfully	successfully	ADV
biomedich-346	338	6	produced	produce	VERB
biomedich-346	338	7	ferritin	ferritin	ADJ
biomedich-346	338	8	nanoparticles	nanoparticle	NOUN
biomedich-346	338	9	carrying	carry	VERB
biomedich-346	338	10	the	the	DET
biomedich-346	338	11	neutralizing	neutralizing	ADJ
biomedich-346	338	12	hla121	hla121	PROPN
biomedich-346	338	13	-	-	PUNCT
biomedich-346	338	14	138	138	NUM
biomedich-346	338	15	epitope	epitope	NOUN
biomedich-346	338	16	(	(	PUNCT
biomedich-346	338	17	epnp	epnp	NOUN
biomedich-346	338	18	)	)	PUNCT
biomedich-346	338	19	in	in	ADP
biomedich-346	338	20	e.	e.	PROPN
biomedich-346	338	21	coli	coli	PROPN
biomedich-346	338	22	.	.	PUNCT
biomedich-346	339	1	epnp	epnp	PROPN
biomedich-346	339	2	presented	present	VERB
biomedich-346	339	3	as	as	ADP
biomedich-346	339	4	homogenous	homogenous	ADJ
biomedich-346	339	5	nanoparticles	nanoparticle	NOUN
biomedich-346	339	6	in	in	ADP
biomedich-346	339	7	an	an	DET
biomedich-346	339	8	aqueous	aqueous	ADJ
biomedich-346	339	9	solution	solution	NOUN
biomedich-346	339	10	.	.	PUNCT
biomedich-346	340	1	immunization	immunization	NOUN
biomedich-346	340	2	with	with	ADP
biomedich-346	340	3	epnp	epnp	NOUN
biomedich-346	340	4	elicited	elicit	VERB
biomedich-346	340	5	potent	potent	ADJ
biomedich-346	340	6	hemolysisneutralizing	hemolysisneutralizing	NOUN
biomedich-346	340	7	antibodies	antibody	NOUN
biomedich-346	340	8	and	and	CCONJ
biomedich-346	340	9	conferred	confer	VERB
biomedich-346	340	10	significant	significant	ADJ
biomedich-346	340	11	protection	protection	NOUN
biomedich-346	340	12	in	in	ADP
biomedich-346	340	13	a	a	DET
biomedich-346	340	14	mouse	mouse	NOUN
biomedich-346	340	15	model	model	NOUN
biomedich-346	340	16	of	of	ADP
biomedich-346	340	17	sa	sa	PROPN
biomedich-346	340	18	skin	skin	NOUN
biomedich-346	340	19	infection	infection	NOUN
biomedich-346	340	20	.	.	PUNCT
biomedich-346	341	1	data	datum	NOUN
biomedich-346	341	2	suggest	suggest	VERB
biomedich-346	341	3	that	that	SCONJ
biomedich-346	341	4	epnp	epnp	NOUN
biomedich-346	341	5	,	,	PUNCT
biomedich-346	341	6	carrying	carry	VERB
biomedich-346	341	7	the	the	DET
biomedich-346	341	8	neutralizing	neutralizing	ADJ
biomedich-346	341	9	epitope	epitope	NOUN
biomedich-346	341	10	hla121	hla121	PROPN
biomedich-346	341	11	-	-	PUNCT
biomedich-346	341	12	138	138	NUM
biomedich-346	341	13	,	,	PUNCT
biomedich-346	341	14	is	be	AUX
biomedich-346	341	15	a	a	DET
biomedich-346	341	16	good	good	ADJ
biomedich-346	341	17	candidate	candidate	NOUN
biomedich-346	341	18	for	for	ADP
biomedich-346	341	19	a	a	DET
biomedich-346	341	20	vaccine	vaccine	NOUN
biomedich-346	341	21	against	against	ADP
biomedich-346	341	22	sa	sa	PROPN
biomedich-346	341	23	.	.	PUNCT
biomedich-346	342	1	conclusions	conclusion	NOUN
biomedich-346	342	2	vaccination	vaccination	NOUN
biomedich-346	342	3	has	have	AUX
biomedich-346	342	4	had	have	VERB
biomedich-346	342	5	a	a	DET
biomedich-346	342	6	major	major	ADJ
biomedich-346	342	7	impact	impact	NOUN
biomedich-346	342	8	on	on	ADP
biomedich-346	342	9	the	the	DET
biomedich-346	342	10	control	control	NOUN
biomedich-346	342	11	of	of	ADP
biomedich-346	342	12	infectious	infectious	ADJ
biomedich-346	342	13	diseases	disease	NOUN
biomedich-346	342	14	.	.	PUNCT
biomedich-346	343	1	older	old	ADJ
biomedich-346	343	2	vaccines	vaccine	NOUN
biomedich-346	343	3	,	,	PUNCT
biomedich-346	343	4	including	include	VERB
biomedich-346	343	5	those	those	PRON
biomedich-346	343	6	that	that	PRON
biomedich-346	343	7	successfully	successfully	ADV
biomedich-346	343	8	prevent	prevent	VERB
biomedich-346	343	9	measles	measle	NOUN
biomedich-346	343	10	and	and	CCONJ
biomedich-346	343	11	polio	polio	NOUN
biomedich-346	343	12	,	,	PUNCT
biomedich-346	343	13	work	work	VERB
biomedich-346	343	14	by	by	ADP
biomedich-346	343	15	stimulating	stimulate	VERB
biomedich-346	343	16	the	the	DET
biomedich-346	343	17	body	body	NOUN
biomedich-346	343	18	's	's	PART
biomedich-346	343	19	immune	immune	ADJ
biomedich-346	343	20	system	system	NOUN
biomedich-346	343	21	and	and	CCONJ
biomedich-346	343	22	antibody	antibody	NOUN
biomedich-346	343	23	production	production	NOUN
biomedich-346	343	24	using	use	VERB
biomedich-346	343	25	a	a	DET
biomedich-346	343	26	dead	dead	ADJ
biomedich-346	343	27	or	or	CCONJ
biomedich-346	343	28	weakened	weaken	VERB
biomedich-346	343	29	(	(	PUNCT
biomedich-346	343	30	attenuated	attenuated	ADJ
biomedich-346	343	31	)	)	PUNCT
biomedich-346	343	32	pathogen	pathogen	NOUN
biomedich-346	343	33	.	.	PUNCT
biomedich-346	344	1	however	however	ADV
biomedich-346	344	2	,	,	PUNCT
biomedich-346	344	3	in	in	ADP
biomedich-346	344	4	someone	someone	PRON
biomedich-346	344	5	with	with	ADP
biomedich-346	344	6	a	a	DET
biomedich-346	344	7	compromised	compromise	VERB
biomedich-346	344	8	immune	immune	ADJ
biomedich-346	344	9	system	system	NOUN
biomedich-346	344	10	,	,	PUNCT
biomedich-346	344	11	an	an	DET
biomedich-346	344	12	attenuated	attenuate	VERB
biomedich-346	344	13	pathogen	pathogen	NOUN
biomedich-346	344	14	may	may	AUX
biomedich-346	344	15	still	still	ADV
biomedich-346	344	16	cause	cause	VERB
biomedich-346	344	17	the	the	DET
biomedich-346	344	18	disease	disease	NOUN
biomedich-346	344	19	,	,	PUNCT
biomedich-346	344	20	and	and	CCONJ
biomedich-346	344	21	a	a	DET
biomedich-346	344	22	dead	dead	ADJ
biomedich-346	344	23	pathogen	pathogen	NOUN
biomedich-346	344	24	may	may	AUX
biomedich-346	344	25	not	not	PART
biomedich-346	344	26	result	result	VERB
biomedich-346	344	27	in	in	ADP
biomedich-346	344	28	a	a	DET
biomedich-346	344	29	strong	strong	ADJ
biomedich-346	344	30	enough	enough	ADV
biomedich-346	344	31	or	or	CCONJ
biomedich-346	344	32	long	long	ADV
biomedich-346	344	33	-	-	PUNCT
biomedich-346	344	34	lasting	last	VERB
biomedich-346	344	35	immune	immune	ADJ
biomedich-346	344	36	response	response	NOUN
biomedich-346	344	37	.	.	PUNCT
biomedich-346	345	1	many	many	ADJ
biomedich-346	345	2	of	of	ADP
biomedich-346	345	3	these	these	DET
biomedich-346	345	4	vaccines	vaccine	NOUN
biomedich-346	345	5	have	have	AUX
biomedich-346	345	6	been	be	AUX
biomedich-346	345	7	shown	show	VERB
biomedich-346	345	8	to	to	PART
biomedich-346	345	9	elicit	elicit	VERB
biomedich-346	345	10	protective	protective	ADJ
biomedich-346	345	11	immunity	immunity	NOUN
biomedich-346	345	12	against	against	ADP
biomedich-346	345	13	many	many	ADJ
biomedich-346	345	14	diseases	disease	NOUN
biomedich-346	345	15	,	,	PUNCT
biomedich-346	345	16	but	but	CCONJ
biomedich-346	345	17	they	they	PRON
biomedich-346	345	18	are	be	AUX
biomedich-346	345	19	associated	associate	VERB
biomedich-346	345	20	with	with	ADP
biomedich-346	345	21	certain	certain	ADJ
biomedich-346	345	22	challenges	challenge	NOUN
biomedich-346	345	23	that	that	PRON
biomedich-346	345	24	limit	limit	VERB
biomedich-346	345	25	their	their	PRON
biomedich-346	345	26	effectiveness	effectiveness	NOUN
biomedich-346	345	27	in	in	ADP
biomedich-346	345	28	a	a	DET
biomedich-346	345	29	clinical	clinical	ADJ
biomedich-346	345	30	setting	setting	NOUN
biomedich-346	345	31	.	.	PUNCT
biomedich-346	346	1	dna	dna	PROPN
biomedich-346	346	2	and	and	CCONJ
biomedich-346	346	3	rna	rna	NOUN
biomedich-346	346	4	vaccines	vaccine	NOUN
biomedich-346	346	5	,	,	PUNCT
biomedich-346	346	6	for	for	ADP
biomedich-346	346	7	example	example	NOUN
biomedich-346	346	8	,	,	PUNCT
biomedich-346	346	9	are	be	AUX
biomedich-346	346	10	cost	cost	NOUN
biomedich-346	346	11	-	-	PUNCT
biomedich-346	346	12	effective	effective	ADJ
biomedich-346	346	13	and	and	CCONJ
biomedich-346	346	14	associated	associate	VERB
biomedich-346	346	15	with	with	ADP
biomedich-346	346	16	minimal	minimal	ADJ
biomedich-346	346	17	infection	infection	NOUN
biomedich-346	346	18	risks	risk	NOUN
biomedich-346	346	19	but	but	CCONJ
biomedich-346	346	20	can	can	AUX
biomedich-346	346	21	be	be	AUX
biomedich-346	346	22	easily	easily	ADV
biomedich-346	346	23	degraded	degrade	VERB
biomedich-346	346	24	as	as	ADP
biomedich-346	346	25	a	a	DET
biomedich-346	346	26	result	result	NOUN
biomedich-346	346	27	of	of	ADP
biomedich-346	346	28	delivery	delivery	NOUN
biomedich-346	346	29	challenges	challenge	NOUN
biomedich-346	346	30	to	to	PART
biomedich-346	346	31	target	target	VERB
biomedich-346	346	32	sites	site	NOUN
biomedich-346	346	33	.	.	PUNCT
biomedich-346	347	1	nanoscale	nanoscale	NOUN
biomedich-346	347	2	size	size	NOUN
biomedich-346	347	3	(	(	PUNCT
biomedich-346	347	4	<	<	X
biomedich-346	347	5	1000	1000	NUM
biomedich-346	347	6	nm	nm	NOUN
biomedich-346	347	7	)	)	PUNCT
biomedich-346	347	8	materials	material	NOUN
biomedich-346	347	9	such	such	ADJ
biomedich-346	347	10	as	as	ADP
biomedich-346	347	11	virus	virus	NOUN
biomedich-346	347	12	-	-	PUNCT
biomedich-346	347	13	like	like	ADJ
biomedich-346	347	14	particles	particle	NOUN
biomedich-346	347	15	,	,	PUNCT
biomedich-346	347	16	liposomes	liposome	NOUN
biomedich-346	347	17	,	,	PUNCT
biomedich-346	347	18	iscoms	iscom	NOUN
biomedich-346	347	19	,	,	PUNCT
biomedich-346	347	20	polymeric	polymeric	NOUN
biomedich-346	347	21	,	,	PUNCT
biomedich-346	347	22	and	and	CCONJ
biomedich-346	347	23	non	non	ADJ
biomedich-346	347	24	-	-	ADJ
biomedich-346	347	25	degradable	degradable	ADJ
biomedich-346	347	26	nanospheres	nanosphere	NOUN
biomedich-346	347	27	hussein	hussein	PROPN
biomedich-346	347	28	et	et	PROPN
biomedich-346	347	29	al	al	PROPN
biomedich-346	347	30	.	.	PROPN
biomedich-346	347	31	–	–	PUNCT
biomedich-346	347	32	nanotechnology	nanotechnology	NOUN
biomedich-346	347	33	-	-	PUNCT
biomedich-346	347	34	based	base	VERB
biomedich-346	347	35	vaccines	vaccine	NOUN
biomedich-346	347	36	359	359	NUM
biomedich-346	347	37	have	have	AUX
biomedich-346	347	38	received	receive	VERB
biomedich-346	347	39	attention	attention	NOUN
biomedich-346	347	40	as	as	ADP
biomedich-346	347	41	potential	potential	ADJ
biomedich-346	347	42	delivery	delivery	NOUN
biomedich-346	347	43	vehicles	vehicle	NOUN
biomedich-346	347	44	for	for	ADP
biomedich-346	347	45	vaccines	vaccine	NOUN
biomedich-346	347	46	.	.	PUNCT
biomedich-346	348	1	the	the	DET
biomedich-346	348	2	vaccine	vaccine	NOUN
biomedich-346	348	3	antigen	antigen	NOUN
biomedich-346	348	4	is	be	AUX
biomedich-346	348	5	either	either	CCONJ
biomedich-346	348	6	encapsulated	encapsulate	VERB
biomedich-346	348	7	within	within	ADP
biomedich-346	348	8	or	or	CCONJ
biomedich-346	348	9	decorated	decorate	VERB
biomedich-346	348	10	onto	onto	ADP
biomedich-346	348	11	the	the	DET
biomedich-346	348	12	surface	surface	NOUN
biomedich-346	348	13	of	of	ADP
biomedich-346	348	14	the	the	DET
biomedich-346	348	15	np	np	NOUN
biomedich-346	348	16	.	.	PUNCT
biomedich-346	348	17	by	by	ADP
biomedich-346	348	18	encapsulating	encapsulate	VERB
biomedich-346	348	19	antigenic	antigenic	ADJ
biomedich-346	348	20	material	material	NOUN
biomedich-346	348	21	,	,	PUNCT
biomedich-346	348	22	nps	nps	PROPN
biomedich-346	348	23	provide	provide	VERB
biomedich-346	348	24	a	a	DET
biomedich-346	348	25	method	method	NOUN
biomedich-346	348	26	for	for	ADP
biomedich-346	348	27	delivering	deliver	VERB
biomedich-346	348	28	antigens	antigen	NOUN
biomedich-346	348	29	that	that	PRON
biomedich-346	348	30	may	may	AUX
biomedich-346	348	31	otherwise	otherwise	ADV
biomedich-346	348	32	degrade	degrade	VERB
biomedich-346	348	33	rapidly	rapidly	ADV
biomedich-346	348	34	upon	upon	SCONJ
biomedich-346	348	35	injection	injection	NOUN
biomedich-346	348	36	or	or	CCONJ
biomedich-346	348	37	induce	induce	VERB
biomedich-346	348	38	a	a	DET
biomedich-346	348	39	short	short	ADV
biomedich-346	348	40	-	-	PUNCT
biomedich-346	348	41	lived	live	VERB
biomedich-346	348	42	,	,	PUNCT
biomedich-346	348	43	localized	localized	ADJ
biomedich-346	348	44	immune	immune	ADJ
biomedich-346	348	45	response	response	NOUN
biomedich-346	348	46	.	.	PUNCT
biomedich-346	349	1	in	in	ADP
biomedich-346	349	2	this	this	DET
biomedich-346	349	3	review	review	NOUN
biomedich-346	349	4	,	,	PUNCT
biomedich-346	349	5	we	we	PRON
biomedich-346	349	6	assess	assess	VERB
biomedich-346	349	7	the	the	DET
biomedich-346	349	8	potential	potential	NOUN
biomedich-346	349	9	of	of	ADP
biomedich-346	349	10	these	these	DET
biomedich-346	349	11	delivery	delivery	NOUN
biomedich-346	349	12	systems	system	NOUN
biomedich-346	349	13	for	for	ADP
biomedich-346	349	14	the	the	DET
biomedich-346	349	15	creation	creation	NOUN
biomedich-346	349	16	of	of	ADP
biomedich-346	349	17	new	new	ADJ
biomedich-346	349	18	vaccines	vaccine	NOUN
biomedich-346	349	19	against	against	ADP
biomedich-346	349	20	a	a	DET
biomedich-346	349	21	variety	variety	NOUN
biomedich-346	349	22	of	of	ADP
biomedich-346	349	23	infections	infection	NOUN
biomedich-346	349	24	and	and	CCONJ
biomedich-346	349	25	compare	compare	VERB
biomedich-346	349	26	the	the	DET
biomedich-346	349	27	usefulness	usefulness	NOUN
biomedich-346	349	28	of	of	ADP
biomedich-346	349	29	various	various	ADJ
biomedich-346	349	30	np	np	NOUN
biomedich-346	349	31	systems	system	NOUN
biomedich-346	349	32	for	for	ADP
biomedich-346	349	33	the	the	DET
biomedich-346	349	34	delivery	delivery	NOUN
biomedich-346	349	35	of	of	ADP
biomedich-346	349	36	subunit	subunit	NOUN
biomedich-346	349	37	vaccines	vaccine	NOUN
biomedich-346	349	38	.	.	PUNCT
biomedich-346	350	1	the	the	DET
biomedich-346	350	2	effectiveness	effectiveness	NOUN
biomedich-346	350	3	of	of	ADP
biomedich-346	350	4	vaccines	vaccine	NOUN
biomedich-346	350	5	is	be	AUX
biomedich-346	350	6	determined	determine	VERB
biomedich-346	350	7	in	in	ADP
biomedich-346	350	8	large	large	ADJ
biomedich-346	350	9	part	part	NOUN
biomedich-346	350	10	by	by	ADP
biomedich-346	350	11	a	a	DET
biomedich-346	350	12	number	number	NOUN
biomedich-346	350	13	of	of	ADP
biomedich-346	350	14	physicochemical	physicochemical	ADJ
biomedich-346	350	15	characteristics	characteristic	NOUN
biomedich-346	350	16	of	of	ADP
biomedich-346	350	17	nanoparticles	nanoparticle	NOUN
biomedich-346	350	18	.	.	PUNCT
biomedich-346	351	1	clinical	clinical	ADJ
biomedich-346	351	2	trial	trial	NOUN
biomedich-346	351	3	studies	study	NOUN
biomedich-346	351	4	have	have	AUX
biomedich-346	351	5	shown	show	VERB
biomedich-346	351	6	that	that	SCONJ
biomedich-346	351	7	nanocarriers	nanocarrier	NOUN
biomedich-346	351	8	can	can	AUX
biomedich-346	351	9	function	function	VERB
biomedich-346	351	10	as	as	ADP
biomedich-346	351	11	effective	effective	ADJ
biomedich-346	351	12	middlemen	middleman	NOUN
biomedich-346	351	13	in	in	ADP
biomedich-346	351	14	the	the	DET
biomedich-346	351	15	creation	creation	NOUN
biomedich-346	351	16	of	of	ADP
biomedich-346	351	17	vaccinations	vaccination	NOUN
biomedich-346	351	18	against	against	ADP
biomedich-346	351	19	a	a	DET
biomedich-346	351	20	variety	variety	NOUN
biomedich-346	351	21	of	of	ADP
biomedich-346	351	22	diseases	disease	NOUN
biomedich-346	351	23	.	.	PUNCT
biomedich-346	352	1	development	development	NOUN
biomedich-346	352	2	of	of	ADP
biomedich-346	352	3	np	np	NOUN
biomedich-346	352	4	formulations	formulation	NOUN
biomedich-346	352	5	that	that	PRON
biomedich-346	352	6	can	can	AUX
biomedich-346	352	7	deliver	deliver	VERB
biomedich-346	352	8	immunogens	immunogen	NOUN
biomedich-346	352	9	to	to	ADP
biomedich-346	352	10	apcs	apc	NOUN
biomedich-346	352	11	,	,	PUNCT
biomedich-346	352	12	particularly	particularly	ADV
biomedich-346	352	13	dcs	dcs	PROPN
biomedich-346	352	14	,	,	PUNCT
biomedich-346	352	15	is	be	AUX
biomedich-346	352	16	crucial	crucial	ADJ
biomedich-346	352	17	in	in	ADP
biomedich-346	352	18	this	this	DET
biomedich-346	352	19	situation	situation	NOUN
biomedich-346	352	20	to	to	PART
biomedich-346	352	21	promote	promote	VERB
biomedich-346	352	22	efficient	efficient	ADJ
biomedich-346	352	23	antigenspecific	antigenspecific	PROPN
biomedich-346	352	24	t	t	PROPN
biomedich-346	352	25	-	-	PUNCT
biomedich-346	352	26	cell	cell	NOUN
biomedich-346	352	27	responses	response	NOUN
biomedich-346	352	28	.	.	PUNCT
biomedich-346	353	1	via	via	ADP
biomedich-346	353	2	b	b	X
biomedich-346	353	3	-	-	PUNCT
biomedich-346	353	4	cell	cell	NOUN
biomedich-346	353	5	receptors	receptor	NOUN
biomedich-346	353	6	,	,	PUNCT
biomedich-346	353	7	b	b	NOUN
biomedich-346	353	8	cells	cell	NOUN
biomedich-346	353	9	are	be	AUX
biomedich-346	353	10	able	able	ADJ
biomedich-346	353	11	to	to	PART
biomedich-346	353	12	identify	identify	VERB
biomedich-346	353	13	and	and	CCONJ
biomedich-346	353	14	react	react	VERB
biomedich-346	353	15	to	to	ADP
biomedich-346	353	16	microbial	microbial	ADJ
biomedich-346	353	17	surface	surface	NOUN
biomedich-346	353	18	antigens	antigen	NOUN
biomedich-346	353	19	.	.	PUNCT
biomedich-346	354	1	for	for	ADP
biomedich-346	354	2	the	the	DET
biomedich-346	354	3	creation	creation	NOUN
biomedich-346	354	4	of	of	ADP
biomedich-346	354	5	vaccines	vaccine	NOUN
biomedich-346	354	6	against	against	ADP
biomedich-346	354	7	various	various	ADJ
biomedich-346	354	8	diseases	disease	NOUN
biomedich-346	354	9	,	,	PUNCT
biomedich-346	354	10	artificial	artificial	ADJ
biomedich-346	354	11	nps	nps	PROPN
biomedich-346	354	12	have	have	AUX
biomedich-346	354	13	been	be	AUX
biomedich-346	354	14	used	use	VERB
biomedich-346	354	15	to	to	PART
biomedich-346	354	16	activate	activate	VERB
biomedich-346	354	17	and	and	CCONJ
biomedich-346	354	18	clonally	clonally	ADV
biomedich-346	354	19	expand	expand	VERB
biomedich-346	354	20	antigen	antigen	NOUN
biomedich-346	354	21	-	-	PUNCT
biomedich-346	354	22	specific	specific	ADJ
biomedich-346	354	23	b	b	NOUN
biomedich-346	354	24	-	-	PUNCT
biomedich-346	354	25	cells	cell	NOUN
biomedich-346	354	26	.	.	PUNCT
biomedich-346	355	1	comparing	compare	VERB
biomedich-346	355	2	the	the	DET
biomedich-346	355	3	delivery	delivery	NOUN
biomedich-346	355	4	of	of	ADP
biomedich-346	355	5	exposed	expose	VERB
biomedich-346	355	6	vaccine	vaccine	NOUN
biomedich-346	355	7	molecules	molecule	NOUN
biomedich-346	355	8	to	to	ADP
biomedich-346	355	9	the	the	DET
biomedich-346	355	10	encapsulation	encapsulation	NOUN
biomedich-346	355	11	of	of	ADP
biomedich-346	355	12	antigens	antigen	NOUN
biomedich-346	355	13	in	in	ADP
biomedich-346	355	14	virus	virus	NOUN
biomedich-346	355	15	-	-	PUNCT
biomedich-346	355	16	like	like	ADJ
biomedich-346	355	17	particles	particle	NOUN
biomedich-346	355	18	(	(	PUNCT
biomedich-346	355	19	vlps	vlps	PROPN
biomedich-346	355	20	)	)	PUNCT
biomedich-346	355	21	,	,	PUNCT
biomedich-346	355	22	studies	study	NOUN
biomedich-346	355	23	found	find	VERB
biomedich-346	355	24	that	that	SCONJ
biomedich-346	355	25	the	the	DET
biomedich-346	355	26	vlps	vlps	NOUN
biomedich-346	355	27	were	be	AUX
biomedich-346	355	28	able	able	ADJ
biomedich-346	355	29	to	to	PART
biomedich-346	355	30	elicit	elicit	VERB
biomedich-346	355	31	robust	robust	ADJ
biomedich-346	355	32	and	and	CCONJ
biomedich-346	355	33	long	long	ADV
biomedich-346	355	34	-	-	PUNCT
biomedich-346	355	35	lasting	last	VERB
biomedich-346	355	36	humoral	humoral	ADJ
biomedich-346	355	37	responses	response	NOUN
biomedich-346	355	38	.	.	PUNCT
biomedich-346	356	1	several	several	ADJ
biomedich-346	356	2	research	research	NOUN
biomedich-346	356	3	clearly	clearly	ADV
biomedich-346	356	4	proved	prove	VERB
biomedich-346	356	5	the	the	DET
biomedich-346	356	6	effectiveness	effectiveness	NOUN
biomedich-346	356	7	of	of	ADP
biomedich-346	356	8	non	non	ADJ
biomedich-346	356	9	-	-	ADJ
biomedich-346	356	10	invasively	invasively	ADV
biomedich-346	356	11	given	give	VERB
biomedich-346	356	12	vaccines	vaccine	NOUN
biomedich-346	356	13	.	.	PUNCT
biomedich-346	357	1	concerns	concern	NOUN
biomedich-346	357	2	about	about	ADP
biomedich-346	357	3	particle	particle	NOUN
biomedich-346	357	4	toxicity	toxicity	NOUN
biomedich-346	357	5	,	,	PUNCT
biomedich-346	357	6	production	production	NOUN
biomedich-346	357	7	challenges	challenge	NOUN
biomedich-346	357	8	,	,	PUNCT
biomedich-346	357	9	and	and	CCONJ
biomedich-346	357	10	delivering	deliver	VERB
biomedich-346	357	11	antigens	antigen	NOUN
biomedich-346	357	12	in	in	ADP
biomedich-346	357	13	their	their	PRON
biomedich-346	357	14	natural	natural	ADJ
biomedich-346	357	15	state	state	NOUN
biomedich-346	357	16	are	be	AUX
biomedich-346	357	17	just	just	ADV
biomedich-346	357	18	a	a	DET
biomedich-346	357	19	few	few	ADJ
biomedich-346	357	20	of	of	ADP
biomedich-346	357	21	the	the	DET
biomedich-346	357	22	difficulties	difficulty	NOUN
biomedich-346	357	23	of	of	ADP
biomedich-346	357	24	using	use	VERB
biomedich-346	357	25	nps	nps	PROPN
biomedich-346	357	26	for	for	ADP
biomedich-346	357	27	vaccine	vaccine	NOUN
biomedich-346	357	28	administration	administration	NOUN
biomedich-346	357	29	.	.	PUNCT
biomedich-346	358	1	future	future	ADJ
biomedich-346	358	2	research	research	NOUN
biomedich-346	358	3	on	on	ADP
biomedich-346	358	4	nano	nano	NOUN
biomedich-346	358	5	vaccines	vaccine	NOUN
biomedich-346	358	6	will	will	AUX
biomedich-346	358	7	focus	focus	VERB
biomedich-346	358	8	on	on	ADP
biomedich-346	358	9	the	the	DET
biomedich-346	358	10	action	action	NOUN
biomedich-346	358	11	of	of	ADP
biomedich-346	358	12	nps	nps	PROPN
biomedich-346	358	13	as	as	ADV
biomedich-346	358	14	well	well	ADV
biomedich-346	358	15	as	as	ADP
biomedich-346	358	16	the	the	DET
biomedich-346	358	17	potential	potential	NOUN
biomedich-346	358	18	to	to	PART
biomedich-346	358	19	elicit	elicit	VERB
biomedich-346	358	20	an	an	DET
biomedich-346	358	21	immune	immune	ADJ
biomedich-346	358	22	response	response	NOUN
biomedich-346	358	23	for	for	ADP
biomedich-346	358	24	the	the	DET
biomedich-346	358	25	treatment	treatment	NOUN
biomedich-346	358	26	of	of	ADP
biomedich-346	358	27	diseases	disease	NOUN
biomedich-346	358	28	.	.	PUNCT
biomedich-346	359	1	acknowledgements	acknowledgement	NOUN
biomedich-346	359	2	:	:	PUNCT
biomedich-346	359	3	authors	author	NOUN
biomedich-346	359	4	would	would	AUX
biomedich-346	359	5	like	like	VERB
biomedich-346	359	6	to	to	PART
biomedich-346	359	7	appreciate	appreciate	VERB
biomedich-346	359	8	professors	professor	NOUN
biomedich-346	359	9	of	of	ADP
biomedich-346	359	10	biomedical	biomedical	ADJ
biomedich-346	359	11	science	science	NOUN
biomedich-346	359	12	at	at	ADP
biomedich-346	359	13	dubai	dubai	PROPN
biomedich-346	359	14	medical	medical	PROPN
biomedich-346	359	15	college	college	PROPN
biomedich-346	359	16	for	for	ADP
biomedich-346	359	17	girls	girl	NOUN
biomedich-346	359	18	,	,	PUNCT
biomedich-346	359	19	for	for	ADP
biomedich-346	359	20	their	their	PRON
biomedich-346	359	21	continuous	continuous	ADJ
biomedich-346	359	22	support	support	NOUN
biomedich-346	359	23	during	during	ADP
biomedich-346	359	24	the	the	DET
biomedich-346	359	25	conceptualization	conceptualization	NOUN
biomedich-346	359	26	and	and	CCONJ
biomedich-346	359	27	preparation	preparation	NOUN
biomedich-346	359	28	of	of	ADP
biomedich-346	359	29	this	this	DET
biomedich-346	359	30	manuscript	manuscript	NOUN
biomedich-346	359	31	.	.	PUNCT
biomedich-346	360	1	competing	compete	VERB
biomedich-346	360	2	interests	interest	NOUN
biomedich-346	360	3	:	:	PUNCT
biomedich-346	360	4	the	the	DET
biomedich-346	360	5	authors	author	NOUN
biomedich-346	360	6	declare	declare	VERB
biomedich-346	360	7	that	that	SCONJ
biomedich-346	360	8	there	there	PRON
biomedich-346	360	9	are	be	VERB
biomedich-346	360	10	no	no	DET
biomedich-346	360	11	competing	compete	VERB
biomedich-346	360	12	interests	interest	NOUN
biomedich-346	360	13	.	.	PUNCT
biomedich-346	361	1	funding	funding	NOUN
biomedich-346	361	2	:	:	PUNCT
biomedich-346	361	3	there	there	PRON
biomedich-346	361	4	are	be	VERB
biomedich-346	361	5	no	no	DET
biomedich-346	361	6	sources	source	NOUN
biomedich-346	361	7	of	of	ADP
biomedich-346	361	8	funding	funding	NOUN
biomedich-346	361	9	to	to	PART
biomedich-346	361	10	declare	declare	VERB
biomedich-346	361	11	.	.	PUNCT
biomedich-346	362	1	references	reference	NOUN
biomedich-346	362	2	doria	doria	PROPN
biomedich-346	362	3	-	-	PUNCT
biomedich-346	362	4	rose	rise	VERB
biomedich-346	362	5	,	,	PUNCT
biomedich-346	362	6	n.	n.	NOUN
biomedich-346	362	7	,	,	PUNCT
biomedich-346	362	8	suthar	suthar	PROPN
biomedich-346	362	9	,	,	PUNCT
biomedich-346	362	10	m.	m.	NOUN
biomedich-346	362	11	s.	s.	PROPN
biomedich-346	362	12	,	,	PUNCT
biomedich-346	362	13	makowski	makowski	PROPN
biomedich-346	362	14	,	,	PUNCT
biomedich-346	362	15	m.	m.	NOUN
biomedich-346	362	16	,	,	PUNCT
biomedich-346	362	17	o’connell	o’connell	INTJ
biomedich-346	362	18	,	,	PUNCT
biomedich-346	362	19	s.	s.	PROPN
biomedich-346	362	20	,	,	PUNCT
biomedich-346	362	21	mcdermott	mcdermott	PROPN
biomedich-346	362	22	,	,	PUNCT
biomedich-346	362	23	a.	a.	PROPN
biomedich-346	362	24	b.	b.	PROPN
biomedich-346	362	25	,	,	PUNCT
biomedich-346	362	26	flach	flach	PROPN
biomedich-346	362	27	,	,	PUNCT
biomedich-346	362	28	b.	b.	PROPN
biomedich-346	362	29	,	,	PUNCT
biomedich-346	362	30	…	…	PUNCT
biomedich-346	362	31	mrna-1273	mrna-1273	ADJ
biomedich-346	362	32	study	study	NOUN
biomedich-346	362	33	group	group	NOUN
biomedich-346	362	34	.	.	PUNCT
biomedich-346	363	1	(	(	PUNCT
biomedich-346	363	2	2021	2021	NUM
biomedich-346	363	3	)	)	PUNCT
biomedich-346	363	4	.	.	PUNCT
biomedich-346	364	1	antibody	antibody	NOUN
biomedich-346	364	2	persistence	persistence	NOUN
biomedich-346	364	3	through	through	ADP
biomedich-346	364	4	6	6	NUM
biomedich-346	364	5	months	month	NOUN
biomedich-346	364	6	after	after	ADP
biomedich-346	364	7	the	the	DET
biomedich-346	364	8	second	second	ADJ
biomedich-346	364	9	dose	dose	NOUN
biomedich-346	364	10	of	of	ADP
biomedich-346	364	11	mrna-1273	mrna-1273	ADJ
biomedich-346	364	12	vaccine	vaccine	NOUN
biomedich-346	364	13	for	for	ADP
biomedich-346	364	14	covid-19	covid-19	PROPN
biomedich-346	364	15	.	.	PUNCT
biomedich-346	365	1	the	the	DET
biomedich-346	365	2	new	new	PROPN
biomedich-346	365	3	england	england	PROPN
biomedich-346	365	4	journal	journal	PROPN
biomedich-346	365	5	of	of	ADP
biomedich-346	365	6	medicine	medicine	NOUN
biomedich-346	365	7	,	,	PUNCT
biomedich-346	365	8	384(23	384(23	NOUN
biomedich-346	365	9	)	)	PUNCT
biomedich-346	365	10	,	,	PUNCT
biomedich-346	365	11	2259–2261	2259–2261	NUM
biomedich-346	365	12	.	.	PUNCT
biomedich-346	365	13	doi:10.1056	doi:10.1056	PROPN
biomedich-346	365	14	/	/	SYM
biomedich-346	365	15	nejmc2103916	nejmc2103916	PROPN
biomedich-346	365	16	.	.	PUNCT
biomedich-346	366	1	braz	braz	PROPN
biomedich-346	366	2	gomes	gomes	PROPN
biomedich-346	366	3	,	,	PUNCT
biomedich-346	366	4	k.	k.	PROPN
biomedich-346	366	5	,	,	PUNCT
biomedich-346	366	6	d’sa	d’sa	PROPN
biomedich-346	366	7	,	,	PUNCT
biomedich-346	366	8	s.	s.	PROPN
biomedich-346	366	9	,	,	PUNCT
biomedich-346	366	10	allotey	allotey	PROPN
biomedich-346	366	11	-	-	PUNCT
biomedich-346	366	12	babington	babington	PROPN
biomedich-346	366	13	,	,	PUNCT
biomedich-346	366	14	g.	g.	PROPN
biomedich-346	366	15	l.	l.	PROPN
biomedich-346	366	16	,	,	PUNCT
biomedich-346	366	17	kang	kang	PROPN
biomedich-346	366	18	,	,	PUNCT
biomedich-346	366	19	s.-m	s.-m	PROPN
biomedich-346	366	20	.	.	PROPN
biomedich-346	366	21	,	,	PUNCT
biomedich-346	366	22	&	&	CCONJ
biomedich-346	366	23	d’souza	d’souza	PROPN
biomedich-346	366	24	,	,	PUNCT
biomedich-346	366	25	m.	m.	NOUN
biomedich-346	366	26	j.	j.	PROPN
biomedich-346	366	27	(	(	PUNCT
biomedich-346	366	28	2021	2021	NUM
biomedich-346	366	29	)	)	PUNCT
biomedich-346	366	30	.	.	PUNCT
biomedich-346	367	1	transdermal	transdermal	ADJ
biomedich-346	367	2	vaccination	vaccination	NOUN
biomedich-346	367	3	with	with	ADP
biomedich-346	367	4	the	the	DET
biomedich-346	367	5	matrix-2	matrix-2	NUM
biomedich-346	367	6	protein	protein	NOUN
biomedich-346	367	7	virus	virus	NOUN
biomedich-346	367	8	-	-	PUNCT
biomedich-346	367	9	like	like	ADJ
biomedich-346	367	10	particle	particle	NOUN
biomedich-346	367	11	(	(	PUNCT
biomedich-346	367	12	m2e	m2e	PROPN
biomedich-346	367	13	vlp	vlp	PROPN
biomedich-346	367	14	)	)	PUNCT
biomedich-346	367	15	induces	induce	VERB
biomedich-346	367	16	immunity	immunity	NOUN
biomedich-346	367	17	in	in	ADP
biomedich-346	367	18	mice	mouse	NOUN
biomedich-346	367	19	against	against	ADP
biomedich-346	367	20	influenza	influenza	NOUN
biomedich-346	367	21	a	a	DET
biomedich-346	367	22	virus	virus	NOUN
biomedich-346	367	23	.	.	PUNCT
biomedich-346	368	1	vaccines	vaccine	NOUN
biomedich-346	368	2	,	,	PUNCT
biomedich-346	368	3	9(11	9(11	NUM
biomedich-346	368	4	)	)	PUNCT
biomedich-346	368	5	,	,	PUNCT
biomedich-346	368	6	1324	1324	NUM
biomedich-346	368	7	.	.	PUNCT
biomedich-346	369	1	doi:10.3390	doi:10.3390	NOUN
biomedich-346	369	2	/	/	SYM
biomedich-346	369	3	vaccines9111324	vaccines9111324	PROPN
biomedich-346	369	4	bachmann	bachmann	PROPN
biomedich-346	369	5	,	,	PUNCT
biomedich-346	369	6	m.	m.	PROPN
biomedich-346	369	7	f.	f.	PROPN
biomedich-346	369	8	,	,	PUNCT
biomedich-346	369	9	&	&	CCONJ
biomedich-346	369	10	jennings	jennings	PROPN
biomedich-346	369	11	,	,	PUNCT
biomedich-346	369	12	g.	g.	PROPN
biomedich-346	369	13	t.	t.	PROPN
biomedich-346	369	14	(	(	PUNCT
biomedich-346	369	15	2010	2010	NUM
biomedich-346	369	16	)	)	PUNCT
biomedich-346	369	17	.	.	PUNCT
biomedich-346	370	1	vaccine	vaccine	NOUN
biomedich-346	370	2	delivery	delivery	NOUN
biomedich-346	370	3	:	:	PUNCT
biomedich-346	370	4	a	a	DET
biomedich-346	370	5	matter	matter	NOUN
biomedich-346	370	6	of	of	ADP
biomedich-346	370	7	size	size	NOUN
biomedich-346	370	8	,	,	PUNCT
biomedich-346	370	9	geometry	geometry	NOUN
biomedich-346	370	10	,	,	PUNCT
biomedich-346	370	11	kinetics	kinetic	NOUN
biomedich-346	370	12	,	,	PUNCT
biomedich-346	370	13	and	and	CCONJ
biomedich-346	370	14	molecular	molecular	ADJ
biomedich-346	370	15	patterns	pattern	NOUN
biomedich-346	370	16	.	.	PUNCT
biomedich-346	371	1	nature	nature	NOUN
biomedich-346	371	2	reviews	review	NOUN
biomedich-346	371	3	.	.	PUNCT
biomedich-346	372	1	immunology	immunology	NOUN
biomedich-346	372	2	,	,	PUNCT
biomedich-346	372	3	10(11	10(11	NUM
biomedich-346	372	4	)	)	PUNCT
biomedich-346	372	5	,	,	PUNCT
biomedich-346	372	6	787–796	787–796	NUM
biomedich-346	372	7	.	.	PUNCT
biomedich-346	372	8	doi:10.1038	doi:10.1038	NOUN
biomedich-346	372	9	/	/	SYM
biomedich-346	372	10	nri2868	nri2868	VERB
biomedich-346	372	11	bachmann	bachmann	PROPN
biomedich-346	372	12	,	,	PUNCT
biomedich-346	372	13	m.	m.	PROPN
biomedich-346	372	14	f.	f.	PROPN
biomedich-346	372	15	,	,	PUNCT
biomedich-346	372	16	rohrer	rohrer	PROPN
biomedich-346	372	17	,	,	PUNCT
biomedich-346	372	18	u.	u.	PROPN
biomedich-346	372	19	h.	h.	PROPN
biomedich-346	372	20	,	,	PUNCT
biomedich-346	372	21	kündig	kündig	PROPN
biomedich-346	372	22	,	,	PUNCT
biomedich-346	372	23	t.	t.	NOUN
biomedich-346	372	24	m.	m.	NOUN
biomedich-346	372	25	,	,	PUNCT
biomedich-346	372	26	bürki	bürki	PROPN
biomedich-346	372	27	,	,	PUNCT
biomedich-346	372	28	k.	k.	PROPN
biomedich-346	372	29	,	,	PUNCT
biomedich-346	372	30	hengartner	hengartner	NOUN
biomedich-346	372	31	,	,	PUNCT
biomedich-346	372	32	h.	h.	PROPN
biomedich-346	372	33	,	,	PUNCT
biomedich-346	372	34	&	&	CCONJ
biomedich-346	372	35	zinkernagel	zinkernagel	PROPN
biomedich-346	372	36	,	,	PUNCT
biomedich-346	372	37	r.	r.	PROPN
biomedich-346	372	38	m.	m.	PROPN
biomedich-346	372	39	(	(	PUNCT
biomedich-346	372	40	1993	1993	NUM
biomedich-346	372	41	)	)	PUNCT
biomedich-346	372	42	.	.	PUNCT
biomedich-346	373	1	the	the	DET
biomedich-346	373	2	influence	influence	NOUN
biomedich-346	373	3	of	of	ADP
biomedich-346	373	4	antigen	antigen	ADJ
biomedich-346	373	5	organization	organization	NOUN
biomedich-346	373	6	on	on	ADP
biomedich-346	373	7	b	b	PROPN
biomedich-346	373	8	cell	cell	NOUN
biomedich-346	373	9	responsiveness	responsiveness	NOUN
biomedich-346	373	10	.	.	PUNCT
biomedich-346	374	1	science	science	NOUN
biomedich-346	374	2	(	(	PUNCT
biomedich-346	374	3	new	new	PROPN
biomedich-346	374	4	york	york	PROPN
biomedich-346	374	5	,	,	PUNCT
biomedich-346	374	6	n.y	n.y	PROPN
biomedich-346	374	7	.	.	PROPN
biomedich-346	374	8	)	)	PUNCT
biomedich-346	374	9	,	,	PUNCT
biomedich-346	374	10	262(5138	262(5138	NUM
biomedich-346	374	11	)	)	PUNCT
biomedich-346	374	12	,	,	PUNCT
biomedich-346	374	13	1448–1451	1448–1451	NUM
biomedich-346	374	14	.	.	PUNCT
biomedich-346	375	1	doi:10.1126	doi:10.1126	NOUN
biomedich-346	375	2	/	/	SYM
biomedich-346	375	3	science.8248784	science.8248784	NOUN
biomedich-346	375	4	baranov	baranov	NOUN
biomedich-346	375	5	,	,	PUNCT
biomedich-346	375	6	m.	m.	NOUN
biomedich-346	375	7	v.	v.	PROPN
biomedich-346	375	8	,	,	PUNCT
biomedich-346	375	9	kumar	kumar	PROPN
biomedich-346	375	10	,	,	PUNCT
biomedich-346	375	11	m.	m.	NOUN
biomedich-346	375	12	,	,	PUNCT
biomedich-346	375	13	sacanna	sacanna	NOUN
biomedich-346	375	14	,	,	PUNCT
biomedich-346	375	15	s.	s.	PROPN
biomedich-346	375	16	,	,	PUNCT
biomedich-346	375	17	thutupalli	thutupalli	PROPN
biomedich-346	375	18	,	,	PUNCT
biomedich-346	375	19	s.	s.	PROPN
biomedich-346	375	20	,	,	PUNCT
biomedich-346	375	21	&	&	CCONJ
biomedich-346	375	22	van	van	PROPN
biomedich-346	375	23	den	den	PROPN
biomedich-346	375	24	bogaart	bogaart	NOUN
biomedich-346	375	25	,	,	PUNCT
biomedich-346	375	26	g.	g.	PROPN
biomedich-346	375	27	(	(	PUNCT
biomedich-346	375	28	2020	2020	NUM
biomedich-346	375	29	)	)	PUNCT
biomedich-346	375	30	.	.	PUNCT
biomedich-346	376	1	modulation	modulation	NOUN
biomedich-346	376	2	of	of	ADP
biomedich-346	376	3	immune	immune	ADJ
biomedich-346	376	4	responses	response	NOUN
biomedich-346	376	5	by	by	ADP
biomedich-346	376	6	particle	particle	NOUN
biomedich-346	376	7	size	size	NOUN
biomedich-346	376	8	and	and	CCONJ
biomedich-346	376	9	shape	shape	NOUN
biomedich-346	376	10	.	.	PUNCT
biomedich-346	377	1	frontiers	frontier	NOUN
biomedich-346	377	2	in	in	ADP
biomedich-346	377	3	immunology	immunology	NOUN
biomedich-346	377	4	,	,	PUNCT
biomedich-346	377	5	11	11	NUM
biomedich-346	377	6	,	,	PUNCT
biomedich-346	377	7	607945	607945	NUM
biomedich-346	377	8	.	.	PUNCT
biomedich-346	378	1	doi:10.3389	doi:10.3389	PROPN
biomedich-346	378	2	/	/	SYM
biomedich-346	378	3	fimmu.2020.607945	fimmu.2020.607945	PROPN
biomedich-346	378	4	de	de	X
biomedich-346	378	5	souza	souza	PROPN
biomedich-346	378	6	,	,	PUNCT
biomedich-346	378	7	g.	g.	PROPN
biomedich-346	378	8	a.	a.	PROPN
biomedich-346	378	9	p.	p.	PROPN
biomedich-346	378	10	,	,	PUNCT
biomedich-346	378	11	rocha	rocha	PROPN
biomedich-346	378	12	,	,	PUNCT
biomedich-346	378	13	r.	r.	PROPN
biomedich-346	378	14	p.	p.	PROPN
biomedich-346	378	15	,	,	PUNCT
biomedich-346	378	16	gonçalves	gonçalves	PROPN
biomedich-346	378	17	,	,	PUNCT
biomedich-346	378	18	r.	r.	PROPN
biomedich-346	378	19	l.	l.	PROPN
biomedich-346	378	20	,	,	PUNCT
biomedich-346	378	21	ferreira	ferreira	PROPN
biomedich-346	378	22	,	,	PUNCT
biomedich-346	378	23	c.	c.	PROPN
biomedich-346	378	24	s.	s.	PROPN
biomedich-346	378	25	,	,	PUNCT
biomedich-346	378	26	de	de	PROPN
biomedich-346	378	27	mello	mello	PROPN
biomedich-346	378	28	silva	silva	PROPN
biomedich-346	378	29	,	,	PUNCT
biomedich-346	378	30	b.	b.	PROPN
biomedich-346	378	31	,	,	PUNCT
biomedich-346	378	32	de	de	PROPN
biomedich-346	378	33	castro	castro	PROPN
biomedich-346	378	34	,	,	PUNCT
biomedich-346	378	35	r.	r.	PROPN
biomedich-346	378	36	f.	f.	PROPN
biomedich-346	378	37	g.	g.	PROPN
biomedich-346	378	38	,	,	PUNCT
biomedich-346	378	39	…	…	PUNCT
biomedich-346	378	40	coelho	coelho	NOUN
biomedich-346	378	41	,	,	PUNCT
biomedich-346	378	42	l.	l.	PROPN
biomedich-346	378	43	f.	f.	PROPN
biomedich-346	378	44	l.	l.	PROPN
biomedich-346	378	45	(	(	PUNCT
biomedich-346	378	46	2021	2021	NUM
biomedich-346	378	47	)	)	PUNCT
biomedich-346	378	48	.	.	PUNCT
biomedich-346	379	1	nanoparticles	nanoparticle	NOUN
biomedich-346	379	2	as	as	ADP
biomedich-346	379	3	vaccines	vaccine	NOUN
biomedich-346	379	4	to	to	PART
biomedich-346	379	5	prevent	prevent	VERB
biomedich-346	379	6	arbovirus	arbovirus	NOUN
biomedich-346	379	7	infection	infection	NOUN
biomedich-346	379	8	:	:	PUNCT
biomedich-346	379	9	a	a	DET
biomedich-346	379	10	long	long	ADJ
biomedich-346	379	11	road	road	NOUN
biomedich-346	379	12	ahead	ahead	ADV
biomedich-346	379	13	.	.	PUNCT
biomedich-346	380	1	pathogens	pathogen	NOUN
biomedich-346	380	2	,	,	PUNCT
biomedich-346	380	3	10(1	10(1	NUM
biomedich-346	380	4	)	)	PUNCT
biomedich-346	380	5	,	,	PUNCT
biomedich-346	380	6	36	36	NUM
biomedich-346	380	7	.	.	PUNCT
biomedich-346	380	8	doi:10.3390	doi:10.3390	NOUN
biomedich-346	380	9	/	/	SYM
biomedich-346	380	10	pathogens10010036	pathogens10010036	NOUN
biomedich-346	380	11	abo	abo	NOUN
biomedich-346	380	12	-	-	PUNCT
biomedich-346	380	13	zeid	zeid	NOUN
biomedich-346	380	14	,	,	PUNCT
biomedich-346	380	15	y.	y.	PROPN
biomedich-346	380	16	,	,	PUNCT
biomedich-346	380	17	&	&	CCONJ
biomedich-346	380	18	garnett	garnett	PROPN
biomedich-346	380	19	,	,	PUNCT
biomedich-346	380	20	m.	m.	NOUN
biomedich-346	380	21	c.	c.	PROPN
biomedich-346	380	22	(	(	PUNCT
biomedich-346	380	23	2020	2020	NUM
biomedich-346	380	24	)	)	PUNCT
biomedich-346	380	25	.	.	PUNCT
biomedich-346	381	1	polymer	polymer	NOUN
biomedich-346	381	2	nanoparticle	nanoparticle	NOUN
biomedich-346	381	3	as	as	ADP
biomedich-346	381	4	a	a	DET
biomedich-346	381	5	delivery	delivery	NOUN
biomedich-346	381	6	system	system	NOUN
biomedich-346	381	7	for	for	ADP
biomedich-346	381	8	ribavirin	ribavirin	NOUN
biomedich-346	381	9	:	:	PUNCT
biomedich-346	381	10	do	do	AUX
biomedich-346	381	11	nanoparticle	nanoparticle	NOUN
biomedich-346	381	12	avoid	avoid	VERB
biomedich-346	381	13	uptake	uptake	NOUN
biomedich-346	381	14	by	by	ADP
biomedich-346	381	15	red	red	ADJ
biomedich-346	381	16	blood	blood	NOUN
biomedich-346	381	17	cells	cell	NOUN
biomedich-346	381	18	?	?	PUNCT
biomedich-346	382	1	journal	journal	NOUN
biomedich-346	382	2	of	of	ADP
biomedich-346	382	3	drug	drug	NOUN
biomedich-346	382	4	delivery	delivery	NOUN
biomedich-346	382	5	science	science	NOUN
biomedich-346	382	6	and	and	CCONJ
biomedich-346	382	7	technology	technology	NOUN
biomedich-346	382	8	,	,	PUNCT
biomedich-346	382	9	56(101552	56(101552	NUM
biomedich-346	382	10	)	)	PUNCT
biomedich-346	382	11	,	,	PUNCT
biomedich-346	382	12	101552	101552	NUM
biomedich-346	382	13	.	.	PUNCT
biomedich-346	383	1	doi:10.1016	doi:10.1016	PROPN
biomedich-346	383	2	/	/	SYM
biomedich-346	383	3	j.jddst.2020.101552	j.jddst.2020.101552	PROPN
biomedich-346	383	4	chen	chen	PROPN
biomedich-346	383	5	,	,	PUNCT
biomedich-346	383	6	l.	l.	PROPN
biomedich-346	383	7	,	,	PUNCT
biomedich-346	383	8	&	&	CCONJ
biomedich-346	383	9	liang	liang	PROPN
biomedich-346	383	10	,	,	PUNCT
biomedich-346	383	11	j.	j.	PROPN
biomedich-346	383	12	(	(	PUNCT
biomedich-346	383	13	2020	2020	NUM
biomedich-346	383	14	)	)	PUNCT
biomedich-346	383	15	.	.	PUNCT
biomedich-346	384	1	an	an	DET
biomedich-346	384	2	overview	overview	NOUN
biomedich-346	384	3	of	of	ADP
biomedich-346	384	4	functional	functional	ADJ
biomedich-346	384	5	nanoparticles	nanoparticle	NOUN
biomedich-346	384	6	as	as	ADP
biomedich-346	384	7	novel	novel	ADJ
biomedich-346	384	8	emerging	emerge	VERB
biomedich-346	384	9	antiviral	antiviral	ADJ
biomedich-346	384	10	therapeutic	therapeutic	ADJ
biomedich-346	384	11	agents	agent	NOUN
biomedich-346	384	12	.	.	PUNCT
biomedich-346	385	1	materials	material	NOUN
biomedich-346	385	2	science	science	NOUN
biomedich-346	385	3	&	&	CCONJ
biomedich-346	385	4	engineering	engineering	PROPN
biomedich-346	385	5	.	.	PUNCT
biomedich-346	386	1	c	c	X
biomedich-346	386	2	,	,	PUNCT
biomedich-346	386	3	materials	material	NOUN
biomedich-346	386	4	for	for	ADP
biomedich-346	386	5	biological	biological	ADJ
biomedich-346	386	6	applications	application	NOUN
biomedich-346	386	7	,	,	PUNCT
biomedich-346	386	8	112(110924	112(110924	NUM
biomedich-346	386	9	)	)	PUNCT
biomedich-346	386	10	,	,	PUNCT
biomedich-346	386	11	110924	110924	NUM
biomedich-346	386	12	.	.	PUNCT
biomedich-346	387	1	doi:10.1016	doi:10.1016	PROPN
biomedich-346	387	2	/	/	SYM
biomedich-346	387	3	j.msec.2020.110924	j.msec.2020.110924	PROPN
biomedich-346	387	4	chen	chen	PROPN
biomedich-346	387	5	,	,	PUNCT
biomedich-346	387	6	n.	n.	PROPN
biomedich-346	387	7	,	,	PUNCT
biomedich-346	387	8	zheng	zheng	PROPN
biomedich-346	387	9	,	,	PUNCT
biomedich-346	387	10	y.	y.	PROPN
biomedich-346	387	11	,	,	PUNCT
biomedich-346	387	12	yin	yin	PROPN
biomedich-346	387	13	,	,	PUNCT
biomedich-346	387	14	j.	j.	PROPN
biomedich-346	387	15	,	,	PUNCT
biomedich-346	387	16	li	li	PROPN
biomedich-346	387	17	,	,	PUNCT
biomedich-346	387	18	x.	x.	PROPN
biomedich-346	387	19	,	,	PUNCT
biomedich-346	387	20	&	&	CCONJ
biomedich-346	387	21	zheng	zheng	PROPN
biomedich-346	387	22	,	,	PUNCT
biomedich-346	387	23	c.	c.	PROPN
biomedich-346	387	24	(	(	PUNCT
biomedich-346	387	25	2013	2013	NUM
biomedich-346	387	26	)	)	PUNCT
biomedich-346	387	27	.	.	PUNCT
biomedich-346	388	1	inhibitory	inhibitory	ADJ
biomedich-346	388	2	effects	effect	NOUN
biomedich-346	388	3	of	of	ADP
biomedich-346	388	4	silver	silver	ADJ
biomedich-346	388	5	nanoparticles	nanoparticle	NOUN
biomedich-346	388	6	against	against	ADP
biomedich-346	388	7	adenovirus	adenovirus	NOUN
biomedich-346	388	8	type	type	NOUN
biomedich-346	388	9	3	3	NUM
biomedich-346	388	10	in	in	ADP
biomedich-346	388	11	vitro	vitro	X
biomedich-346	388	12	.	.	PUNCT
biomedich-346	389	1	journal	journal	NOUN
biomedich-346	389	2	of	of	ADP
biomedich-346	389	3	virological	virological	ADJ
biomedich-346	389	4	methods	method	NOUN
biomedich-346	389	5	,	,	PUNCT
biomedich-346	389	6	193(2	193(2	NUM
biomedich-346	389	7	)	)	PUNCT
biomedich-346	389	8	,	,	PUNCT
biomedich-346	389	9	470	470	NUM
biomedich-346	389	10	–	–	PUNCT
biomedich-346	389	11	477	477	NUM
biomedich-346	389	12	.	.	PUNCT
biomedich-346	389	13	doi:10.1016	doi:10.1016	PROPN
biomedich-346	389	14	/	/	SYM
biomedich-346	389	15	j.jviromet.2013.07.020	j.jviromet.2013.07.020	PROPN
biomedich-346	389	16	choi	choi	NOUN
biomedich-346	389	17	,	,	PUNCT
biomedich-346	389	18	a.	a.	PROPN
biomedich-346	389	19	,	,	PUNCT
biomedich-346	389	20	koch	koch	PROPN
biomedich-346	389	21	,	,	PUNCT
biomedich-346	389	22	m.	m.	NOUN
biomedich-346	389	23	,	,	PUNCT
biomedich-346	389	24	wu	wu	PROPN
biomedich-346	389	25	,	,	PUNCT
biomedich-346	389	26	k.	k.	PROPN
biomedich-346	389	27	,	,	PUNCT
biomedich-346	389	28	chu	chu	PROPN
biomedich-346	389	29	,	,	PUNCT
biomedich-346	389	30	l.	l.	PROPN
biomedich-346	389	31	,	,	PUNCT
biomedich-346	389	32	ma	ma	PROPN
biomedich-346	389	33	,	,	PUNCT
biomedich-346	389	34	l.	l.	PROPN
biomedich-346	389	35	,	,	PUNCT
biomedich-346	389	36	hill	hill	PROPN
biomedich-346	389	37	,	,	PUNCT
biomedich-346	389	38	a.	a.	PROPN
biomedich-346	389	39	,	,	PUNCT
biomedich-346	389	40	…	…	PUNCT
biomedich-346	389	41	edwards	edwards	PROPN
biomedich-346	389	42	,	,	PUNCT
biomedich-346	389	43	d.	d.	PROPN
biomedich-346	389	44	k.	k.	PROPN
biomedich-346	389	45	(	(	PUNCT
biomedich-346	389	46	2021	2021	NUM
biomedich-346	389	47	)	)	PUNCT
biomedich-346	389	48	.	.	PUNCT
biomedich-346	390	1	safety	safety	NOUN
biomedich-346	390	2	and	and	CCONJ
biomedich-346	390	3	immunogenicity	immunogenicity	NOUN
biomedich-346	390	4	of	of	ADP
biomedich-346	390	5	sars	sar	NOUN
biomedich-346	390	6	-	-	PUNCT
biomedich-346	390	7	cov-2	cov-2	PART
biomedich-346	390	8	variant	variant	ADJ
biomedich-346	390	9	mrna	mrna	NOUN
biomedich-346	390	10	vaccine	vaccine	NOUN
biomedich-346	390	11	boosters	booster	NOUN
biomedich-346	390	12	in	in	ADP
biomedich-346	390	13	healthy	healthy	ADJ
biomedich-346	390	14	adults	adult	NOUN
biomedich-346	390	15	:	:	PUNCT
biomedich-346	390	16	an	an	DET
biomedich-346	390	17	interim	interim	ADJ
biomedich-346	390	18	analysis	analysis	NOUN
biomedich-346	390	19	.	.	PUNCT
biomedich-346	391	1	nature	nature	NOUN
biomedich-346	391	2	medicine	medicine	NOUN
biomedich-346	391	3	,	,	PUNCT
biomedich-346	391	4	27(11	27(11	NUM
biomedich-346	391	5	)	)	PUNCT
biomedich-346	391	6	,	,	PUNCT
biomedich-346	391	7	2025–2031	2025–2031	NOUN
biomedich-346	391	8	.	.	PUNCT
biomedich-346	392	1	doi:10.1038	doi:10.1038	NOUN
biomedich-346	392	2	/	/	SYM
biomedich-346	392	3	s41591	s41591	NOUN
biomedich-346	392	4	-	-	PUNCT
biomedich-346	392	5	021	021	NUM
biomedich-346	392	6	-	-	PUNCT
biomedich-346	392	7	01527	01527	NUM
biomedich-346	392	8	-	-	PUNCT
biomedich-346	392	9	y	y	PROPN
biomedich-346	392	10	chen	chen	PROPN
biomedich-346	392	11	,	,	PUNCT
biomedich-346	392	12	l.	l.	PROPN
biomedich-346	392	13	,	,	PUNCT
biomedich-346	392	14	valentine	valentine	PROPN
biomedich-346	392	15	,	,	PUNCT
biomedich-346	392	16	j.	j.	PROPN
biomedich-346	392	17	l.	l.	PROPN
biomedich-346	392	18	,	,	PUNCT
biomedich-346	392	19	huang	huang	PROPN
biomedich-346	392	20	,	,	PUNCT
biomedich-346	392	21	c.-j	c.-j	PROPN
biomedich-346	392	22	.	.	PROPN
biomedich-346	392	23	,	,	PUNCT
biomedich-346	392	24	endicott	endicott	PROPN
biomedich-346	392	25	,	,	PUNCT
biomedich-346	392	26	c.	c.	PROPN
biomedich-346	392	27	e.	e.	PROPN
biomedich-346	392	28	,	,	PUNCT
biomedich-346	392	29	moeller	moeller	PROPN
biomedich-346	392	30	,	,	PUNCT
biomedich-346	392	31	t.	t.	PROPN
biomedich-346	392	32	d.	d.	PROPN
biomedich-346	392	33	,	,	PUNCT
biomedich-346	392	34	rasmussen	rasmussen	PROPN
biomedich-346	392	35	,	,	PUNCT
biomedich-346	392	36	j.	j.	PROPN
biomedich-346	392	37	a.	a.	PROPN
biomedich-346	392	38	,	,	PUNCT
biomedich-346	392	39	…	…	PUNCT
biomedich-346	392	40	delisa	delisa	NOUN
biomedich-346	392	41	,	,	PUNCT
biomedich-346	392	42	m.	m.	NOUN
biomedich-346	392	43	p.	p.	NOUN
biomedich-346	392	44	(	(	PUNCT
biomedich-346	392	45	2016	2016	NUM
biomedich-346	392	46	)	)	PUNCT
biomedich-346	392	47	.	.	PUNCT
biomedich-346	393	1	outer	outer	ADJ
biomedich-346	393	2	membrane	membrane	NOUN
biomedich-346	393	3	vesicles	vesicle	NOUN
biomedich-346	393	4	displaying	display	VERB
biomedich-346	393	5	engineered	engineer	VERB
biomedich-346	393	6	glycotopes	glycotope	NOUN
biomedich-346	393	7	elicit	elicit	VERB
biomedich-346	393	8	protective	protective	ADJ
biomedich-346	393	9	antibodies	antibody	NOUN
biomedich-346	393	10	.	.	PUNCT
biomedich-346	394	1	proceedings	proceeding	NOUN
biomedich-346	394	2	of	of	ADP
biomedich-346	394	3	the	the	DET
biomedich-346	394	4	national	national	PROPN
biomedich-346	394	5	academy	academy	PROPN
biomedich-346	394	6	of	of	ADP
biomedich-346	394	7	sciences	sciences	PROPN
biomedich-346	394	8	of	of	ADP
biomedich-346	394	9	the	the	DET
biomedich-346	394	10	united	united	PROPN
biomedich-346	394	11	states	states	PROPN
biomedich-346	394	12	of	of	ADP
biomedich-346	394	13	america	america	PROPN
biomedich-346	394	14	,	,	PUNCT
biomedich-346	394	15	113(26	113(26	NUM
biomedich-346	394	16	)	)	PUNCT
biomedich-346	394	17	,	,	PUNCT
biomedich-346	394	18	e3609	e3609	NOUN
biomedich-346	394	19	-	-	PUNCT
biomedich-346	394	20	18	18	NUM
biomedich-346	394	21	.	.	PUNCT
biomedich-346	395	1	doi:10.1073	doi:10.1073	NOUN
biomedich-346	395	2	/	/	SYM
biomedich-346	395	3	pnas.1518311113	pnas.1518311113	PROPN
biomedich-346	395	4	heinz	heinz	PROPN
biomedich-346	395	5	,	,	PUNCT
biomedich-346	395	6	h.	h.	PROPN
biomedich-346	395	7	,	,	PUNCT
biomedich-346	395	8	pramanik	pramanik	PROPN
biomedich-346	395	9	,	,	PUNCT
biomedich-346	395	10	c.	c.	PROPN
biomedich-346	395	11	,	,	PUNCT
biomedich-346	395	12	heinz	heinz	PROPN
biomedich-346	395	13	,	,	PUNCT
biomedich-346	395	14	o.	o.	PROPN
biomedich-346	395	15	,	,	PUNCT
biomedich-346	395	16	ding	ding	NOUN
biomedich-346	395	17	,	,	PUNCT
biomedich-346	395	18	y.	y.	PROPN
biomedich-346	395	19	,	,	PUNCT
biomedich-346	395	20	mishra	mishra	PROPN
biomedich-346	395	21	,	,	PUNCT
biomedich-346	395	22	r.	r.	PROPN
biomedich-346	395	23	k.	k.	PROPN
biomedich-346	395	24	,	,	PUNCT
biomedich-346	395	25	marchon	marchon	PROPN
biomedich-346	395	26	,	,	PUNCT
biomedich-346	395	27	d.	d.	PROPN
biomedich-346	395	28	,	,	PUNCT
biomedich-346	395	29	…	…	PUNCT
biomedich-346	395	30	ziolo	ziolo	PROPN
biomedich-346	395	31	,	,	PUNCT
biomedich-346	395	32	r.	r.	PROPN
biomedich-346	395	33	f.	f.	PROPN
biomedich-346	395	34	(	(	PUNCT
biomedich-346	395	35	2017	2017	NUM
biomedich-346	395	36	)	)	PUNCT
biomedich-346	395	37	.	.	PUNCT
biomedich-346	396	1	nanoparticle	nanoparticle	NOUN
biomedich-346	396	2	decoration	decoration	NOUN
biomedich-346	396	3	with	with	ADP
biomedich-346	396	4	surfactants	surfactant	NOUN
biomedich-346	396	5	:	:	PUNCT
biomedich-346	396	6	molecular	molecular	ADJ
biomedich-346	396	7	interactions	interaction	NOUN
biomedich-346	396	8	,	,	PUNCT
biomedich-346	396	9	assembly	assembly	NOUN
biomedich-346	396	10	,	,	PUNCT
biomedich-346	396	11	and	and	CCONJ
biomedich-346	396	12	applications	application	NOUN
biomedich-346	396	13	.	.	PUNCT
biomedich-346	397	1	surface	surface	NOUN
biomedich-346	397	2	science	science	NOUN
biomedich-346	397	3	reports	report	NOUN
biomedich-346	397	4	,	,	PUNCT
biomedich-346	397	5	72(1	72(1	NOUN
biomedich-346	397	6	)	)	PUNCT
biomedich-346	397	7	,	,	PUNCT
biomedich-346	397	8	1–58	1–58	PROPN
biomedich-346	397	9	.	.	PUNCT
biomedich-346	398	1	doi:10.1016	doi:10.1016	PROPN
biomedich-346	398	2	/	/	SYM
biomedich-346	398	3	j.surfrep.2017.02.001	j.surfrep.2017.02.001	PROPN
biomedich-346	398	4	alimehmeti	alimehmeti	PROPN
biomedich-346	398	5	,	,	PUNCT
biomedich-346	398	6	i.	i.	PROPN
biomedich-346	398	7	(	(	PUNCT
biomedich-346	398	8	2021	2021	NUM
biomedich-346	398	9	)	)	PUNCT
biomedich-346	398	10	.	.	PUNCT
biomedich-346	399	1	efficacy	efficacy	NOUN
biomedich-346	399	2	and	and	CCONJ
biomedich-346	399	3	safety	safety	NOUN
biomedich-346	399	4	of	of	ADP
biomedich-346	399	5	azd1222	azd1222	NOUN
biomedich-346	399	6	,	,	PUNCT
biomedich-346	399	7	bnt162b2	bnt162b2	NOUN
biomedich-346	399	8	and	and	CCONJ
biomedich-346	399	9	mrna-1273	mrna-1273	ADJ
biomedich-346	399	10	vaccines	vaccine	NOUN
biomedich-346	399	11	against	against	ADP
biomedich-346	399	12	sars	sar	NOUN
biomedich-346	399	13	-	-	PUNCT
biomedich-346	399	14	cov-2	cov-2	NOUN
biomedich-346	399	15	.	.	PUNCT
biomedich-346	399	16	albanian	albanian	PROPN
biomedich-346	399	17	journal	journal	PROPN
biomedich-346	399	18	of	of	ADP
biomedich-346	399	19	trauma	trauma	NOUN
biomedich-346	399	20	and	and	CCONJ
biomedich-346	399	21	emergency	emergency	NOUN
biomedich-346	399	22	surgery	surgery	NOUN
biomedich-346	399	23	,	,	PUNCT
biomedich-346	399	24	5(1	5(1	NUM
biomedich-346	399	25	)	)	PUNCT
biomedich-346	399	26	,	,	PUNCT
biomedich-346	399	27	791–796	791–796	NUM
biomedich-346	399	28	.	.	PUNCT
biomedich-346	399	29	doi:10.32391	doi:10.32391	PROPN
biomedich-346	399	30	/	/	SYM
biomedich-346	400	1	ajtes.v5i1.178	ajtes.v5i1.178	PROPN
biomedich-346	400	2	thomas	thomas	PROPN
biomedich-346	400	3	,	,	PUNCT
biomedich-346	400	4	s.	s.	PROPN
biomedich-346	400	5	j.	j.	PROPN
biomedich-346	400	6	,	,	PUNCT
biomedich-346	400	7	moreira	moreira	PROPN
biomedich-346	400	8	,	,	PUNCT
biomedich-346	400	9	e.	e.	PROPN
biomedich-346	400	10	d.	d.	PROPN
biomedich-346	400	11	,	,	PUNCT
biomedich-346	400	12	jr	jr	PROPN
biomedich-346	400	13	,	,	PUNCT
biomedich-346	400	14	kitchin	kitchin	PROPN
biomedich-346	400	15	,	,	PUNCT
biomedich-346	400	16	n.	n.	NOUN
biomedich-346	400	17	,	,	PUNCT
biomedich-346	400	18	absalon	absalon	PROPN
biomedich-346	400	19	,	,	PUNCT
biomedich-346	400	20	j.	j.	PROPN
biomedich-346	400	21	,	,	PUNCT
biomedich-346	400	22	gurtman	gurtman	NOUN
biomedich-346	400	23	,	,	PUNCT
biomedich-346	400	24	a.	a.	NOUN
biomedich-346	400	25	,	,	PUNCT
biomedich-346	400	26	lockhart	lockhart	PROPN
biomedich-346	400	27	,	,	PUNCT
biomedich-346	400	28	s.	s.	PROPN
biomedich-346	400	29	,	,	PUNCT
biomedich-346	400	30	…	…	PUNCT
biomedich-346	400	31	c4591001	c4591001	NOUN
biomedich-346	400	32	clinical	clinical	ADJ
biomedich-346	400	33	trial	trial	NOUN
biomedich-346	400	34	group	group	NOUN
biomedich-346	400	35	.	.	PUNCT
biomedich-346	401	1	(	(	PUNCT
biomedich-346	401	2	2021	2021	NUM
biomedich-346	401	3	)	)	PUNCT
biomedich-346	401	4	.	.	PUNCT
biomedich-346	402	1	safety	safety	NOUN
biomedich-346	402	2	and	and	CCONJ
biomedich-346	402	3	efficacy	efficacy	NOUN
biomedich-346	402	4	of	of	ADP
biomedich-346	402	5	the	the	DET
biomedich-346	402	6	bnt162b2	bnt162b2	PROPN
biomedich-346	402	7	mrna	mrna	PROPN
biomedich-346	402	8	covid-19	covid-19	PROPN
biomedich-346	402	9	vaccine	vaccine	NOUN
biomedich-346	402	10	through	through	ADP
biomedich-346	402	11	6	6	NUM
biomedich-346	402	12	months	month	NOUN
biomedich-346	402	13	.	.	PUNCT
biomedich-346	403	1	the	the	DET
biomedich-346	403	2	new	new	PROPN
biomedich-346	403	3	england	england	PROPN
biomedich-346	403	4	journal	journal	PROPN
biomedich-346	403	5	of	of	ADP
biomedich-346	403	6	medicine	medicine	NOUN
biomedich-346	403	7	,	,	PUNCT
biomedich-346	403	8	385(19	385(19	NUM
biomedich-346	403	9	)	)	PUNCT
biomedich-346	403	10	,	,	PUNCT
biomedich-346	403	11	1761–1773	1761–1773	NUM
biomedich-346	403	12	.	.	PUNCT
biomedich-346	404	1	doi:10.1056	doi:10.1056	PROPN
biomedich-346	404	2	/	/	SYM
biomedich-346	405	1	nejmoa2110345	nejmoa2110345	PROPN
biomedich-346	405	2	heath	heath	PROPN
biomedich-346	405	3	,	,	PUNCT
biomedich-346	405	4	p.	p.	PROPN
biomedich-346	405	5	t.	t.	PROPN
biomedich-346	405	6	,	,	PUNCT
biomedich-346	405	7	galiza	galiza	PROPN
biomedich-346	405	8	,	,	PUNCT
biomedich-346	405	9	e.	e.	PROPN
biomedich-346	405	10	p.	p.	PROPN
biomedich-346	405	11	,	,	PUNCT
biomedich-346	405	12	baxter	baxter	PROPN
biomedich-346	405	13	,	,	PUNCT
biomedich-346	405	14	d.	d.	PROPN
biomedich-346	405	15	n.	n.	PROPN
biomedich-346	405	16	,	,	PUNCT
biomedich-346	405	17	boffito	boffito	ADJ
biomedich-346	405	18	,	,	PUNCT
biomedich-346	405	19	m.	m.	NOUN
biomedich-346	405	20	,	,	PUNCT
biomedich-346	405	21	browne	browne	PROPN
biomedich-346	405	22	,	,	PUNCT
biomedich-346	405	23	d.	d.	PROPN
biomedich-346	405	24	,	,	PUNCT
biomedich-346	405	25	burns	burn	NOUN
biomedich-346	405	26	,	,	PUNCT
biomedich-346	405	27	f.	f.	PROPN
biomedich-346	405	28	,	,	PUNCT
biomedich-346	405	29	…	…	PUNCT
biomedich-346	405	30	2019ncov-302	2019ncov-302	NUM
biomedich-346	405	31	study	study	NOUN
biomedich-346	405	32	group	group	NOUN
biomedich-346	405	33	.	.	PUNCT
biomedich-346	406	1	(	(	PUNCT
biomedich-346	406	2	2021	2021	NUM
biomedich-346	406	3	)	)	PUNCT
biomedich-346	406	4	.	.	PUNCT
biomedich-346	407	1	safety	safety	NOUN
biomedich-346	407	2	and	and	CCONJ
biomedich-346	407	3	efficacy	efficacy	NOUN
biomedich-346	407	4	of	of	ADP
biomedich-346	407	5	nvx	nvx	PROPN
biomedich-346	407	6	-	-	PUNCT
biomedich-346	407	7	cov2373	cov2373	NOUN
biomedich-346	407	8	covid-19	covid-19	PROPN
biomedich-346	407	9	vaccine	vaccine	NOUN
biomedich-346	407	10	.	.	PUNCT
biomedich-346	408	1	the	the	DET
biomedich-346	408	2	new	new	PROPN
biomedich-346	408	3	england	england	PROPN
biomedich-346	408	4	journal	journal	PROPN
biomedich-346	408	5	of	of	ADP
biomedich-346	408	6	medicine	medicine	NOUN
biomedich-346	408	7	,	,	PUNCT
biomedich-346	408	8	385(13	385(13	NUM
biomedich-346	408	9	)	)	PUNCT
biomedich-346	408	10	,	,	PUNCT
biomedich-346	408	11	1172–1183	1172–1183	NUM
biomedich-346	408	12	.	.	PUNCT
biomedich-346	409	1	doi:10.1056	doi:10.1056	PROPN
biomedich-346	409	2	/	/	SYM
biomedich-346	409	3	nejmoa2107659	nejmoa2107659	PROPN
biomedich-346	409	4	360	360	NUM
biomedich-346	409	5	biology	biology	NOUN
biomedich-346	409	6	,	,	PUNCT
biomedich-346	409	7	medicine	medicine	NOUN
biomedich-346	409	8	,	,	PUNCT
biomedich-346	409	9	&	&	CCONJ
biomedich-346	409	10	natural	natural	ADJ
biomedich-346	409	11	product	product	NOUN
biomedich-346	409	12	chemistry	chemistry	NOUN
biomedich-346	409	13	12	12	NUM
biomedich-346	409	14	(	(	PUNCT
biomedich-346	409	15	1	1	NUM
biomedich-346	409	16	)	)	PUNCT
biomedich-346	409	17	,	,	PUNCT
biomedich-346	409	18	2023	2023	NUM
biomedich-346	409	19	:	:	PUNCT
biomedich-346	409	20	343	343	NUM
biomedich-346	409	21	-	-	SYM
biomedich-346	409	22	361	361	NUM
biomedich-346	409	23	houser	houser	PROPN
biomedich-346	409	24	,	,	PUNCT
biomedich-346	409	25	k.	k.	PROPN
biomedich-346	410	1	v.	v.	PROPN
biomedich-346	410	2	,	,	PUNCT
biomedich-346	410	3	chen	chen	PROPN
biomedich-346	410	4	,	,	PUNCT
biomedich-346	410	5	g.	g.	PROPN
biomedich-346	410	6	l.	l.	PROPN
biomedich-346	410	7	,	,	PUNCT
biomedich-346	410	8	carter	carter	PROPN
biomedich-346	410	9	,	,	PUNCT
biomedich-346	410	10	c.	c.	PROPN
biomedich-346	410	11	,	,	PUNCT
biomedich-346	410	12	crank	crank	PROPN
biomedich-346	410	13	,	,	PUNCT
biomedich-346	410	14	m.	m.	PROPN
biomedich-346	410	15	c.	c.	PROPN
biomedich-346	410	16	,	,	PUNCT
biomedich-346	410	17	nguyen	nguyen	NOUN
biomedich-346	410	18	,	,	PUNCT
biomedich-346	410	19	t.	t.	PROPN
biomedich-346	410	20	a.	a.	PROPN
biomedich-346	410	21	,	,	PUNCT
biomedich-346	410	22	burgos	burgos	PROPN
biomedich-346	410	23	florez	florez	PROPN
biomedich-346	410	24	,	,	PUNCT
biomedich-346	410	25	m.	m.	PROPN
biomedich-346	410	26	c.	c.	PROPN
biomedich-346	410	27	,	,	PUNCT
biomedich-346	410	28	…	…	PUNCT
biomedich-346	410	29	vrc	vrc	NOUN
biomedich-346	410	30	316	316	NUM
biomedich-346	410	31	study	study	NOUN
biomedich-346	410	32	team	team	NOUN
biomedich-346	410	33	.	.	PUNCT
biomedich-346	411	1	(	(	PUNCT
biomedich-346	411	2	2022	2022	NUM
biomedich-346	411	3	)	)	PUNCT
biomedich-346	411	4	.	.	PUNCT
biomedich-346	412	1	safety	safety	NOUN
biomedich-346	412	2	and	and	CCONJ
biomedich-346	412	3	immunogenicity	immunogenicity	NOUN
biomedich-346	412	4	of	of	ADP
biomedich-346	412	5	a	a	DET
biomedich-346	412	6	ferritin	ferritin	ADJ
biomedich-346	412	7	nanoparticle	nanoparticle	NOUN
biomedich-346	412	8	h2	h2	NOUN
biomedich-346	412	9	influenza	influenza	NOUN
biomedich-346	412	10	vaccine	vaccine	NOUN
biomedich-346	412	11	in	in	ADP
biomedich-346	412	12	healthy	healthy	ADJ
biomedich-346	412	13	adults	adult	NOUN
biomedich-346	412	14	:	:	PUNCT
biomedich-346	412	15	a	a	DET
biomedich-346	412	16	phase	phase	NOUN
biomedich-346	412	17	1	1	NUM
biomedich-346	412	18	trial	trial	NOUN
biomedich-346	412	19	.	.	PUNCT
biomedich-346	413	1	nature	nature	NOUN
biomedich-346	413	2	medicine	medicine	NOUN
biomedich-346	413	3	,	,	PUNCT
biomedich-346	413	4	28(2	28(2	NUM
biomedich-346	413	5	)	)	PUNCT
biomedich-346	413	6	,	,	PUNCT
biomedich-346	413	7	383–391	383–391	NUM
biomedich-346	413	8	.	.	PUNCT
biomedich-346	413	9	doi:10.1038	doi:10.1038	NOUN
biomedich-346	413	10	/	/	SYM
biomedich-346	413	11	s41591	s41591	NOUN
biomedich-346	413	12	-	-	PUNCT
biomedich-346	413	13	021	021	NUM
biomedich-346	413	14	-	-	PUNCT
biomedich-346	413	15	01660	01660	NUM
biomedich-346	413	16	-	-	SYM
biomedich-346	413	17	8	8	NUM
biomedich-346	413	18	shinde	shinde	NOUN
biomedich-346	413	19	,	,	PUNCT
biomedich-346	413	20	v.	v.	ADP
biomedich-346	413	21	,	,	PUNCT
biomedich-346	413	22	bhikha	bhikha	NOUN
biomedich-346	413	23	,	,	PUNCT
biomedich-346	413	24	s.	s.	PROPN
biomedich-346	413	25	,	,	PUNCT
biomedich-346	413	26	hoosain	hoosain	NOUN
biomedich-346	413	27	,	,	PUNCT
biomedich-346	413	28	z.	z.	PROPN
biomedich-346	413	29	,	,	PUNCT
biomedich-346	413	30	archary	archary	NOUN
biomedich-346	413	31	,	,	PUNCT
biomedich-346	413	32	m.	m.	NOUN
biomedich-346	413	33	,	,	PUNCT
biomedich-346	413	34	bhorat	bhorat	NOUN
biomedich-346	413	35	,	,	PUNCT
biomedich-346	413	36	q.	q.	PROPN
biomedich-346	413	37	,	,	PUNCT
biomedich-346	413	38	fairlie	fairlie	PROPN
biomedich-346	413	39	,	,	PUNCT
biomedich-346	413	40	l.	l.	PROPN
biomedich-346	413	41	,	,	PUNCT
biomedich-346	413	42	…	…	PUNCT
biomedich-346	413	43	2019ncov-501	2019ncov-501	NUM
biomedich-346	413	44	study	study	NOUN
biomedich-346	413	45	group	group	NOUN
biomedich-346	413	46	.	.	PUNCT
biomedich-346	414	1	(	(	PUNCT
biomedich-346	414	2	2021	2021	NUM
biomedich-346	414	3	)	)	PUNCT
biomedich-346	414	4	.	.	PUNCT
biomedich-346	415	1	efficacy	efficacy	NOUN
biomedich-346	415	2	of	of	ADP
biomedich-346	415	3	nvx	nvx	PROPN
biomedich-346	415	4	-	-	PUNCT
biomedich-346	415	5	cov2373	cov2373	NOUN
biomedich-346	415	6	covid-19	covid-19	PROPN
biomedich-346	415	7	vaccine	vaccine	NOUN
biomedich-346	415	8	against	against	ADP
biomedich-346	415	9	the	the	DET
biomedich-346	415	10	b.1.351	b.1.351	NOUN
biomedich-346	415	11	variant	variant	NOUN
biomedich-346	415	12	.	.	PUNCT
biomedich-346	416	1	the	the	DET
biomedich-346	416	2	new	new	PROPN
biomedich-346	416	3	england	england	PROPN
biomedich-346	416	4	journal	journal	PROPN
biomedich-346	416	5	of	of	ADP
biomedich-346	416	6	medicine	medicine	NOUN
biomedich-346	416	7	,	,	PUNCT
biomedich-346	416	8	384(20	384(20	NUM
biomedich-346	416	9	)	)	PUNCT
biomedich-346	416	10	,	,	PUNCT
biomedich-346	416	11	1899–1909	1899–1909	NUM
biomedich-346	416	12	.	.	PUNCT
biomedich-346	416	13	doi:10.1056	doi:10.1056	PROPN
biomedich-346	416	14	/	/	SYM
biomedich-346	416	15	nejmoa2103055	nejmoa2103055	PROPN
biomedich-346	416	16	dunkle	dunkle	PROPN
biomedich-346	416	17	,	,	PUNCT
biomedich-346	416	18	l.	l.	PROPN
biomedich-346	416	19	m.	m.	PROPN
biomedich-346	416	20	,	,	PUNCT
biomedich-346	416	21	kotloff	kotloff	PROPN
biomedich-346	416	22	,	,	PUNCT
biomedich-346	416	23	k.	k.	PROPN
biomedich-346	416	24	l.	l.	PROPN
biomedich-346	416	25	,	,	PUNCT
biomedich-346	416	26	gay	gay	PROPN
biomedich-346	416	27	,	,	PUNCT
biomedich-346	416	28	c.	c.	PROPN
biomedich-346	416	29	l.	l.	PROPN
biomedich-346	416	30	,	,	PUNCT
biomedich-346	416	31	áñez	áñez	NOUN
biomedich-346	416	32	,	,	PUNCT
biomedich-346	416	33	g.	g.	PROPN
biomedich-346	416	34	,	,	PUNCT
biomedich-346	416	35	adelglass	adelglass	PROPN
biomedich-346	416	36	,	,	PUNCT
biomedich-346	416	37	j.	j.	PROPN
biomedich-346	416	38	m.	m.	PROPN
biomedich-346	416	39	,	,	PUNCT
biomedich-346	416	40	barrat	barrat	NOUN
biomedich-346	416	41	hernández	hernández	PROPN
biomedich-346	416	42	,	,	PUNCT
biomedich-346	416	43	a.	a.	NOUN
biomedich-346	416	44	q.	q.	PROPN
biomedich-346	416	45	,	,	PUNCT
biomedich-346	416	46	…	…	PUNCT
biomedich-346	416	47	2019ncov-301	2019ncov-301	NUM
biomedich-346	416	48	study	study	NOUN
biomedich-346	416	49	group	group	NOUN
biomedich-346	416	50	.	.	PUNCT
biomedich-346	417	1	(	(	PUNCT
biomedich-346	417	2	2022	2022	NUM
biomedich-346	417	3	)	)	PUNCT
biomedich-346	417	4	.	.	PUNCT
biomedich-346	418	1	efficacy	efficacy	NOUN
biomedich-346	418	2	and	and	CCONJ
biomedich-346	418	3	safety	safety	NOUN
biomedich-346	418	4	of	of	ADP
biomedich-346	418	5	nvx	nvx	NOUN
biomedich-346	418	6	-	-	PUNCT
biomedich-346	418	7	cov2373	cov2373	NOUN
biomedich-346	418	8	in	in	ADP
biomedich-346	418	9	adults	adult	NOUN
biomedich-346	418	10	in	in	ADP
biomedich-346	418	11	the	the	DET
biomedich-346	418	12	united	united	PROPN
biomedich-346	418	13	states	states	PROPN
biomedich-346	418	14	and	and	CCONJ
biomedich-346	418	15	mexico	mexico	PROPN
biomedich-346	418	16	.	.	PUNCT
biomedich-346	419	1	the	the	DET
biomedich-346	419	2	new	new	PROPN
biomedich-346	419	3	england	england	PROPN
biomedich-346	419	4	journal	journal	PROPN
biomedich-346	419	5	of	of	ADP
biomedich-346	419	6	medicine	medicine	NOUN
biomedich-346	419	7	,	,	PUNCT
biomedich-346	419	8	386(6	386(6	NUM
biomedich-346	419	9	)	)	PUNCT
biomedich-346	419	10	,	,	PUNCT
biomedich-346	419	11	531–543	531–543	NUM
biomedich-346	419	12	.	.	PUNCT
biomedich-346	419	13	doi:10.1056	doi:10.1056	PROPN
biomedich-346	419	14	/	/	SYM
biomedich-346	419	15	nejmoa2116185	nejmoa2116185	PROPN
biomedich-346	419	16	wei	wei	PROPN
biomedich-346	419	17	,	,	PUNCT
biomedich-346	419	18	l.	l.	PROPN
biomedich-346	419	19	,	,	PUNCT
biomedich-346	419	20	zhao	zhao	PROPN
biomedich-346	419	21	,	,	PUNCT
biomedich-346	419	22	t.	t.	PROPN
biomedich-346	419	23	,	,	PUNCT
biomedich-346	419	24	zhang	zhang	PROPN
biomedich-346	419	25	,	,	PUNCT
biomedich-346	419	26	j.	j.	PROPN
biomedich-346	419	27	,	,	PUNCT
biomedich-346	419	28	mao	mao	PROPN
biomedich-346	419	29	,	,	PUNCT
biomedich-346	419	30	q.	q.	PROPN
biomedich-346	419	31	,	,	PUNCT
biomedich-346	419	32	gong	gong	PROPN
biomedich-346	419	33	,	,	PUNCT
biomedich-346	419	34	g.	g.	PROPN
biomedich-346	419	35	,	,	PUNCT
biomedich-346	419	36	sun	sun	NOUN
biomedich-346	419	37	,	,	PUNCT
biomedich-346	419	38	y.	y.	PROPN
biomedich-346	419	39	,	,	PUNCT
biomedich-346	419	40	…	…	PUNCT
biomedich-346	419	41	wu	wu	PROPN
biomedich-346	419	42	,	,	PUNCT
biomedich-346	419	43	y.	y.	PROPN
biomedich-346	419	44	(	(	PUNCT
biomedich-346	419	45	2022	2022	NUM
biomedich-346	419	46	)	)	PUNCT
biomedich-346	419	47	.	.	PUNCT
biomedich-346	420	1	efficacy	efficacy	NOUN
biomedich-346	420	2	and	and	CCONJ
biomedich-346	420	3	safety	safety	NOUN
biomedich-346	420	4	of	of	ADP
biomedich-346	420	5	a	a	DET
biomedich-346	420	6	nanoparticle	nanoparticle	NOUN
biomedich-346	420	7	therapeutic	therapeutic	ADJ
biomedich-346	420	8	vaccine	vaccine	NOUN
biomedich-346	420	9	in	in	ADP
biomedich-346	420	10	patients	patient	NOUN
biomedich-346	420	11	with	with	ADP
biomedich-346	420	12	chronic	chronic	ADJ
biomedich-346	420	13	hepatitis	hepatitis	NOUN
biomedich-346	420	14	b	b	NOUN
biomedich-346	420	15	:	:	PUNCT
biomedich-346	420	16	a	a	DET
biomedich-346	420	17	randomized	randomized	ADJ
biomedich-346	420	18	clinical	clinical	ADJ
biomedich-346	420	19	trial	trial	NOUN
biomedich-346	420	20	.	.	PUNCT
biomedich-346	421	1	hepatology	hepatology	NOUN
biomedich-346	421	2	(	(	PUNCT
biomedich-346	421	3	baltimore	baltimore	PROPN
biomedich-346	421	4	,	,	PUNCT
biomedich-346	421	5	md	md	PROPN
biomedich-346	421	6	.	.	PROPN
biomedich-346	421	7	)	)	PUNCT
biomedich-346	421	8	,	,	PUNCT
biomedich-346	421	9	75(1	75(1	NOUN
biomedich-346	421	10	)	)	PUNCT
biomedich-346	421	11	,	,	PUNCT
biomedich-346	421	12	182–195	182–195	NUM
biomedich-346	421	13	.	.	PUNCT
biomedich-346	421	14	doi:10.1002	doi:10.1002	NOUN
biomedich-346	421	15	/	/	SYM
biomedich-346	421	16	hep.32109	hep.32109	NUM
biomedich-346	421	17	sahin	sahin	NOUN
biomedich-346	421	18	,	,	PUNCT
biomedich-346	421	19	u.	u.	PROPN
biomedich-346	421	20	,	,	PUNCT
biomedich-346	421	21	muik	muik	NOUN
biomedich-346	421	22	,	,	PUNCT
biomedich-346	421	23	a.	a.	NOUN
biomedich-346	421	24	,	,	PUNCT
biomedich-346	421	25	vogler	vogler	NOUN
biomedich-346	421	26	,	,	PUNCT
biomedich-346	421	27	i.	i.	PROPN
biomedich-346	421	28	,	,	PUNCT
biomedich-346	421	29	derhovanessian	derhovanessian	PROPN
biomedich-346	421	30	,	,	PUNCT
biomedich-346	421	31	e.	e.	PROPN
biomedich-346	421	32	,	,	PUNCT
biomedich-346	421	33	kranz	kranz	PROPN
biomedich-346	421	34	,	,	PUNCT
biomedich-346	421	35	l.	l.	PROPN
biomedich-346	421	36	m.	m.	PROPN
biomedich-346	421	37	,	,	PUNCT
biomedich-346	421	38	vormehr	vormehr	NOUN
biomedich-346	421	39	,	,	PUNCT
biomedich-346	421	40	m.	m.	NOUN
biomedich-346	421	41	,	,	PUNCT
biomedich-346	421	42	…	…	PUNCT
biomedich-346	421	43	türeci	türeci	ADJ
biomedich-346	421	44	,	,	PUNCT
biomedich-346	421	45	ö.	ö.	PROPN
biomedich-346	421	46	(	(	PUNCT
biomedich-346	421	47	2021	2021	NUM
biomedich-346	421	48	)	)	PUNCT
biomedich-346	421	49	.	.	PUNCT
biomedich-346	422	1	bnt162b2	bnt162b2	NOUN
biomedich-346	422	2	vaccine	vaccine	NOUN
biomedich-346	422	3	induces	induce	VERB
biomedich-346	422	4	neutralizing	neutralize	VERB
biomedich-346	422	5	antibodies	antibody	NOUN
biomedich-346	422	6	and	and	CCONJ
biomedich-346	422	7	poly	poly	ADJ
biomedich-346	422	8	-	-	PUNCT
biomedich-346	422	9	specific	specific	ADJ
biomedich-346	422	10	t	t	NOUN
biomedich-346	422	11	cells	cell	NOUN
biomedich-346	422	12	in	in	ADP
biomedich-346	422	13	humans	human	NOUN
biomedich-346	422	14	.	.	PUNCT
biomedich-346	423	1	nature	nature	NOUN
biomedich-346	423	2	,	,	PUNCT
biomedich-346	423	3	595(7868	595(7868	NUM
biomedich-346	423	4	)	)	PUNCT
biomedich-346	423	5	,	,	PUNCT
biomedich-346	423	6	572–577	572–577	NUM
biomedich-346	423	7	.	.	PUNCT
biomedich-346	424	1	doi:10.1038	doi:10.1038	NOUN
biomedich-346	424	2	/	/	SYM
biomedich-346	424	3	s41586021	s41586021	NOUN
biomedich-346	424	4	-	-	PUNCT
biomedich-346	424	5	03653	03653	NUM
biomedich-346	424	6	-	-	PUNCT
biomedich-346	424	7	6	6	NUM
biomedich-346	424	8	datoo	datoo	ADJ
biomedich-346	424	9	,	,	PUNCT
biomedich-346	424	10	m.	m.	NOUN
biomedich-346	424	11	s.	s.	PROPN
biomedich-346	424	12	,	,	PUNCT
biomedich-346	424	13	natama	natama	NOUN
biomedich-346	424	14	,	,	PUNCT
biomedich-346	424	15	m.	m.	NOUN
biomedich-346	424	16	h.	h.	PROPN
biomedich-346	424	17	,	,	PUNCT
biomedich-346	424	18	somé	somé	PROPN
biomedich-346	424	19	,	,	PUNCT
biomedich-346	424	20	a.	a.	NOUN
biomedich-346	424	21	,	,	PUNCT
biomedich-346	424	22	traoré	traoré	NOUN
biomedich-346	424	23	,	,	PUNCT
biomedich-346	424	24	o.	o.	NOUN
biomedich-346	424	25	,	,	PUNCT
biomedich-346	424	26	rouamba	rouamba	ADJ
biomedich-346	424	27	,	,	PUNCT
biomedich-346	424	28	t.	t.	PROPN
biomedich-346	424	29	,	,	PUNCT
biomedich-346	424	30	bellamy	bellamy	PROPN
biomedich-346	424	31	,	,	PUNCT
biomedich-346	424	32	d.	d.	PROPN
biomedich-346	424	33	,	,	PUNCT
biomedich-346	424	34	…	…	PUNCT
biomedich-346	424	35	tinto	tinto	PROPN
biomedich-346	424	36	,	,	PUNCT
biomedich-346	424	37	h.	h.	PROPN
biomedich-346	424	38	(	(	PUNCT
biomedich-346	424	39	2021	2021	NUM
biomedich-346	424	40	)	)	PUNCT
biomedich-346	424	41	.	.	PUNCT
biomedich-346	425	1	efficacy	efficacy	NOUN
biomedich-346	425	2	of	of	ADP
biomedich-346	425	3	a	a	DET
biomedich-346	425	4	low	low	ADJ
biomedich-346	425	5	-	-	PUNCT
biomedich-346	425	6	dose	dose	NOUN
biomedich-346	425	7	candidate	candidate	NOUN
biomedich-346	425	8	malaria	malaria	NOUN
biomedich-346	425	9	vaccine	vaccine	NOUN
biomedich-346	425	10	,	,	PUNCT
biomedich-346	425	11	r21	r21	NOUN
biomedich-346	425	12	in	in	ADP
biomedich-346	425	13	adjuvant	adjuvant	ADJ
biomedich-346	425	14	matrix	matrix	NOUN
biomedich-346	425	15	-	-	PUNCT
biomedich-346	425	16	m	m	NOUN
biomedich-346	425	17	,	,	PUNCT
biomedich-346	425	18	with	with	ADP
biomedich-346	425	19	seasonal	seasonal	ADJ
biomedich-346	425	20	administration	administration	NOUN
biomedich-346	425	21	to	to	ADP
biomedich-346	425	22	children	child	NOUN
biomedich-346	425	23	in	in	ADP
biomedich-346	425	24	burkina	burkina	PROPN
biomedich-346	425	25	faso	faso	PROPN
biomedich-346	425	26	:	:	PUNCT
biomedich-346	425	27	a	a	DET
biomedich-346	425	28	randomised	randomised	ADJ
biomedich-346	425	29	controlled	control	VERB
biomedich-346	425	30	trial	trial	NOUN
biomedich-346	425	31	.	.	PUNCT
biomedich-346	426	1	lancet	lancet	NOUN
biomedich-346	426	2	,	,	PUNCT
biomedich-346	426	3	397(10287	397(10287	NUM
biomedich-346	426	4	)	)	PUNCT
biomedich-346	426	5	,	,	PUNCT
biomedich-346	426	6	1809–1818	1809–1818	NUM
biomedich-346	426	7	.	.	PUNCT
biomedich-346	427	1	doi:10.1016	doi:10.1016	PROPN
biomedich-346	427	2	/	/	SYM
biomedich-346	427	3	s0140	s0140	PROPN
biomedich-346	427	4	-	-	PUNCT
biomedich-346	427	5	6736(21)00943	6736(21)00943	NUM
biomedich-346	427	6	-	-	PUNCT
biomedich-346	427	7	0	0	NUM
biomedich-346	427	8	toback	toback	NOUN
biomedich-346	427	9	,	,	PUNCT
biomedich-346	427	10	s.	s.	PROPN
biomedich-346	427	11	,	,	PUNCT
biomedich-346	427	12	galiza	galiza	PROPN
biomedich-346	427	13	,	,	PUNCT
biomedich-346	427	14	e.	e.	PROPN
biomedich-346	427	15	,	,	PUNCT
biomedich-346	427	16	cosgrove	cosgrove	PROPN
biomedich-346	427	17	,	,	PUNCT
biomedich-346	427	18	c.	c.	PROPN
biomedich-346	427	19	,	,	PUNCT
biomedich-346	427	20	galloway	galloway	PROPN
biomedich-346	427	21	,	,	PUNCT
biomedich-346	427	22	j.	j.	PROPN
biomedich-346	427	23	,	,	PUNCT
biomedich-346	427	24	goodman	goodman	PROPN
biomedich-346	427	25	,	,	PUNCT
biomedich-346	427	26	a.	a.	PROPN
biomedich-346	427	27	l.	l.	PROPN
biomedich-346	427	28	,	,	PUNCT
biomedich-346	427	29	swift	swift	ADJ
biomedich-346	427	30	,	,	PUNCT
biomedich-346	427	31	p.	p.	NOUN
biomedich-346	427	32	a.	a.	NOUN
biomedich-346	427	33	,	,	PUNCT
biomedich-346	427	34	…	…	PUNCT
biomedich-346	427	35	2019ncov-302	2019ncov-302	NUM
biomedich-346	427	36	study	study	NOUN
biomedich-346	427	37	group	group	NOUN
biomedich-346	427	38	.	.	PUNCT
biomedich-346	428	1	(	(	PUNCT
biomedich-346	428	2	2022	2022	NUM
biomedich-346	428	3	)	)	PUNCT
biomedich-346	428	4	.	.	PUNCT
biomedich-346	429	1	safety	safety	NOUN
biomedich-346	429	2	,	,	PUNCT
biomedich-346	429	3	immunogenicity	immunogenicity	NOUN
biomedich-346	429	4	,	,	PUNCT
biomedich-346	429	5	and	and	CCONJ
biomedich-346	429	6	efficacy	efficacy	NOUN
biomedich-346	429	7	of	of	ADP
biomedich-346	429	8	a	a	DET
biomedich-346	429	9	covid-19	covid-19	PROPN
biomedich-346	429	10	vaccine	vaccine	NOUN
biomedich-346	429	11	(	(	PUNCT
biomedich-346	429	12	nvx	nvx	NOUN
biomedich-346	429	13	-	-	PUNCT
biomedich-346	429	14	cov2373	cov2373	NOUN
biomedich-346	429	15	)	)	PUNCT
biomedich-346	429	16	co	co	VERB
biomedich-346	429	17	-	-	VERB
biomedich-346	429	18	administered	administer	VERB
biomedich-346	429	19	with	with	ADP
biomedich-346	429	20	seasonal	seasonal	ADJ
biomedich-346	429	21	influenza	influenza	NOUN
biomedich-346	429	22	vaccines	vaccine	NOUN
biomedich-346	429	23	:	:	PUNCT
biomedich-346	429	24	an	an	DET
biomedich-346	429	25	exploratory	exploratory	ADJ
biomedich-346	429	26	substudy	substudy	NOUN
biomedich-346	429	27	of	of	ADP
biomedich-346	429	28	a	a	DET
biomedich-346	429	29	randomised	randomised	ADJ
biomedich-346	429	30	,	,	PUNCT
biomedich-346	429	31	observerblinded	observerblinded	ADJ
biomedich-346	429	32	,	,	PUNCT
biomedich-346	429	33	placebo	placebo	NOUN
biomedich-346	429	34	-	-	PUNCT
biomedich-346	429	35	controlled	control	VERB
biomedich-346	429	36	,	,	PUNCT
biomedich-346	429	37	phase	phase	NOUN
biomedich-346	429	38	3	3	NUM
biomedich-346	429	39	trial	trial	NOUN
biomedich-346	429	40	.	.	PUNCT
biomedich-346	430	1	the	the	DET
biomedich-346	430	2	lancet	lancet	NOUN
biomedich-346	430	3	.	.	PUNCT
biomedich-346	431	1	respiratory	respiratory	ADJ
biomedich-346	431	2	medicine	medicine	NOUN
biomedich-346	431	3	,	,	PUNCT
biomedich-346	431	4	10(2	10(2	NUM
biomedich-346	431	5	)	)	PUNCT
biomedich-346	431	6	,	,	PUNCT
biomedich-346	431	7	167–179	167–179	NUM
biomedich-346	431	8	.	.	PUNCT
biomedich-346	432	1	doi:10.1016	doi:10.1016	PROPN
biomedich-346	432	2	/	/	SYM
biomedich-346	432	3	s22132600(21)00409	s22132600(21)00409	NOUN
biomedich-346	432	4	-	-	ADJ
biomedich-346	432	5	4	4	NUM
biomedich-346	432	6	maruggi	maruggi	NOUN
biomedich-346	432	7	,	,	PUNCT
biomedich-346	432	8	g.	g.	PROPN
biomedich-346	432	9	,	,	PUNCT
biomedich-346	432	10	mallett	mallett	PROPN
biomedich-346	432	11	,	,	PUNCT
biomedich-346	432	12	c.	c.	PROPN
biomedich-346	432	13	p.	p.	PROPN
biomedich-346	432	14	,	,	PUNCT
biomedich-346	432	15	westerbeck	westerbeck	PROPN
biomedich-346	432	16	,	,	PUNCT
biomedich-346	432	17	j.	j.	PROPN
biomedich-346	432	18	w.	w.	PROPN
biomedich-346	432	19	,	,	PUNCT
biomedich-346	432	20	chen	chen	PROPN
biomedich-346	432	21	,	,	PUNCT
biomedich-346	432	22	t.	t.	PROPN
biomedich-346	432	23	,	,	PUNCT
biomedich-346	432	24	lofano	lofano	PROPN
biomedich-346	432	25	,	,	PUNCT
biomedich-346	432	26	g.	g.	PROPN
biomedich-346	432	27	,	,	PUNCT
biomedich-346	432	28	friedrich	friedrich	PROPN
biomedich-346	432	29	,	,	PUNCT
biomedich-346	432	30	k.	k.	PROPN
biomedich-346	432	31	,	,	PUNCT
biomedich-346	432	32	…	…	PUNCT
biomedich-346	432	33	yu	yu	PROPN
biomedich-346	432	34	,	,	PUNCT
biomedich-346	432	35	d.	d.	PROPN
biomedich-346	432	36	(	(	PUNCT
biomedich-346	432	37	2022	2022	NUM
biomedich-346	432	38	)	)	PUNCT
biomedich-346	432	39	.	.	PUNCT
biomedich-346	433	1	a	a	DET
biomedich-346	433	2	self	self	NOUN
biomedich-346	433	3	-	-	PUNCT
biomedich-346	433	4	amplifying	amplifying	ADJ
biomedich-346	433	5	mrna	mrna	PROPN
biomedich-346	433	6	sars	sar	NOUN
biomedich-346	433	7	-	-	PUNCT
biomedich-346	433	8	cov-2	cov-2	PART
biomedich-346	433	9	vaccine	vaccine	NOUN
biomedich-346	433	10	candidate	candidate	NOUN
biomedich-346	433	11	induces	induce	VERB
biomedich-346	433	12	safe	safe	ADJ
biomedich-346	433	13	and	and	CCONJ
biomedich-346	433	14	robust	robust	ADJ
biomedich-346	433	15	protective	protective	ADJ
biomedich-346	433	16	immunity	immunity	NOUN
biomedich-346	433	17	in	in	ADP
biomedich-346	433	18	preclinical	preclinical	ADJ
biomedich-346	433	19	models	model	NOUN
biomedich-346	433	20	.	.	PUNCT
biomedich-346	434	1	molecular	molecular	ADJ
biomedich-346	434	2	therapy	therapy	NOUN
biomedich-346	434	3	:	:	PUNCT
biomedich-346	434	4	the	the	DET
biomedich-346	434	5	journal	journal	NOUN
biomedich-346	434	6	of	of	ADP
biomedich-346	434	7	the	the	DET
biomedich-346	434	8	american	american	ADJ
biomedich-346	434	9	society	society	NOUN
biomedich-346	434	10	of	of	ADP
biomedich-346	434	11	gene	gene	NOUN
biomedich-346	434	12	therapy	therapy	NOUN
biomedich-346	434	13	,	,	PUNCT
biomedich-346	434	14	30(5	30(5	NUM
biomedich-346	434	15	)	)	PUNCT
biomedich-346	434	16	,	,	PUNCT
biomedich-346	434	17	1897–1912	1897–1912	NUM
biomedich-346	434	18	.	.	PUNCT
biomedich-346	435	1	doi:10.1016	doi:10.1016	PROPN
biomedich-346	435	2	/	/	SYM
biomedich-346	435	3	j.ymthe.2022.01.001	j.ymthe.2022.01.001	PROPN
biomedich-346	435	4	madhi	madhi	NOUN
biomedich-346	435	5	,	,	PUNCT
biomedich-346	435	6	s.	s.	PROPN
biomedich-346	435	7	a.	a.	PROPN
biomedich-346	435	8	,	,	PUNCT
biomedich-346	435	9	moodley	moodley	NOUN
biomedich-346	435	10	,	,	PUNCT
biomedich-346	435	11	d.	d.	PROPN
biomedich-346	435	12	,	,	PUNCT
biomedich-346	435	13	hanley	hanley	PROPN
biomedich-346	435	14	,	,	PUNCT
biomedich-346	435	15	s.	s.	PROPN
biomedich-346	435	16	,	,	PUNCT
biomedich-346	435	17	archary	archary	NOUN
biomedich-346	435	18	,	,	PUNCT
biomedich-346	435	19	m.	m.	NOUN
biomedich-346	435	20	,	,	PUNCT
biomedich-346	435	21	hoosain	hoosain	NOUN
biomedich-346	435	22	,	,	PUNCT
biomedich-346	435	23	z.	z.	PROPN
biomedich-346	435	24	,	,	PUNCT
biomedich-346	435	25	lalloo	lalloo	NOUN
biomedich-346	435	26	,	,	PUNCT
biomedich-346	435	27	u.	u.	PROPN
biomedich-346	435	28	,	,	PUNCT
biomedich-346	435	29	…	…	PUNCT
biomedich-346	435	30	2019ncov-501	2019ncov-501	NUM
biomedich-346	435	31	study	study	NOUN
biomedich-346	435	32	group	group	NOUN
biomedich-346	435	33	.	.	PUNCT
biomedich-346	436	1	(	(	PUNCT
biomedich-346	436	2	2022	2022	NUM
biomedich-346	436	3	)	)	PUNCT
biomedich-346	436	4	.	.	PUNCT
biomedich-346	437	1	immunogenicity	immunogenicity	NOUN
biomedich-346	437	2	and	and	CCONJ
biomedich-346	437	3	safety	safety	NOUN
biomedich-346	437	4	of	of	ADP
biomedich-346	437	5	a	a	DET
biomedich-346	437	6	sars	sar	NOUN
biomedich-346	437	7	-	-	PUNCT
biomedich-346	437	8	cov-2	cov-2	NOUN
biomedich-346	437	9	recombinant	recombinant	ADJ
biomedich-346	437	10	spike	spike	ADJ
biomedich-346	437	11	protein	protein	NOUN
biomedich-346	437	12	nanoparticle	nanoparticle	NOUN
biomedich-346	437	13	vaccine	vaccine	NOUN
biomedich-346	437	14	in	in	ADP
biomedich-346	437	15	people	people	NOUN
biomedich-346	437	16	living	live	VERB
biomedich-346	437	17	with	with	ADP
biomedich-346	437	18	and	and	CCONJ
biomedich-346	437	19	without	without	ADP
biomedich-346	437	20	hiv-1	hiv-1	ADJ
biomedich-346	437	21	infection	infection	NOUN
biomedich-346	437	22	:	:	PUNCT
biomedich-346	437	23	a	a	DET
biomedich-346	437	24	randomised	randomised	ADJ
biomedich-346	437	25	,	,	PUNCT
biomedich-346	437	26	controlled	control	VERB
biomedich-346	437	27	,	,	PUNCT
biomedich-346	437	28	phase	phase	NOUN
biomedich-346	437	29	2a/2b	2a/2b	NUM
biomedich-346	437	30	trial	trial	NOUN
biomedich-346	437	31	.	.	PUNCT
biomedich-346	438	1	the	the	DET
biomedich-346	438	2	lancet	lancet	PROPN
biomedich-346	438	3	.	.	PUNCT
biomedich-346	439	1	hiv	hiv	PROPN
biomedich-346	439	2	,	,	PUNCT
biomedich-346	439	3	9(5	9(5	NUM
biomedich-346	439	4	)	)	PUNCT
biomedich-346	439	5	,	,	PUNCT
biomedich-346	439	6	e309	e309	PROPN
biomedich-346	439	7	–	–	PUNCT
biomedich-346	439	8	e322	e322	PROPN
biomedich-346	439	9	.	.	PUNCT
biomedich-346	439	10	doi:10.1016	doi:10.1016	PROPN
biomedich-346	439	11	/	/	SYM
biomedich-346	439	12	s2352	s2352	PROPN
biomedich-346	439	13	-	-	PUNCT
biomedich-346	439	14	3018(22)00041	3018(22)00041	NUM
biomedich-346	439	15	-	-	PUNCT
biomedich-346	439	16	8	8	NUM
biomedich-346	439	17	stuart	stuart	PROPN
biomedich-346	439	18	,	,	PUNCT
biomedich-346	439	19	a.	a.	PROPN
biomedich-346	439	20	s.	s.	PROPN
biomedich-346	439	21	v.	v.	PROPN
biomedich-346	439	22	,	,	PUNCT
biomedich-346	439	23	shaw	shaw	PROPN
biomedich-346	439	24	,	,	PUNCT
biomedich-346	439	25	r.	r.	PROPN
biomedich-346	439	26	h.	h.	PROPN
biomedich-346	439	27	,	,	PUNCT
biomedich-346	439	28	liu	liu	PROPN
biomedich-346	439	29	,	,	PUNCT
biomedich-346	439	30	x.	x.	PROPN
biomedich-346	439	31	,	,	PUNCT
biomedich-346	439	32	greenland	greenland	PROPN
biomedich-346	439	33	,	,	PUNCT
biomedich-346	439	34	m.	m.	NOUN
biomedich-346	439	35	,	,	PUNCT
biomedich-346	439	36	aley	aley	PROPN
biomedich-346	439	37	,	,	PUNCT
biomedich-346	439	38	p.	p.	PROPN
biomedich-346	439	39	k.	k.	PROPN
biomedich-346	439	40	,	,	PUNCT
biomedich-346	439	41	andrews	andrews	PROPN
biomedich-346	439	42	,	,	PUNCT
biomedich-346	439	43	n.	n.	PROPN
biomedich-346	439	44	j.	j.	PROPN
biomedich-346	439	45	,	,	PUNCT
biomedich-346	439	46	…	…	PUNCT
biomedich-346	439	47	com	com	NOUN
biomedich-346	439	48	-	-	PUNCT
biomedich-346	439	49	cov2	cov2	PROPN
biomedich-346	439	50	study	study	NOUN
biomedich-346	439	51	group	group	NOUN
biomedich-346	439	52	.	.	PUNCT
biomedich-346	440	1	(	(	PUNCT
biomedich-346	440	2	2022	2022	NUM
biomedich-346	440	3	)	)	PUNCT
biomedich-346	440	4	.	.	PUNCT
biomedich-346	441	1	immunogenicity	immunogenicity	NOUN
biomedich-346	441	2	,	,	PUNCT
biomedich-346	441	3	safety	safety	NOUN
biomedich-346	441	4	,	,	PUNCT
biomedich-346	441	5	and	and	CCONJ
biomedich-346	441	6	reactogenicity	reactogenicity	NOUN
biomedich-346	441	7	of	of	ADP
biomedich-346	441	8	heterologous	heterologous	ADJ
biomedich-346	441	9	covid-19	covid-19	PROPN
biomedich-346	441	10	primary	primary	ADJ
biomedich-346	441	11	vaccination	vaccination	NOUN
biomedich-346	441	12	incorporating	incorporate	VERB
biomedich-346	441	13	mrna	mrna	PROPN
biomedich-346	441	14	,	,	PUNCT
biomedich-346	441	15	viralvector	viralvector	NOUN
biomedich-346	441	16	,	,	PUNCT
biomedich-346	441	17	and	and	CCONJ
biomedich-346	441	18	protein	protein	NOUN
biomedich-346	441	19	-	-	PUNCT
biomedich-346	441	20	adjuvant	adjuvant	ADJ
biomedich-346	441	21	vaccines	vaccine	NOUN
biomedich-346	441	22	in	in	ADP
biomedich-346	441	23	the	the	DET
biomedich-346	441	24	uk	uk	PROPN
biomedich-346	441	25	(	(	PUNCT
biomedich-346	441	26	com	com	NOUN
biomedich-346	441	27	-	-	PUNCT
biomedich-346	441	28	cov2	cov2	PROPN
biomedich-346	441	29	):	):	PUNCT
biomedich-346	441	30	a	a	DET
biomedich-346	441	31	single	single	ADJ
biomedich-346	441	32	-	-	PUNCT
biomedich-346	441	33	blind	blind	ADJ
biomedich-346	441	34	,	,	PUNCT
biomedich-346	441	35	randomised	randomise	VERB
biomedich-346	441	36	,	,	PUNCT
biomedich-346	441	37	phase	phase	NOUN
biomedich-346	441	38	2	2	NUM
biomedich-346	441	39	,	,	PUNCT
biomedich-346	441	40	non	non	ADJ
biomedich-346	441	41	-	-	ADJ
biomedich-346	441	42	inferiority	inferiority	ADJ
biomedich-346	441	43	trial	trial	NOUN
biomedich-346	441	44	.	.	PUNCT
biomedich-346	442	1	lancet	lancet	PROPN
biomedich-346	442	2	,	,	PUNCT
biomedich-346	442	3	399(10319	399(10319	NUM
biomedich-346	442	4	)	)	PUNCT
biomedich-346	442	5	,	,	PUNCT
biomedich-346	442	6	36–49	36–49	NUM
biomedich-346	442	7	.	.	PUNCT
biomedich-346	443	1	doi:10.1016	doi:10.1016	PROPN
biomedich-346	443	2	/	/	SYM
biomedich-346	444	1	s01406736(21)02718	s01406736(21)02718	PROPN
biomedich-346	444	2	-	-	SYM
biomedich-346	444	3	5	5	NUM
biomedich-346	444	4	aldrich	aldrich	NOUN
biomedich-346	444	5	,	,	PUNCT
biomedich-346	444	6	c.	c.	PROPN
biomedich-346	444	7	,	,	PUNCT
biomedich-346	444	8	leroux	leroux	NOUN
biomedich-346	444	9	-	-	PUNCT
biomedich-346	444	10	roels	roel	NOUN
biomedich-346	444	11	,	,	PUNCT
biomedich-346	444	12	i.	i.	PROPN
biomedich-346	444	13	,	,	PUNCT
biomedich-346	444	14	huang	huang	PROPN
biomedich-346	444	15	,	,	PUNCT
biomedich-346	444	16	k.	k.	PROPN
biomedich-346	444	17	b.	b.	PROPN
biomedich-346	444	18	,	,	PUNCT
biomedich-346	444	19	bica	bica	PROPN
biomedich-346	444	20	,	,	PUNCT
biomedich-346	444	21	m.	m.	NOUN
biomedich-346	444	22	a.	a.	PROPN
biomedich-346	444	23	,	,	PUNCT
biomedich-346	444	24	loeliger	loeliger	NOUN
biomedich-346	444	25	,	,	PUNCT
biomedich-346	444	26	e.	e.	PROPN
biomedich-346	444	27	,	,	PUNCT
biomedich-346	444	28	schoenborn	schoenborn	ADJ
biomedich-346	444	29	-	-	PUNCT
biomedich-346	444	30	kellenberger	kellenberger	NOUN
biomedich-346	444	31	,	,	PUNCT
biomedich-346	444	32	o.	o.	PROPN
biomedich-346	444	33	,	,	PUNCT
biomedich-346	444	34	…	…	PUNCT
biomedich-346	444	35	oostvogels	oostvogel	NOUN
biomedich-346	444	36	,	,	PUNCT
biomedich-346	444	37	l.	l.	PROPN
biomedich-346	444	38	(	(	PUNCT
biomedich-346	444	39	2021	2021	NUM
biomedich-346	444	40	)	)	PUNCT
biomedich-346	444	41	.	.	PUNCT
biomedich-346	445	1	proof	proof	NOUN
biomedich-346	445	2	-	-	PUNCT
biomedich-346	445	3	of	of	ADP
biomedich-346	445	4	-	-	PUNCT
biomedich-346	445	5	concept	concept	NOUN
biomedich-346	445	6	of	of	ADP
biomedich-346	445	7	a	a	DET
biomedich-346	445	8	low	low	ADV
biomedich-346	445	9	-	-	PUNCT
biomedich-346	445	10	dose	dose	NOUN
biomedich-346	445	11	unmodified	unmodified	ADJ
biomedich-346	445	12	mrna	mrna	PROPN
biomedich-346	445	13	-	-	PUNCT
biomedich-346	445	14	based	base	VERB
biomedich-346	445	15	rabies	rabie	NOUN
biomedich-346	445	16	vaccine	vaccine	NOUN
biomedich-346	445	17	formulated	formulate	VERB
biomedich-346	445	18	with	with	ADP
biomedich-346	445	19	lipid	lipid	ADJ
biomedich-346	445	20	nanoparticles	nanoparticle	NOUN
biomedich-346	445	21	in	in	ADP
biomedich-346	445	22	human	human	ADJ
biomedich-346	445	23	volunteers	volunteer	NOUN
biomedich-346	445	24	:	:	PUNCT
biomedich-346	445	25	a	a	DET
biomedich-346	445	26	phase	phase	NOUN
biomedich-346	445	27	1	1	NUM
biomedich-346	445	28	trial	trial	NOUN
biomedich-346	445	29	.	.	PUNCT
biomedich-346	446	1	vaccine	vaccine	NOUN
biomedich-346	446	2	,	,	PUNCT
biomedich-346	446	3	39(8	39(8	NUM
biomedich-346	446	4	)	)	PUNCT
biomedich-346	446	5	,	,	PUNCT
biomedich-346	446	6	1310–1318	1310–1318	NUM
biomedich-346	446	7	.	.	PUNCT
biomedich-346	447	1	doi:10.1016	doi:10.1016	PROPN
biomedich-346	447	2	/	/	SYM
biomedich-346	447	3	j.vaccine.2020.12.070	j.vaccine.2020.12.070	PROPN
biomedich-346	447	4	shinde	shinde	PROPN
biomedich-346	447	5	,	,	PUNCT
biomedich-346	447	6	v.	v.	PROPN
biomedich-346	447	7	,	,	PUNCT
biomedich-346	447	8	cho	cho	PROPN
biomedich-346	447	9	,	,	PUNCT
biomedich-346	447	10	i.	i.	PROPN
biomedich-346	447	11	,	,	PUNCT
biomedich-346	447	12	plested	pleste	VERB
biomedich-346	447	13	,	,	PUNCT
biomedich-346	447	14	j.	j.	PROPN
biomedich-346	447	15	s.	s.	PROPN
biomedich-346	447	16	,	,	PUNCT
biomedich-346	447	17	agrawal	agrawal	PROPN
biomedich-346	447	18	,	,	PUNCT
biomedich-346	447	19	s.	s.	PROPN
biomedich-346	447	20	,	,	PUNCT
biomedich-346	447	21	fiske	fiske	PROPN
biomedich-346	447	22	,	,	PUNCT
biomedich-346	447	23	j.	j.	PROPN
biomedich-346	447	24	,	,	PUNCT
biomedich-346	447	25	cai	cai	PROPN
biomedich-346	447	26	,	,	PUNCT
biomedich-346	447	27	r.	r.	PROPN
biomedich-346	447	28	,	,	PUNCT
biomedich-346	447	29	…	…	PUNCT
biomedich-346	447	30	glenn	glenn	PROPN
biomedich-346	447	31	,	,	PUNCT
biomedich-346	447	32	g.	g.	PROPN
biomedich-346	447	33	m.	m.	PROPN
biomedich-346	447	34	(	(	PUNCT
biomedich-346	447	35	2022	2022	NUM
biomedich-346	447	36	)	)	PUNCT
biomedich-346	447	37	.	.	PUNCT
biomedich-346	448	1	comparison	comparison	NOUN
biomedich-346	448	2	of	of	ADP
biomedich-346	448	3	the	the	DET
biomedich-346	448	4	safety	safety	NOUN
biomedich-346	448	5	and	and	CCONJ
biomedich-346	448	6	immunogenicity	immunogenicity	NOUN
biomedich-346	448	7	of	of	ADP
biomedich-346	448	8	a	a	DET
biomedich-346	448	9	novel	novel	ADJ
biomedich-346	448	10	matrix	matrix	NOUN
biomedich-346	448	11	-	-	PUNCT
biomedich-346	448	12	m	m	NOUN
biomedich-346	448	13	-	-	PUNCT
biomedich-346	448	14	adjuvanted	adjuvante	VERB
biomedich-346	448	15	nanoparticle	nanoparticle	NOUN
biomedich-346	448	16	influenza	influenza	NOUN
biomedich-346	448	17	vaccine	vaccine	NOUN
biomedich-346	448	18	with	with	ADP
biomedich-346	448	19	a	a	DET
biomedich-346	448	20	quadrivalent	quadrivalent	ADJ
biomedich-346	448	21	seasonal	seasonal	ADJ
biomedich-346	448	22	influenza	influenza	NOUN
biomedich-346	448	23	vaccine	vaccine	NOUN
biomedich-346	448	24	in	in	ADP
biomedich-346	448	25	older	old	ADJ
biomedich-346	448	26	adults	adult	NOUN
biomedich-346	448	27	:	:	PUNCT
biomedich-346	448	28	a	a	DET
biomedich-346	448	29	phase	phase	NOUN
biomedich-346	448	30	3	3	NUM
biomedich-346	448	31	randomised	randomise	VERB
biomedich-346	448	32	controlled	control	VERB
biomedich-346	448	33	trial	trial	NOUN
biomedich-346	448	34	.	.	PUNCT
biomedich-346	449	1	the	the	DET
biomedich-346	449	2	lancet	lancet	ADJ
biomedich-346	449	3	infectious	infectious	ADJ
biomedich-346	449	4	diseases	disease	NOUN
biomedich-346	449	5	,	,	PUNCT
biomedich-346	449	6	22(1	22(1	NUM
biomedich-346	449	7	)	)	PUNCT
biomedich-346	449	8	,	,	PUNCT
biomedich-346	449	9	73–84	73–84	PROPN
biomedich-346	449	10	.	.	PUNCT
biomedich-346	450	1	doi:10.1016	doi:10.1016	PROPN
biomedich-346	450	2	/	/	SYM
biomedich-346	450	3	s1473	s1473	PROPN
biomedich-346	450	4	-	-	PUNCT
biomedich-346	450	5	3099(21)00192	3099(21)00192	NUM
biomedich-346	450	6	-	-	SYM
biomedich-346	450	7	4	4	NUM
biomedich-346	450	8	formica	formica	NOUN
biomedich-346	450	9	,	,	PUNCT
biomedich-346	450	10	n.	n.	NOUN
biomedich-346	450	11	,	,	PUNCT
biomedich-346	450	12	mallory	mallory	PROPN
biomedich-346	450	13	,	,	PUNCT
biomedich-346	450	14	r.	r.	PROPN
biomedich-346	450	15	,	,	PUNCT
biomedich-346	450	16	albert	albert	PROPN
biomedich-346	450	17	,	,	PUNCT
biomedich-346	450	18	g.	g.	PROPN
biomedich-346	450	19	,	,	PUNCT
biomedich-346	450	20	robinson	robinson	PROPN
biomedich-346	450	21	,	,	PUNCT
biomedich-346	450	22	m.	m.	NOUN
biomedich-346	450	23	,	,	PUNCT
biomedich-346	450	24	plested	pleste	VERB
biomedich-346	450	25	,	,	PUNCT
biomedich-346	450	26	j.	j.	PROPN
biomedich-346	450	27	s.	s.	PROPN
biomedich-346	450	28	,	,	PUNCT
biomedich-346	450	29	cho	cho	PROPN
biomedich-346	450	30	,	,	PUNCT
biomedich-346	450	31	i.	i.	PROPN
biomedich-346	450	32	,	,	PUNCT
biomedich-346	450	33	…	…	PUNCT
biomedich-346	450	34	2019ncov-101	2019ncov-101	NUM
biomedich-346	450	35	study	study	NOUN
biomedich-346	450	36	group	group	NOUN
biomedich-346	450	37	.	.	PUNCT
biomedich-346	451	1	(	(	PUNCT
biomedich-346	451	2	2021	2021	NUM
biomedich-346	451	3	)	)	PUNCT
biomedich-346	451	4	.	.	PUNCT
biomedich-346	452	1	different	different	ADJ
biomedich-346	452	2	dose	dose	NOUN
biomedich-346	452	3	regimens	regimen	NOUN
biomedich-346	452	4	of	of	ADP
biomedich-346	452	5	a	a	DET
biomedich-346	452	6	sars	sar	NOUN
biomedich-346	452	7	-	-	PUNCT
biomedich-346	452	8	cov-2	cov-2	NOUN
biomedich-346	452	9	recombinant	recombinant	ADJ
biomedich-346	452	10	spike	spike	ADJ
biomedich-346	452	11	protein	protein	NOUN
biomedich-346	452	12	vaccine	vaccine	NOUN
biomedich-346	452	13	(	(	PUNCT
biomedich-346	452	14	nvx	nvx	NOUN
biomedich-346	452	15	-	-	PUNCT
biomedich-346	452	16	cov2373	cov2373	NOUN
biomedich-346	452	17	)	)	PUNCT
biomedich-346	452	18	in	in	ADP
biomedich-346	452	19	younger	young	ADJ
biomedich-346	452	20	and	and	CCONJ
biomedich-346	452	21	older	old	ADJ
biomedich-346	452	22	adults	adult	NOUN
biomedich-346	452	23	:	:	PUNCT
biomedich-346	452	24	a	a	DET
biomedich-346	452	25	phase	phase	NOUN
biomedich-346	452	26	2	2	NUM
biomedich-346	452	27	randomized	randomize	VERB
biomedich-346	452	28	placebo	placebo	NOUN
biomedich-346	452	29	-	-	PUNCT
biomedich-346	452	30	controlled	control	VERB
biomedich-346	452	31	trial	trial	NOUN
biomedich-346	452	32	.	.	PUNCT
biomedich-346	453	1	plos	plos	PROPN
biomedich-346	453	2	medicine	medicine	PROPN
biomedich-346	453	3	,	,	PUNCT
biomedich-346	453	4	18(10	18(10	NUM
biomedich-346	453	5	)	)	PUNCT
biomedich-346	453	6	,	,	PUNCT
biomedich-346	453	7	e1003769	e1003769	NOUN
biomedich-346	453	8	.	.	PUNCT
biomedich-346	453	9	doi:10.1371	doi:10.1371	PROPN
biomedich-346	453	10	/	/	SYM
biomedich-346	453	11	journal.pmed.1003769	journal.pmed.1003769	PROPN
biomedich-346	453	12	h	h	PROPN
biomedich-346	453	13	s	s	PROPN
biomedich-346	453	14	,	,	PUNCT
biomedich-346	453	15	r.	r.	PROPN
biomedich-346	453	16	,	,	PUNCT
biomedich-346	453	17	khobragade	khobragade	PROPN
biomedich-346	453	18	,	,	PUNCT
biomedich-346	453	19	a.	a.	NOUN
biomedich-346	453	20	,	,	PUNCT
biomedich-346	453	21	satapathy	satapathy	ADJ
biomedich-346	453	22	,	,	PUNCT
biomedich-346	453	23	d.	d.	PROPN
biomedich-346	453	24	,	,	PUNCT
biomedich-346	453	25	gupta	gupta	PROPN
biomedich-346	453	26	,	,	PUNCT
biomedich-346	453	27	m.	m.	NOUN
biomedich-346	453	28	,	,	PUNCT
biomedich-346	453	29	kumar	kumar	PROPN
biomedich-346	453	30	,	,	PUNCT
biomedich-346	453	31	s.	s.	PROPN
biomedich-346	453	32	,	,	PUNCT
biomedich-346	453	33	bhomia	bhomia	NOUN
biomedich-346	453	34	,	,	PUNCT
biomedich-346	453	35	v.	v.	ADV
biomedich-346	453	36	,	,	PUNCT
biomedich-346	453	37	…	…	PUNCT
biomedich-346	453	38	agrawal	agrawal	PROPN
biomedich-346	453	39	,	,	PUNCT
biomedich-346	453	40	a.	a.	PROPN
biomedich-346	453	41	d.	d.	PROPN
biomedich-346	453	42	(	(	PUNCT
biomedich-346	453	43	2021	2021	NUM
biomedich-346	453	44	)	)	PUNCT
biomedich-346	453	45	.	.	PUNCT
biomedich-346	454	1	safety	safety	NOUN
biomedich-346	454	2	and	and	CCONJ
biomedich-346	454	3	immunogenicity	immunogenicity	NOUN
biomedich-346	454	4	of	of	ADP
biomedich-346	454	5	a	a	DET
biomedich-346	454	6	novel	novel	ADJ
biomedich-346	454	7	three	three	NUM
biomedich-346	454	8	-	-	PUNCT
biomedich-346	454	9	dose	dose	NOUN
biomedich-346	454	10	recombinant	recombinant	ADJ
biomedich-346	454	11	nanoparticle	nanoparticle	NOUN
biomedich-346	454	12	rabies	rabie	NOUN
biomedich-346	454	13	g	g	NOUN
biomedich-346	454	14	protein	protein	NOUN
biomedich-346	454	15	vaccine	vaccine	NOUN
biomedich-346	454	16	administered	administer	VERB
biomedich-346	454	17	as	as	ADP
biomedich-346	454	18	simulated	simulate	VERB
biomedich-346	454	19	post	post	NOUN
biomedich-346	454	20	exposure	exposure	NOUN
biomedich-346	454	21	immunization	immunization	NOUN
biomedich-346	454	22	:	:	PUNCT
biomedich-346	454	23	a	a	DET
biomedich-346	454	24	randomized	randomized	ADJ
biomedich-346	454	25	,	,	PUNCT
biomedich-346	454	26	comparator	comparator	NOUN
biomedich-346	454	27	controlled	control	VERB
biomedich-346	454	28	,	,	PUNCT
biomedich-346	454	29	multicenter	multicenter	NOUN
biomedich-346	454	30	,	,	PUNCT
biomedich-346	454	31	phase	phase	NOUN
biomedich-346	454	32	iii	iii	NUM
biomedich-346	454	33	clinical	clinical	ADJ
biomedich-346	454	34	study	study	NOUN
biomedich-346	454	35	.	.	PUNCT
biomedich-346	455	1	human	human	ADJ
biomedich-346	455	2	vaccines	vaccine	NOUN
biomedich-346	455	3	&	&	CCONJ
biomedich-346	455	4	immunotherapeutics	immunotherapeutic	NOUN
biomedich-346	455	5	,	,	PUNCT
biomedich-346	455	6	17(11	17(11	NUM
biomedich-346	455	7	)	)	PUNCT
biomedich-346	455	8	,	,	PUNCT
biomedich-346	455	9	4239–4245	4239–4245	NUM
biomedich-346	455	10	.	.	PUNCT
biomedich-346	456	1	doi:10.1080/21645515.2021.1957413	doi:10.1080/21645515.2021.1957413	PROPN
biomedich-346	456	2	august	august	PROPN
biomedich-346	456	3	,	,	PUNCT
biomedich-346	456	4	a.	a.	NOUN
biomedich-346	456	5	,	,	PUNCT
biomedich-346	456	6	attarwala	attarwala	NOUN
biomedich-346	456	7	,	,	PUNCT
biomedich-346	456	8	h.	h.	PROPN
biomedich-346	456	9	z.	z.	PROPN
biomedich-346	456	10	,	,	PUNCT
biomedich-346	456	11	himansu	himansu	PROPN
biomedich-346	456	12	,	,	PUNCT
biomedich-346	456	13	s.	s.	PROPN
biomedich-346	456	14	,	,	PUNCT
biomedich-346	456	15	kalidindi	kalidindi	PROPN
biomedich-346	456	16	,	,	PUNCT
biomedich-346	456	17	s.	s.	PROPN
biomedich-346	456	18	,	,	PUNCT
biomedich-346	456	19	lu	lu	PROPN
biomedich-346	456	20	,	,	PUNCT
biomedich-346	456	21	s.	s.	PROPN
biomedich-346	456	22	,	,	PUNCT
biomedich-346	456	23	pajon	pajon	PROPN
biomedich-346	456	24	,	,	PUNCT
biomedich-346	456	25	r.	r.	PROPN
biomedich-346	456	26	,	,	PUNCT
biomedich-346	456	27	…	…	PUNCT
biomedich-346	456	28	zaks	zak	NOUN
biomedich-346	456	29	,	,	PUNCT
biomedich-346	456	30	t.	t.	NOUN
biomedich-346	456	31	(	(	PUNCT
biomedich-346	456	32	2021	2021	NUM
biomedich-346	456	33	)	)	PUNCT
biomedich-346	456	34	.	.	PUNCT
biomedich-346	457	1	a	a	DET
biomedich-346	457	2	phase	phase	NOUN
biomedich-346	457	3	1	1	NUM
biomedich-346	457	4	trial	trial	NOUN
biomedich-346	457	5	of	of	ADP
biomedich-346	457	6	lipidencapsulated	lipidencapsulate	VERB
biomedich-346	457	7	mrna	mrna	PROPN
biomedich-346	457	8	encoding	encode	VERB
biomedich-346	457	9	a	a	DET
biomedich-346	457	10	monoclonal	monoclonal	NOUN
biomedich-346	457	11	antibody	antibody	NOUN
biomedich-346	457	12	with	with	ADP
biomedich-346	457	13	neutralizing	neutralizing	ADJ
biomedich-346	457	14	activity	activity	NOUN
biomedich-346	457	15	against	against	ADP
biomedich-346	457	16	chikungunya	chikungunya	NOUN
biomedich-346	457	17	virus	virus	NOUN
biomedich-346	457	18	.	.	PUNCT
biomedich-346	458	1	nature	nature	NOUN
biomedich-346	458	2	medicine	medicine	NOUN
biomedich-346	458	3	,	,	PUNCT
biomedich-346	458	4	27(12	27(12	NUM
biomedich-346	458	5	)	)	PUNCT
biomedich-346	458	6	,	,	PUNCT
biomedich-346	458	7	2224–2233	2224–2233	NUM
biomedich-346	458	8	.	.	PUNCT
biomedich-346	459	1	doi:10.1038	doi:10.1038	NOUN
biomedich-346	459	2	/	/	SYM
biomedich-346	459	3	s41591	s41591	NOUN
biomedich-346	459	4	-	-	PUNCT
biomedich-346	459	5	02101573	02101573	NUM
biomedich-346	459	6	-	-	SYM
biomedich-346	459	7	6	6	NUM
biomedich-346	459	8	shinde	shinde	NOUN
biomedich-346	459	9	,	,	PUNCT
biomedich-346	459	10	v.	v.	PROPN
biomedich-346	459	11	,	,	PUNCT
biomedich-346	459	12	cai	cai	PROPN
biomedich-346	459	13	,	,	PUNCT
biomedich-346	459	14	r.	r.	PROPN
biomedich-346	459	15	,	,	PUNCT
biomedich-346	459	16	plested	pleste	VERB
biomedich-346	459	17	,	,	PUNCT
biomedich-346	459	18	j.	j.	PROPN
biomedich-346	459	19	,	,	PUNCT
biomedich-346	459	20	cho	cho	PROPN
biomedich-346	459	21	,	,	PUNCT
biomedich-346	459	22	i.	i.	PROPN
biomedich-346	459	23	,	,	PUNCT
biomedich-346	459	24	fiske	fiske	PROPN
biomedich-346	459	25	,	,	PUNCT
biomedich-346	459	26	j.	j.	PROPN
biomedich-346	459	27	,	,	PUNCT
biomedich-346	459	28	pham	pham	PROPN
biomedich-346	459	29	,	,	PUNCT
biomedich-346	459	30	x.	x.	PROPN
biomedich-346	459	31	,	,	PUNCT
biomedich-346	459	32	…	…	PUNCT
biomedich-346	459	33	glenn	glenn	PROPN
biomedich-346	459	34	,	,	PUNCT
biomedich-346	459	35	g.	g.	PROPN
biomedich-346	459	36	m.	m.	PROPN
biomedich-346	459	37	(	(	PUNCT
biomedich-346	459	38	2021	2021	NUM
biomedich-346	459	39	)	)	PUNCT
biomedich-346	459	40	.	.	PUNCT
biomedich-346	460	1	induction	induction	NOUN
biomedich-346	460	2	of	of	ADP
biomedich-346	460	3	cross	cross	ADJ
biomedich-346	460	4	-	-	ADJ
biomedich-346	460	5	reactive	reactive	ADJ
biomedich-346	460	6	hemagglutination	hemagglutination	NOUN
biomedich-346	460	7	inhibiting	inhibit	VERB
biomedich-346	460	8	antibody	antibody	NOUN
biomedich-346	460	9	and	and	CCONJ
biomedich-346	460	10	polyfunctional	polyfunctional	ADJ
biomedich-346	460	11	cd4	cd4	PROPN
biomedich-346	460	12	+	+	PROPN
biomedich-346	460	13	t	t	PROPN
biomedich-346	460	14	-	-	PUNCT
biomedich-346	460	15	cell	cell	NOUN
biomedich-346	460	16	responses	response	NOUN
biomedich-346	460	17	by	by	ADP
biomedich-346	460	18	a	a	DET
biomedich-346	460	19	recombinant	recombinant	ADJ
biomedich-346	460	20	matrix	matrix	NOUN
biomedich-346	460	21	-	-	PUNCT
biomedich-346	460	22	m	m	PRON
biomedich-346	460	23	-	-	PUNCT
biomedich-346	460	24	adjuvanted	adjuvante	VERB
biomedich-346	460	25	hemagglutinin	hemagglutinin	ADJ
biomedich-346	460	26	nanoparticle	nanoparticle	NOUN
biomedich-346	460	27	influenza	influenza	NOUN
biomedich-346	460	28	vaccine	vaccine	NOUN
biomedich-346	460	29	.	.	PUNCT
biomedich-346	461	1	clinical	clinical	ADJ
biomedich-346	461	2	infectious	infectious	ADJ
biomedich-346	461	3	diseases	disease	NOUN
biomedich-346	461	4	:	:	PUNCT
biomedich-346	461	5	an	an	DET
biomedich-346	461	6	official	official	ADJ
biomedich-346	461	7	publication	publication	NOUN
biomedich-346	461	8	of	of	ADP
biomedich-346	461	9	the	the	DET
biomedich-346	461	10	infectious	infectious	ADJ
biomedich-346	461	11	diseases	disease	NOUN
biomedich-346	461	12	society	society	NOUN
biomedich-346	461	13	of	of	ADP
biomedich-346	461	14	america	america	PROPN
biomedich-346	461	15	,	,	PUNCT
biomedich-346	461	16	73(11	73(11	NUM
biomedich-346	461	17	)	)	PUNCT
biomedich-346	461	18	,	,	PUNCT
biomedich-346	461	19	e4278	e4278	NOUN
biomedich-346	461	20	–	–	PUNCT
biomedich-346	461	21	e4287	e4287	ADJ
biomedich-346	461	22	.	.	PUNCT
biomedich-346	462	1	doi:10.1093	doi:10.1093	NOUN
biomedich-346	462	2	/	/	SYM
biomedich-346	462	3	cid	cid	PROPN
biomedich-346	462	4	/	/	SYM
biomedich-346	462	5	ciaa1673	ciaa1673	PROPN
biomedich-346	462	6	kremsner	kremsner	NOUN
biomedich-346	462	7	,	,	PUNCT
biomedich-346	462	8	p.	p.	NOUN
biomedich-346	462	9	g.	g.	PROPN
biomedich-346	462	10	,	,	PUNCT
biomedich-346	462	11	mann	mann	PROPN
biomedich-346	462	12	,	,	PUNCT
biomedich-346	462	13	p.	p.	PROPN
biomedich-346	462	14	,	,	PUNCT
biomedich-346	462	15	kroidl	kroidl	PROPN
biomedich-346	462	16	,	,	PUNCT
biomedich-346	462	17	a.	a.	NOUN
biomedich-346	462	18	,	,	PUNCT
biomedich-346	462	19	leroux	leroux	NOUN
biomedich-346	462	20	-	-	PUNCT
biomedich-346	462	21	roels	roel	NOUN
biomedich-346	462	22	,	,	PUNCT
biomedich-346	462	23	i.	i.	NOUN
biomedich-346	462	24	,	,	PUNCT
biomedich-346	462	25	schindler	schindler	PROPN
biomedich-346	462	26	,	,	PUNCT
biomedich-346	462	27	c.	c.	PROPN
biomedich-346	462	28	,	,	PUNCT
biomedich-346	462	29	gabor	gabor	PROPN
biomedich-346	462	30	,	,	PUNCT
biomedich-346	462	31	j.	j.	PROPN
biomedich-346	462	32	j.	j.	PROPN
biomedich-346	462	33	,	,	PUNCT
biomedich-346	462	34	…	…	PUNCT
biomedich-346	462	35	cv	cv	ADJ
biomedich-346	462	36	-	-	PUNCT
biomedich-346	462	37	ncov-001	ncov-001	ADJ
biomedich-346	462	38	study	study	NOUN
biomedich-346	462	39	group	group	NOUN
biomedich-346	462	40	.	.	PUNCT
biomedich-346	463	1	(	(	PUNCT
biomedich-346	463	2	2021	2021	NUM
biomedich-346	463	3	)	)	PUNCT
biomedich-346	463	4	.	.	PUNCT
biomedich-346	464	1	safety	safety	NOUN
biomedich-346	464	2	and	and	CCONJ
biomedich-346	464	3	immunogenicity	immunogenicity	NOUN
biomedich-346	464	4	of	of	ADP
biomedich-346	464	5	an	an	DET
biomedich-346	464	6	mrna	mrna	NOUN
biomedich-346	464	7	-	-	PUNCT
biomedich-346	464	8	lipid	lipid	NOUN
biomedich-346	464	9	nanoparticle	nanoparticle	NOUN
biomedich-346	464	10	vaccine	vaccine	NOUN
biomedich-346	464	11	candidate	candidate	NOUN
biomedich-346	464	12	against	against	ADP
biomedich-346	464	13	sars	sar	NOUN
biomedich-346	464	14	-	-	PUNCT
biomedich-346	464	15	cov-2	cov-2	NOUN
biomedich-346	464	16	 	 	SPACE
biomedich-346	464	17	:	:	PUNCT
biomedich-346	464	18	a	a	DET
biomedich-346	464	19	phase	phase	NOUN
biomedich-346	464	20	1	1	NUM
biomedich-346	464	21	randomized	randomize	VERB
biomedich-346	464	22	clinical	clinical	ADJ
biomedich-346	464	23	trial	trial	NOUN
biomedich-346	464	24	:	:	PUNCT
biomedich-346	464	25	a	a	DET
biomedich-346	464	26	phase	phase	NOUN
biomedich-346	464	27	1	1	NUM
biomedich-346	464	28	randomized	randomize	VERB
biomedich-346	464	29	clinical	clinical	ADJ
biomedich-346	464	30	trial	trial	NOUN
biomedich-346	464	31	.	.	PUNCT
biomedich-346	465	1	wiener	wiener	NOUN
biomedich-346	465	2	klinische	klinische	NOUN
biomedich-346	465	3	wochenschrift	wochenschrift	NOUN
biomedich-346	465	4	,	,	PUNCT
biomedich-346	465	5	133(17–18	133(17–18	NUM
biomedich-346	465	6	)	)	PUNCT
biomedich-346	465	7	,	,	PUNCT
biomedich-346	465	8	931–941	931–941	NUM
biomedich-346	465	9	.	.	PUNCT
biomedich-346	465	10	doi:10.1007	doi:10.1007	VERB
biomedich-346	465	11	/	/	SYM
biomedich-346	465	12	s00508	s00508	NOUN
biomedich-346	465	13	-	-	PUNCT
biomedich-346	465	14	021	021	NUM
biomedich-346	465	15	-	-	PUNCT
biomedich-346	465	16	01922	01922	NUM
biomedich-346	465	17	-	-	PUNCT
biomedich-346	465	18	y	y	PROPN
biomedich-346	465	19	mallory	mallory	PROPN
biomedich-346	465	20	,	,	PUNCT
biomedich-346	465	21	r.	r.	PROPN
biomedich-346	465	22	m.	m.	PROPN
biomedich-346	465	23	,	,	PUNCT
biomedich-346	465	24	formica	formica	NOUN
biomedich-346	465	25	,	,	PUNCT
biomedich-346	465	26	n.	n.	PROPN
biomedich-346	465	27	,	,	PUNCT
biomedich-346	465	28	pfeiffer	pfeiffer	PROPN
biomedich-346	465	29	,	,	PUNCT
biomedich-346	465	30	s.	s.	PROPN
biomedich-346	465	31	,	,	PUNCT
biomedich-346	465	32	wilkinson	wilkinson	PROPN
biomedich-346	465	33	,	,	PUNCT
biomedich-346	465	34	b.	b.	PROPN
biomedich-346	465	35	,	,	PUNCT
biomedich-346	465	36	marcheschi	marcheschi	PROPN
biomedich-346	465	37	,	,	PUNCT
biomedich-346	465	38	a.	a.	PROPN
biomedich-346	465	39	,	,	PUNCT
biomedich-346	465	40	albert	albert	PROPN
biomedich-346	465	41	,	,	PUNCT
biomedich-346	465	42	g.	g.	PROPN
biomedich-346	465	43	,	,	PUNCT
biomedich-346	465	44	…	…	PUNCT
biomedich-346	465	45	novavax	novavax	NOUN
biomedich-346	465	46	2019ncov101	2019ncov101	NUM
biomedich-346	465	47	study	study	NOUN
biomedich-346	465	48	group	group	NOUN
biomedich-346	465	49	.	.	PUNCT
biomedich-346	466	1	(	(	PUNCT
biomedich-346	466	2	2022	2022	NUM
biomedich-346	466	3	)	)	PUNCT
biomedich-346	466	4	.	.	PUNCT
biomedich-346	467	1	safety	safety	NOUN
biomedich-346	467	2	and	and	CCONJ
biomedich-346	467	3	immunogenicity	immunogenicity	NOUN
biomedich-346	467	4	following	follow	VERB
biomedich-346	467	5	a	a	DET
biomedich-346	467	6	homologous	homologous	ADJ
biomedich-346	467	7	booster	booster	NOUN
biomedich-346	467	8	dose	dose	NOUN
biomedich-346	467	9	of	of	ADP
biomedich-346	467	10	a	a	DET
biomedich-346	467	11	sars	sar	NOUN
biomedich-346	467	12	-	-	PUNCT
biomedich-346	467	13	cov-2	cov-2	NOUN
biomedich-346	467	14	recombinant	recombinant	ADJ
biomedich-346	467	15	spike	spike	ADJ
biomedich-346	467	16	protein	protein	NOUN
biomedich-346	467	17	vaccine	vaccine	NOUN
biomedich-346	467	18	(	(	PUNCT
biomedich-346	467	19	nvx	nvx	NOUN
biomedich-346	467	20	-	-	PUNCT
biomedich-346	467	21	cov2373	cov2373	PROPN
biomedich-346	467	22	):	):	PUNCT
biomedich-346	467	23	a	a	DET
biomedich-346	467	24	secondary	secondary	ADJ
biomedich-346	467	25	analysis	analysis	NOUN
biomedich-346	467	26	of	of	ADP
biomedich-346	467	27	a	a	DET
biomedich-346	467	28	randomised	randomise	VERB
biomedich-346	467	29	,	,	PUNCT
biomedich-346	467	30	placebo	placebo	NOUN
biomedich-346	467	31	-	-	PUNCT
biomedich-346	467	32	controlled	control	VERB
biomedich-346	467	33	,	,	PUNCT
biomedich-346	467	34	phase	phase	NOUN
biomedich-346	467	35	2	2	NUM
biomedich-346	467	36	trial	trial	NOUN
biomedich-346	467	37	.	.	PUNCT
biomedich-346	468	1	the	the	DET
biomedich-346	468	2	lancet	lancet	ADJ
biomedich-346	468	3	infectious	infectious	ADJ
biomedich-346	468	4	diseases	disease	NOUN
biomedich-346	468	5	,	,	PUNCT
biomedich-346	468	6	22(11	22(11	NUM
biomedich-346	468	7	)	)	PUNCT
biomedich-346	468	8	,	,	PUNCT
biomedich-346	468	9	1565–1576	1565–1576	NUM
biomedich-346	468	10	.	.	PUNCT
biomedich-346	469	1	doi:10.1016	doi:10.1016	PROPN
biomedich-346	469	2	/	/	SYM
biomedich-346	469	3	s14733099(22)00420	s14733099(22)00420	PROPN
biomedich-346	469	4	-	-	PUNCT
biomedich-346	469	5	0	0	NUM
biomedich-346	469	6	heath	heath	PROPN
biomedich-346	469	7	,	,	PUNCT
biomedich-346	469	8	p.	p.	PROPN
biomedich-346	469	9	t.	t.	PROPN
biomedich-346	469	10	,	,	PUNCT
biomedich-346	469	11	galiza	galiza	PROPN
biomedich-346	469	12	,	,	PUNCT
biomedich-346	469	13	e.	e.	PROPN
biomedich-346	469	14	p.	p.	PROPN
biomedich-346	469	15	,	,	PUNCT
biomedich-346	469	16	baxter	baxter	PROPN
biomedich-346	469	17	,	,	PUNCT
biomedich-346	469	18	d.	d.	PROPN
biomedich-346	469	19	n.	n.	PROPN
biomedich-346	469	20	,	,	PUNCT
biomedich-346	469	21	boffito	boffito	ADJ
biomedich-346	469	22	,	,	PUNCT
biomedich-346	469	23	m.	m.	NOUN
biomedich-346	469	24	,	,	PUNCT
biomedich-346	469	25	browne	browne	PROPN
biomedich-346	469	26	,	,	PUNCT
biomedich-346	469	27	d.	d.	PROPN
biomedich-346	469	28	,	,	PUNCT
biomedich-346	469	29	burns	burn	NOUN
biomedich-346	469	30	,	,	PUNCT
biomedich-346	469	31	f.	f.	PROPN
biomedich-346	469	32	,	,	PUNCT
biomedich-346	469	33	…	…	PUNCT
biomedich-346	469	34	toback	toback	NOUN
biomedich-346	469	35	,	,	PUNCT
biomedich-346	469	36	s.	s.	PROPN
biomedich-346	469	37	(	(	PUNCT
biomedich-346	469	38	2023	2023	NUM
biomedich-346	469	39	)	)	PUNCT
biomedich-346	469	40	.	.	PUNCT
biomedich-346	470	1	safety	safety	NOUN
biomedich-346	470	2	and	and	CCONJ
biomedich-346	470	3	efficacy	efficacy	NOUN
biomedich-346	470	4	of	of	ADP
biomedich-346	470	5	the	the	DET
biomedich-346	470	6	nvx	nvx	PROPN
biomedich-346	470	7	-	-	PUNCT
biomedich-346	470	8	cov2373	cov2373	NOUN
biomedich-346	470	9	coronavirus	coronavirus	NOUN
biomedich-346	470	10	disease	disease	NOUN
biomedich-346	470	11	2019	2019	NUM
biomedich-346	470	12	vaccine	vaccine	NOUN
biomedich-346	470	13	at	at	ADP
biomedich-346	470	14	completion	completion	NOUN
biomedich-346	470	15	of	of	ADP
biomedich-346	470	16	the	the	DET
biomedich-346	470	17	placebo	placebo	NOUN
biomedich-346	470	18	-	-	PUNCT
biomedich-346	470	19	controlled	control	VERB
biomedich-346	470	20	phase	phase	NOUN
biomedich-346	470	21	of	of	ADP
biomedich-346	470	22	a	a	DET
biomedich-346	470	23	randomized	randomized	ADJ
biomedich-346	470	24	controlled	control	VERB
biomedich-346	470	25	trial	trial	NOUN
biomedich-346	470	26	.	.	PUNCT
biomedich-346	471	1	clinical	clinical	ADJ
biomedich-346	471	2	infectious	infectious	ADJ
biomedich-346	471	3	diseases	disease	NOUN
biomedich-346	471	4	:	:	PUNCT
biomedich-346	471	5	an	an	DET
biomedich-346	471	6	official	official	ADJ
biomedich-346	471	7	publication	publication	NOUN
biomedich-346	471	8	of	of	ADP
biomedich-346	471	9	the	the	DET
biomedich-346	471	10	infectious	infectious	ADJ
biomedich-346	471	11	diseases	disease	NOUN
biomedich-346	471	12	society	society	NOUN
biomedich-346	471	13	of	of	ADP
biomedich-346	471	14	america	america	PROPN
biomedich-346	471	15	,	,	PUNCT
biomedich-346	471	16	76(3	76(3	PROPN
biomedich-346	471	17	)	)	PUNCT
biomedich-346	471	18	,	,	PUNCT
biomedich-346	471	19	398–407	398–407	NUM
biomedich-346	471	20	.	.	PUNCT
biomedich-346	472	1	doi:10.1093	doi:10.1093	NOUN
biomedich-346	472	2	/	/	SYM
biomedich-346	472	3	cid	cid	NOUN
biomedich-346	472	4	/	/	SYM
biomedich-346	472	5	ciac803	ciac803	NOUN
biomedich-346	472	6	lovell	lovell	PROPN
biomedich-346	472	7	,	,	PUNCT
biomedich-346	472	8	j.	j.	PROPN
biomedich-346	472	9	f.	f.	PROPN
biomedich-346	472	10	,	,	PUNCT
biomedich-346	472	11	baik	baik	PROPN
biomedich-346	472	12	,	,	PUNCT
biomedich-346	472	13	y.	y.	PROPN
biomedich-346	472	14	o.	o.	PROPN
biomedich-346	472	15	,	,	PUNCT
biomedich-346	472	16	choi	choi	NOUN
biomedich-346	472	17	,	,	PUNCT
biomedich-346	472	18	s.	s.	PROPN
biomedich-346	472	19	k.	k.	PROPN
biomedich-346	472	20	,	,	PUNCT
biomedich-346	472	21	lee	lee	PROPN
biomedich-346	472	22	,	,	PUNCT
biomedich-346	472	23	c.	c.	PROPN
biomedich-346	472	24	,	,	PUNCT
biomedich-346	472	25	lee	lee	PROPN
biomedich-346	472	26	,	,	PUNCT
biomedich-346	472	27	j.-y	j.-y	PROPN
biomedich-346	472	28	.	.	PROPN
biomedich-346	472	29	,	,	PUNCT
biomedich-346	472	30	miura	miura	PROPN
biomedich-346	472	31	,	,	PUNCT
biomedich-346	472	32	k.	k.	PROPN
biomedich-346	472	33	,	,	PUNCT
biomedich-346	472	34	…	…	PUNCT
biomedich-346	472	35	choi	choi	NOUN
biomedich-346	472	36	,	,	PUNCT
biomedich-346	472	37	j.-h	j.-h	PROPN
biomedich-346	472	38	.	.	PUNCT
biomedich-346	473	1	(	(	PUNCT
biomedich-346	473	2	2022	2022	NUM
biomedich-346	473	3	)	)	PUNCT
biomedich-346	473	4	.	.	PUNCT
biomedich-346	474	1	interim	interim	ADJ
biomedich-346	474	2	analysis	analysis	NOUN
biomedich-346	474	3	from	from	ADP
biomedich-346	474	4	a	a	DET
biomedich-346	474	5	phase	phase	NOUN
biomedich-346	474	6	2	2	NUM
biomedich-346	474	7	randomized	randomize	VERB
biomedich-346	474	8	trial	trial	NOUN
biomedich-346	474	9	of	of	ADP
biomedich-346	474	10	eucorvac-19	eucorvac-19	PROPN
biomedich-346	474	11	:	:	PUNCT
biomedich-346	474	12	a	a	DET
biomedich-346	474	13	recombinant	recombinant	ADJ
biomedich-346	474	14	protein	protein	NOUN
biomedich-346	474	15	sars	sar	NOUN
biomedich-346	474	16	-	-	PUNCT
biomedich-346	474	17	cov-2	cov-2	NOUN
biomedich-346	474	18	rbd	rbd	NOUN
biomedich-346	474	19	nanoliposome	nanoliposome	NOUN
biomedich-346	474	20	vaccine	vaccine	NOUN
biomedich-346	474	21	.	.	PUNCT
biomedich-346	475	1	bmc	bmc	ADJ
biomedich-346	475	2	medicine	medicine	NOUN
biomedich-346	475	3	,	,	PUNCT
biomedich-346	475	4	20(1	20(1	NUM
biomedich-346	475	5	)	)	PUNCT
biomedich-346	475	6	,	,	PUNCT
biomedich-346	475	7	462	462	NUM
biomedich-346	475	8	.	.	PUNCT
biomedich-346	476	1	doi:10.1186	doi:10.1186	PROPN
biomedich-346	476	2	/	/	SYM
biomedich-346	476	3	s12916	s12916	PROPN
biomedich-346	476	4	-	-	PUNCT
biomedich-346	476	5	022	022	NUM
biomedich-346	476	6	-	-	PUNCT
biomedich-346	476	7	02661	02661	NUM
biomedich-346	476	8	-	-	SYM
biomedich-346	476	9	1	1	NUM
biomedich-346	476	10	hussein	hussein	NOUN
biomedich-346	476	11	et	et	PROPN
biomedich-346	476	12	al	al	PROPN
biomedich-346	476	13	.	.	PROPN
biomedich-346	476	14	–	–	PUNCT
biomedich-346	476	15	nanotechnology	nanotechnology	NOUN
biomedich-346	476	16	-	-	PUNCT
biomedich-346	476	17	based	base	VERB
biomedich-346	476	18	vaccines	vaccine	NOUN
biomedich-346	476	19	361	361	NUM
biomedich-346	476	20	gatechompol	gatechompol	NOUN
biomedich-346	476	21	,	,	PUNCT
biomedich-346	476	22	s.	s.	PROPN
biomedich-346	476	23	,	,	PUNCT
biomedich-346	476	24	kittanamongkolchai	kittanamongkolchai	PROPN
biomedich-346	476	25	,	,	PUNCT
biomedich-346	476	26	w.	w.	PROPN
biomedich-346	476	27	,	,	PUNCT
biomedich-346	476	28	ketloy	ketloy	PROPN
biomedich-346	476	29	,	,	PUNCT
biomedich-346	476	30	c.	c.	PROPN
biomedich-346	476	31	,	,	PUNCT
biomedich-346	476	32	prompetchara	prompetchara	PROPN
biomedich-346	476	33	,	,	PUNCT
biomedich-346	476	34	e.	e.	PROPN
biomedich-346	476	35	,	,	PUNCT
biomedich-346	476	36	thitithanyanont	thitithanyanont	PROPN
biomedich-346	476	37	,	,	PUNCT
biomedich-346	476	38	a.	a.	NOUN
biomedich-346	476	39	,	,	PUNCT
biomedich-346	476	40	jongkaewwattana	jongkaewwattana	PROPN
biomedich-346	476	41	,	,	PUNCT
biomedich-346	476	42	a.	a.	NOUN
biomedich-346	476	43	,	,	PUNCT
biomedich-346	476	44	…	…	PUNCT
biomedich-346	476	45	chulavac-001	chulavac-001	NOUN
biomedich-346	476	46	study	study	NOUN
biomedich-346	476	47	team	team	NOUN
biomedich-346	476	48	.	.	PUNCT
biomedich-346	477	1	(	(	PUNCT
biomedich-346	477	2	2022	2022	NUM
biomedich-346	477	3	)	)	PUNCT
biomedich-346	477	4	.	.	PUNCT
biomedich-346	478	1	safety	safety	NOUN
biomedich-346	478	2	and	and	CCONJ
biomedich-346	478	3	immunogenicity	immunogenicity	NOUN
biomedich-346	478	4	of	of	ADP
biomedich-346	478	5	a	a	DET
biomedich-346	478	6	prefusion	prefusion	NOUN
biomedich-346	478	7	non	non	ADJ
biomedich-346	478	8	-	-	ADJ
biomedich-346	478	9	stabilized	stabilized	ADJ
biomedich-346	478	10	spike	spike	ADJ
biomedich-346	478	11	protein	protein	NOUN
biomedich-346	478	12	mrna	mrna	PROPN
biomedich-346	478	13	covid-19	covid-19	PROPN
biomedich-346	478	14	vaccine	vaccine	NOUN
biomedich-346	478	15	:	:	PUNCT
biomedich-346	478	16	a	a	DET
biomedich-346	478	17	phase	phase	NOUN
biomedich-346	478	18	i	i	PRON
biomedich-346	478	19	trial	trial	NOUN
biomedich-346	478	20	.	.	PUNCT
biomedich-346	479	1	nature	nature	NOUN
biomedich-346	479	2	microbiology	microbiology	NOUN
biomedich-346	479	3	,	,	PUNCT
biomedich-346	479	4	7(12	7(12	NUM
biomedich-346	479	5	)	)	PUNCT
biomedich-346	479	6	,	,	PUNCT
biomedich-346	479	7	1987–1995	1987–1995	NUM
biomedich-346	479	8	.	.	PUNCT
biomedich-346	479	9	doi:10.1038	doi:10.1038	PROPN
biomedich-346	479	10	/	/	SYM
biomedich-346	479	11	s41564	s41564	NOUN
biomedich-346	479	12	-	-	PUNCT
biomedich-346	479	13	02201271	02201271	NUM
biomedich-346	479	14	-	-	PUNCT
biomedich-346	479	15	0	0	NUM
biomedich-346	479	16	masuda	masuda	PROPN
biomedich-346	479	17	,	,	PUNCT
biomedich-346	479	18	t.	t.	PROPN
biomedich-346	479	19	,	,	PUNCT
biomedich-346	479	20	murakami	murakami	NOUN
biomedich-346	479	21	,	,	PUNCT
biomedich-346	479	22	k.	k.	PROPN
biomedich-346	479	23	,	,	PUNCT
biomedich-346	479	24	sugiura	sugiura	NOUN
biomedich-346	479	25	,	,	PUNCT
biomedich-346	479	26	k.	k.	PROPN
biomedich-346	479	27	,	,	PUNCT
biomedich-346	479	28	sakui	sakui	PROPN
biomedich-346	479	29	,	,	PUNCT
biomedich-346	479	30	s.	s.	PROPN
biomedich-346	479	31	,	,	PUNCT
biomedich-346	479	32	schuring	schuring	PROPN
biomedich-346	479	33	,	,	PUNCT
biomedich-346	479	34	r.	r.	PROPN
biomedich-346	479	35	p.	p.	PROPN
biomedich-346	479	36	,	,	PUNCT
biomedich-346	479	37	&	&	CCONJ
biomedich-346	479	38	mori	mori	PROPN
biomedich-346	479	39	,	,	PUNCT
biomedich-346	479	40	m.	m.	NOUN
biomedich-346	479	41	(	(	PUNCT
biomedich-346	479	42	2022	2022	NUM
biomedich-346	479	43	)	)	PUNCT
biomedich-346	479	44	.	.	PUNCT
biomedich-346	480	1	safety	safety	NOUN
biomedich-346	480	2	and	and	CCONJ
biomedich-346	480	3	immunogenicity	immunogenicity	NOUN
biomedich-346	480	4	of	of	ADP
biomedich-346	480	5	nvxcov2373	nvxcov2373	PROPN
biomedich-346	480	6	(	(	PUNCT
biomedich-346	480	7	tak-019	tak-019	NOUN
biomedich-346	480	8	)	)	PUNCT
biomedich-346	480	9	vaccine	vaccine	NOUN
biomedich-346	480	10	in	in	ADP
biomedich-346	480	11	healthy	healthy	ADJ
biomedich-346	480	12	japanese	japanese	ADJ
biomedich-346	480	13	adults	adult	NOUN
biomedich-346	480	14	:	:	PUNCT
biomedich-346	480	15	interim	interim	ADJ
biomedich-346	480	16	report	report	NOUN
biomedich-346	480	17	of	of	ADP
biomedich-346	480	18	a	a	DET
biomedich-346	480	19	phase	phase	NOUN
biomedich-346	480	20	i	i	PRON
biomedich-346	480	21	/	/	SYM
biomedich-346	480	22	ii	ii	PROPN
biomedich-346	480	23	randomized	randomize	VERB
biomedich-346	480	24	controlled	control	VERB
biomedich-346	480	25	trial	trial	NOUN
biomedich-346	480	26	.	.	PUNCT
biomedich-346	481	1	vaccine	vaccine	NOUN
biomedich-346	481	2	,	,	PUNCT
biomedich-346	481	3	40(24	40(24	NUM
biomedich-346	481	4	)	)	PUNCT
biomedich-346	481	5	,	,	PUNCT
biomedich-346	481	6	3380–3388	3380–3388	NUM
biomedich-346	481	7	.	.	PUNCT
biomedich-346	481	8	doi:10.1016	doi:10.1016	PROPN
biomedich-346	481	9	/	/	SYM
biomedich-346	481	10	j.vaccine.2022.04.035	j.vaccine.2022.04.035	NUM
biomedich-346	481	11	ishikawa	ishikawa	PROPN
biomedich-346	481	12	,	,	PUNCT
biomedich-346	481	13	t.	t.	PROPN
biomedich-346	481	14	,	,	PUNCT
biomedich-346	481	15	kageyama	kageyama	PROPN
biomedich-346	481	16	,	,	PUNCT
biomedich-346	481	17	s.	s.	PROPN
biomedich-346	481	18	,	,	PUNCT
biomedich-346	481	19	miyahara	miyahara	PROPN
biomedich-346	481	20	,	,	PUNCT
biomedich-346	481	21	y.	y.	PROPN
biomedich-346	481	22	,	,	PUNCT
biomedich-346	481	23	okayama	okayama	PROPN
biomedich-346	481	24	,	,	PUNCT
biomedich-346	481	25	t.	t.	PROPN
biomedich-346	481	26	,	,	PUNCT
biomedich-346	481	27	kokura	kokura	NOUN
biomedich-346	481	28	,	,	PUNCT
biomedich-346	481	29	s.	s.	PROPN
biomedich-346	481	30	,	,	PUNCT
biomedich-346	481	31	wang	wang	PROPN
biomedich-346	481	32	,	,	PUNCT
biomedich-346	481	33	l.	l.	PROPN
biomedich-346	481	34	,	,	PUNCT
biomedich-346	481	35	…	…	PUNCT
biomedich-346	481	36	shiku	shiku	NOUN
biomedich-346	481	37	,	,	PUNCT
biomedich-346	481	38	h.	h.	PROPN
biomedich-346	481	39	(	(	PUNCT
biomedich-346	481	40	2021	2021	NUM
biomedich-346	481	41	)	)	PUNCT
biomedich-346	481	42	.	.	PUNCT
biomedich-346	482	1	safety	safety	NOUN
biomedich-346	482	2	and	and	CCONJ
biomedich-346	482	3	antibody	antibody	NOUN
biomedich-346	482	4	immune	immune	ADJ
biomedich-346	482	5	response	response	NOUN
biomedich-346	482	6	of	of	ADP
biomedich-346	482	7	chp	chp	PROPN
biomedich-346	482	8	-	-	PUNCT
biomedich-346	482	9	ny	ny	NOUN
biomedich-346	482	10	-	-	PUNCT
biomedich-346	482	11	eso-1	eso-1	NOUN
biomedich-346	482	12	vaccine	vaccine	NOUN
biomedich-346	482	13	combined	combine	VERB
biomedich-346	482	14	with	with	ADP
biomedich-346	482	15	poly	poly	ADJ
biomedich-346	482	16	-	-	PUNCT
biomedich-346	482	17	iclc	iclc	NOUN
biomedich-346	482	18	in	in	ADP
biomedich-346	482	19	advanced	advanced	ADJ
biomedich-346	482	20	or	or	CCONJ
biomedich-346	482	21	recurrent	recurrent	ADJ
biomedich-346	482	22	esophageal	esophageal	ADJ
biomedich-346	482	23	cancer	cancer	NOUN
biomedich-346	482	24	patients	patient	NOUN
biomedich-346	482	25	.	.	PUNCT
biomedich-346	483	1	cancer	cancer	NOUN
biomedich-346	483	2	immunology	immunology	NOUN
biomedich-346	483	3	,	,	PUNCT
biomedich-346	483	4	immunotherapy	immunotherapy	NOUN
biomedich-346	483	5	:	:	PUNCT
biomedich-346	483	6	cii	cii	PROPN
biomedich-346	483	7	,	,	PUNCT
biomedich-346	483	8	70(11	70(11	NUM
biomedich-346	483	9	)	)	PUNCT
biomedich-346	483	10	,	,	PUNCT
biomedich-346	483	11	3081–3091	3081–3091	X
biomedich-346	483	12	.	.	PUNCT
biomedich-346	484	1	doi:10.1007	doi:10.1007	PROPN
biomedich-346	484	2	/	/	SYM
biomedich-346	484	3	s00262	s00262	PROPN
biomedich-346	484	4	-	-	PUNCT
biomedich-346	484	5	021	021	NUM
biomedich-346	484	6	-	-	PUNCT
biomedich-346	484	7	02892	02892	NUM
biomedich-346	484	8	-	-	PUNCT
biomedich-346	484	9	w	w	NOUN
biomedich-346	484	10	li	li	PROPN
biomedich-346	484	11	,	,	PUNCT
biomedich-346	484	12	j.	j.	PROPN
biomedich-346	484	13	,	,	PUNCT
biomedich-346	484	14	hui	hui	PROPN
biomedich-346	484	15	,	,	PUNCT
biomedich-346	484	16	a.-m	a.-m	PROPN
biomedich-346	484	17	.	.	PUNCT
biomedich-346	484	18	,	,	PUNCT
biomedich-346	484	19	zhang	zhang	PROPN
biomedich-346	484	20	,	,	PUNCT
biomedich-346	484	21	x.	x.	PROPN
biomedich-346	484	22	,	,	PUNCT
biomedich-346	484	23	ge	ge	PROPN
biomedich-346	484	24	,	,	PUNCT
biomedich-346	484	25	l.	l.	PROPN
biomedich-346	484	26	,	,	PUNCT
biomedich-346	484	27	qiu	qiu	PROPN
biomedich-346	484	28	,	,	PUNCT
biomedich-346	484	29	y.	y.	PROPN
biomedich-346	484	30	,	,	PUNCT
biomedich-346	484	31	tang	tang	PROPN
biomedich-346	484	32	,	,	PUNCT
biomedich-346	484	33	r.	r.	PROPN
biomedich-346	484	34	,	,	PUNCT
biomedich-346	484	35	…	…	PUNCT
biomedich-346	484	36	zhu	zhu	PROPN
biomedich-346	484	37	,	,	PUNCT
biomedich-346	484	38	f.	f.	PROPN
biomedich-346	484	39	(	(	PUNCT
biomedich-346	484	40	2022	2022	NUM
biomedich-346	484	41	)	)	PUNCT
biomedich-346	484	42	.	.	PUNCT
biomedich-346	485	1	immune	immune	ADJ
biomedich-346	485	2	persistence	persistence	NOUN
biomedich-346	485	3	and	and	CCONJ
biomedich-346	485	4	safety	safety	NOUN
biomedich-346	485	5	after	after	ADP
biomedich-346	485	6	sars	sar	NOUN
biomedich-346	485	7	-	-	PUNCT
biomedich-346	485	8	cov-2	cov-2	NOUN
biomedich-346	485	9	bnt162b1	bnt162b1	NOUN
biomedich-346	485	10	mrna	mrna	NOUN
biomedich-346	485	11	vaccination	vaccination	NOUN
biomedich-346	485	12	in	in	ADP
biomedich-346	485	13	chinese	chinese	ADJ
biomedich-346	485	14	adults	adult	NOUN
biomedich-346	485	15	:	:	PUNCT
biomedich-346	485	16	a	a	DET
biomedich-346	485	17	randomized	randomized	ADJ
biomedich-346	485	18	,	,	PUNCT
biomedich-346	485	19	placebo	placebo	NOUN
biomedich-346	485	20	-	-	PUNCT
biomedich-346	485	21	controlled	control	VERB
biomedich-346	485	22	,	,	PUNCT
biomedich-346	485	23	double	double	ADJ
biomedich-346	485	24	-	-	PUNCT
biomedich-346	485	25	blind	blind	ADJ
biomedich-346	485	26	phase	phase	NOUN
biomedich-346	485	27	1	1	NUM
biomedich-346	485	28	trial	trial	NOUN
biomedich-346	485	29	.	.	PUNCT
biomedich-346	486	1	advances	advance	NOUN
biomedich-346	486	2	in	in	ADP
biomedich-346	486	3	therapy	therapy	NOUN
biomedich-346	486	4	,	,	PUNCT
biomedich-346	486	5	39(8	39(8	NUM
biomedich-346	486	6	)	)	PUNCT
biomedich-346	486	7	,	,	PUNCT
biomedich-346	486	8	3789–3798	3789–3798	NUM
biomedich-346	486	9	.	.	PUNCT
biomedich-346	487	1	doi:10.1007	doi:10.1007	PROPN
biomedich-346	487	2	/	/	SYM
biomedich-346	487	3	s12325022	s12325022	NOUN
biomedich-346	487	4	-	-	PUNCT
biomedich-346	487	5	02206	02206	NUM
biomedich-346	487	6	-	-	PUNCT
biomedich-346	487	7	1	1	NUM
biomedich-346	487	8	wei	wei	PROPN
biomedich-346	487	9	,	,	PUNCT
biomedich-346	487	10	j.	j.	PROPN
biomedich-346	487	11	,	,	PUNCT
biomedich-346	487	12	cheng	cheng	PROPN
biomedich-346	487	13	,	,	PUNCT
biomedich-346	487	14	x.	x.	PROPN
biomedich-346	487	15	,	,	PUNCT
biomedich-346	487	16	zhang	zhang	PROPN
biomedich-346	487	17	,	,	PUNCT
biomedich-346	487	18	y.	y.	PROPN
biomedich-346	487	19	,	,	PUNCT
biomedich-346	487	20	gao	gao	PROPN
biomedich-346	487	21	,	,	PUNCT
biomedich-346	487	22	c.	c.	PROPN
biomedich-346	487	23	,	,	PUNCT
biomedich-346	487	24	wang	wang	PROPN
biomedich-346	487	25	,	,	PUNCT
biomedich-346	487	26	y.	y.	PROPN
biomedich-346	487	27	,	,	PUNCT
biomedich-346	487	28	peng	peng	PROPN
biomedich-346	487	29	,	,	PUNCT
biomedich-346	487	30	q.	q.	PROPN
biomedich-346	487	31	,	,	PUNCT
biomedich-346	487	32	…	…	PUNCT
biomedich-346	487	33	gu	gu	NOUN
biomedich-346	487	34	,	,	PUNCT
biomedich-346	487	35	j.	j.	PROPN
biomedich-346	487	36	(	(	PUNCT
biomedich-346	487	37	2021	2021	NUM
biomedich-346	487	38	)	)	PUNCT
biomedich-346	487	39	.	.	PUNCT
biomedich-346	488	1	identification	identification	NOUN
biomedich-346	488	2	and	and	CCONJ
biomedich-346	488	3	application	application	NOUN
biomedich-346	488	4	of	of	ADP
biomedich-346	488	5	a	a	DET
biomedich-346	488	6	neutralizing	neutralizing	ADJ
biomedich-346	488	7	epitope	epitope	NOUN
biomedich-346	488	8	within	within	ADP
biomedich-346	488	9	alpha	alpha	NOUN
biomedich-346	488	10	-	-	PUNCT
biomedich-346	488	11	hemolysin	hemolysin	NOUN
biomedich-346	488	12	using	use	VERB
biomedich-346	488	13	human	human	ADJ
biomedich-346	488	14	serum	serum	NOUN
biomedich-346	488	15	antibodies	antibody	NOUN
biomedich-346	488	16	elicited	elicit	VERB
biomedich-346	488	17	by	by	ADP
biomedich-346	488	18	vaccination	vaccination	NOUN
biomedich-346	488	19	.	.	PUNCT
biomedich-346	489	1	molecular	molecular	ADJ
biomedich-346	489	2	immunology	immunology	NOUN
biomedich-346	489	3	,	,	PUNCT
biomedich-346	489	4	135	135	NUM
biomedich-346	489	5	,	,	PUNCT
biomedich-346	489	6	45–52	45–52	NUM
biomedich-346	489	7	.	.	PUNCT
biomedich-346	490	1	doi:10.1016	doi:10.1016	PROPN
biomedich-346	490	2	/	/	SYM
biomedich-346	490	3	j.molimm.2021.03.028	j.molimm.2021.03.028	PROPN
biomedich-346	490	4	this	this	DET
biomedich-346	490	5	page	page	NOUN
biomedich-346	490	6	intentionally	intentionally	ADV
biomedich-346	490	7	left	leave	VERB
biomedich-346	490	8	blank	blank	ADV